[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1i7cbgqK-uQk9FUXHXZ-GdPgpYi3-AJLr9h3Rc8q8pg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"University of California, San Francisco",[4],2120,false,453,89,11697042,187,1412,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"HIV",62,{"name":18,"count":19},"HIV Infections",56,{"name":21,"count":22},"Prostate Cancer",44,{"name":24,"count":25},"Breast Cancer",42,{"name":27,"count":28},"Depression",40,{"name":30,"count":31},"Healthy",36,{"name":33,"count":34},"HIV\u002FAIDS",32,{"name":36,"count":37},"Asthma",31,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03433469","Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery","2023-01-31","Osimertinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05065294","Psilocybin Therapy for Depression in Bipolar II Disorder","2024-08-01","Psilocybin therapy",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03174977","Pharmacokinetics Distribution of Raltegravir by PET\u002FMR","2024-11-01","18F-Raltegravir",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06366217","Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients","2024-12-31","MydCombi Drug",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05317689","Comparing the Effects of Psilocin and Psilocybin in Healthy Adults","2025-01-16","Psilocin",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04716712","Infant Mortality Reduction by the Mass Administration of Azithromycin","2025-01-30","Azithromycin",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04645355","Guselkumab Immunogenetics","2025-04-04","Guselkumab",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05296837","Ocular Rosacea Biome Study","2025-07-11","Doxycycline 40 MG",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT02797275","Secondhand Smoke Respiratory Health Study","2025-12-31","Albuterol",{"nctId":85,"briefTitle":86,"date":82,"intervention":87},"NCT05266040","Valacyclovir in Pain Management of Acute Apical Abscesses","Valacyclovir 500 MG",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,327,405,479,529,572,599,632,660,723,767,830,860,906,958,1013,1041,1078,1108,1130,1155,1189,1227,1270,1296,1322,1347,1371,1389,1418,1447,1475,1493,1511,1533,1551,1575,1593,1614,1643,1661,1688,1713,1738,1756,1783,1811,1829,1853,1878,1896,1920,1938,1956,1974,1992,2010,2028,2046,2064,2082,2100,2118,2136,2154,2172,2190,2208,2226,2244,2262,2280,2298,2316,2343,2471,2563,2613,2639,2678,2729,2824,2865,2918,2957,2979,3014,3039,3057,3081,3108,3134,3152,3170,3188,3206,3232,3250,3268,3292,3319,3337,3355,3383,3408,3606,3750,3887,3935,3961,3990,4048,4100,4122,4185,4265,4296,4327,4349,4376,4394,4415,4441,4465,4490,4508,4526,4555,4573,4591,4615,4633,4658,4685,4703,4730,4748,4766,4784,4806,4831,4855,4883,4901,4925,4952,4970,4990,5017,5041,5059,5084,5105,5131,5149,5167,5185,5203,5282,5317,5352,5370,5392,5410,5437,5455,5473,5496,5517,5535,5553,5583,5601,5626,5649,5671,5744,5790,5809,5834,5858,5890,5913,5938,5956,5984,6007,6030,6155,6245,6297,6363,6412,6451,6501,6528,6550,6583,6610,6644,6676,6711,6738,6772,6805,6835,6853,6871,6889,6912,6930,6953,6971,6995,7013,7038,7061,7079,7104,7128,7150,7176,7194,7212,7234,7258,7276,7299,7324,7347,7370,7393,7417,7451,7469,7495,7513,7537,7562,7586,7609,7632,7659,7677,7701,7719,7737,7766,7784,7817,7835,7858,7883,7901,7925,7946,7967,7985,8003,8027,8049,8073,8091,8117,8140,8164,8190,8208,8226,8249,8267,8290,8308,8337,8355,8373,8391,8409,8427,8453,8471,8494,8520,8544,8562,8580,8598,8616,8634,8657,8679,8702,8727,8754,8772,8797,8819,8842,8864,8889,8912,8930,8948,8966,8988,9012,9030,9052,9073,9095,9120,9138,9156,9181,9204,9222,9247,9271,9297,9315,9333,9357,9380,9405,9428,9452,9470,9493,9527,9560,9586,9618,9647,9679,9706,9728,9764,9796,9832,9854,9878,9896,9923,9941,9959,9982,10005,10023,10048,10071,10089,10110,10138,10156,10182,10200,10221,10243,10269,10287,10305,10327,10345,10363,10390,10408,10433,10455,10481,10506,10529,10553,10571,10595,10613,10640,10658,10684,10702,10720,10743,10768,10786,10804,10822,10846,10864,10882,10900,10964,11000,11032,11064,11097,11123,11156,11188,11214,11236,11261,11283,11310,11332,11366,11388,11410,11449,11475,11497,11524,11553,11583,11615,11641,11663,11695,11720,11738,11761,11784,11807,11830,11854,11872,11899,11926,11944,11969,11987,12005,12023,12041,12063,12092,12117,12139,12157,12182,12200,12221,12243,12267,12292,12310,12328,12351,12374,12392,12410,12435,12461,12479,12507,12525,12552,12574,12599,12617,12635,12653,12678,12702,12736,12754,12772,12790,12808,12830,12848,12872,12898,12916,12934,12959,12977,12995,13013,13036,13059,13083,13101,13125,13143,13166,13189,13211,13236,13254,13272,13290,13308,13329,13353,13371,13405,13423,13441,13459,13481,13499,13523,13551,13575,13593,13615,13639,13657,13675,13702,13720,13743,13764,13789,13807,13831,13855,13877,13895,13916,13934,13952,13970,13992,14017,14039,14062,14080,14098,14120,14143,14161,14185,14212,14234,14252,14270,14291,14318,14336,14362,14380,14401,14426,14444,14462,14480,14498,14516,14534,14558,14576,14600,14618,14640,14663,14688,14730,14766,14788,14816,14845,14875,14909,14946,14968,14996,15024,15050,15068,15089,15107,15128,15146,15168,15186,15204,15222,15245,15268,15293,15311,15333,15351,15374,15399,15422,15444,15469,15487,15505,15532,15550,15572,15594,15612,15630,15648,15671,15695,15716,15734,15752,15773,15794,15816,15839,15860,15883,15901,15919,15942,15960,15978,15996,16014,16032,16057,16075,16096,16119,16137,16155,16177,16199,16229,16251,16269,16294,16318,16341,16359,16382,16400,16423,16448,16471,16489,16507,16530,16548,16566,16589,16612,16637,16655,16673,16691,16715,16746,16767,16785,16803,16821,16839,16860,16883,16907,16931,16949,16967,16985,17013,17031,17049,17067,17091,17116,17134,17168,17197,17219,17244,17262,17287,17311,17334,17359,17377,17395,17419,17472,17514,17556,17594,17643,17687,17726,17763,17808,17849,17879,17909,17951,17981,18023,18071,18097,18123,18153,18185,18215,18253,18283,18312,18340,18362,18396,18426,18448,18475,18499,18527,18549,18579,18608,18637,18669,18700,18718,18736,18758,18781,18807,18828,18853,18871,18889,18912,18930,18955,18973,18991,19012,19034,19056,19079,19097,19120,19138,19156,19180,19202,19225,19250,19268,19286,19304,19326,19348,19381,19404,19422,19444,19462,19486,19504,19522,19544,19566,19589,19610,19632,19653,19679,19700,19718,19736,19759,19783,19805,19828,19846,19868,19886,19904,19922,19947,19965,19983,20007,20029,20052,20070,20088,20106,20133,20151,20169,20193,20219,20241,20264,20282,20306,20328,20350,20371,20395,20413,20436,20457],{"intervention":68,"totalTrials":97,"cells":98},21,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":149,"NA":325},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[108,117,129,140],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"start":113,"enrollment":101,"conditions":114,"interventions":116},"NCT02176057","Nepal Elimination of Trachoma Study","WITHDRAWN",[91,92],"2014-08",[115],"Trachoma",[68],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT05473234","Azithromycin for Severe Acute Malnutrition in CMAM, Nigeria","TERMINATED",[92],"2023-11-29","2022-10-06",310,[126],"Severe Acute Malnutrition",[68,128],"Amoxicillin",{"nctId":130,"briefTitle":131,"status":132,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":139},"NCT03568643","Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot)","COMPLETED",[92],"2020-12-25","2020-06-03",301,[138],"Uncomplicated Severe Acute Malnutrition",[68,128],{"nctId":141,"briefTitle":142,"status":132,"phases":143,"primaryCompletion":57,"completion":57,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT02754583","Sanitation, Water, and Instruction in Face-washing for Trachoma I\u002FII",[92],"2015-12-05",47605,[115],[68,148],"Tetracycline",{"trials":150,"activeCount":324,"soonestReadout":67},[151,160,170,180,192,200,209,220,232,241,250,261,270,282,294,304,314],{"nctId":65,"briefTitle":66,"status":152,"phases":153,"primaryCompletion":67,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"ACTIVE_NOT_RECRUITING",[93],"2026-01-30","2021-10-04",694400,[158],"Child Mortality",[68],{"nctId":161,"briefTitle":162,"status":132,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT02048007","Mortality Reduction After Oral Azithromycin: Morbidity Study",[93],"2020-08-27","2014-11",72000,[168],"Childhood Mortality",[68],{"nctId":171,"briefTitle":172,"status":132,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"NCT03676764","Community Health Azithromycin Trial in Burkina Faso",[93],"2023-12-01","2019-08-01",77664,[168],[68,179],"Placebos",{"nctId":181,"briefTitle":182,"status":132,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":191},"NCT03676751","MORDOR II Burkina Faso: Longitudinal Trial",[93],"2020-07-06","2019-10-10",500,[188,189,158,190],"Child Growth","Diversity of Microbiome","Resistance Bacterial",[68],{"nctId":193,"briefTitle":194,"status":111,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":101,"conditions":198,"interventions":199},"NCT06289647","Azithromycin Reduction to Reach Elimination of Trachoma B",[93],"2029-08-31","2024-10",[115],[68],{"nctId":201,"briefTitle":202,"status":132,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":208},"NCT02047981","Mortality Reduction After Oral Azithromycin: Mortality Study",[93],"2018-09","2014-12",190238,[168],[68],{"nctId":210,"briefTitle":211,"status":132,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":219},"NCT04224987","Azithromycin for Child Survival in Niger: Mortality and Resistance Trial",[93],"2024-07-31","2020-11-24",864493,[217,190,218],"Mortality","Child, Only",[68],{"nctId":221,"briefTitle":222,"status":111,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":101,"conditions":227,"interventions":229},"NCT03032042","Intestinal Microbiome Post-Azythromycin\u002FAlbendazole Treatment",[93],"2017-02","2018-02","2017-01",[228],"Helminth Infection",[68,230,231],"Albendazole","Delayed treatment",{"nctId":233,"briefTitle":234,"status":111,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":101,"conditions":239,"interventions":240},"NCT00286026","Azithromycin in Control of Trachoma II",[93],"2007-08","2009-08","2005-06",[115],[68],{"nctId":242,"briefTitle":243,"status":132,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":249},"NCT03338244","Mortality Reduction After Oral Azithromycin Contingency: Mortality Study",[93],"2020-07-31","2017-10-20",66228,[168],[68],{"nctId":251,"briefTitle":252,"status":132,"phases":253,"primaryCompletion":254,"completion":237,"start":255,"enrollment":256,"conditions":257,"interventions":259},"NCT00618449","Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger",[93],"2009-05","2008-01",1139,[115,258],"Chlamydia Trachomatis",[260,68],"Azithromcyin",{"nctId":262,"briefTitle":263,"status":132,"phases":264,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},"NCT04185402","Azithromycin Reduction to Reach Elimination of Trachoma",[93],"2024-12-18","2021-05-29",3931,[115],[68],{"nctId":271,"briefTitle":272,"status":132,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},"NCT03187834","Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso",[93],"2017-09-01","2019-09-01","2017-07-04",252,[279],"Child Development",[68,128,281],"Cotrimoxazole",{"nctId":283,"briefTitle":284,"status":285,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT06010719","Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition","RECRUITING",[93],"2028-06-30","2028-12-29","2024-10-23",3000,[292,126],"Malnutrition, Child",[68,128],{"nctId":295,"briefTitle":296,"status":152,"phases":297,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":303},"NCT03335072","Kebele Elimination of Trachoma for Ocular Health",[93],"2027-03-01","2028-03-01","2022-02-07",320000,[115],[68],{"nctId":305,"briefTitle":306,"status":132,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT03682653","Neonates and Azithromycin, an Innovation in the Treatment of Children in Burkina Faso",[93],"2022-05-01","2022-12-31","2019-04-11",21832,[168],[68],{"nctId":315,"briefTitle":316,"status":132,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT04315272","Gut and Azithromycin Mechanisms in Infants and Children II",[93],"2022-06-01","2020-08-21",449,[322],"Malaria",[68],3,{"trials":326,"activeCount":101},[],{"intervention":73,"totalTrials":324,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":335,"PHASE4":337,"NA":403},{"trials":330,"activeCount":101},[],{"trials":332,"activeCount":101},[],{"trials":334,"activeCount":101},[],{"trials":336,"activeCount":101},[],{"trials":338,"activeCount":324,"soonestReadout":72},[339,349,358],{"nctId":340,"briefTitle":341,"status":285,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":348},"NCT05858632","Immune Spatial Features of Guselkumab Cutaneous Response",[93],"2026-06-30","2023-07-01",10,[347],"Psoriasis of Scalp",[73],{"nctId":70,"briefTitle":71,"status":152,"phases":350,"primaryCompletion":72,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":357},[93],"2026-04-15","2021-03-01",25,[355,356],"Psoriasis Guttate","Plaque Psoriasis",[73],{"nctId":359,"briefTitle":360,"status":361,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":365,"interventions":368},"NCT07352566","Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","NOT_YET_RECRUITING",[93],"2030-06-01","2026-01-01",[366,367],"Psoriasis","Atopic Dermatitis",[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],"Triamcinolone","5-Fluorouracil","Calcipotriene","Tapinarof","Crisaborole","Tacrolimus","Adalimumab","Etanercept","Certolizumab","Infliximab","Secukinumab","Ixekizumab","Apremilast","Risankizumab","Ustekinumab","Hydroxychloroquine","Methotrexate","Mycophenolate","Azathioprine","Chloroquine","Cyclosporine","Tofacitinib","Deucravacitinib","Dupilumab","Tralokinumab","Tildrakizumab","Baractinib","Abrocitinib","Upadacitinib","Lebrikizumab","Nemolizumab","Ruxolitinib","Bimekizumab","Roflumilast",{"trials":404,"activeCount":101},[],{"intervention":406,"totalTrials":407,"cells":408},"Normal saline",5,{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":425,"PHASE3":441,"PHASE4":453,"NA":477},{"trials":410,"activeCount":101},[],{"trials":412,"activeCount":424,"soonestReadout":298},[413],{"nctId":414,"briefTitle":415,"status":285,"phases":416,"primaryCompletion":298,"completion":298,"start":417,"enrollment":418,"conditions":419,"interventions":422},"NCT06428097","Levothyroxine Supplementation for Heart Transplant Recipients",[90],"2024-03-29",97,[420,421],"Heart Transplant Failure","Heart Transplant Infection",[423,406],"Levothyroxine",1,{"trials":426,"activeCount":101},[427],{"nctId":428,"briefTitle":429,"status":132,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":439},"NCT01913340","Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)",[90,91],"2016-01","2016-09","2013-09",50,[436,437,438],"Hypoxic-ischemic Encephalopathy","Neonatal Encephalopathy","Birth Asphyxia",[440,406],"Erythropoietin",{"trials":442,"activeCount":101},[443],{"nctId":444,"briefTitle":445,"status":111,"phases":446,"primaryCompletion":447,"start":448,"enrollment":101,"conditions":449,"interventions":451},"NCT01375361","Nebulized Albuterol for Congestive Heart Failure Exacerbation",[91,92],"2010-07","2009-04",[450],"Congestive Heart Failure",[83,452],"Normal Saline",{"trials":454,"activeCount":424,"soonestReadout":459},[455,468],{"nctId":456,"briefTitle":457,"status":285,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":465},"NCT05157126","Gentamicin Open Tibia Study",[93],"2028-04","2029-04","2022-09-01",890,[464],"Fracture Open Tibia",[466,467],"Gentamicin","normal Saline",{"nctId":469,"briefTitle":470,"status":111,"phases":471,"primaryCompletion":472,"completion":472,"start":472,"enrollment":101,"conditions":473,"interventions":475},"NCT03037736","Outpatient Performed Pterygium Surgery Study",[93],"2020-03-01",[474],"Pterygium of Conjunctiva and Cornea",[370,476,406],"Bevacizumab",{"trials":478,"activeCount":101},[],{"intervention":392,"totalTrials":480,"cells":481},4,{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":527},{"trials":483,"activeCount":101},[],{"trials":485,"activeCount":101},[],{"trials":487,"activeCount":101},[],{"trials":489,"activeCount":101},[],{"trials":491,"activeCount":526,"soonestReadout":517},[492,504,513,522],{"nctId":493,"briefTitle":494,"status":132,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":503},"NCT03293030","Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis",[93],"2023-02-23","2018-10-22",17,[367,500,501,502],"Atopic Dermatitis Eczema","Eczema","Atopic Dermatitis and Related Conditions",[392],{"nctId":505,"briefTitle":506,"status":132,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":512},"NCT03667014","The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients",[93],"2022-12-15","2018-11-01",34,[367,500],[392],{"nctId":514,"briefTitle":515,"status":285,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":521},"NCT05858619","Molecular Signatures of Cutaneous Dupilumab Response",[93],"2026-02-01","2023-02-01",15,[367],[392],{"nctId":359,"briefTitle":360,"status":361,"phases":523,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":524,"interventions":525},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],2,{"trials":528,"activeCount":101},[],{"intervention":378,"totalTrials":324,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":546,"PHASE3":562,"PHASE4":564,"NA":570},{"trials":532,"activeCount":101},[],{"trials":534,"activeCount":101},[535],{"nctId":536,"briefTitle":537,"status":132,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":545},"NCT01971814","Early Serum Infliximab Levels in Severe Ulcerative Colitis.",[90],"2015-01","2013-11",11,[543,544],"Ulcerative Colitis (UC)","Inflammatory Bowel Disease",[378],{"trials":547,"activeCount":424,"soonestReadout":552},[548],{"nctId":549,"briefTitle":550,"status":285,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":561},"NCT02638701","Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms",[90,91],"2027-06","2027-12","2024-10-01",8,[557,558,559,560],"Aneurysm","Stroke","Vasculitis","Tumor Necrosis Factor-alpha",[378],{"trials":563,"activeCount":101},[],{"trials":565,"activeCount":424,"soonestReadout":363},[566],{"nctId":359,"briefTitle":360,"status":361,"phases":567,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":568,"interventions":569},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":571,"activeCount":101},[],{"intervention":397,"totalTrials":526,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":597},{"trials":575,"activeCount":101},[],{"trials":577,"activeCount":101},[],{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":101},[],{"trials":583,"activeCount":526,"soonestReadout":588},[584,593],{"nctId":585,"briefTitle":586,"status":361,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":434,"conditions":590,"interventions":592},"NCT07502339","Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis",[93],"2028-08-01","2026-07-01",[591],"UC - Ulcerative Colitis",[397],{"nctId":359,"briefTitle":360,"status":361,"phases":594,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":595,"interventions":596},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":598,"activeCount":101},[],{"intervention":600,"totalTrials":526,"cells":601},"Sodium chloride",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":610,"NA":630},{"trials":603,"activeCount":101},[],{"trials":605,"activeCount":101},[],{"trials":607,"activeCount":101},[],{"trials":609,"activeCount":101},[],{"trials":611,"activeCount":526,"soonestReadout":616},[612,621],{"nctId":613,"briefTitle":614,"status":361,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":28,"conditions":619,"interventions":620},"NCT07447063","The Impact of Dietary Salt on the Severity of Eczema",[93],"2028-03-05","2028-05-05","2026-03-06",[501,367],[600],{"nctId":622,"briefTitle":623,"status":361,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":434,"conditions":627,"interventions":629},"NCT07487831","The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease",[93],"2028-03-17","2026-03-16",[628,366],"Atopic Dermatitis (Eczema)",[600],{"trials":631,"activeCount":101},[],{"intervention":633,"totalTrials":526,"cells":634},"deucravacitinib",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":643,"NA":658},{"trials":636,"activeCount":101},[],{"trials":638,"activeCount":101},[],{"trials":640,"activeCount":101},[],{"trials":642,"activeCount":101},[],{"trials":644,"activeCount":526,"soonestReadout":649},[645,654],{"nctId":646,"briefTitle":647,"status":285,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":353,"conditions":651,"interventions":653},"NCT05858645","Correction of Psoriatic T Cell Signatures by Deucravacitinib",[93],"2026-06","2023-10-01",[652],"Psoriasis Vulgaris",[633],{"nctId":359,"briefTitle":360,"status":361,"phases":655,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":656,"interventions":657},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":659,"activeCount":101},[],{"intervention":661,"totalTrials":480,"cells":662},"cyclosporine",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":699,"PHASE4":701,"NA":707},{"trials":664,"activeCount":101},[],{"trials":666,"activeCount":101},[],{"trials":668,"activeCount":424,"soonestReadout":693},[669,688],{"nctId":670,"briefTitle":671,"status":132,"phases":672,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":682},"NCT00301834","Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders",[91],"2011-09","2005-01",35,[677,678,679,680,681],"Congenital Amegakaryocytic Thrombocytopenia","Diamond-blackfan Anemia","Leukemia","Myelodysplastic Syndromes","Severe Congenital Neutropenia",[683,684,661,685,686,687],"alemtuzumab","busulfan","fludarabine phosphate","methotrexate","methylprednisolone",{"nctId":689,"briefTitle":690,"status":691,"phases":692,"primaryCompletion":693,"completion":694,"start":649,"enrollment":695,"conditions":696,"interventions":698},"NCT06790095","TRACK-TBI Precision Medicine Part 3 - Option II","ENROLLING_BY_INVITATION",[91],"2026-12","2027-05",26,[697],"Traumatic Brain Injury",[389],{"trials":700,"activeCount":101},[],{"trials":702,"activeCount":424,"soonestReadout":363},[703],{"nctId":359,"briefTitle":360,"status":361,"phases":704,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":705,"interventions":706},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":708,"activeCount":101},[709],{"nctId":710,"briefTitle":711,"status":120,"phases":712,"primaryCompletion":713,"completion":714,"start":715,"enrollment":555,"conditions":716,"interventions":718},"NCT00301860","Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer",[94],"2007-03","2007-11","2003-01",[679,717],"Lymphoma",[719,720,721,661,685,722,686],"anti-thymocyte globulin","filgrastim","therapeutic allogeneic lymphocytes","melphalan",{"intervention":724,"totalTrials":324,"cells":725},"Ocrelizumab",{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":756},{"trials":727,"activeCount":101},[],{"trials":729,"activeCount":101},[],{"trials":731,"activeCount":101},[],{"trials":733,"activeCount":101},[],{"trials":735,"activeCount":526,"soonestReadout":693},[736,745],{"nctId":737,"briefTitle":738,"status":691,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":407,"conditions":742,"interventions":744},"NCT06495593","Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis",[93],"2027-06-30","2025-02-04",[743],"Multiple Sclerosis, Relapsing-Remitting",[724],{"nctId":746,"briefTitle":747,"status":152,"phases":748,"primaryCompletion":693,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":755},"NCT04466150","Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset",[93],"2027-07","2020-08-30",30,[753,754],"Relapsing Multiple Sclerosis","Clinically Isolated Syndrome",[724],{"trials":757,"activeCount":101},[758],{"nctId":759,"briefTitle":760,"status":132,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":751,"conditions":764,"interventions":766},"NCT04387110","Ocrelizumab in Breastmilk",[],"2022-03-01","2020-08-07",[765,754],"Multiple Sclerosis",[724],{"intervention":768,"totalTrials":407,"cells":769},"5-fluorouracil",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":784,"PHASE3":799,"PHASE4":818,"NA":828},{"trials":771,"activeCount":101},[],{"trials":773,"activeCount":101},[774],{"nctId":775,"briefTitle":776,"status":111,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":101,"conditions":781,"interventions":783},"NCT05505539","Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia",[90],"2023-08-31","2023-12-31","2022-09-30",[782],"Oral Leukoplakia",[768],{"trials":785,"activeCount":101},[786],{"nctId":787,"briefTitle":788,"status":120,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT00539617","Chemotherapy & Erlotinib in Treating Patients w\u002F Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery",[91],"2011-05-12","2007-10-05",7,[794],"Esophageal Cancer",[796,768,797,798],"Erlotinib","Leucovorin","Oxaliplatin",{"trials":800,"activeCount":101},[801],{"nctId":802,"briefTitle":803,"status":120,"phases":804,"primaryCompletion":805,"completion":806,"start":807,"enrollment":31,"conditions":808,"interventions":814},"NCT00227617","Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors",[91,92],"2012-01","2016-02","2005-06-08",[809,810,811,812,813],"Gastrointestinal Carcinoid Tumor","Islet Cell Tumor","Lung Cancer","Neoplastic Syndrome","Neuroendocrine Tumor",[815,768,816,817],"bevacizumab","leucovorin","oxaliplatin",{"trials":819,"activeCount":424,"soonestReadout":363},[820,824],{"nctId":469,"briefTitle":470,"status":111,"phases":821,"primaryCompletion":472,"completion":472,"start":472,"enrollment":101,"conditions":822,"interventions":823},[93],[474],[370,476,406],{"nctId":359,"briefTitle":360,"status":361,"phases":825,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":826,"interventions":827},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":829,"activeCount":101},[],{"intervention":128,"totalTrials":480,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":848,"NA":858},{"trials":833,"activeCount":101},[],{"trials":835,"activeCount":101},[],{"trials":837,"activeCount":101},[],{"trials":839,"activeCount":101},[840,844],{"nctId":118,"briefTitle":119,"status":120,"phases":841,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":842,"interventions":843},[92],[126],[68,128],{"nctId":130,"briefTitle":131,"status":132,"phases":845,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":846,"interventions":847},[92],[138],[68,128],{"trials":849,"activeCount":424,"soonestReadout":287},[850,854],{"nctId":271,"briefTitle":272,"status":132,"phases":851,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":852,"interventions":853},[93],[279],[68,128,281],{"nctId":283,"briefTitle":284,"status":285,"phases":855,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":856,"interventions":857},[93],[292,126],[68,128],{"trials":859,"activeCount":101},[],{"intervention":861,"totalTrials":324,"cells":862},"Azithromycin for Oral Suspension",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":904},{"trials":864,"activeCount":101},[],{"trials":866,"activeCount":101},[],{"trials":868,"activeCount":101},[],{"trials":870,"activeCount":101},[],{"trials":872,"activeCount":424,"soonestReadout":898},[873,884,894],{"nctId":874,"briefTitle":875,"status":132,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":883},"NCT04774991","Azithromycin for Child Survival in Niger: Delivery Trial",[93],"2023-06-30","2021-06-28",10925,[217,881,882],"Child Health","Implementation",[861],{"nctId":885,"briefTitle":886,"status":120,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":893},"NCT05288023","Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)",[93],"2024-01-15","2022-12-01",169707,[190,892,881,882],"Morality",[861],{"nctId":895,"briefTitle":896,"status":285,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":900,"conditions":901,"interventions":903},"NCT06358872","Azithromycin for Child Survival in Niger II",[93],"2028-04-29","2024-04-29",3300000,[217,902],"Antimicrobial Resistance",[861],{"trials":905,"activeCount":101},[],{"intervention":907,"totalTrials":324,"cells":908},"Trimethoprim-sulfamethoxazole",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":939,"NA":956},{"trials":910,"activeCount":101},[],{"trials":912,"activeCount":101},[],{"trials":914,"activeCount":101},[],{"trials":916,"activeCount":101},[917,927],{"nctId":918,"briefTitle":919,"status":132,"phases":920,"primaryCompletion":921,"completion":921,"start":236,"enrollment":922,"conditions":923,"interventions":924},"NCT00527800","Interactions Between HIV and Malaria in African Children",[92],"2013-03",351,[322,18],[925,926,907],"Dihydroartemisinin-piperaquine","Artemether-lumefantrine",{"nctId":928,"briefTitle":929,"status":132,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":935},"NCT00948896","Chemopreventive Therapy for Malaria in Ugandan Children",[92],"2014-04","2010-06",600,[322],[936,937,938],"trimethoprim-sulfamethoxazole","sulfadoxine-pyrimethamine","dihydroartemisinin-piperaquine",{"trials":940,"activeCount":424,"soonestReadout":945},[941],{"nctId":942,"briefTitle":943,"status":361,"phases":944,"primaryCompletion":945,"completion":946,"start":947,"enrollment":434,"conditions":948,"interventions":954},"NCT07106125","Antibiotics for Kidney Transplant Recipients",[93],"2028-12","2029-01","2026-11",[949,950,951,952,953],"Kidney Transplant","Urinary Tract Infection(UTI)","Antibiotic Prophylaxis","Remote Patient Monitoring","Feasibility Pilot Study",[955],"Trimethoprim-Sulfamethoxazole",{"trials":957,"activeCount":101},[],{"intervention":959,"totalTrials":324,"cells":960},"Phenylephrine",{"EARLY_PHASE1":961,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":1011},{"trials":962,"activeCount":101},[963],{"nctId":964,"briefTitle":965,"status":132,"phases":966,"primaryCompletion":967,"completion":967,"start":968,"enrollment":28,"conditions":969,"interventions":971},"NCT03719001","Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study",[89],"2022-06-15","2018-10-23",[970],"Vascular Diseases",[959,972,973,974],"Dexmedetomidine","Clevidipine","Calcium Chloride",{"trials":976,"activeCount":101},[],{"trials":978,"activeCount":101},[],{"trials":980,"activeCount":101},[],{"trials":982,"activeCount":424,"soonestReadout":1000},[983,996],{"nctId":984,"briefTitle":985,"status":132,"phases":986,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":994},"NCT04789330","Norepinephrine vs Phenylephrine During General Anesthesia",[93],"2022-04-01","2021-07-01",3626,[991,992,993],"Anesthesia","Surgery","Hypotension",[995,959],"Norepinephrine",{"nctId":997,"briefTitle":998,"status":285,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1010},"NCT06802224","The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery",[93],"2028-07","2025-04-01",18000,[991,1004,1005,1006,1007,1008,1009],"Surgery With General Anesthesia","Noncardiac Surgery","Hypotension During Surgery","Acute Kidney Injury (AKI)","Myocardial Injury After Noncardiac Surgery (MINS)","Vasopressor",[995,959],{"trials":1012,"activeCount":101},[],{"intervention":400,"totalTrials":526,"cells":1014},{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1031,"PHASE4":1033,"NA":1039},{"trials":1016,"activeCount":101},[],{"trials":1018,"activeCount":101},[],{"trials":1020,"activeCount":101},[1021],{"nctId":1022,"briefTitle":1023,"status":120,"phases":1024,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1030},"NCT03153982","Ruxolitinib in Operable Head and Neck Cancer",[91],"2023-10-18","2018-06-08",16,[1029],"Head and Neck Squamous Cell Carcinoma",[400],{"trials":1032,"activeCount":101},[],{"trials":1034,"activeCount":424,"soonestReadout":363},[1035],{"nctId":359,"briefTitle":360,"status":361,"phases":1036,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1037,"interventions":1038},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1040,"activeCount":101},[],{"intervention":1042,"totalTrials":526,"cells":1043},"Oral Methamphetamine",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1076},{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":101},[],{"trials":1049,"activeCount":101},[],{"trials":1051,"activeCount":101},[],{"trials":1053,"activeCount":424,"soonestReadout":1058},[1054,1065],{"nctId":1055,"briefTitle":1056,"status":361,"phases":1057,"primaryCompletion":1058,"completion":1059,"start":589,"enrollment":1060,"conditions":1061,"interventions":1064},"NCT07584369","Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study",[93],"2029-07","2030-05",20,[1062,1063],"HIV -1 Infection","Methamphetamine Use",[1042],{"nctId":1066,"briefTitle":1067,"status":132,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1075},"NCT03825536","Effect of Methamphetamine on Residual Latent HIV Disease Study",[93],"2023-01-11","2021-01-01",14,[1073,1074],"HIV-1-infection","Methamphetamine-dependence",[1042],{"trials":1077,"activeCount":101},[],{"intervention":83,"totalTrials":526,"cells":1079},{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1092,"NA":1106},{"trials":1081,"activeCount":101},[],{"trials":1083,"activeCount":101},[],{"trials":1085,"activeCount":101},[],{"trials":1087,"activeCount":101},[1088],{"nctId":444,"briefTitle":445,"status":111,"phases":1089,"primaryCompletion":447,"start":448,"enrollment":101,"conditions":1090,"interventions":1091},[91,92],[450],[83,452],{"trials":1093,"activeCount":424,"soonestReadout":82},[1094],{"nctId":80,"briefTitle":81,"status":152,"phases":1095,"primaryCompletion":82,"completion":82,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1105},[93],"2016-06-06",107,[1099,1100,1101,1102,1103,1104],"Secondhand Smoke","Air Trapping","Tobacco","Airflow Limitation","Hyperinflation","Obstructive Lung Disease",[83],{"trials":1107,"activeCount":101},[],{"intervention":995,"totalTrials":526,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1128},{"trials":1111,"activeCount":101},[],{"trials":1113,"activeCount":101},[],{"trials":1115,"activeCount":101},[],{"trials":1117,"activeCount":101},[],{"trials":1119,"activeCount":424,"soonestReadout":1000},[1120,1124],{"nctId":984,"briefTitle":985,"status":132,"phases":1121,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":1122,"interventions":1123},[93],[991,992,993],[995,959],{"nctId":997,"briefTitle":998,"status":285,"phases":1125,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1126,"interventions":1127},[93],[991,1004,1005,1006,1007,1008,1009],[995,959],{"trials":1129,"activeCount":101},[],{"intervention":383,"totalTrials":526,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1153},{"trials":1133,"activeCount":101},[],{"trials":1135,"activeCount":101},[],{"trials":1137,"activeCount":101},[],{"trials":1139,"activeCount":101},[],{"trials":1141,"activeCount":424,"soonestReadout":363},[1142,1149],{"nctId":1143,"briefTitle":1144,"status":132,"phases":1145,"primaryCompletion":205,"completion":205,"start":1146,"enrollment":31,"conditions":1147,"interventions":1148},"NCT01511315","The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment",[93],"2012-03",[366],[383],{"nctId":359,"briefTitle":360,"status":361,"phases":1150,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1151,"interventions":1152},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1154,"activeCount":101},[],{"intervention":1156,"totalTrials":526,"cells":1157},"Lemborexant",{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1187},{"trials":1159,"activeCount":101},[],{"trials":1161,"activeCount":101},[],{"trials":1163,"activeCount":101},[],{"trials":1165,"activeCount":101},[],{"trials":1167,"activeCount":424,"soonestReadout":1172},[1168,1177],{"nctId":1169,"briefTitle":1170,"status":285,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":1173,"enrollment":519,"conditions":1174,"interventions":1176},"NCT06874855","Lemborexant in Delayed Sleep Phase Syndrome",[93],"2027-05-31","2023-03-13",[1175],"Delayed Sleep Phase Syndrome",[1156],{"nctId":1178,"briefTitle":1179,"status":132,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1186},"NCT05344443","Lemborexant Shift Work Treatment Study",[93],"2024-11-30","2022-03-10",29,[1185],"Shift-Work Related Sleep Disturbance",[1156],{"trials":1188,"activeCount":101},[],{"intervention":1190,"totalTrials":526,"cells":1191},"Losartan",{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1208,"PHASE3":1210,"PHASE4":1212,"NA":1225},{"trials":1193,"activeCount":101},[],{"trials":1195,"activeCount":101},[1196],{"nctId":1197,"briefTitle":1198,"status":132,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT01087749","Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers",[90],"2012-12","2010-03",24,[1204],"Kidney Disease",[1206,1190,1207],"Propranolol","Eprosartan",{"trials":1209,"activeCount":101},[],{"trials":1211,"activeCount":101},[],{"trials":1213,"activeCount":424,"soonestReadout":1218},[1214],{"nctId":1215,"briefTitle":1216,"status":285,"phases":1217,"primaryCompletion":1218,"completion":1218,"start":1219,"enrollment":1220,"conditions":1221,"interventions":1224},"NCT04715568","Secondhand Tobacco Smoke and Cardiovascular Disease",[93],"2026-12-31","2021-03-30",100,[1222,1223],"Cardiovascular Diseases","Hypertension",[1190],{"trials":1226,"activeCount":101},[],{"intervention":1228,"totalTrials":526,"cells":1229},"Mirabegron",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1236,"PHASE4":1238,"NA":1268},{"trials":1231,"activeCount":101},[],{"trials":1233,"activeCount":101},[],{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[],{"trials":1239,"activeCount":424,"soonestReadout":1256},[1240,1252],{"nctId":1241,"briefTitle":1242,"status":132,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":806,"enrollment":1246,"conditions":1247,"interventions":1250},"NCT02436889","Treatment of Incontinence Without Memory Problems",[93],"2017-12","2018-07",23,[1248,1249],"Urge Incontinence","Urinary Incontinence, Urge",[1228,1251],"Tolterodine Tartrate",{"nctId":1253,"briefTitle":1254,"status":285,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1266},"NCT05362292","TReating Incontinence for Underlying Mental and Physical Health",[93],"2027-05-02","2027-08-02","2022-10-04",270,[1249,1261,1262,1263,1264,1265],"Urinary Incontinence","Overactive Bladder","Incontinence, Urge","Incontinence, Urinary","Incontinence",[1267,1228],"Tolterodine Tartrate ER",{"trials":1269,"activeCount":101},[],{"intervention":394,"totalTrials":526,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1278,"PHASE4":1280,"NA":1294},{"trials":1273,"activeCount":101},[],{"trials":1275,"activeCount":101},[],{"trials":1277,"activeCount":101},[],{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":424,"soonestReadout":363},[1282,1290],{"nctId":1283,"briefTitle":1284,"status":132,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":792,"conditions":1288,"interventions":1289},"NCT04541329","Predicting Inflammatory Skin Disease Response to IL-23 Blockade",[93],"2023-01-15","2020-09-16",[652],[394],{"nctId":359,"briefTitle":360,"status":361,"phases":1291,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1292,"interventions":1293},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1295,"activeCount":101},[],{"intervention":379,"totalTrials":526,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1320},{"trials":1299,"activeCount":101},[],{"trials":1301,"activeCount":101},[],{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":101},[],{"trials":1307,"activeCount":424,"soonestReadout":363},[1308,1316],{"nctId":1309,"briefTitle":1310,"status":132,"phases":1311,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":519,"conditions":1314,"interventions":1315},"NCT02592018","Immunologic Response to Secukinumab in Plaque Psoriasis",[93],"2018-12","2016-10",[366],[379],{"nctId":359,"briefTitle":360,"status":361,"phases":1317,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1318,"interventions":1319},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1321,"activeCount":101},[],{"intervention":1323,"totalTrials":424,"cells":1324},"Atropine 1%",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1345},{"trials":1326,"activeCount":101},[],{"trials":1328,"activeCount":101},[],{"trials":1330,"activeCount":101},[],{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":424,"soonestReadout":1339},[1335],{"nctId":1336,"briefTitle":1337,"status":285,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":16,"conditions":1342,"interventions":1344},"NCT07434635","APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes",[93],"2028-02","2029-02","2026-02",[1343],"Eye Disorders",[1323],{"trials":1346,"activeCount":101},[],{"intervention":1348,"totalTrials":424,"cells":1349},"Multiple standard of care antibiotics for appendicitis, at physicians' discretion",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1369},{"trials":1351,"activeCount":101},[],{"trials":1353,"activeCount":101},[],{"trials":1355,"activeCount":101},[],{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":424,"soonestReadout":343},[1360],{"nctId":1361,"briefTitle":1362,"status":285,"phases":1363,"primaryCompletion":343,"completion":343,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1368},"NCT05966454","Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure - UCSF",[93],"2023-06-06",145,[1367],"Appendicitis",[1348,1348],{"trials":1370,"activeCount":101},[],{"intervention":466,"totalTrials":424,"cells":1372},{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1381,"NA":1387},{"trials":1374,"activeCount":101},[],{"trials":1376,"activeCount":101},[],{"trials":1378,"activeCount":101},[],{"trials":1380,"activeCount":101},[],{"trials":1382,"activeCount":424,"soonestReadout":459},[1383],{"nctId":456,"briefTitle":457,"status":285,"phases":1384,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":1385,"interventions":1386},[93],[464],[466,467],{"trials":1388,"activeCount":101},[],{"intervention":1390,"totalTrials":424,"cells":1391},"Magnesium sulfate administration",{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1398,"PHASE4":1400,"NA":1416},{"trials":1393,"activeCount":101},[],{"trials":1395,"activeCount":101},[],{"trials":1397,"activeCount":101},[],{"trials":1399,"activeCount":101},[],{"trials":1401,"activeCount":424,"soonestReadout":1406},[1402],{"nctId":1403,"briefTitle":1404,"status":285,"phases":1405,"primaryCompletion":1406,"completion":1406,"start":1407,"enrollment":1060,"conditions":1408,"interventions":1415},"NCT06975072","Effect of Magnesium on Neuromonitoring",[93],"2026-04-30","2025-07-01",[1409,1410,1411,1412,1413,1414],"Spine","Pain","Spine Surgery","Spine Surgery With Neuromonitoring","Spine Surgery With Motor Evoked Potential Monitoring","Spine Fusion",[1390],{"trials":1417,"activeCount":101},[],{"intervention":1419,"totalTrials":424,"cells":1420},"Letrozole 2.5mg",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1429,"NA":1445},{"trials":1422,"activeCount":101},[],{"trials":1424,"activeCount":101},[],{"trials":1426,"activeCount":101},[],{"trials":1428,"activeCount":101},[],{"trials":1430,"activeCount":424,"soonestReadout":1435},[1431],{"nctId":1432,"briefTitle":1433,"status":285,"phases":1434,"primaryCompletion":1435,"completion":1436,"start":1437,"enrollment":1438,"conditions":1439,"interventions":1444},"NCT06143631","Prescription of Letrozole for Uterine Myoma",[93],"2027-09-06","2027-12-13","2024-07-24",140,[1440,1441,1442,1443],"Leiomyoma, Uterine","Leiomyoma","Fibroid","Fibroid Uterus",[1419],{"trials":1446,"activeCount":101},[],{"intervention":1448,"totalTrials":424,"cells":1449},"Pramipexole",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1458,"NA":1473},{"trials":1451,"activeCount":101},[],{"trials":1453,"activeCount":101},[],{"trials":1455,"activeCount":101},[],{"trials":1457,"activeCount":101},[],{"trials":1459,"activeCount":424,"soonestReadout":1464},[1460],{"nctId":1461,"briefTitle":1462,"status":691,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1470},"NCT06580041","Precision Care for Major Depressive Disorder",[93],"2029-09-01","2024-11-12",150,[1468,27,1469],"Major Depressive Disorder","Depressive Disorder, Major",[1448,1471,1472],"Methylphenidate","Phenelzine",{"trials":1474,"activeCount":101},[],{"intervention":1471,"totalTrials":424,"cells":1476},{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1485,"NA":1491},{"trials":1478,"activeCount":101},[],{"trials":1480,"activeCount":101},[],{"trials":1482,"activeCount":101},[],{"trials":1484,"activeCount":101},[],{"trials":1486,"activeCount":424,"soonestReadout":1464},[1487],{"nctId":1461,"briefTitle":1462,"status":691,"phases":1488,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1489,"interventions":1490},[93],[1468,27,1469],[1448,1471,1472],{"trials":1492,"activeCount":101},[],{"intervention":1472,"totalTrials":424,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1509},{"trials":1496,"activeCount":101},[],{"trials":1498,"activeCount":101},[],{"trials":1500,"activeCount":101},[],{"trials":1502,"activeCount":101},[],{"trials":1504,"activeCount":424,"soonestReadout":1464},[1505],{"nctId":1461,"briefTitle":1462,"status":691,"phases":1506,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":1466,"conditions":1507,"interventions":1508},[93],[1468,27,1469],[1448,1471,1472],{"trials":1510,"activeCount":101},[],{"intervention":78,"totalTrials":424,"cells":1512},{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1531},{"trials":1514,"activeCount":101},[],{"trials":1516,"activeCount":101},[],{"trials":1518,"activeCount":101},[],{"trials":1520,"activeCount":101},[],{"trials":1522,"activeCount":424,"soonestReadout":77},[1523],{"nctId":75,"briefTitle":76,"status":152,"phases":1524,"primaryCompletion":77,"completion":1525,"start":1526,"enrollment":434,"conditions":1527,"interventions":1529},[93],"2026-07-31","2023-06-22",[1528,902],"Ocular Rosacea",[78,1530],"Doxycycline 200 MG",{"trials":1532,"activeCount":101},[],{"intervention":1530,"totalTrials":424,"cells":1534},{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1543,"NA":1549},{"trials":1536,"activeCount":101},[],{"trials":1538,"activeCount":101},[],{"trials":1540,"activeCount":101},[],{"trials":1542,"activeCount":101},[],{"trials":1544,"activeCount":424,"soonestReadout":77},[1545],{"nctId":75,"briefTitle":76,"status":152,"phases":1546,"primaryCompletion":77,"completion":1525,"start":1526,"enrollment":434,"conditions":1547,"interventions":1548},[93],[1528,902],[78,1530],{"trials":1550,"activeCount":101},[],{"intervention":1552,"totalTrials":424,"cells":1553},"Injectable buprenorphine",{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1573},{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":101},[],{"trials":1559,"activeCount":101},[],{"trials":1561,"activeCount":101},[],{"trials":1563,"activeCount":424,"soonestReadout":694},[1564],{"nctId":1565,"briefTitle":1566,"status":361,"phases":1567,"primaryCompletion":694,"completion":694,"start":649,"enrollment":434,"conditions":1568,"interventions":1571},"NCT07469501","Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation",[93],[1569,1570],"Opioid Use Disorder","Fentanyl",[1552,1572],"Sublingual Buprenorphine",{"trials":1574,"activeCount":101},[],{"intervention":1572,"totalTrials":424,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1585,"NA":1591},{"trials":1578,"activeCount":101},[],{"trials":1580,"activeCount":101},[],{"trials":1582,"activeCount":101},[],{"trials":1584,"activeCount":101},[],{"trials":1586,"activeCount":424,"soonestReadout":694},[1587],{"nctId":1565,"briefTitle":1566,"status":361,"phases":1588,"primaryCompletion":694,"completion":694,"start":649,"enrollment":434,"conditions":1589,"interventions":1590},[93],[1569,1570],[1552,1572],{"trials":1592,"activeCount":101},[],{"intervention":58,"totalTrials":424,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1612},{"trials":1596,"activeCount":101},[],{"trials":1598,"activeCount":101},[],{"trials":1600,"activeCount":101},[],{"trials":1602,"activeCount":101},[],{"trials":1604,"activeCount":424,"soonestReadout":57},[1605],{"nctId":55,"briefTitle":56,"status":361,"phases":1606,"primaryCompletion":57,"completion":57,"start":1607,"enrollment":1220,"conditions":1608,"interventions":1611},[93],"2024-09-30",[1609,1610],"Dilation","Pupil Reaction Absent",[58],{"trials":1613,"activeCount":101},[],{"intervention":1615,"totalTrials":424,"cells":1616},"Dropless Regimen",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1623,"PHASE4":1625,"NA":1641},{"trials":1618,"activeCount":101},[],{"trials":1620,"activeCount":101},[],{"trials":1622,"activeCount":101},[],{"trials":1624,"activeCount":101},[],{"trials":1626,"activeCount":424,"soonestReadout":1631},[1627],{"nctId":1628,"briefTitle":1629,"status":285,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1639},"NCT05157113","Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population",[93],"2026-06-01","2022-05-31",70,[1635,992,1636,1637,1638],"Cataract","Compliance, Patient","Compliance, Medication","Satisfaction, Patient",[1615,1640],"Standard Regimen",{"trials":1642,"activeCount":101},[],{"intervention":1640,"totalTrials":424,"cells":1644},{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1651,"PHASE4":1653,"NA":1659},{"trials":1646,"activeCount":101},[],{"trials":1648,"activeCount":101},[],{"trials":1650,"activeCount":101},[],{"trials":1652,"activeCount":101},[],{"trials":1654,"activeCount":424,"soonestReadout":1631},[1655],{"nctId":1628,"briefTitle":1629,"status":285,"phases":1656,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1657,"interventions":1658},[93],[1635,992,1636,1637,1638],[1615,1640],{"trials":1660,"activeCount":101},[],{"intervention":1662,"totalTrials":424,"cells":1663},"Study Drug Placebo",{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1670,"PHASE4":1672,"NA":1686},{"trials":1665,"activeCount":101},[],{"trials":1667,"activeCount":101},[],{"trials":1669,"activeCount":101},[],{"trials":1671,"activeCount":101},[],{"trials":1673,"activeCount":424,"soonestReadout":1678},[1674],{"nctId":1675,"briefTitle":1676,"status":691,"phases":1677,"primaryCompletion":1678,"completion":1678,"start":1679,"enrollment":1680,"conditions":1681,"interventions":1685},"NCT07322146","Trial of Reducing Inpatient Antibiotic Durations in Children",[93],"2031-08","2026-02-13",1200,[1682,1683,1684],"Pneumonia","Skin and Soft Tissue (SST) Infection","Urinary Tract Infections (UTIs)",[1662],{"trials":1687,"activeCount":101},[],{"intervention":1689,"totalTrials":424,"cells":1690},"Vaseline",{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1697,"PHASE4":1699,"NA":1711},{"trials":1692,"activeCount":101},[],{"trials":1694,"activeCount":101},[],{"trials":1696,"activeCount":101},[],{"trials":1698,"activeCount":101},[],{"trials":1700,"activeCount":424,"soonestReadout":351},[1701],{"nctId":1702,"briefTitle":1703,"status":285,"phases":1704,"primaryCompletion":351,"completion":351,"start":1705,"enrollment":34,"conditions":1706,"interventions":1710},"NCT06750653","Skin Barrier Function and Inflammation in Aging: The BIA Study",[93],"2025-02-06",[1707,1708,1709],"Inflammation","Skin Inflammation","Aging",[1689],{"trials":1712,"activeCount":101},[],{"intervention":1714,"totalTrials":424,"cells":1715},"Hormone Replacement Therapy",{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1736},{"trials":1717,"activeCount":101},[],{"trials":1719,"activeCount":101},[],{"trials":1721,"activeCount":101},[],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":424,"soonestReadout":693},[1726],{"nctId":1727,"briefTitle":1728,"status":361,"phases":1729,"primaryCompletion":693,"completion":693,"start":364,"enrollment":1730,"conditions":1731,"interventions":1734},"NCT07278323","Frozen Shoulder and Hormone Replacement Therapy",[93],60,[1732,1733],"Adhesive Capsulitis of the Shoulder","Frozen Shoulder",[1714,1735],"Corticosteroid and 1%lidocain",{"trials":1737,"activeCount":101},[],{"intervention":1735,"totalTrials":424,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1746,"PHASE4":1748,"NA":1754},{"trials":1741,"activeCount":101},[],{"trials":1743,"activeCount":101},[],{"trials":1745,"activeCount":101},[],{"trials":1747,"activeCount":101},[],{"trials":1749,"activeCount":424,"soonestReadout":693},[1750],{"nctId":1727,"briefTitle":1728,"status":361,"phases":1751,"primaryCompletion":693,"completion":693,"start":364,"enrollment":1730,"conditions":1752,"interventions":1753},[93],[1732,1733],[1714,1735],{"trials":1755,"activeCount":101},[],{"intervention":1757,"totalTrials":424,"cells":1758},"Platelet Rich Plasma",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1767,"NA":1781},{"trials":1760,"activeCount":101},[],{"trials":1762,"activeCount":101},[],{"trials":1764,"activeCount":101},[],{"trials":1766,"activeCount":101},[],{"trials":1768,"activeCount":424,"soonestReadout":1773},[1769],{"nctId":1770,"briefTitle":1771,"status":361,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1060,"conditions":1776,"interventions":1780},"NCT07491367","Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems",[93],"2028-03","2028-09","2026-03",[1777,1778,1757,1779],"Knee Osteoarthristis","Cartilage Damage","Platelet Rich Plasma Injection",[1757],{"trials":1782,"activeCount":101},[],{"intervention":1784,"totalTrials":424,"cells":1785},"Azithromycin at Baseline",{"EARLY_PHASE1":1786,"PHASE1":1788,"PHASE2":1790,"PHASE3":1792,"PHASE4":1794,"NA":1809},{"trials":1787,"activeCount":101},[],{"trials":1789,"activeCount":101},[],{"trials":1791,"activeCount":101},[],{"trials":1793,"activeCount":101},[],{"trials":1795,"activeCount":424,"soonestReadout":1800},[1796],{"nctId":1797,"briefTitle":1798,"status":361,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":1802,"conditions":1803,"interventions":1807},"NCT05763693","Vitality in Infants Via Azithromycin for Neonates Trial",[93],"2030-04","2026-04",4000,[1804,1805,1806],"Neonatal Death","Infectious Disease","Nutritional Deficiency",[1784,1808],"Azithromycin at Day 21",{"trials":1810,"activeCount":101},[],{"intervention":1808,"totalTrials":424,"cells":1812},{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1821,"NA":1827},{"trials":1814,"activeCount":101},[],{"trials":1816,"activeCount":101},[],{"trials":1818,"activeCount":101},[],{"trials":1820,"activeCount":101},[],{"trials":1822,"activeCount":424,"soonestReadout":1800},[1823],{"nctId":1797,"briefTitle":1798,"status":361,"phases":1824,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":1802,"conditions":1825,"interventions":1826},[93],[1804,1805,1806],[1784,1808],{"trials":1828,"activeCount":101},[],{"intervention":1830,"totalTrials":424,"cells":1831},"n-acetylcystine (NAC)+ albuterol",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1840,"NA":1851},{"trials":1833,"activeCount":101},[],{"trials":1835,"activeCount":101},[],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":101},[],{"trials":1841,"activeCount":424,"soonestReadout":1846},[1842],{"nctId":1843,"briefTitle":1844,"status":285,"phases":1845,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":28,"conditions":1848,"interventions":1850},"NCT06152653","The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)",[93],"2027-04","2024-04-09",[36,1849],"COPD",[1830],{"trials":1852,"activeCount":101},[],{"intervention":1854,"totalTrials":424,"cells":1855},"Dolutegravir",{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1876},{"trials":1857,"activeCount":101},[],{"trials":1859,"activeCount":101},[],{"trials":1861,"activeCount":101},[],{"trials":1863,"activeCount":101},[],{"trials":1865,"activeCount":424,"soonestReadout":694},[1866],{"nctId":1867,"briefTitle":1868,"status":152,"phases":1869,"primaryCompletion":694,"completion":1870,"start":1871,"enrollment":1872,"conditions":1873,"interventions":1874},"NCT02656511","Immediate Initiation of Antiretroviral Therapy During \"Hyperacute\" HIV Infection",[93],"2028-05","2015-12",74,[15],[1854,1875],"Emtricitabine\u002FTenofovir",{"trials":1877,"activeCount":101},[],{"intervention":1875,"totalTrials":424,"cells":1879},{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1886,"PHASE4":1888,"NA":1894},{"trials":1881,"activeCount":101},[],{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[],{"trials":1889,"activeCount":424,"soonestReadout":694},[1890],{"nctId":1867,"briefTitle":1868,"status":152,"phases":1891,"primaryCompletion":694,"completion":1870,"start":1871,"enrollment":1872,"conditions":1892,"interventions":1893},[93],[15],[1854,1875],{"trials":1895,"activeCount":101},[],{"intervention":1897,"totalTrials":424,"cells":1898},"Florbetapir F 18",{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1903,"PHASE3":1905,"PHASE4":1907,"NA":1918},{"trials":1900,"activeCount":101},[],{"trials":1902,"activeCount":101},[],{"trials":1904,"activeCount":101},[],{"trials":1906,"activeCount":101},[],{"trials":1908,"activeCount":424,"soonestReadout":649},[1909],{"nctId":1910,"briefTitle":1911,"status":152,"phases":1912,"primaryCompletion":649,"completion":649,"start":1913,"enrollment":1914,"conditions":1915,"interventions":1917},"NCT01606488","Effects of Brain Beta-Amyloid on Postoperative Cognition",[93],"2012-05",66,[1916],"Postoperative Cognitive Dysfunction",[1897],{"trials":1919,"activeCount":101},[],{"intervention":369,"totalTrials":424,"cells":1921},{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1936},{"trials":1923,"activeCount":101},[],{"trials":1925,"activeCount":101},[],{"trials":1927,"activeCount":101},[],{"trials":1929,"activeCount":101},[],{"trials":1931,"activeCount":424,"soonestReadout":363},[1932],{"nctId":359,"briefTitle":360,"status":361,"phases":1933,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1934,"interventions":1935},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1937,"activeCount":101},[],{"intervention":371,"totalTrials":424,"cells":1939},{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1946,"PHASE4":1948,"NA":1954},{"trials":1941,"activeCount":101},[],{"trials":1943,"activeCount":101},[],{"trials":1945,"activeCount":101},[],{"trials":1947,"activeCount":101},[],{"trials":1949,"activeCount":424,"soonestReadout":363},[1950],{"nctId":359,"briefTitle":360,"status":361,"phases":1951,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1952,"interventions":1953},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1955,"activeCount":101},[],{"intervention":372,"totalTrials":424,"cells":1957},{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1966,"NA":1972},{"trials":1959,"activeCount":101},[],{"trials":1961,"activeCount":101},[],{"trials":1963,"activeCount":101},[],{"trials":1965,"activeCount":101},[],{"trials":1967,"activeCount":424,"soonestReadout":363},[1968],{"nctId":359,"briefTitle":360,"status":361,"phases":1969,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1970,"interventions":1971},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1973,"activeCount":101},[],{"intervention":373,"totalTrials":424,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1984,"NA":1990},{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":101},[],{"trials":1983,"activeCount":101},[],{"trials":1985,"activeCount":424,"soonestReadout":363},[1986],{"nctId":359,"briefTitle":360,"status":361,"phases":1987,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":1988,"interventions":1989},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":1991,"activeCount":101},[],{"intervention":375,"totalTrials":424,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2002,"NA":2008},{"trials":1995,"activeCount":101},[],{"trials":1997,"activeCount":101},[],{"trials":1999,"activeCount":101},[],{"trials":2001,"activeCount":101},[],{"trials":2003,"activeCount":424,"soonestReadout":363},[2004],{"nctId":359,"briefTitle":360,"status":361,"phases":2005,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2006,"interventions":2007},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2009,"activeCount":101},[],{"intervention":377,"totalTrials":424,"cells":2011},{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2018,"PHASE4":2020,"NA":2026},{"trials":2013,"activeCount":101},[],{"trials":2015,"activeCount":101},[],{"trials":2017,"activeCount":101},[],{"trials":2019,"activeCount":101},[],{"trials":2021,"activeCount":424,"soonestReadout":363},[2022],{"nctId":359,"briefTitle":360,"status":361,"phases":2023,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2024,"interventions":2025},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2027,"activeCount":101},[],{"intervention":380,"totalTrials":424,"cells":2029},{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2036,"PHASE4":2038,"NA":2044},{"trials":2031,"activeCount":101},[],{"trials":2033,"activeCount":101},[],{"trials":2035,"activeCount":101},[],{"trials":2037,"activeCount":101},[],{"trials":2039,"activeCount":424,"soonestReadout":363},[2040],{"nctId":359,"briefTitle":360,"status":361,"phases":2041,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2042,"interventions":2043},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2045,"activeCount":101},[],{"intervention":381,"totalTrials":424,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2054,"PHASE4":2056,"NA":2062},{"trials":2049,"activeCount":101},[],{"trials":2051,"activeCount":101},[],{"trials":2053,"activeCount":101},[],{"trials":2055,"activeCount":101},[],{"trials":2057,"activeCount":424,"soonestReadout":363},[2058],{"nctId":359,"briefTitle":360,"status":361,"phases":2059,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2060,"interventions":2061},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2063,"activeCount":101},[],{"intervention":382,"totalTrials":424,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2072,"PHASE4":2074,"NA":2080},{"trials":2067,"activeCount":101},[],{"trials":2069,"activeCount":101},[],{"trials":2071,"activeCount":101},[],{"trials":2073,"activeCount":101},[],{"trials":2075,"activeCount":424,"soonestReadout":363},[2076],{"nctId":359,"briefTitle":360,"status":361,"phases":2077,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2078,"interventions":2079},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2081,"activeCount":101},[],{"intervention":384,"totalTrials":424,"cells":2083},{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2088,"PHASE3":2090,"PHASE4":2092,"NA":2098},{"trials":2085,"activeCount":101},[],{"trials":2087,"activeCount":101},[],{"trials":2089,"activeCount":101},[],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":424,"soonestReadout":363},[2094],{"nctId":359,"briefTitle":360,"status":361,"phases":2095,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2096,"interventions":2097},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2099,"activeCount":101},[],{"intervention":386,"totalTrials":424,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2116},{"trials":2103,"activeCount":101},[],{"trials":2105,"activeCount":101},[],{"trials":2107,"activeCount":101},[],{"trials":2109,"activeCount":101},[],{"trials":2111,"activeCount":424,"soonestReadout":363},[2112],{"nctId":359,"briefTitle":360,"status":361,"phases":2113,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2114,"interventions":2115},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2117,"activeCount":101},[],{"intervention":387,"totalTrials":424,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2134},{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":101},[],{"trials":2127,"activeCount":101},[],{"trials":2129,"activeCount":424,"soonestReadout":363},[2130],{"nctId":359,"briefTitle":360,"status":361,"phases":2131,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2132,"interventions":2133},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2135,"activeCount":101},[],{"intervention":388,"totalTrials":424,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2144,"PHASE4":2146,"NA":2152},{"trials":2139,"activeCount":101},[],{"trials":2141,"activeCount":101},[],{"trials":2143,"activeCount":101},[],{"trials":2145,"activeCount":101},[],{"trials":2147,"activeCount":424,"soonestReadout":363},[2148],{"nctId":359,"briefTitle":360,"status":361,"phases":2149,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2150,"interventions":2151},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2153,"activeCount":101},[],{"intervention":390,"totalTrials":424,"cells":2155},{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2162,"PHASE4":2164,"NA":2170},{"trials":2157,"activeCount":101},[],{"trials":2159,"activeCount":101},[],{"trials":2161,"activeCount":101},[],{"trials":2163,"activeCount":101},[],{"trials":2165,"activeCount":424,"soonestReadout":363},[2166],{"nctId":359,"briefTitle":360,"status":361,"phases":2167,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2168,"interventions":2169},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2171,"activeCount":101},[],{"intervention":393,"totalTrials":424,"cells":2173},{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2182,"NA":2188},{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":101},[],{"trials":2179,"activeCount":101},[],{"trials":2181,"activeCount":101},[],{"trials":2183,"activeCount":424,"soonestReadout":363},[2184],{"nctId":359,"briefTitle":360,"status":361,"phases":2185,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2186,"interventions":2187},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2189,"activeCount":101},[],{"intervention":395,"totalTrials":424,"cells":2191},{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2198,"PHASE4":2200,"NA":2206},{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":101},[],{"trials":2197,"activeCount":101},[],{"trials":2199,"activeCount":101},[],{"trials":2201,"activeCount":424,"soonestReadout":363},[2202],{"nctId":359,"briefTitle":360,"status":361,"phases":2203,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2204,"interventions":2205},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2207,"activeCount":101},[],{"intervention":396,"totalTrials":424,"cells":2209},{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2216,"PHASE4":2218,"NA":2224},{"trials":2211,"activeCount":101},[],{"trials":2213,"activeCount":101},[],{"trials":2215,"activeCount":101},[],{"trials":2217,"activeCount":101},[],{"trials":2219,"activeCount":424,"soonestReadout":363},[2220],{"nctId":359,"briefTitle":360,"status":361,"phases":2221,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2222,"interventions":2223},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2225,"activeCount":101},[],{"intervention":398,"totalTrials":424,"cells":2227},{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2242},{"trials":2229,"activeCount":101},[],{"trials":2231,"activeCount":101},[],{"trials":2233,"activeCount":101},[],{"trials":2235,"activeCount":101},[],{"trials":2237,"activeCount":424,"soonestReadout":363},[2238],{"nctId":359,"briefTitle":360,"status":361,"phases":2239,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2240,"interventions":2241},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2243,"activeCount":101},[],{"intervention":399,"totalTrials":424,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2260},{"trials":2247,"activeCount":101},[],{"trials":2249,"activeCount":101},[],{"trials":2251,"activeCount":101},[],{"trials":2253,"activeCount":101},[],{"trials":2255,"activeCount":424,"soonestReadout":363},[2256],{"nctId":359,"briefTitle":360,"status":361,"phases":2257,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2258,"interventions":2259},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2261,"activeCount":101},[],{"intervention":401,"totalTrials":424,"cells":2263},{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2270,"PHASE4":2272,"NA":2278},{"trials":2265,"activeCount":101},[],{"trials":2267,"activeCount":101},[],{"trials":2269,"activeCount":101},[],{"trials":2271,"activeCount":101},[],{"trials":2273,"activeCount":424,"soonestReadout":363},[2274],{"nctId":359,"briefTitle":360,"status":361,"phases":2275,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2276,"interventions":2277},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2279,"activeCount":101},[],{"intervention":402,"totalTrials":424,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2290,"NA":2296},{"trials":2283,"activeCount":101},[],{"trials":2285,"activeCount":101},[],{"trials":2287,"activeCount":101},[],{"trials":2289,"activeCount":101},[],{"trials":2291,"activeCount":424,"soonestReadout":363},[2292],{"nctId":359,"briefTitle":360,"status":361,"phases":2293,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2294,"interventions":2295},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2297,"activeCount":101},[],{"intervention":1267,"totalTrials":424,"cells":2299},{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2306,"PHASE4":2308,"NA":2314},{"trials":2301,"activeCount":101},[],{"trials":2303,"activeCount":101},[],{"trials":2305,"activeCount":101},[],{"trials":2307,"activeCount":101},[],{"trials":2309,"activeCount":424,"soonestReadout":1256},[2310],{"nctId":1253,"briefTitle":1254,"status":285,"phases":2311,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":2312,"interventions":2313},[93],[1249,1261,1262,1263,1264,1265],[1267,1228],{"trials":2315,"activeCount":101},[],{"intervention":2317,"totalTrials":424,"cells":2318},"methylprednisolone, prednisolone, prednisone",{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2341},{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":101},[],{"trials":2326,"activeCount":101},[],{"trials":2328,"activeCount":424,"soonestReadout":2333},[2329],{"nctId":2330,"briefTitle":2331,"status":691,"phases":2332,"primaryCompletion":2333,"completion":2334,"start":650,"enrollment":2335,"conditions":2336,"interventions":2340},"NCT06040255","Focal Cerebral Arteriopathy Steroid Trial",[93],"2029-07-31","2030-01-31",80,[2337,2338,2339],"Pediatric Stroke","Arteriopathy","Arterial Ischemic Stroke",[2317],{"trials":2342,"activeCount":101},[],{"intervention":686,"totalTrials":541,"cells":2344},{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2400,"PHASE4":2423,"NA":2429},{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[],{"trials":2350,"activeCount":101},[2351,2363,2367,2389],{"nctId":2352,"briefTitle":2353,"status":111,"phases":2354,"primaryCompletion":714,"start":2355,"enrollment":101,"conditions":2356,"interventions":2361},"NCT00301912","Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",[91],"2002-01",[2357,2358,679,717,2359,680,2360],"Anemia","Chronic Myeloproliferative Disorders","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Diseases",[720,684,685,686,2362],"tacrolimus",{"nctId":670,"briefTitle":671,"status":132,"phases":2364,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":2365,"interventions":2366},[91],[677,678,679,680,681],[683,684,661,685,686,687],{"nctId":2368,"briefTitle":2369,"status":120,"phases":2370,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":2374,"interventions":2376},"NCT00632827","Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)",[91],"2014-06-23","2016-06-23","2008-07-01",[2375],"Peripheral T-Cell Lymphoma",[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],"Gemcitabine","Navelbine","Doxorubicin Hydrochloride Liposome","Granulocyte-colony stimulating factor","Pegfilgrastim","Cyclophosphamide","Vincristine","Doxorubicin Hydrochloride","Cytarabine","Etoposide","Carmustine","Denileukin diftitox",{"nctId":2390,"briefTitle":2391,"status":120,"phases":2392,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":34,"conditions":2396,"interventions":2397},"NCT00616122","Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer",[90,91],"2011-03-01","2012-12-01","2006-03-01",[24],[2398,686,2399],"cyclophosphamide","sunitinib malate",{"trials":2401,"activeCount":101},[2402,2412],{"nctId":2403,"briefTitle":2404,"status":132,"phases":2405,"primaryCompletion":2406,"completion":2406,"start":2407,"enrollment":2335,"conditions":2408,"interventions":2410},"NCT01232920","First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial",[92],"2012-06","2010-10",[2409],"Uveitis",[385,2411],"Mycophenolate mofetil",{"nctId":2413,"briefTitle":2414,"status":132,"phases":2415,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":2419,"conditions":2420,"interventions":2421},"NCT01829295","Methotrexate and Mycophenolate Mofetil for UVEITIS",[92],"2018-02-21","2018-08-09","2013-08",216,[2409],[2411,385,2422],"Prednisone",{"trials":2424,"activeCount":424,"soonestReadout":363},[2425],{"nctId":359,"briefTitle":360,"status":361,"phases":2426,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2427,"interventions":2428},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2430,"activeCount":101},[2431,2446,2450,2459],{"nctId":2432,"briefTitle":2433,"status":132,"phases":2434,"primaryCompletion":2435,"completion":2436,"start":2437,"enrollment":345,"conditions":2438,"interventions":2440},"NCT00416819","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma",[94],"2005-12","2012-02","2003-09",[2439,717],"Brain and Central Nervous System Tumors",[720,2441,2442,2443,2444,686,2445],"rituximab","cytarabine","etoposide phosphate","leucovorin calcium","temozolomide",{"nctId":710,"briefTitle":711,"status":120,"phases":2447,"primaryCompletion":713,"completion":714,"start":715,"enrollment":555,"conditions":2448,"interventions":2449},[94],[679,717],[719,720,721,661,685,722,686],{"nctId":2451,"briefTitle":2452,"status":132,"phases":2453,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":353,"conditions":2457,"interventions":2458},"NCT00296023","Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer",[94],"2007-06","2008-06","1999-01",[2358,679,717,2359,680],[719,720,721,684,685,686,2362],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":2463,"start":2464,"enrollment":675,"conditions":2465,"interventions":2468},"NCT00295997","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia","UNKNOWN",[94],"2005-05",[2358,2466,679,717,2359,680,2467],"Kidney Cancer","Myelodysplastic\u002FMyeloproliferative Neoplasms",[719,720,2469,721,684,2398,685,686,2470,2362],"graft-versus-tumor induction therapy","mycophenolate mofetil",{"intervention":925,"totalTrials":2472,"cells":2473},9,{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2502,"PHASE4":2520,"NA":2551},{"trials":2475,"activeCount":101},[],{"trials":2477,"activeCount":101},[],{"trials":2479,"activeCount":101},[2480,2491],{"nctId":2481,"briefTitle":2482,"status":132,"phases":2483,"primaryCompletion":226,"completion":226,"start":2484,"enrollment":2335,"conditions":2485,"interventions":2486},"NCT02831023","Phase 2 Efficacy Study of Primaquine and Methylene Blue",[91],"2016-07",[322],[2487,2488,925,2489,2490],"Sulphadoxine-pyrimethamine","0.25 mg\u002Fkg primaquine","Methylene blue","Amodiaquine",{"nctId":2492,"briefTitle":2493,"status":132,"phases":2494,"primaryCompletion":205,"completion":205,"start":433,"enrollment":2495,"conditions":2496,"interventions":2497},"NCT01743820","Phase2a Primaquine Dose Escalation Study",[91],81,[322],[938,2498,2499,2500,2501],"0.125 mg\u002Fkg Primaquine","0.5 mg\u002Fkg Primaquine","0.25 mg\u002Fkg Primaquine","0.0625 mg\u002Fkg Primaquine",{"trials":2503,"activeCount":101},[2504,2508,2512],{"nctId":918,"briefTitle":919,"status":132,"phases":2505,"primaryCompletion":921,"completion":921,"start":236,"enrollment":922,"conditions":2506,"interventions":2507},[92],[322,18],[925,926,907],{"nctId":928,"briefTitle":929,"status":132,"phases":2509,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":2510,"interventions":2511},[92],[322],[936,937,938],{"nctId":2513,"briefTitle":2514,"status":132,"phases":2515,"primaryCompletion":2516,"completion":2516,"start":2517,"enrollment":1802,"conditions":2518,"interventions":2519},"NCT02315690","Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland",[92],"2017-07","2015-09",[322],[938],{"trials":2521,"activeCount":424,"soonestReadout":196},[2522,2530,2541],{"nctId":2523,"briefTitle":2524,"status":361,"phases":2525,"primaryCompletion":196,"completion":196,"start":2526,"enrollment":2527,"conditions":2528,"interventions":2529},"NCT07246525","Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission",[93],"2026-08-01",4800,[322],[938],{"nctId":2531,"briefTitle":2532,"status":132,"phases":2533,"primaryCompletion":2534,"completion":2534,"start":2535,"enrollment":2536,"conditions":2537,"interventions":2540},"NCT04487145","Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy",[93],"2022-04-11","2020-11-23",194,[2538,2539],"Drug-Drug Interaction","HIV Infection",[925],{"nctId":2542,"briefTitle":2543,"status":132,"phases":2544,"primaryCompletion":2545,"completion":2546,"start":236,"conditions":2547,"interventions":2549},"NCT00845533","Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso",[93],"2007-12","2009-01",[2548],"Uncomplicated Malaria",[2550],"Dihydroartemisinin-Piperaquine",{"trials":2552,"activeCount":101},[2553],{"nctId":2554,"briefTitle":2555,"status":132,"phases":2556,"primaryCompletion":309,"completion":877,"start":2557,"enrollment":2558,"conditions":2559,"interventions":2561},"NCT04864444","Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities",[94],"2021-06-19",10715,[2560,322],"Malaria,Falciparum",[925,2562],"Primaquine",{"intervention":2362,"totalTrials":2564,"cells":2565},6,{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2589,"PHASE3":2595,"PHASE4":2597,"NA":2603},{"trials":2567,"activeCount":101},[],{"trials":2569,"activeCount":101},[2570,2579],{"nctId":2571,"briefTitle":2572,"status":132,"phases":2573,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":792,"conditions":2576,"interventions":2577},"NCT00301951","Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer",[90],"2009-07","2004-09",[679,717,2359,680],[719,2578,684,685,2470,2362],"sargramostim",{"nctId":2580,"briefTitle":2581,"status":132,"phases":2582,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":407,"conditions":2585,"interventions":2586},"NCT00304018","Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer",[90],"2009-03","2002-10",[679,717,2359,680],[719,2578,684,2587,685,2588,2362],"etoposide","prednisone",{"trials":2590,"activeCount":101},[2591],{"nctId":2352,"briefTitle":2353,"status":111,"phases":2592,"primaryCompletion":714,"start":2355,"enrollment":101,"conditions":2593,"interventions":2594},[91],[2357,2358,679,717,2359,680,2360],[720,684,685,686,2362],{"trials":2596,"activeCount":101},[],{"trials":2598,"activeCount":424,"soonestReadout":363},[2599],{"nctId":359,"briefTitle":360,"status":361,"phases":2600,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2601,"interventions":2602},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2604,"activeCount":101},[2605,2609],{"nctId":2451,"briefTitle":2452,"status":132,"phases":2606,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":353,"conditions":2607,"interventions":2608},[94],[2358,679,717,2359,680],[719,720,721,684,685,686,2362],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":2610,"start":2464,"enrollment":675,"conditions":2611,"interventions":2612},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":2614,"totalTrials":526,"cells":2615},"etanercept",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2622,"PHASE4":2624,"NA":2630},{"trials":2617,"activeCount":101},[],{"trials":2619,"activeCount":101},[],{"trials":2621,"activeCount":101},[],{"trials":2623,"activeCount":101},[],{"trials":2625,"activeCount":424,"soonestReadout":363},[2626],{"nctId":359,"briefTitle":360,"status":361,"phases":2627,"primaryCompletion":363,"completion":363,"start":364,"enrollment":345,"conditions":2628,"interventions":2629},[93],[366,367],[369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,73,394,395,396,397,398,399,400,401,402],{"trials":2631,"activeCount":101},[2632],{"nctId":2633,"briefTitle":2634,"status":132,"phases":2635,"primaryCompletion":805,"completion":1146,"start":2636,"enrollment":751,"conditions":2637,"interventions":2638},"NCT00800982","Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis",[94],"2008-10",[366],[2614],{"intervention":2640,"totalTrials":526,"cells":2641},"Nicotine Replacement Therapy",{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2648,"PHASE4":2650,"NA":2664},{"trials":2643,"activeCount":101},[],{"trials":2645,"activeCount":101},[],{"trials":2647,"activeCount":101},[],{"trials":2649,"activeCount":101},[],{"trials":2651,"activeCount":424,"soonestReadout":740},[2652],{"nctId":2653,"briefTitle":2654,"status":285,"phases":2655,"primaryCompletion":740,"completion":740,"start":2656,"enrollment":1466,"conditions":2657,"interventions":2663},"NCT07148232","Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness",[93],"2025-11-14",[2658,2659,2660,2661,2662],"Tobacco Cessation","Tobacco Abstinence","Tobacco Use","Tobacco Use Cessation","Tobacco Dependence",[2640],{"trials":2665,"activeCount":101},[2666],{"nctId":2667,"briefTitle":2668,"status":132,"phases":2669,"primaryCompletion":236,"completion":236,"start":2670,"conditions":2671,"interventions":2676},"NCT00139516","Chinese Community Smoking Cessation Project",[94],"2001-09",[1222,2672,2673,2674,2675],"Heart Diseases","Lung Diseases","Diabetes Mellitus","Chronic Obstructive Pulmonary Disease",[2677],"nicotine replacement therapy",{"intervention":2679,"totalTrials":324,"cells":2680},"Valganciclovir",{"EARLY_PHASE1":2681,"PHASE1":2683,"PHASE2":2685,"PHASE3":2701,"PHASE4":2716,"NA":2727},{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":101},[],{"trials":2686,"activeCount":424,"soonestReadout":2691},[2687],{"nctId":2688,"briefTitle":2689,"status":361,"phases":2690,"primaryCompletion":2691,"completion":2692,"start":589,"enrollment":2693,"conditions":2694,"interventions":2699},"NCT07513623","Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II",[91],"2031-12-31","2032-10-31",117,[2695,2696,2697,2698],"Cytomegalovirus (CMV)","Anterior Uveitis","Infectious Uveitis","CMV Infection",[2679,2700],"Ganciclovir",{"trials":2702,"activeCount":424,"soonestReadout":2707},[2703],{"nctId":2704,"briefTitle":2705,"status":285,"phases":2706,"primaryCompletion":2707,"completion":2708,"start":2709,"enrollment":2710,"conditions":2711,"interventions":2714},"NCT06798909","Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients",[92],"2030-11-30","2031-05-31","2025-07-22",360,[2695,2712,2713],"Kidney Transplant; Complications","Kidney Diseases",[2679,2715],"Valganciclovir CMV Prophylaxis",{"trials":2717,"activeCount":101},[2718],{"nctId":2719,"briefTitle":2720,"status":132,"phases":2721,"primaryCompletion":2636,"completion":2722,"start":2723,"enrollment":751,"conditions":2724,"interventions":2726},"NCT00264290","Valganciclovir to Reduce T Cell Activation in HIV Infection",[93],"2008-11","2006-08",[18,2725],"Cytomegalovirus Infections",[2679],{"trials":2728,"activeCount":101},[],{"intervention":2730,"totalTrials":2564,"cells":2731},"Letrozole",{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2765,"PHASE3":2799,"PHASE4":2811,"NA":2822},{"trials":2733,"activeCount":101},[],{"trials":2735,"activeCount":101},[2736],{"nctId":2737,"briefTitle":2738,"status":132,"phases":2739,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":2741,"interventions":2756},"NCT03554044","T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer",[90],"2020-02-05",[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],"Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Estrogen Receptor Positive","HER2\u002FNeu Negative","Invasive Breast Carcinoma","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8","Recurrent Breast Carcinoma",[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],"Anastrozole","Exemestane","Fulvestrant","Paclitaxel","Talimogene Laherparepvec","Tamoxifen","Nab paclitaxel","Carboplatin",{"trials":2766,"activeCount":101},[2767,2778,2789],{"nctId":2768,"briefTitle":2769,"status":132,"phases":2770,"primaryCompletion":2771,"completion":2772,"start":2773,"enrollment":2774,"conditions":2775,"interventions":2776},"NCT00305825","Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery",[91],"2006-05-30","2016-05-24","2004-08",43,[24],[815,2777],"letrozole",{"nctId":2779,"briefTitle":2780,"status":132,"phases":2781,"primaryCompletion":2782,"completion":2783,"start":2784,"enrollment":2785,"conditions":2786,"interventions":2787},"NCT00290745","Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ",[90,91],"2009-07-31","2011-06-30","2002-02-19",79,[24],[2777,2788],"tamoxifen citrate",{"nctId":2790,"briefTitle":2791,"status":132,"phases":2792,"primaryCompletion":650,"completion":2793,"start":2794,"enrollment":1730,"conditions":2795,"interventions":2798},"NCT04002141","Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis",[91],"2025-01-01","2019-09-17",[2796,2797],"Endometriosis","Ovarian Hyperstimulation",[2730],{"trials":2800,"activeCount":424,"soonestReadout":2805},[2801],{"nctId":2802,"briefTitle":2803,"status":285,"phases":2804,"primaryCompletion":2805,"completion":2805,"start":2806,"enrollment":2807,"conditions":2808,"interventions":2810},"NCT03011684","Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial",[92],"2026-03-31","2016-07-21",309,[2809],"Infertility",[2762,2730],{"trials":2812,"activeCount":101},[2813],{"nctId":2814,"briefTitle":2815,"status":132,"phases":2816,"primaryCompletion":1244,"completion":1244,"start":2817,"enrollment":2818,"conditions":2819,"interventions":2821},"NCT02470741","Pilot of Letrozole for Uterine Myomas",[93],"2015-07",12,[1441,2820],"Uterine Fibroids",[2730],{"trials":2823,"activeCount":101},[],{"intervention":2825,"totalTrials":526,"cells":2826},"Moxifloxacin",{"EARLY_PHASE1":2827,"PHASE1":2829,"PHASE2":2831,"PHASE3":2833,"PHASE4":2850,"NA":2863},{"trials":2828,"activeCount":101},[],{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[],{"trials":2834,"activeCount":424,"soonestReadout":1678},[2835],{"nctId":2836,"briefTitle":2837,"status":285,"phases":2838,"primaryCompletion":1678,"completion":1678,"start":2839,"enrollment":2840,"conditions":2841,"interventions":2845},"NCT06441006","Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis",[91,92],"2025-10-03",400,[2842,2843,2844],"Tuberculosis, Pulmonary","Tuberculosis, Multidrug-Resistant","Tuberculosis, MDR",[2846,2847,2848,2825,2849],"Bedaquiline","Linezolid","Pretomanid","Control Arm FQ-S MDR\u002FRR-TB regimen, designed according to latest international guidelines",{"trials":2851,"activeCount":101},[2852],{"nctId":2853,"briefTitle":2854,"status":132,"phases":2855,"primaryCompletion":2856,"completion":778,"start":352,"enrollment":2857,"conditions":2858,"interventions":2862},"NCT04750655","Antibiotic Resistance In Eye Surgeries",[93],"2023-08-10",108,[2859,2860,2861],"Antibiotic Resistance","Ocular Surface Microbiome","Gut Resistome",[2825],{"trials":2864,"activeCount":101},[],{"intervention":2762,"totalTrials":407,"cells":2866},{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2875,"PHASE3":2908,"PHASE4":2914,"NA":2916},{"trials":2868,"activeCount":101},[],{"trials":2870,"activeCount":101},[2871],{"nctId":2737,"briefTitle":2738,"status":132,"phases":2872,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":2873,"interventions":2874},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"trials":2876,"activeCount":101},[2877,2888,2898],{"nctId":2878,"briefTitle":2879,"status":132,"phases":2880,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":1633,"conditions":2883,"interventions":2886},"NCT02384239","A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer",[91],"2021-01-31","2015-10-19",[2884,2885],"Metastatic Breast Cancer","Hormone Receptor Positive",[2887,2762,2759],"Palbociclib",{"nctId":2889,"briefTitle":2890,"status":120,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":424,"conditions":2894,"interventions":2895},"NCT04190056","Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer",[91],"2023-06-15","2021-03-11",[2746,2754],[2896,2762,2897],"Pembrolizumab","Vorinostat",{"nctId":2899,"briefTitle":2900,"status":120,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2904,"conditions":2905,"interventions":2907},"NCT02395627","Reversing Therapy Resistance With Epigenetic-Immune Modification",[91],"2019-06-08","2015-05-04",38,[2906],"Breast Neoplasms",[2762,2897,2896],{"trials":2909,"activeCount":424,"soonestReadout":2805},[2910],{"nctId":2802,"briefTitle":2803,"status":285,"phases":2911,"primaryCompletion":2805,"completion":2805,"start":2806,"enrollment":2807,"conditions":2912,"interventions":2913},[92],[2809],[2762,2730],{"trials":2915,"activeCount":101},[],{"trials":2917,"activeCount":101},[],{"intervention":2919,"totalTrials":526,"cells":2920},"Moxifloxacin Ophthalmic",{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2927,"PHASE4":2953,"NA":2955},{"trials":2922,"activeCount":101},[],{"trials":2924,"activeCount":101},[],{"trials":2926,"activeCount":101},[],{"trials":2928,"activeCount":424,"soonestReadout":343},[2929,2944],{"nctId":2930,"briefTitle":2931,"status":132,"phases":2932,"primaryCompletion":2933,"completion":2934,"start":2935,"enrollment":2936,"conditions":2937,"interventions":2940},"NCT05110001","Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction",[92],"2024-12-14","2025-06-30","2022-08-03",330,[2938,2939],"Acanthamoeba Keratitis","Fungal Keratitis",[2919,2941,2942,2943],"Chlorhexidine Gluconate","Natamycin","Rose Bengal",{"nctId":2945,"briefTitle":2946,"status":152,"phases":2947,"primaryCompletion":343,"completion":1218,"start":2948,"enrollment":1730,"conditions":2949,"interventions":2951},"NCT06271772","Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II",[92],"2024-07-01",[2950],"Bacterial Keratitis",[2952,2943,2919],"Difluprednate Ophthalmic",{"trials":2954,"activeCount":101},[],{"trials":2956,"activeCount":101},[],{"intervention":2943,"totalTrials":526,"cells":2958},{"EARLY_PHASE1":2959,"PHASE1":2961,"PHASE2":2963,"PHASE3":2965,"PHASE4":2975,"NA":2977},{"trials":2960,"activeCount":101},[],{"trials":2962,"activeCount":101},[],{"trials":2964,"activeCount":101},[],{"trials":2966,"activeCount":424,"soonestReadout":343},[2967,2971],{"nctId":2930,"briefTitle":2931,"status":132,"phases":2968,"primaryCompletion":2933,"completion":2934,"start":2935,"enrollment":2936,"conditions":2969,"interventions":2970},[92],[2938,2939],[2919,2941,2942,2943],{"nctId":2945,"briefTitle":2946,"status":152,"phases":2972,"primaryCompletion":343,"completion":1218,"start":2948,"enrollment":1730,"conditions":2973,"interventions":2974},[92],[2950],[2952,2943,2919],{"trials":2976,"activeCount":101},[],{"trials":2978,"activeCount":101},[],{"intervention":2980,"totalTrials":526,"cells":2981},"Ketamine",{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2997,"PHASE3":2999,"PHASE4":3010,"NA":3012},{"trials":2983,"activeCount":101},[],{"trials":2985,"activeCount":101},[2986],{"nctId":2987,"briefTitle":2988,"status":120,"phases":2989,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":424,"conditions":2992,"interventions":2995},"NCT03933865","Acute Pain Management in Patients on Opioid Replacement Therapy",[90],"2022-02-24","2018-10-31",[2993,2994],"Opioid-use Disorder","Pain, Acute",[2996,2980,179],"HYDROmorphone Injectable Solution",{"trials":2998,"activeCount":101},[],{"trials":3000,"activeCount":424,"soonestReadout":3005},[3001],{"nctId":3002,"briefTitle":3003,"status":285,"phases":3004,"primaryCompletion":3005,"completion":3005,"start":174,"enrollment":1060,"conditions":3006,"interventions":3009},"NCT06140927","Effect of Ketamine on Intraoperative Motor Evoked Potentials",[92],"2026-12-01",[1414,3007,3008],"Spine Tumor","Spinal Stenosis",[2980],{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":101},[],{"intervention":3015,"totalTrials":424,"cells":3016},"Ropivacaine + Fentanyl",{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3021,"PHASE3":3023,"PHASE4":3035,"NA":3037},{"trials":3018,"activeCount":101},[],{"trials":3020,"activeCount":101},[],{"trials":3022,"activeCount":101},[],{"trials":3024,"activeCount":424,"soonestReadout":1525},[3025],{"nctId":3026,"briefTitle":3027,"status":285,"phases":3028,"primaryCompletion":1525,"completion":1525,"start":3029,"enrollment":434,"conditions":3030,"interventions":3034},"NCT07076368","Ropivacaine and Fentanyl for Labor Epidural Initiation",[92],"2025-10-24",[3031,3032,3033],"Pregnancy","Labor and Delivery","Labor Analgesia",[3015],{"trials":3036,"activeCount":101},[],{"trials":3038,"activeCount":101},[],{"intervention":2715,"totalTrials":424,"cells":3040},{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3053,"NA":3055},{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":424,"soonestReadout":2707},[3049],{"nctId":2704,"briefTitle":2705,"status":285,"phases":3050,"primaryCompletion":2707,"completion":2708,"start":2709,"enrollment":2710,"conditions":3051,"interventions":3052},[92],[2695,2712,2713],[2679,2715],{"trials":3054,"activeCount":101},[],{"trials":3056,"activeCount":101},[],{"intervention":3058,"totalTrials":424,"cells":3059},"Cyclosporine A",{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3077,"NA":3079},{"trials":3061,"activeCount":101},[],{"trials":3063,"activeCount":101},[],{"trials":3065,"activeCount":101},[],{"trials":3067,"activeCount":424,"soonestReadout":3072},[3068],{"nctId":3069,"briefTitle":3070,"status":285,"phases":3071,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":1466,"conditions":3074,"interventions":3076},"NCT06658002","Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A",[92],"2027-09-01","2025-09-01",[2939,3075],"Corneal Ulcer",[3058],{"trials":3078,"activeCount":101},[],{"trials":3080,"activeCount":101},[],{"intervention":3082,"totalTrials":424,"cells":3083},"Lidocaine IV",{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3090,"PHASE4":3104,"NA":3106},{"trials":3085,"activeCount":101},[],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":424,"soonestReadout":3096},[3092],{"nctId":3093,"briefTitle":3094,"status":285,"phases":3095,"primaryCompletion":3096,"completion":3096,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3103},"NCT05010148","A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain",[92],"2027-09","2021-09-17",278,[3100,3101,3102],"Postoperative Delirium","Postoperative Pain","Spinal Fusion",[3082],{"trials":3105,"activeCount":101},[],{"trials":3107,"activeCount":101},[],{"intervention":3109,"totalTrials":424,"cells":3110},"Ropivacaine Hydrocloride",{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3117,"PHASE4":3130,"NA":3132},{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":424,"soonestReadout":3123},[3119],{"nctId":3120,"briefTitle":3121,"status":285,"phases":3122,"primaryCompletion":3123,"completion":3123,"start":3124,"enrollment":25,"conditions":3125,"interventions":3129},"NCT07561827","The Effect of Erector Spinae Plane Block (ESPB) on Pediatric Pain Management Following Posterior Spinal Fusion (PSF) Surgery",[92],"2027-01-26","2025-06-06",[3126,3127,3128],"Adolescent Idiopathic Scoliosis (AIS)","Neuromuscular Scoliosis","Adolescent Idiopathic Scoliosis",[3109],{"trials":3131,"activeCount":101},[],{"trials":3133,"activeCount":101},[],{"intervention":2846,"totalTrials":424,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3148,"NA":3150},{"trials":3137,"activeCount":101},[],{"trials":3139,"activeCount":101},[],{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":424,"soonestReadout":1678},[3144],{"nctId":2836,"briefTitle":2837,"status":285,"phases":3145,"primaryCompletion":1678,"completion":1678,"start":2839,"enrollment":2840,"conditions":3146,"interventions":3147},[91,92],[2842,2843,2844],[2846,2847,2848,2825,2849],{"trials":3149,"activeCount":101},[],{"trials":3151,"activeCount":101},[],{"intervention":2847,"totalTrials":424,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3166,"NA":3168},{"trials":3155,"activeCount":101},[],{"trials":3157,"activeCount":101},[],{"trials":3159,"activeCount":101},[],{"trials":3161,"activeCount":424,"soonestReadout":1678},[3162],{"nctId":2836,"briefTitle":2837,"status":285,"phases":3163,"primaryCompletion":1678,"completion":1678,"start":2839,"enrollment":2840,"conditions":3164,"interventions":3165},[91,92],[2842,2843,2844],[2846,2847,2848,2825,2849],{"trials":3167,"activeCount":101},[],{"trials":3169,"activeCount":101},[],{"intervention":2848,"totalTrials":424,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3178,"PHASE4":3184,"NA":3186},{"trials":3173,"activeCount":101},[],{"trials":3175,"activeCount":101},[],{"trials":3177,"activeCount":101},[],{"trials":3179,"activeCount":424,"soonestReadout":1678},[3180],{"nctId":2836,"briefTitle":2837,"status":285,"phases":3181,"primaryCompletion":1678,"completion":1678,"start":2839,"enrollment":2840,"conditions":3182,"interventions":3183},[91,92],[2842,2843,2844],[2846,2847,2848,2825,2849],{"trials":3185,"activeCount":101},[],{"trials":3187,"activeCount":101},[],{"intervention":2849,"totalTrials":424,"cells":3189},{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3196,"PHASE4":3202,"NA":3204},{"trials":3191,"activeCount":101},[],{"trials":3193,"activeCount":101},[],{"trials":3195,"activeCount":101},[],{"trials":3197,"activeCount":424,"soonestReadout":1678},[3198],{"nctId":2836,"briefTitle":2837,"status":285,"phases":3199,"primaryCompletion":1678,"completion":1678,"start":2839,"enrollment":2840,"conditions":3200,"interventions":3201},[91,92],[2842,2843,2844],[2846,2847,2848,2825,2849],{"trials":3203,"activeCount":101},[],{"trials":3205,"activeCount":101},[],{"intervention":3207,"totalTrials":424,"cells":3208},"Standard Buccal Harvest",{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3228,"NA":3230},{"trials":3210,"activeCount":101},[],{"trials":3212,"activeCount":101},[],{"trials":3214,"activeCount":101},[],{"trials":3216,"activeCount":424,"soonestReadout":3221},[3217],{"nctId":3218,"briefTitle":3219,"status":285,"phases":3220,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":1730,"conditions":3223,"interventions":3225},"NCT05300685","Peri-operative Oral Pain Control Following Buccal Graft Urethroplasty",[92],"2026-03-01","2022-02-15",[3224],"Urethral Stricture, Male",[3207,3226,3227],"Basic buccal procedure + Long acting local","Basic buccal procedure + Buccal block",{"trials":3229,"activeCount":101},[],{"trials":3231,"activeCount":101},[],{"intervention":3226,"totalTrials":424,"cells":3233},{"EARLY_PHASE1":3234,"PHASE1":3236,"PHASE2":3238,"PHASE3":3240,"PHASE4":3246,"NA":3248},{"trials":3235,"activeCount":101},[],{"trials":3237,"activeCount":101},[],{"trials":3239,"activeCount":101},[],{"trials":3241,"activeCount":424,"soonestReadout":3221},[3242],{"nctId":3218,"briefTitle":3219,"status":285,"phases":3243,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":1730,"conditions":3244,"interventions":3245},[92],[3224],[3207,3226,3227],{"trials":3247,"activeCount":101},[],{"trials":3249,"activeCount":101},[],{"intervention":3227,"totalTrials":424,"cells":3251},{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3258,"PHASE4":3264,"NA":3266},{"trials":3253,"activeCount":101},[],{"trials":3255,"activeCount":101},[],{"trials":3257,"activeCount":101},[],{"trials":3259,"activeCount":424,"soonestReadout":3221},[3260],{"nctId":3218,"briefTitle":3219,"status":285,"phases":3261,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":1730,"conditions":3262,"interventions":3263},[92],[3224],[3207,3226,3227],{"trials":3265,"activeCount":101},[],{"trials":3267,"activeCount":101},[],{"intervention":3269,"totalTrials":424,"cells":3270},"IM naltrexone",{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3275,"PHASE3":3277,"PHASE4":3288,"NA":3290},{"trials":3272,"activeCount":101},[],{"trials":3274,"activeCount":101},[],{"trials":3276,"activeCount":101},[],{"trials":3278,"activeCount":424,"soonestReadout":3283},[3279],{"nctId":3280,"briefTitle":3281,"status":285,"phases":3282,"primaryCompletion":3283,"completion":3283,"start":3284,"enrollment":1220,"conditions":3285,"interventions":3287},"NCT06633900","Naltrexone for Overdose Prevention",[91,92],"2027-04-15","2025-04-10",[3286],"Overdose Accidental",[3269],{"trials":3289,"activeCount":101},[],{"trials":3291,"activeCount":101},[],{"intervention":3293,"totalTrials":424,"cells":3294},"Angiotensin II",{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3301,"PHASE4":3315,"NA":3317},{"trials":3296,"activeCount":101},[],{"trials":3298,"activeCount":101},[],{"trials":3300,"activeCount":101},[],{"trials":3302,"activeCount":424,"soonestReadout":3307},[3303],{"nctId":3304,"briefTitle":3305,"status":152,"phases":3306,"primaryCompletion":3307,"completion":3308,"start":3309,"enrollment":434,"conditions":3310,"interventions":3313},"NCT04901169","Angiotensin II in Liver Transplantation",[91,92],"2026-03-18","2027-03-18","2022-06-28",[3311,3312],"Liver Transplant; Complications","Vasoplegia",[3293,3314],"Saline",{"trials":3316,"activeCount":101},[],{"trials":3318,"activeCount":101},[],{"intervention":3314,"totalTrials":424,"cells":3320},{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3333,"NA":3335},{"trials":3322,"activeCount":101},[],{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":424,"soonestReadout":3307},[3329],{"nctId":3304,"briefTitle":3305,"status":152,"phases":3330,"primaryCompletion":3307,"completion":3308,"start":3309,"enrollment":434,"conditions":3331,"interventions":3332},[91,92],[3311,3312],[3293,3314],{"trials":3334,"activeCount":101},[],{"trials":3336,"activeCount":101},[],{"intervention":2952,"totalTrials":424,"cells":3338},{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3343,"PHASE3":3345,"PHASE4":3351,"NA":3353},{"trials":3340,"activeCount":101},[],{"trials":3342,"activeCount":101},[],{"trials":3344,"activeCount":101},[],{"trials":3346,"activeCount":424,"soonestReadout":343},[3347],{"nctId":2945,"briefTitle":2946,"status":152,"phases":3348,"primaryCompletion":343,"completion":1218,"start":2948,"enrollment":1730,"conditions":3349,"interventions":3350},[92],[2950],[2952,2943,2919],{"trials":3352,"activeCount":101},[],{"trials":3354,"activeCount":101},[],{"intervention":3356,"totalTrials":424,"cells":3357},"Pharmacologic Pain Management",{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3362,"PHASE3":3364,"PHASE4":3379,"NA":3381},{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":424,"soonestReadout":3370},[3366],{"nctId":3367,"briefTitle":3368,"status":361,"phases":3369,"primaryCompletion":3370,"completion":3371,"start":3372,"enrollment":3373,"conditions":3374,"interventions":3378},"NCT07296770","An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service",[92],"2027-12-01","2028-07-01","2026-05-01",126,[3375,3376,3377],"Postsurgical Pain Management","Postsurgical Pain, Chronic","Opioid Use After Surgery",[3356],{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"intervention":3384,"totalTrials":424,"cells":3385},"Focal Mass Drug Administration",{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3392,"PHASE4":3404,"NA":3406},{"trials":3387,"activeCount":101},[],{"trials":3389,"activeCount":101},[],{"trials":3391,"activeCount":101},[],{"trials":3393,"activeCount":424,"soonestReadout":3398},[3394],{"nctId":3395,"briefTitle":3396,"status":285,"phases":3397,"primaryCompletion":3398,"completion":3398,"start":3399,"enrollment":3400,"conditions":3401,"interventions":3403},"NCT05690841","FocaL Mass Drug Administration for Vivax Malaria Elimination",[92],"2027-05-01","2024-10-14",7530,[3402,322],"Plasmodium Vivax Malaria",[3384],{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"intervention":2896,"totalTrials":519,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3430,"PHASE3":3600,"PHASE4":3602,"NA":3604},{"trials":3411,"activeCount":101},[],{"trials":3413,"activeCount":101},[3414],{"nctId":3415,"briefTitle":3416,"status":132,"phases":3417,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":2774,"conditions":3420,"interventions":3428},"NCT03805594","177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",[90],"2024-01-10","2019-05-10",[3421,3422,3423,3424,3425,3426,3427],"Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Stage IV Prostate Cancer","Stage IVA Prostate Cancer","Stage IVB Prostate Cancer",[3429,2896],"Lutetium Lu 177-PSMA-617",{"trials":3431,"activeCount":324,"soonestReadout":1172},[3432,3436,3446,3457,3474,3488,3492,3503,3514,3528,3548,3560,3577,3590],{"nctId":2889,"briefTitle":2890,"status":120,"phases":3433,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":424,"conditions":3434,"interventions":3435},[91],[2746,2754],[2896,2762,2897],{"nctId":3437,"briefTitle":3438,"status":111,"phases":3439,"primaryCompletion":3440,"completion":3440,"start":3441,"enrollment":101,"conditions":3442,"interventions":3444},"NCT03311672","T-Cell PET Imaging With [18F]F-AraG in Lung Cancer",[91],"2019-10-15","2017-11-26",[3443],"Non-small Cell Lung Cancer",[3445,2896],"[18F]F-Ara-G",{"nctId":3447,"briefTitle":3448,"status":132,"phases":3449,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":1202,"conditions":3453,"interventions":3455},"NCT02493361","Trial of pIL-12\u002FMK-3475 in Metastatic Melanoma",[91],"2018-04-26","2020-03-02","2015-08-17",[3454],"Melanoma",[2896,3456],"pIL-12",{"nctId":3458,"briefTitle":3459,"status":132,"phases":3460,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":22,"conditions":3463,"interventions":3472},"NCT03396926","Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer",[91],"2024-01-30","2018-04-18",[3464,3465,3466,3467,3468,3469,3470,3471],"Microsatellite Stable","Mismatch Repair Protein Proficient","Stage III Colorectal Cancer AJCC v7","Stage IIIB Colorectal Cancer AJCC v7","Stage IIIC Colorectal Cancer AJCC v7","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7",[476,3473,2896],"Capecitabine",{"nctId":3475,"briefTitle":3476,"status":285,"phases":3477,"primaryCompletion":3478,"completion":3479,"start":3480,"enrollment":1183,"conditions":3481,"interventions":3485},"NCT05746208","Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors",[91],"2028-01-31","2028-03-31","2023-07-17",[3482,3483,3484],"Neuroendocrine Tumors","Well-Differentiated Neuroendocrine Carcinoma","High Grade Neuroendocrine Carcinoma, Any Site",[3486,2896,3487],"Lenvatinib","Hyperpolarized 13C-Pyruvate",{"nctId":2899,"briefTitle":2900,"status":120,"phases":3489,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2904,"conditions":3490,"interventions":3491},[91],[2906],[2762,2897,2896],{"nctId":3493,"briefTitle":3494,"status":132,"phases":3495,"primaryCompletion":3496,"completion":3496,"start":3497,"enrollment":695,"conditions":3498,"interventions":3501},"NCT03248570","Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects",[91],"2023-09-28","2018-02-20",[3499,3500],"Castration Resistant Prostatic Cancer","Metastatic Prostate Cancer",[2896,3502],"Chemotherapy",{"nctId":3504,"briefTitle":3505,"status":111,"phases":3506,"primaryCompletion":3507,"completion":309,"start":3508,"enrollment":101,"conditions":3509,"interventions":3513},"NCT03419130","Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer",[91],"2020-12-31","2018-07-18",[3510,3511,3512],"Infiltrating Bladder Urothelial Carcinoma","Stage II Bladder Urothelial Carcinoma AJCC v6 and v7","Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",[2896],{"nctId":3515,"briefTitle":3516,"status":120,"phases":3517,"primaryCompletion":3518,"completion":3518,"start":3519,"enrollment":2564,"conditions":3520,"interventions":3526},"NCT04370509","Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery",[91],"2025-02-28","2021-02-09",[3521,3522,3523,3524,3525],"Metastatic Clear Cell Renal Cell Carcinoma","Recurrent Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Clear Cell Renal Cell Carcinoma",[3527,2896],"Axitinib",{"nctId":3529,"briefTitle":3530,"status":111,"phases":3531,"primaryCompletion":778,"completion":778,"start":3532,"enrollment":101,"conditions":3533,"interventions":3544},"NCT04061590","Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer",[91],"2020-05-29",[3534,3535,3536,3537,3538,3539,3540,3541,3542,3543],"Lung Non-Small Cell Carcinoma","Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8",[3545,2896,3546,3547],"Cisplatin","Pemetrexed","Pemetrexed Disodium",{"nctId":3549,"briefTitle":3550,"status":285,"phases":3551,"primaryCompletion":1172,"completion":2708,"start":3552,"enrollment":3553,"conditions":3554,"interventions":3558},"NCT05766371","Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer",[91],"2023-12-15",48,[3555,3556,21,3557],"Castrate Resistant Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Prostate Carcinoma",[2896,3559],"177Lu-PSMA-617",{"nctId":3561,"briefTitle":3562,"status":132,"phases":3563,"primaryCompletion":3564,"completion":3565,"start":3566,"enrollment":3567,"conditions":3568,"interventions":3574},"NCT03396952","Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma",[91],"2020-04-30","2022-06-30","2018-04-19",27,[3569,3570,3571,3572,3573],"Stage III Cutaneous Melanoma","Stage IIIA Cutaneous Melanoma","Stage IIIB Cutaneous Melanoma","Stage IIIC Cutaneous Melanoma","Stage IV Cutaneous Melanoma",[3575,3576,2896],"Aspirin","Ipilimumab",{"nctId":3578,"briefTitle":3579,"status":285,"phases":3580,"primaryCompletion":3478,"completion":3478,"start":3581,"enrollment":3582,"conditions":3583,"interventions":3588},"NCT06470282","Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer",[90,91],"2025-03-31",47,[3584,3585,3586,3587],"Bladder Cancer","Muscle-Invasive Bladder Carcinoma","Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8",[3589,2896],"Enfortumab Vedotin",{"nctId":3591,"briefTitle":3592,"status":132,"phases":3593,"primaryCompletion":3594,"completion":3594,"start":3595,"enrollment":31,"conditions":3596,"interventions":3598},"NCT03136055","Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas",[91],"2021-10-31","2017-06-20",[3597],"High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)",[2896,3599,2760],"Irinotecan",{"trials":3601,"activeCount":101},[],{"trials":3603,"activeCount":101},[],{"trials":3605,"activeCount":101},[],{"intervention":3607,"totalTrials":1071,"cells":3608},"Metformin",{"EARLY_PHASE1":3609,"PHASE1":3619,"PHASE2":3654,"PHASE3":3688,"PHASE4":3690,"NA":3737},{"trials":3610,"activeCount":424,"soonestReadout":1218},[3611],{"nctId":3612,"briefTitle":3613,"status":285,"phases":3614,"primaryCompletion":1218,"completion":1218,"start":3615,"enrollment":1060,"conditions":3616,"interventions":3618},"NCT06120881","Precision Dosing of Metformin in Youth With T2D",[89],"2024-04-25",[3617],"Type 2 Diabetes",[3607],{"trials":3620,"activeCount":101},[3621,3629,3636,3644],{"nctId":3622,"briefTitle":3623,"status":132,"phases":3624,"primaryCompletion":3625,"completion":3625,"start":2407,"enrollment":3626,"conditions":3627,"interventions":3628},"NCT01681680","Effect of Genetic Variation in the Transporter OCT2, MATE1 and MATE2-K on the PKPD of Metformin",[90],"2013-10",41,[30],[3607],{"nctId":3630,"briefTitle":3631,"status":132,"phases":3632,"primaryCompletion":921,"completion":921,"start":673,"enrollment":345,"conditions":3633,"interventions":3634},"NCT01409395","Drug-Drug Interaction Study With Metformin and Nizatidine",[90],[30],[3635,3607],"Metformin and nizatidine",{"nctId":3637,"briefTitle":3638,"status":132,"phases":3639,"primaryCompletion":921,"completion":921,"start":3640,"enrollment":541,"conditions":3641,"interventions":3642},"NCT01404715","Drug-drug Interaction Study With Metformin and Imatinib",[90],"2011-10",[30],[3607,3643],"Imatinib",{"nctId":3645,"briefTitle":3646,"status":132,"phases":3647,"primaryCompletion":3648,"completion":3648,"start":3649,"enrollment":3650,"conditions":3651,"interventions":3653},"NCT01681693","Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans",[90],"2013-07","2010-02",33,[30,3652],"Type 2 Diabetes Mellitus",[3607],{"trials":3655,"activeCount":526,"soonestReadout":1341},[3656,3669,3679],{"nctId":3657,"briefTitle":3658,"status":132,"phases":3659,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":1914,"conditions":3663,"interventions":3668},"NCT02684578","Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD",[91],"2022-04","2022-10","2016-04",[3664,3665,3666,3667],"Age-Related Macular Degeneration","Macular Degeneration, Age-Related","Dry Macular Degeneration","Geographic Atrophy",[3607],{"nctId":3670,"briefTitle":3671,"status":285,"phases":3672,"primaryCompletion":3673,"completion":3674,"start":3675,"enrollment":751,"conditions":3676,"interventions":3678},"NCT07226453","Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma",[91],"2028-04-30","2030-03-31","2026-05-05",[3677],"Posterior Fossa Ependymal Tumor",[3607],{"nctId":3680,"briefTitle":3681,"status":285,"phases":3682,"primaryCompletion":1341,"completion":1341,"start":3683,"enrollment":345,"conditions":3684,"interventions":3687},"NCT03629340","Metformin for Pulmonary Hypertension HFpEF",[91],"2019-02-26",[3685,3686],"Pulmonary Hypertension","Heart Failure",[3607],{"trials":3689,"activeCount":101},[],{"trials":3691,"activeCount":101},[3692,3701,3709,3717,3727],{"nctId":3693,"briefTitle":3694,"status":132,"phases":3695,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":1246,"conditions":3698,"interventions":3700},"NCT00187720","Genetic Basis for Variation in the Renal Elimination of Metformin",[93],"2008-04","2002-05",[3699],"Other Conditions That May Be A Focus of Clinical Attention",[3607],{"nctId":3702,"briefTitle":3703,"status":111,"phases":3704,"primaryCompletion":1313,"completion":1313,"start":3705,"enrollment":101,"conditions":3706,"interventions":3708},"NCT01910246","Cardiovascular Effects of Metformin on Obesity",[93],"2015-04",[3707],"Insulin Resistance",[3607],{"nctId":3710,"briefTitle":3711,"status":132,"phases":3712,"primaryCompletion":3713,"completion":3713,"start":3714,"enrollment":1060,"conditions":3715,"interventions":3716},"NCT00187681","Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects",[93],"2008-03","2003-07",[3699],[3607],{"nctId":3718,"briefTitle":3719,"status":120,"phases":3720,"primaryCompletion":275,"completion":275,"start":3721,"enrollment":407,"conditions":3722,"interventions":3725},"NCT03380091","Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial",[93],"2017-12-12",[3723,27,3724,3707],"PCOS","Vitamin D Deficiency",[3607,3726],"Vitamin D",{"nctId":3728,"briefTitle":3729,"status":132,"phases":3730,"primaryCompletion":2856,"completion":2856,"start":3731,"enrollment":792,"conditions":3732,"interventions":3735},"NCT03746106","The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine",[93],"2019-01-28",[3733,3734],"Vitamin B1 Deficiency","Thiamine Deficiency",[3736,3607],"Trimethoprim",{"trials":3738,"activeCount":101},[3739],{"nctId":3740,"briefTitle":3741,"status":132,"phases":3742,"primaryCompletion":1312,"completion":1312,"start":3743,"enrollment":3744,"conditions":3745,"interventions":3746},"NCT02846233","Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?",[94],"2016-08",22,[3652],[3747,3748,3749,3607],"GLP1 receptor agonist","basal insulin","SGLT2 inhibitor",{"intervention":3751,"totalTrials":541,"cells":3752},"Temozolomide",{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3788,"PHASE3":3877,"PHASE4":3879,"NA":3881},{"trials":3754,"activeCount":101},[],{"trials":3756,"activeCount":424,"soonestReadout":343},[3757,3777],{"nctId":3758,"briefTitle":3759,"status":152,"phases":3760,"primaryCompletion":343,"completion":3761,"start":3762,"enrollment":3763,"conditions":3764,"interventions":3775},"NCT03749187","BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1\u002F2-Mutant Grade I-IV Gliomas",[90],"2029-07-30","2019-04-03",78,[3765,3766,3767,3768,3769,3770,3771,3772,3773,3774],"Glioblastoma","IDH1 Gene Mutation","IDH2 Gene Mutation","Low Grade Glioma","Malignant Glioma","Recurrent Glioblastoma","Recurrent WHO Grade II Glioma","Recurrent WHO Grade III Glioma","WHO Grade II Glioma","WHO Grade III Glioma",[3776,3751],"PARP Inhibitor BGB-290",{"nctId":3778,"briefTitle":3779,"status":132,"phases":3780,"primaryCompletion":3440,"completion":3781,"start":3782,"enrollment":1027,"conditions":3783,"interventions":3786},"NCT03139331","PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma",[90],"2020-09-30","2017-06-06",[3784,3785],"Sarcoma","Refractory Sarcoma",[3787,3599,3751],"Pazopanib",{"trials":3789,"activeCount":526,"soonestReadout":3478},[3790,3801,3814,3824,3834,3843,3854,3865],{"nctId":3791,"briefTitle":3792,"status":132,"phases":3793,"primaryCompletion":3794,"completion":3795,"start":3796,"enrollment":3797,"conditions":3798,"interventions":3800},"NCT00313729","Temozolomide in Treating Patients With Low-Grade Glioma",[91],"2014-09-25","2017-06-12","1999-05",120,[3799],"CNS Tumor, Adult",[2445],{"nctId":3802,"briefTitle":3803,"status":285,"phases":3804,"primaryCompletion":3478,"completion":3805,"start":3806,"enrollment":1633,"conditions":3807,"interventions":3811},"NCT06504381","DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma",[90,91],"2042-01-31","2025-01-08",[3808,3809,3810],"High Grade Glioma","MGMT-Unmethylated Glioblastoma","MGMT-Methylated Glioblastoma",[3812,3813,3751],"DB107-RRV","DB107-FC",{"nctId":3815,"briefTitle":3816,"status":132,"phases":3817,"primaryCompletion":3818,"completion":3818,"start":3819,"enrollment":1872,"conditions":3820,"interventions":3822},"NCT00525525","Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma",[91],"2013-05","2007-09",[3765,3821],"Gliosarcoma",[476,3823,3751],"Tarceva",{"nctId":3825,"briefTitle":3826,"status":132,"phases":3827,"primaryCompletion":3828,"completion":3829,"start":3830,"enrollment":1730,"conditions":3831,"interventions":3833},"NCT00619112","Temozolomide in Treating Patients With Recurrent High-Grade Glioma",[91],"2011-12","2012-09","2007-10",[3832],"Recurrent Central Nervous System Neoplasm",[2445],{"nctId":3835,"briefTitle":3836,"status":132,"phases":3837,"primaryCompletion":3838,"completion":3838,"start":3839,"enrollment":1633,"conditions":3840,"interventions":3841},"NCT00905060","HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM",[91],"2014-06-03","2009-06-29",[2439],[3842,3751],"HSPPC-96",{"nctId":3844,"briefTitle":3845,"status":285,"phases":3846,"primaryCompletion":3847,"completion":3848,"start":3849,"enrollment":1633,"conditions":3850,"interventions":3852},"NCT06861244","Embryonal Tumor With Multilayered Rosettes",[91],"2030-09-30","2032-03-31","2025-03-06",[3845,3851],"Embryonal Tumor With Multilayered Rosettes, Nos",[3853,3751],"Chemotherapy Drug, Cancer - Physician's Choice",{"nctId":3855,"briefTitle":3856,"status":132,"phases":3857,"primaryCompletion":3858,"completion":3859,"start":3860,"enrollment":751,"conditions":3861,"interventions":3863},"NCT00617539","Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases",[91],"2013-01","2014-01","2005-02",[24,3862],"Metastatic Cancer",[3864,2445],"irinotecan hydrochloride",{"nctId":3866,"briefTitle":3867,"status":120,"phases":3868,"primaryCompletion":3869,"completion":3869,"start":3870,"enrollment":3567,"conditions":3871,"interventions":3875},"NCT02023905","Everolimus With and Without Temozolomide in Adult Low Grade Glioma",[91],"2021-09-30","2014-03-19",[3768,3872,3873,3874],"World Health Organization (WHO) Grade II Astrocytomas","Oligodendrogliomas","Mixed Oligoastrocytomas",[3876,3751],"Everolimus",{"trials":3878,"activeCount":101},[],{"trials":3880,"activeCount":101},[],{"trials":3882,"activeCount":101},[3883],{"nctId":2432,"briefTitle":2433,"status":132,"phases":3884,"primaryCompletion":2435,"completion":2436,"start":2437,"enrollment":345,"conditions":3885,"interventions":3886},[94],[2439,717],[720,2441,2442,2443,2444,686,2445],{"intervention":3888,"totalTrials":324,"cells":3889},"Clemastine Fumarate",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3902,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3891,"activeCount":101},[],{"trials":3893,"activeCount":101},[3894],{"nctId":3895,"briefTitle":3896,"status":132,"phases":3897,"primaryCompletion":432,"start":3662,"enrollment":1246,"conditions":3898,"interventions":3900},"NCT02613091","Effect of Clemastine Fumarate on Color Vision in Healthy Controls",[90],[3899],"Healthy Subjects",[3901],"Clemastine fumarate",{"trials":3903,"activeCount":526,"soonestReadout":1631},[3904,3917],{"nctId":3905,"briefTitle":3906,"status":361,"phases":3907,"primaryCompletion":3908,"completion":3908,"start":3909,"enrollment":22,"conditions":3910,"interventions":3916},"NCT06065670","Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy",[90,91],"2028-10-30","2026-09-15",[3911,3912,3913,3914,3915],"Demyelinating Diseases","Demyelination; Corpus Callosum","Multiple Sclerosis Brain Lesion","Multiple Sclerosis Acute and Progressive","Clinically Isolated Syndrome, CNS Demyelinating",[3888],{"nctId":3918,"briefTitle":3919,"status":285,"phases":3920,"primaryCompletion":1631,"completion":1631,"start":3921,"enrollment":1872,"conditions":3922,"interventions":3928},"NCT05359653","Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy",[90,91],"2023-08-01",[3923,743,3924,3925,3926,3913,3927],"Multiple Sclerosis (MS)","Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Chronic Progressive","Multiple Sclerosis Relapse","Multiple Sclerosis Benign",[3888],{"trials":3930,"activeCount":101},[],{"trials":3932,"activeCount":101},[],{"trials":3934,"activeCount":101},[],{"intervention":3559,"totalTrials":526,"cells":3936},{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3949,"PHASE3":3955,"PHASE4":3957,"NA":3959},{"trials":3938,"activeCount":101},[],{"trials":3940,"activeCount":424,"soonestReadout":3945},[3941],{"nctId":3942,"briefTitle":3943,"status":285,"phases":3944,"primaryCompletion":3945,"completion":3946,"start":626,"enrollment":751,"conditions":3947,"interventions":3948},"NCT07145177","177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer",[90],"2028-10-31","2030-10-31",[3500,21],[3559],{"trials":3950,"activeCount":424,"soonestReadout":1172},[3951],{"nctId":3549,"briefTitle":3550,"status":285,"phases":3952,"primaryCompletion":1172,"completion":2708,"start":3552,"enrollment":3553,"conditions":3953,"interventions":3954},[91],[3555,3556,21,3557],[2896,3559],{"trials":3956,"activeCount":101},[],{"trials":3958,"activeCount":101},[],{"trials":3960,"activeCount":101},[],{"intervention":3487,"totalTrials":526,"cells":3962},{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3973,"PHASE4":3975,"NA":3977},{"trials":3964,"activeCount":101},[],{"trials":3966,"activeCount":101},[],{"trials":3968,"activeCount":424,"soonestReadout":3478},[3969],{"nctId":3475,"briefTitle":3476,"status":285,"phases":3970,"primaryCompletion":3478,"completion":3479,"start":3480,"enrollment":1183,"conditions":3971,"interventions":3972},[91],[3482,3483,3484],[3486,2896,3487],{"trials":3974,"activeCount":101},[],{"trials":3976,"activeCount":101},[],{"trials":3978,"activeCount":424,"soonestReadout":3983},[3979],{"nctId":3980,"briefTitle":3981,"status":285,"phases":3982,"primaryCompletion":3983,"completion":3984,"start":554,"enrollment":1633,"conditions":3985,"interventions":3989},"NCT06600906","Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer",[],"2030-08-01","2032-09-01",[3986,3987,3988],"Pancreatic Ductal Adenocarcinoma","Metastatic Pancreatic Ductal Adenocarcinoma","Locally Advanced Pancreatic Ductal Adenocarcinoma",[3487],{"intervention":3991,"totalTrials":480,"cells":3992},"Maraviroc",{"EARLY_PHASE1":3993,"PHASE1":3995,"PHASE2":3997,"PHASE3":4023,"PHASE4":4035,"NA":4046},{"trials":3994,"activeCount":101},[],{"trials":3996,"activeCount":101},[],{"trials":3998,"activeCount":424,"soonestReadout":4003},[3999,4012],{"nctId":4000,"briefTitle":4001,"status":285,"phases":4002,"primaryCompletion":4003,"completion":4004,"start":4005,"enrollment":3797,"conditions":4006,"interventions":4011},"NCT06853223","This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction",[91],"2028-04-01","2028-08-14","2025-12-07",[4007,4008,4009,4010],"Primary Graft Dysfunction","Lung Transplantation","Acute Lung Injury(ALI)","Natural Killer Cell Mediated Immunity",[3991],{"nctId":4013,"briefTitle":4014,"status":132,"phases":4015,"primaryCompletion":4016,"completion":4017,"start":4018,"enrollment":4019,"conditions":4020,"interventions":4022},"NCT01276236","Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)",[91],"2015-01-31","2015-04-30","2011-03-09",13,[4021],"Kaposi's Sarcoma",[3991],{"trials":4024,"activeCount":101},[4025],{"nctId":4026,"briefTitle":4027,"status":132,"phases":4028,"primaryCompletion":1200,"completion":4029,"start":4030,"enrollment":4031,"conditions":4032,"interventions":4034},"NCT00844519","Effect of Maraviroc on Endothelial Function in HIV-Infected Patients",[92],"2014-06","2010-01",52,[2539,4033,1707,18],"Cardiovascular Disease",[3991],{"trials":4036,"activeCount":101},[4037],{"nctId":4038,"briefTitle":4039,"status":132,"phases":4040,"primaryCompletion":4041,"completion":447,"start":4042,"enrollment":4043,"conditions":4044,"interventions":4045},"NCT00735072","Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure",[93],"2010-04","2008-09",45,[2539],[3991],{"trials":4047,"activeCount":101},[],{"intervention":4049,"totalTrials":480,"cells":4050},"Cannabis",{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4062,"PHASE3":4085,"PHASE4":4096,"NA":4098},{"trials":4052,"activeCount":101},[],{"trials":4054,"activeCount":101},[4055],{"nctId":4056,"briefTitle":4057,"status":132,"phases":4058,"primaryCompletion":2583,"completion":2583,"start":4059,"enrollment":1202,"conditions":4060,"interventions":4061},"NCT00308555","Opioid and Cannabinoid Pharmacokinetic Interactions",[90],"2006-05",[1410],[4049],{"trials":4063,"activeCount":424,"soonestReadout":4068},[4064,4076],{"nctId":4065,"briefTitle":4066,"status":285,"phases":4067,"primaryCompletion":4068,"completion":4068,"start":1407,"enrollment":3553,"conditions":4069,"interventions":4074},"NCT05999383","Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration",[91],"2028-02-01",[4070,4049,4071,4072,2660,4073],"THC","Cannabis Use","Cannabis Smoking","Vaping",[4049,4075],"Nicotine",{"nctId":4077,"briefTitle":4078,"status":132,"phases":4079,"primaryCompletion":4080,"completion":4081,"start":113,"enrollment":3567,"conditions":4082,"interventions":4084},"NCT01771731","Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease",[90,91],"2017-05-12","2017-05-19",[4083],"Sickle Cell Disease",[4049],{"trials":4086,"activeCount":101},[4087],{"nctId":4088,"briefTitle":4089,"status":132,"phases":4090,"primaryCompletion":4091,"completion":4091,"start":4092,"enrollment":555,"conditions":4093,"interventions":4095},"NCT02955329","Vaping THC From Electronic Cigarettes",[92],"2019-11-30","2019-03-20",[4094],"Marijuana Dependence",[4075,4049],{"trials":4097,"activeCount":101},[],{"trials":4099,"activeCount":101},[],{"intervention":4075,"totalTrials":526,"cells":4101},{"EARLY_PHASE1":4102,"PHASE1":4104,"PHASE2":4106,"PHASE3":4112,"PHASE4":4118,"NA":4120},{"trials":4103,"activeCount":101},[],{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":424,"soonestReadout":4068},[4108],{"nctId":4065,"briefTitle":4066,"status":285,"phases":4109,"primaryCompletion":4068,"completion":4068,"start":1407,"enrollment":3553,"conditions":4110,"interventions":4111},[91],[4070,4049,4071,4072,2660,4073],[4049,4075],{"trials":4113,"activeCount":101},[4114],{"nctId":4088,"briefTitle":4089,"status":132,"phases":4115,"primaryCompletion":4091,"completion":4091,"start":4092,"enrollment":555,"conditions":4116,"interventions":4117},[92],[4094],[4075,4049],{"trials":4119,"activeCount":101},[],{"trials":4121,"activeCount":101},[],{"intervention":4123,"totalTrials":407,"cells":4124},"Trametinib",{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4149,"PHASE3":4179,"PHASE4":4181,"NA":4183},{"trials":4126,"activeCount":101},[],{"trials":4128,"activeCount":101},[4129,4140],{"nctId":4130,"briefTitle":4131,"status":4132,"phases":4133,"primaryCompletion":4134,"completion":4134,"start":4135,"enrollment":434,"conditions":4136,"interventions":4139},"NCT04485559","Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)","SUSPENDED",[90],"2027-12-31","2020-12-09",[4137,4138,3808],"Recurrent World Health Organization (WHO) Grade II Glioma","Low-grade Glioma",[3876,4123],{"nctId":4141,"briefTitle":4142,"status":120,"phases":4143,"primaryCompletion":4144,"completion":4144,"start":4145,"enrollment":2472,"conditions":4146,"interventions":4147},"NCT03087448","Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)",[90],"2022-04-30","2017-09-09",[3443],[4148,4123],"Ceritinib",{"trials":4150,"activeCount":424,"soonestReadout":3848},[4151,4160,4168],{"nctId":4152,"briefTitle":4153,"status":120,"phases":4154,"primaryCompletion":431,"completion":431,"start":4155,"enrollment":526,"conditions":4156,"interventions":4158},"NCT01721603","Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets",[91],"2013-04",[4157],"BRAFV600E Melanoma Patients",[4159,4123],"Dabrafenib",{"nctId":4161,"briefTitle":4162,"status":120,"phases":4163,"primaryCompletion":4164,"completion":4164,"start":4165,"enrollment":424,"conditions":4166,"interventions":4167},"NCT03232892","Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer",[91],"2019-09-11","2018-02-13",[3443],[4123],{"nctId":4169,"briefTitle":4170,"status":285,"phases":4171,"primaryCompletion":3848,"completion":3848,"start":4172,"enrollment":4173,"conditions":4174,"interventions":4178},"NCT07110246","Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas",[91],"2025-11-07",96,[4175,4138,4176,4177],"BRAF V600 Mutation","Low Grade Glioma of Brain","Recurrent Low Grade Glioma",[4159,4123],{"trials":4180,"activeCount":101},[],{"trials":4182,"activeCount":101},[],{"trials":4184,"activeCount":101},[],{"intervention":4186,"totalTrials":324,"cells":4187},"Binimetinib",{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4247,"PHASE3":4259,"PHASE4":4261,"NA":4263},{"trials":4189,"activeCount":101},[],{"trials":4191,"activeCount":101},[4192,4209],{"nctId":4193,"briefTitle":4194,"status":120,"phases":4195,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":324,"conditions":4198,"interventions":4207},"NCT04005144","Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer",[90],"2022-10-01","2020-02-25",[4199,3534,4200,4201,4202,4203,4204,4205,4206],"ALK Gene Rearrangement","Progressive Disease","ROS1 Gene Rearrangement","Stage IIIB Lung Cancer","Stage IIIC Lung Cancer","Stage IV Lung Cancer","Stage IVA Lung Cancer","Stage IVB Lung Cancer",[4186,4208],"Brigatinib",{"nctId":4210,"briefTitle":4211,"status":120,"phases":4212,"primaryCompletion":4213,"completion":4213,"start":4214,"enrollment":526,"conditions":4215,"interventions":4244},"NCT04044430","Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer",[90],"2022-07-31","2020-08-31",[4216,4217,4218,4219,4220,4221,4222,4223,4224,4225,4226,4227,4228,4229,4230,4231,4232,4233,4234,4235,4236,4237,4238,4239,4240,4241,4242,4243],"Metastatic Colon Adenocarcinoma","Metastatic Colorectal Adenocarcinoma","Metastatic Microsatellite Stable Colorectal Carcinoma","Metastatic Rectal Adenocarcinoma","Stage III Colon Cancer","Stage III Colorectal Cancer","Stage III Rectal Cancer","Stage IIIA Colon Cancer","Stage IIIA Colorectal Cancer","Stage IIIA Rectal Cancer","Stage IIIB Colon Cancer","Stage IIIB Colorectal Cancer","Stage IIIB Rectal Cancer","Stage IIIC Colon Cancer","Stage IIIC Colorectal Cancer","Stage IIIC Rectal Cancer","Stage IV Colon Cancer","Stage IV Colorectal Cancer","Stage IV Rectal Cancer","Stage IVA Colon Cancer","Stage IVA Colorectal Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Colorectal Cancer","Stage IVB Rectal Cancer","Stage IVC Colon Cancer","Stage IVC Colorectal Cancer","Stage IVC Rectal Cancer",[4186,4245,4246],"Encorafenib","Nivolumab",{"trials":4248,"activeCount":424,"soonestReadout":4253},[4249],{"nctId":4250,"briefTitle":4251,"status":285,"phases":4252,"primaryCompletion":4253,"completion":1172,"start":4254,"enrollment":353,"conditions":4255,"interventions":4258},"NCT04598009","Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma",[91],"2026-05-31","2021-03-03",[4256,4257],"Melanoma Stage III","Melanoma Stage IV",[4186,3643],{"trials":4260,"activeCount":101},[],{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"intervention":3643,"totalTrials":324,"cells":4266},{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4284,"PHASE3":4290,"PHASE4":4292,"NA":4294},{"trials":4268,"activeCount":101},[],{"trials":4270,"activeCount":101},[4271,4280],{"nctId":4272,"briefTitle":4273,"status":132,"phases":4274,"primaryCompletion":4275,"completion":4275,"start":2723,"enrollment":675,"conditions":4276,"interventions":4278},"NCT00390156","Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors",[90],"2011-01",[4277],"Unspecified Adult Solid Tumor",[815,2398,4279],"imatinib",{"nctId":3637,"briefTitle":3638,"status":132,"phases":4281,"primaryCompletion":921,"completion":921,"start":3640,"enrollment":541,"conditions":4282,"interventions":4283},[90],[30],[3607,3643],{"trials":4285,"activeCount":424,"soonestReadout":4253},[4286],{"nctId":4250,"briefTitle":4251,"status":285,"phases":4287,"primaryCompletion":4253,"completion":1172,"start":4254,"enrollment":353,"conditions":4288,"interventions":4289},[91],[4256,4257],[4186,3643],{"trials":4291,"activeCount":101},[],{"trials":4293,"activeCount":101},[],{"trials":4295,"activeCount":101},[],{"intervention":4297,"totalTrials":526,"cells":4298},"Clemastine",{"EARLY_PHASE1":4299,"PHASE1":4301,"PHASE2":4303,"PHASE3":4321,"PHASE4":4323,"NA":4325},{"trials":4300,"activeCount":101},[],{"trials":4302,"activeCount":101},[],{"trials":4304,"activeCount":424,"soonestReadout":4315},[4305,4311],{"nctId":4306,"briefTitle":4307,"status":132,"phases":4308,"primaryCompletion":2517,"completion":3662,"start":3859,"enrollment":434,"conditions":4309,"interventions":4310},"NCT02040298","Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis",[91],[743],[4297],{"nctId":4312,"briefTitle":4313,"status":285,"phases":4314,"primaryCompletion":4315,"completion":4315,"start":4316,"enrollment":4317,"conditions":4318,"interventions":4320},"NCT02521311","Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)",[91],"2028-08","2017-02-28",90,[4319],"Optic Neuritis",[4297],{"trials":4322,"activeCount":101},[],{"trials":4324,"activeCount":101},[],{"trials":4326,"activeCount":101},[],{"intervention":4159,"totalTrials":526,"cells":4328},{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4333,"PHASE3":4343,"PHASE4":4345,"NA":4347},{"trials":4330,"activeCount":101},[],{"trials":4332,"activeCount":101},[],{"trials":4334,"activeCount":424,"soonestReadout":3848},[4335,4339],{"nctId":4152,"briefTitle":4153,"status":120,"phases":4336,"primaryCompletion":431,"completion":431,"start":4155,"enrollment":526,"conditions":4337,"interventions":4338},[91],[4157],[4159,4123],{"nctId":4169,"briefTitle":4170,"status":285,"phases":4340,"primaryCompletion":3848,"completion":3848,"start":4172,"enrollment":4173,"conditions":4341,"interventions":4342},[91],[4175,4138,4176,4177],[4159,4123],{"trials":4344,"activeCount":101},[],{"trials":4346,"activeCount":101},[],{"trials":4348,"activeCount":101},[],{"intervention":4350,"totalTrials":424,"cells":4351},"Naloxone 2 MG",{"EARLY_PHASE1":4352,"PHASE1":4354,"PHASE2":4356,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4353,"activeCount":101},[],{"trials":4355,"activeCount":101},[],{"trials":4357,"activeCount":424,"soonestReadout":4362},[4358],{"nctId":4359,"briefTitle":4360,"status":361,"phases":4361,"primaryCompletion":4362,"completion":4362,"start":947,"enrollment":4363,"conditions":4364,"interventions":4368},"NCT06251609","Naloxone for Opioid Associated Out of Hospital Cardiac Arrest",[91],"2028-12-31",98,[4365,4366,4367],"Heart Arrest, Out-Of-Hospital","Opioid Overdose","Naloxone",[4350,4369],"Saline 2ml",{"trials":4371,"activeCount":101},[],{"trials":4373,"activeCount":101},[],{"trials":4375,"activeCount":101},[],{"intervention":4369,"totalTrials":424,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4382,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4379,"activeCount":101},[],{"trials":4381,"activeCount":101},[],{"trials":4383,"activeCount":424,"soonestReadout":4362},[4384],{"nctId":4359,"briefTitle":4360,"status":361,"phases":4385,"primaryCompletion":4362,"completion":4362,"start":947,"enrollment":4363,"conditions":4386,"interventions":4387},[91],[4365,4366,4367],[4350,4369],{"trials":4389,"activeCount":101},[],{"trials":4391,"activeCount":101},[],{"trials":4393,"activeCount":101},[],{"intervention":4395,"totalTrials":424,"cells":4396},"Hyperpolarized Carbon C 13 Pyruvate",{"EARLY_PHASE1":4397,"PHASE1":4399,"PHASE2":4401,"PHASE3":4409,"PHASE4":4411,"NA":4413},{"trials":4398,"activeCount":101},[],{"trials":4400,"activeCount":101},[],{"trials":4402,"activeCount":424,"soonestReadout":4134},[4403],{"nctId":4404,"briefTitle":4405,"status":285,"phases":4406,"primaryCompletion":4134,"completion":287,"start":3508,"enrollment":1730,"conditions":4407,"interventions":4408},"NCT03933670","Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance",[91],[3424,21],[4395],{"trials":4410,"activeCount":101},[],{"trials":4412,"activeCount":101},[],{"trials":4414,"activeCount":101},[],{"intervention":4416,"totalTrials":424,"cells":4417},"Urea in the dialysate",{"EARLY_PHASE1":4418,"PHASE1":4420,"PHASE2":4422,"PHASE3":4435,"PHASE4":4437,"NA":4439},{"trials":4419,"activeCount":101},[],{"trials":4421,"activeCount":101},[],{"trials":4423,"activeCount":424,"soonestReadout":287},[4424],{"nctId":4425,"briefTitle":4426,"status":285,"phases":4427,"primaryCompletion":287,"completion":287,"start":4428,"enrollment":1060,"conditions":4429,"interventions":4434},"NCT06366230","Adding Urea to the Final Dialysis Fluid",[90,91],"2025-09-16",[4430,4431,4432,4433],"Dysequilibrium Syndrome","ESRD","Hyperkalemia","Metabolic Acidosis",[4416],{"trials":4436,"activeCount":101},[],{"trials":4438,"activeCount":101},[],{"trials":4440,"activeCount":101},[],{"intervention":4442,"totalTrials":424,"cells":4443},"Emapalumab",{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[],{"trials":4449,"activeCount":424,"soonestReadout":4454},[4450],{"nctId":4451,"briefTitle":4452,"status":361,"phases":4453,"primaryCompletion":4454,"completion":4454,"start":4455,"enrollment":28,"conditions":4456,"interventions":4458},"NCT07538336","Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction",[91],"2028-11-01","2026-11-02",[4457],"Lung Transplant",[4442],{"trials":4460,"activeCount":101},[],{"trials":4462,"activeCount":101},[],{"trials":4464,"activeCount":101},[],{"intervention":4466,"totalTrials":424,"cells":4467},"Atorvastatin Calcium",{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4484,"PHASE4":4486,"NA":4488},{"trials":4469,"activeCount":101},[],{"trials":4471,"activeCount":101},[],{"trials":4473,"activeCount":424,"soonestReadout":4478},[4474],{"nctId":4475,"briefTitle":4476,"status":691,"phases":4477,"primaryCompletion":4478,"completion":196,"start":47,"enrollment":4479,"conditions":4480,"interventions":4481},"NCT05826912","Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury",[91],"2028-08-31",672,[697],[4466,4482,4483],"Minocycline Hydrochloride","Candesartan Cilexetil",{"trials":4485,"activeCount":101},[],{"trials":4487,"activeCount":101},[],{"trials":4489,"activeCount":101},[],{"intervention":4482,"totalTrials":424,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4502,"PHASE4":4504,"NA":4506},{"trials":4493,"activeCount":101},[],{"trials":4495,"activeCount":101},[],{"trials":4497,"activeCount":424,"soonestReadout":4478},[4498],{"nctId":4475,"briefTitle":4476,"status":691,"phases":4499,"primaryCompletion":4478,"completion":196,"start":47,"enrollment":4479,"conditions":4500,"interventions":4501},[91],[697],[4466,4482,4483],{"trials":4503,"activeCount":101},[],{"trials":4505,"activeCount":101},[],{"trials":4507,"activeCount":101},[],{"intervention":4483,"totalTrials":424,"cells":4509},{"EARLY_PHASE1":4510,"PHASE1":4512,"PHASE2":4514,"PHASE3":4520,"PHASE4":4522,"NA":4524},{"trials":4511,"activeCount":101},[],{"trials":4513,"activeCount":101},[],{"trials":4515,"activeCount":424,"soonestReadout":4478},[4516],{"nctId":4475,"briefTitle":4476,"status":691,"phases":4517,"primaryCompletion":4478,"completion":196,"start":47,"enrollment":4479,"conditions":4518,"interventions":4519},[91],[697],[4466,4482,4483],{"trials":4521,"activeCount":101},[],{"trials":4523,"activeCount":101},[],{"trials":4525,"activeCount":101},[],{"intervention":4527,"totalTrials":424,"cells":4528},"ONC201",{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4533,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4530,"activeCount":101},[],{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":424,"soonestReadout":4134},[4535],{"nctId":4536,"briefTitle":4537,"status":285,"phases":4538,"primaryCompletion":4134,"completion":4539,"start":4540,"enrollment":2710,"conditions":4541,"interventions":4546},"NCT05009992","Combination Therapy for the Treatment of Diffuse Midline Gliomas",[91],"2029-06-30","2021-10-20",[4542,4543,4544,4545,3772,3774],"Diffuse Intrinsic Pontine Glioma","Diffuse Midline Glioma, H3 K27M-Mutant","Recurrent Diffuse Intrinsic Pontine Glioma","Recurrent Diffuse Midline Glioma, H3 K27M-Mutant",[4527,4547,4548],"Paxalisib","DNX-2401",{"trials":4550,"activeCount":101},[],{"trials":4552,"activeCount":101},[],{"trials":4554,"activeCount":101},[],{"intervention":4547,"totalTrials":424,"cells":4556},{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4567,"PHASE4":4569,"NA":4571},{"trials":4558,"activeCount":101},[],{"trials":4560,"activeCount":101},[],{"trials":4562,"activeCount":424,"soonestReadout":4134},[4563],{"nctId":4536,"briefTitle":4537,"status":285,"phases":4564,"primaryCompletion":4134,"completion":4539,"start":4540,"enrollment":2710,"conditions":4565,"interventions":4566},[91],[4542,4543,4544,4545,3772,3774],[4527,4547,4548],{"trials":4568,"activeCount":101},[],{"trials":4570,"activeCount":101},[],{"trials":4572,"activeCount":101},[],{"intervention":4548,"totalTrials":424,"cells":4574},{"EARLY_PHASE1":4575,"PHASE1":4577,"PHASE2":4579,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4576,"activeCount":101},[],{"trials":4578,"activeCount":101},[],{"trials":4580,"activeCount":424,"soonestReadout":4134},[4581],{"nctId":4536,"briefTitle":4537,"status":285,"phases":4582,"primaryCompletion":4134,"completion":4539,"start":4540,"enrollment":2710,"conditions":4583,"interventions":4584},[91],[4542,4543,4544,4545,3772,3774],[4527,4547,4548],{"trials":4586,"activeCount":101},[],{"trials":4588,"activeCount":101},[],{"trials":4590,"activeCount":101},[],{"intervention":4592,"totalTrials":424,"cells":4593},"25 mg\u002Fday zinc",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4609,"PHASE4":4611,"NA":4613},{"trials":4595,"activeCount":101},[],{"trials":4597,"activeCount":101},[],{"trials":4599,"activeCount":424,"soonestReadout":4604},[4600],{"nctId":4601,"briefTitle":4602,"status":285,"phases":4603,"primaryCompletion":4604,"completion":4134,"start":4605,"enrollment":510,"conditions":4606,"interventions":4607},"NCT06260891","Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial",[91],"2027-07-31","2026-02-14",[4083],[4592,4608],"40 mg\u002Fday zinc",{"trials":4610,"activeCount":101},[],{"trials":4612,"activeCount":101},[],{"trials":4614,"activeCount":101},[],{"intervention":4608,"totalTrials":424,"cells":4616},{"EARLY_PHASE1":4617,"PHASE1":4619,"PHASE2":4621,"PHASE3":4627,"PHASE4":4629,"NA":4631},{"trials":4618,"activeCount":101},[],{"trials":4620,"activeCount":101},[],{"trials":4622,"activeCount":424,"soonestReadout":4604},[4623],{"nctId":4601,"briefTitle":4602,"status":285,"phases":4624,"primaryCompletion":4604,"completion":4134,"start":4605,"enrollment":510,"conditions":4625,"interventions":4626},[91],[4083],[4592,4608],{"trials":4628,"activeCount":101},[],{"trials":4630,"activeCount":101},[],{"trials":4632,"activeCount":101},[],{"intervention":4634,"totalTrials":424,"cells":4635},"EXE-346 Probiotic",{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4640,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":424,"soonestReadout":4646},[4642],{"nctId":4643,"briefTitle":4644,"status":361,"phases":4645,"primaryCompletion":4646,"completion":1172,"start":1631,"enrollment":4317,"conditions":4647,"interventions":4651},"NCT06949800","CASCADE 2002: PROTECT Study, \"PRObiotics to TrEat Anal preCancer Trial",[91],"2027-04-30",[4648,4649,4650],"HSIL, High Grade Squamous Intraepithelial Lesion","HPV-Related Squamous Cell Carcinoma","Anal HSIL",[4634],{"trials":4653,"activeCount":101},[],{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[],{"intervention":4659,"totalTrials":424,"cells":4660},"Platelet-Rich Plasma (PRP) Injections",{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4665,"PHASE3":4679,"PHASE4":4681,"NA":4683},{"trials":4662,"activeCount":101},[],{"trials":4664,"activeCount":101},[],{"trials":4666,"activeCount":424,"soonestReadout":4671},[4667],{"nctId":4668,"briefTitle":4669,"status":285,"phases":4670,"primaryCompletion":4671,"completion":4671,"start":4672,"enrollment":1730,"conditions":4673,"interventions":4677},"NCT06451120","Platelet Rich Plasma Injections In Young And Old Human Subjects",[91],"2027-02-16","2024-06-01",[4674,4675,4676],"Osteoarthritis","Articular Cartilage","Musculoskeletal Disorders",[4659,4678],"Control saline",{"trials":4680,"activeCount":101},[],{"trials":4682,"activeCount":101},[],{"trials":4684,"activeCount":101},[],{"intervention":4678,"totalTrials":424,"cells":4686},{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4697,"PHASE4":4699,"NA":4701},{"trials":4688,"activeCount":101},[],{"trials":4690,"activeCount":101},[],{"trials":4692,"activeCount":424,"soonestReadout":4671},[4693],{"nctId":4668,"briefTitle":4669,"status":285,"phases":4694,"primaryCompletion":4671,"completion":4671,"start":4672,"enrollment":1730,"conditions":4695,"interventions":4696},[91],[4674,4675,4676],[4659,4678],{"trials":4698,"activeCount":101},[],{"trials":4700,"activeCount":101},[],{"trials":4702,"activeCount":101},[],{"intervention":4704,"totalTrials":424,"cells":4705},"Perampanel",{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4724,"PHASE4":4726,"NA":4728},{"trials":4707,"activeCount":101},[],{"trials":4709,"activeCount":101},[],{"trials":4711,"activeCount":424,"soonestReadout":4716},[4712],{"nctId":4713,"briefTitle":4714,"status":285,"phases":4715,"primaryCompletion":4716,"completion":4717,"start":4718,"enrollment":4031,"conditions":4719,"interventions":4723},"NCT06401707","PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest",[91],"2026-05-20","2026-10-20","2024-05-20",[4720,4721,4722],"Heart Arrest","Seizures","Status Epilepticus",[4704],{"trials":4725,"activeCount":101},[],{"trials":4727,"activeCount":101},[],{"trials":4729,"activeCount":101},[],{"intervention":3486,"totalTrials":424,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4742,"PHASE4":4744,"NA":4746},{"trials":4733,"activeCount":101},[],{"trials":4735,"activeCount":101},[],{"trials":4737,"activeCount":424,"soonestReadout":3478},[4738],{"nctId":3475,"briefTitle":3476,"status":285,"phases":4739,"primaryCompletion":3478,"completion":3479,"start":3480,"enrollment":1183,"conditions":4740,"interventions":4741},[91],[3482,3483,3484],[3486,2896,3487],{"trials":4743,"activeCount":101},[],{"trials":4745,"activeCount":101},[],{"trials":4747,"activeCount":101},[],{"intervention":3812,"totalTrials":424,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4760,"PHASE4":4762,"NA":4764},{"trials":4751,"activeCount":101},[],{"trials":4753,"activeCount":101},[],{"trials":4755,"activeCount":424,"soonestReadout":3478},[4756],{"nctId":3802,"briefTitle":3803,"status":285,"phases":4757,"primaryCompletion":3478,"completion":3805,"start":3806,"enrollment":1633,"conditions":4758,"interventions":4759},[90,91],[3808,3809,3810],[3812,3813,3751],{"trials":4761,"activeCount":101},[],{"trials":4763,"activeCount":101},[],{"trials":4765,"activeCount":101},[],{"intervention":3813,"totalTrials":424,"cells":4767},{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4778,"PHASE4":4780,"NA":4782},{"trials":4769,"activeCount":101},[],{"trials":4771,"activeCount":101},[],{"trials":4773,"activeCount":424,"soonestReadout":3478},[4774],{"nctId":3802,"briefTitle":3803,"status":285,"phases":4775,"primaryCompletion":3478,"completion":3805,"start":3806,"enrollment":1633,"conditions":4776,"interventions":4777},[90,91],[3808,3809,3810],[3812,3813,3751],{"trials":4779,"activeCount":101},[],{"trials":4781,"activeCount":101},[],{"trials":4783,"activeCount":101},[],{"intervention":4785,"totalTrials":424,"cells":4786},"Combination Intervention",{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4800,"PHASE4":4802,"NA":4804},{"trials":4788,"activeCount":101},[],{"trials":4790,"activeCount":101},[],{"trials":4792,"activeCount":424,"soonestReadout":649},[4793],{"nctId":4794,"briefTitle":4795,"status":152,"phases":4796,"primaryCompletion":649,"completion":649,"start":4797,"enrollment":541,"conditions":4798,"interventions":4799},"NCT04357821","Combinatorial Therapy to Induce an HIV Remission",[90,91],"2020-08-01",[33],[4785],{"trials":4801,"activeCount":101},[],{"trials":4803,"activeCount":101},[],{"trials":4805,"activeCount":101},[],{"intervention":4807,"totalTrials":424,"cells":4808},"AProArt-CD34",{"EARLY_PHASE1":4809,"PHASE1":4811,"PHASE2":4813,"PHASE3":4825,"PHASE4":4827,"NA":4829},{"trials":4810,"activeCount":101},[],{"trials":4812,"activeCount":101},[],{"trials":4814,"activeCount":424,"soonestReadout":4819},[4815],{"nctId":4816,"briefTitle":4817,"status":285,"phases":4818,"primaryCompletion":4819,"completion":4819,"start":4820,"enrollment":1202,"conditions":4821,"interventions":4823},"NCT03538899","Autologous Gene Therapy for Artemis-Deficient SCID",[90,91],"2038-06","2018-05-31",[4822],"Severe Combined Immunodeficiency",[4807,4824],"Busulfan",{"trials":4826,"activeCount":101},[],{"trials":4828,"activeCount":101},[],{"trials":4830,"activeCount":101},[],{"intervention":4832,"totalTrials":424,"cells":4833},"Intravenous TXA",{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4849,"PHASE4":4851,"NA":4853},{"trials":4835,"activeCount":101},[],{"trials":4837,"activeCount":101},[],{"trials":4839,"activeCount":424,"soonestReadout":4844},[4840],{"nctId":4841,"briefTitle":4842,"status":285,"phases":4843,"primaryCompletion":4844,"completion":4844,"start":3496,"enrollment":1466,"conditions":4845,"interventions":4848},"NCT05794321","Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy",[91],"2026-05",[4846,4847],"Postoperative Hematoma","Postoperative Seroma",[4832],{"trials":4850,"activeCount":101},[],{"trials":4852,"activeCount":101},[],{"trials":4854,"activeCount":101},[],{"intervention":4856,"totalTrials":424,"cells":4857},"Burst Suppression EEG Target Intravenous Anesthesia",{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4862,"PHASE3":4877,"PHASE4":4879,"NA":4881},{"trials":4859,"activeCount":101},[],{"trials":4861,"activeCount":101},[],{"trials":4863,"activeCount":424,"soonestReadout":4868},[4864],{"nctId":4865,"briefTitle":4866,"status":285,"phases":4867,"primaryCompletion":4868,"completion":4646,"start":4869,"enrollment":751,"conditions":4870,"interventions":4875},"NCT05851391","buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest",[91],"2026-11-30","2023-08-07",[4871,4720,4722,4872,4721,4873,4874],"Hypoxia-Ischemia, Brain","Refractory Status Epilepticus","Anoxic-Ischemic Encephalopathy","Anoxia-Ischemia, Cerebral",[4856,4876],"Seizure Suppression EEG Target Intravenous Anesthesia",{"trials":4878,"activeCount":101},[],{"trials":4880,"activeCount":101},[],{"trials":4882,"activeCount":101},[],{"intervention":4876,"totalTrials":424,"cells":4884},{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4895,"PHASE4":4897,"NA":4899},{"trials":4886,"activeCount":101},[],{"trials":4888,"activeCount":101},[],{"trials":4890,"activeCount":424,"soonestReadout":4868},[4891],{"nctId":4865,"briefTitle":4866,"status":285,"phases":4892,"primaryCompletion":4868,"completion":4646,"start":4869,"enrollment":751,"conditions":4893,"interventions":4894},[91],[4871,4720,4722,4872,4721,4873,4874],[4856,4876],{"trials":4896,"activeCount":101},[],{"trials":4898,"activeCount":101},[],{"trials":4900,"activeCount":101},[],{"intervention":4902,"totalTrials":424,"cells":4903},"Colesevelam",{"EARLY_PHASE1":4904,"PHASE1":4906,"PHASE2":4908,"PHASE3":4919,"PHASE4":4921,"NA":4923},{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[],{"trials":4909,"activeCount":424,"soonestReadout":945},[4910],{"nctId":4911,"briefTitle":4912,"status":285,"phases":4913,"primaryCompletion":945,"completion":945,"start":3221,"enrollment":434,"conditions":4914,"interventions":4918},"NCT07226440","Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)",[90,91],[4915,4916,4917],"Toxicant Exposure","Firefighter","Occupational Exposure to Chemicals",[4902],{"trials":4920,"activeCount":101},[],{"trials":4922,"activeCount":101},[],{"trials":4924,"activeCount":101},[],{"intervention":4926,"totalTrials":424,"cells":4927},"Radium-223",{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4946,"PHASE4":4948,"NA":4950},{"trials":4929,"activeCount":101},[],{"trials":4931,"activeCount":101},[],{"trials":4933,"activeCount":424,"soonestReadout":4938},[4934],{"nctId":4935,"briefTitle":4936,"status":152,"phases":4937,"primaryCompletion":4938,"completion":4939,"start":4940,"enrollment":526,"conditions":4941,"interventions":4944},"NCT05924672","Efficacy of Ra-223 in PSMA PET Optimally Selected Patients",[91],"2026-01-07","2027-03-31","2024-08-30",[3422,4942,4943],"Metastatic Malignant Neoplasm in the Bone","Stage IVB Prostate Cancer AJCC v8",[4926,4945],"Technetium Tc 99M Medronate",{"trials":4947,"activeCount":101},[],{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[],{"intervention":4945,"totalTrials":424,"cells":4953},{"EARLY_PHASE1":4954,"PHASE1":4956,"PHASE2":4958,"PHASE3":4964,"PHASE4":4966,"NA":4968},{"trials":4955,"activeCount":101},[],{"trials":4957,"activeCount":101},[],{"trials":4959,"activeCount":424,"soonestReadout":4938},[4960],{"nctId":4935,"briefTitle":4936,"status":152,"phases":4961,"primaryCompletion":4938,"completion":4939,"start":4940,"enrollment":526,"conditions":4962,"interventions":4963},[91],[3422,4942,4943],[4926,4945],{"trials":4965,"activeCount":101},[],{"trials":4967,"activeCount":101},[],{"trials":4969,"activeCount":101},[],{"intervention":87,"totalTrials":424,"cells":4971},{"EARLY_PHASE1":4972,"PHASE1":4974,"PHASE2":4976,"PHASE3":4984,"PHASE4":4986,"NA":4988},{"trials":4973,"activeCount":101},[],{"trials":4975,"activeCount":101},[],{"trials":4977,"activeCount":424,"soonestReadout":82},[4978],{"nctId":85,"briefTitle":86,"status":285,"phases":4979,"primaryCompletion":82,"completion":82,"start":4980,"enrollment":1730,"conditions":4981,"interventions":4983},[91],"2023-10-25",[4982,2994],"Acute Apical Abscess",[87],{"trials":4985,"activeCount":101},[],{"trials":4987,"activeCount":101},[],{"trials":4989,"activeCount":101},[],{"intervention":43,"totalTrials":424,"cells":4991},{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":4996,"PHASE3":5011,"PHASE4":5013,"NA":5015},{"trials":4993,"activeCount":101},[],{"trials":4995,"activeCount":101},[],{"trials":4997,"activeCount":424,"soonestReadout":42},[4998],{"nctId":40,"briefTitle":41,"status":152,"phases":4999,"primaryCompletion":42,"completion":5000,"start":5001,"enrollment":3567,"conditions":5002,"interventions":5010},[91],"2027-09-30","2018-07-31",[5003,5004,5005,5006,5007,5008,5009],"Stage I Non-Small Cell Lung Cancer","Stage IA Non-Small Cell Lung Cancer","Stage IB Non-Small Cell Lung Cancer","Stage II Non-Small Cell Lung Cancer","Stage IIA Non-Small Cell Lung Cancer","Stage IIB Non-Small Cell Lung Cancer","Stage IIIA Non-Small Cell Lung Cancer",[43],{"trials":5012,"activeCount":101},[],{"trials":5014,"activeCount":101},[],{"trials":5016,"activeCount":101},[],{"intervention":5018,"totalTrials":424,"cells":5019},"NisinZ® P",{"EARLY_PHASE1":5020,"PHASE1":5022,"PHASE2":5024,"PHASE3":5035,"PHASE4":5037,"NA":5039},{"trials":5021,"activeCount":101},[],{"trials":5023,"activeCount":101},[],{"trials":5025,"activeCount":424,"soonestReadout":299},[5026],{"nctId":5027,"briefTitle":5028,"status":285,"phases":5029,"primaryCompletion":299,"completion":5030,"start":5031,"enrollment":28,"conditions":5032,"interventions":5034},"NCT06097468","Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)",[90,91],"2028-10-01","2024-02-02",[5033],"Oral Cavity Squamous Cell Carcinoma",[5018],{"trials":5036,"activeCount":101},[],{"trials":5038,"activeCount":101},[],{"trials":5040,"activeCount":101},[],{"intervention":3853,"totalTrials":424,"cells":5042},{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5053,"PHASE4":5055,"NA":5057},{"trials":5044,"activeCount":101},[],{"trials":5046,"activeCount":101},[],{"trials":5048,"activeCount":424,"soonestReadout":3847},[5049],{"nctId":3844,"briefTitle":3845,"status":285,"phases":5050,"primaryCompletion":3847,"completion":3848,"start":3849,"enrollment":1633,"conditions":5051,"interventions":5052},[91],[3845,3851],[3853,3751],{"trials":5054,"activeCount":101},[],{"trials":5056,"activeCount":101},[],{"trials":5058,"activeCount":101},[],{"intervention":5060,"totalTrials":424,"cells":5061},"Vosoritide Injection [Voxzogo]",{"EARLY_PHASE1":5062,"PHASE1":5064,"PHASE2":5066,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5063,"activeCount":101},[],{"trials":5065,"activeCount":101},[],{"trials":5067,"activeCount":424,"soonestReadout":4362},[5068],{"nctId":5069,"briefTitle":5070,"status":152,"phases":5071,"primaryCompletion":4362,"completion":5072,"start":5073,"enrollment":2564,"conditions":5074,"interventions":5077},"NCT05845749","Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI",[90,91],"2029-12-31","2023-09-25",[5075,5076],"MPS IVA","MPS VI",[5060],{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":101},[],{"intervention":48,"totalTrials":424,"cells":5085},{"EARLY_PHASE1":5086,"PHASE1":5088,"PHASE2":5090,"PHASE3":5099,"PHASE4":5101,"NA":5103},{"trials":5087,"activeCount":101},[],{"trials":5089,"activeCount":101},[],{"trials":5091,"activeCount":424,"soonestReadout":47},[5092],{"nctId":45,"briefTitle":46,"status":152,"phases":5093,"primaryCompletion":47,"completion":5094,"start":5095,"enrollment":1071,"conditions":5096,"interventions":5098},[91],"2025-07","2022-01-28",[5097],"Bipolar II Disorder",[48],{"trials":5100,"activeCount":101},[],{"trials":5102,"activeCount":101},[],{"trials":5104,"activeCount":101},[],{"intervention":5106,"totalTrials":424,"cells":5107},"Obinutuzumab",{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5112,"PHASE3":5125,"PHASE4":5127,"NA":5129},{"trials":5109,"activeCount":101},[],{"trials":5111,"activeCount":101},[],{"trials":5113,"activeCount":424,"soonestReadout":5118},[5114],{"nctId":5115,"briefTitle":5116,"status":285,"phases":5117,"primaryCompletion":5118,"completion":5118,"start":5119,"enrollment":751,"conditions":5120,"interventions":5122},"NCT06252675","Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma",[91],"2028-07-31","2024-06-11",[5121],"Mantle Cell Lymphoma",[5106,5123,5124],"Glofitamab","Pirtobrutinib",{"trials":5126,"activeCount":101},[],{"trials":5128,"activeCount":101},[],{"trials":5130,"activeCount":101},[],{"intervention":5123,"totalTrials":424,"cells":5132},{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5137,"PHASE3":5143,"PHASE4":5145,"NA":5147},{"trials":5134,"activeCount":101},[],{"trials":5136,"activeCount":101},[],{"trials":5138,"activeCount":424,"soonestReadout":5118},[5139],{"nctId":5115,"briefTitle":5116,"status":285,"phases":5140,"primaryCompletion":5118,"completion":5118,"start":5119,"enrollment":751,"conditions":5141,"interventions":5142},[91],[5121],[5106,5123,5124],{"trials":5144,"activeCount":101},[],{"trials":5146,"activeCount":101},[],{"trials":5148,"activeCount":101},[],{"intervention":5124,"totalTrials":424,"cells":5150},{"EARLY_PHASE1":5151,"PHASE1":5153,"PHASE2":5155,"PHASE3":5161,"PHASE4":5163,"NA":5165},{"trials":5152,"activeCount":101},[],{"trials":5154,"activeCount":101},[],{"trials":5156,"activeCount":424,"soonestReadout":5118},[5157],{"nctId":5115,"briefTitle":5116,"status":285,"phases":5158,"primaryCompletion":5118,"completion":5118,"start":5119,"enrollment":751,"conditions":5159,"interventions":5160},[91],[5121],[5106,5123,5124],{"trials":5162,"activeCount":101},[],{"trials":5164,"activeCount":101},[],{"trials":5166,"activeCount":101},[],{"intervention":3589,"totalTrials":424,"cells":5168},{"EARLY_PHASE1":5169,"PHASE1":5171,"PHASE2":5173,"PHASE3":5179,"PHASE4":5181,"NA":5183},{"trials":5170,"activeCount":101},[],{"trials":5172,"activeCount":101},[],{"trials":5174,"activeCount":424,"soonestReadout":3478},[5175],{"nctId":3578,"briefTitle":3579,"status":285,"phases":5176,"primaryCompletion":3478,"completion":3478,"start":3581,"enrollment":3582,"conditions":5177,"interventions":5178},[90,91],[3584,3585,3586,3587],[3589,2896],{"trials":5180,"activeCount":101},[],{"trials":5182,"activeCount":101},[],{"trials":5184,"activeCount":101},[],{"intervention":2700,"totalTrials":424,"cells":5186},{"EARLY_PHASE1":5187,"PHASE1":5189,"PHASE2":5191,"PHASE3":5197,"PHASE4":5199,"NA":5201},{"trials":5188,"activeCount":101},[],{"trials":5190,"activeCount":101},[],{"trials":5192,"activeCount":424,"soonestReadout":2691},[5193],{"nctId":2688,"briefTitle":2689,"status":361,"phases":5194,"primaryCompletion":2691,"completion":2692,"start":589,"enrollment":2693,"conditions":5195,"interventions":5196},[91],[2695,2696,2697,2698],[2679,2700],{"trials":5198,"activeCount":101},[],{"trials":5200,"activeCount":101},[],{"trials":5202,"activeCount":101},[],{"intervention":684,"totalTrials":345,"cells":5204},{"EARLY_PHASE1":5205,"PHASE1":5207,"PHASE2":5227,"PHASE3":5268,"PHASE4":5270,"NA":5272},{"trials":5206,"activeCount":101},[],{"trials":5208,"activeCount":101},[5209,5213,5223],{"nctId":2571,"briefTitle":2572,"status":132,"phases":5210,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":792,"conditions":5211,"interventions":5212},[90],[679,717,2359,680],[719,2578,684,685,2470,2362],{"nctId":5214,"briefTitle":5215,"status":132,"phases":5216,"primaryCompletion":5217,"completion":5218,"start":5219,"enrollment":2818,"conditions":5220,"interventions":5222},"NCT01048827","Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen",[90],"2013-12-31","2015-02-25","2009-11",[5221],"Acute Myeloid Leukemia",[4824],{"nctId":2580,"briefTitle":2581,"status":132,"phases":5224,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":407,"conditions":5225,"interventions":5226},[90],[679,717,2359,680],[719,2578,684,2587,685,2588,2362],{"trials":5228,"activeCount":424,"soonestReadout":4819},[5229,5246,5250,5260,5264],{"nctId":5230,"briefTitle":5231,"status":120,"phases":5232,"primaryCompletion":5233,"completion":5233,"start":5234,"enrollment":1027,"conditions":5235,"interventions":5242},"NCT01596699","Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation",[91],"2019-06","2012-05-24",[5236,5237,5238,5239,5240,5241],"Myeloid Malignancy","Bone Marrow Failure Syndrome","Transfusion-dependent Red Blood Cell (RBC) Defect","Congenital Immunodeficiency","Metabolic Disease","Severe Immune Dysregulation",[5243,4824,5244,5245],"Alemtuzumab","Fludarabine","Clofarabine",{"nctId":2352,"briefTitle":2353,"status":111,"phases":5247,"primaryCompletion":714,"start":2355,"enrollment":101,"conditions":5248,"interventions":5249},[91],[2357,2358,679,717,2359,680,2360],[720,684,685,686,2362],{"nctId":5251,"briefTitle":5252,"status":132,"phases":5253,"primaryCompletion":5254,"completion":5254,"start":5255,"enrollment":28,"conditions":5256,"interventions":5259},"NCT00305708","Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission",[90,91],"2004-07","2000-08",[677,678,5257,679,681,5258],"Fanconi Anemia","Thrombocytopenia",[719,684,685],{"nctId":670,"briefTitle":671,"status":132,"phases":5261,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":5262,"interventions":5263},[91],[677,678,679,680,681],[683,684,661,685,686,687],{"nctId":4816,"briefTitle":4817,"status":285,"phases":5265,"primaryCompletion":4819,"completion":4819,"start":4820,"enrollment":1202,"conditions":5266,"interventions":5267},[90,91],[4822],[4807,4824],{"trials":5269,"activeCount":101},[],{"trials":5271,"activeCount":101},[],{"trials":5273,"activeCount":101},[5274,5278],{"nctId":2451,"briefTitle":2452,"status":132,"phases":5275,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":353,"conditions":5276,"interventions":5277},[94],[2358,679,717,2359,680],[719,720,721,684,685,686,2362],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":5279,"start":2464,"enrollment":675,"conditions":5280,"interventions":5281},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":5283,"totalTrials":526,"cells":5284},"cephalexin",{"EARLY_PHASE1":5285,"PHASE1":5287,"PHASE2":5289,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5286,"activeCount":101},[],{"trials":5288,"activeCount":101},[],{"trials":5290,"activeCount":424,"soonestReadout":1218},[5291],{"nctId":5292,"briefTitle":5293,"status":285,"phases":5294,"primaryCompletion":1218,"completion":1218,"start":5295,"enrollment":5296,"conditions":5297,"interventions":5300},"NCT05020574","Microbiome and Association With Implant Infections",[91],"2021-09-28",200,[24,5298,5299],"Breast Cancer Female","Genetic Predisposition to Disease",[5301],"Cephalexin",{"trials":5303,"activeCount":101},[],{"trials":5305,"activeCount":101},[],{"trials":5307,"activeCount":101},[5308],{"nctId":5309,"briefTitle":5310,"status":132,"phases":5311,"completion":5312,"start":5313,"enrollment":186,"conditions":5314,"interventions":5316},"NCT00187759","Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection",[94],"2005-03","2004-11",[5315],"Soft Tissue Infections",[5283],{"intervention":3599,"totalTrials":324,"cells":5318},{"EARLY_PHASE1":5319,"PHASE1":5321,"PHASE2":5340,"PHASE3":5346,"PHASE4":5348,"NA":5350},{"trials":5320,"activeCount":101},[],{"trials":5322,"activeCount":424,"soonestReadout":3478},[5323,5336],{"nctId":5324,"briefTitle":5325,"status":285,"phases":5326,"primaryCompletion":3478,"completion":3478,"start":5327,"enrollment":1202,"conditions":5328,"interventions":5334},"NCT05694715","Combination Therapy in Cancers With Mutations in DNA Repair Genes",[90],"2023-05-23",[5329,5330,5331,5332,5333],"Metastatic Solid Tumor","BRCA1 Mutation","BRCA2 Mutation","ATM Gene Mutation","PALB2 Gene Mutation",[5335,3599],"Niraparib",{"nctId":3778,"briefTitle":3779,"status":132,"phases":5337,"primaryCompletion":3440,"completion":3781,"start":3782,"enrollment":1027,"conditions":5338,"interventions":5339},[90],[3784,3785],[3787,3599,3751],{"trials":5341,"activeCount":101},[5342],{"nctId":3591,"briefTitle":3592,"status":132,"phases":5343,"primaryCompletion":3594,"completion":3594,"start":3595,"enrollment":31,"conditions":5344,"interventions":5345},[91],[3597],[2896,3599,2760],{"trials":5347,"activeCount":101},[],{"trials":5349,"activeCount":101},[],{"trials":5351,"activeCount":101},[],{"intervention":423,"totalTrials":424,"cells":5353},{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5362,"PHASE3":5364,"PHASE4":5366,"NA":5368},{"trials":5355,"activeCount":101},[],{"trials":5357,"activeCount":424,"soonestReadout":298},[5358],{"nctId":414,"briefTitle":415,"status":285,"phases":5359,"primaryCompletion":298,"completion":298,"start":417,"enrollment":418,"conditions":5360,"interventions":5361},[90],[420,421],[423,406],{"trials":5363,"activeCount":101},[],{"trials":5365,"activeCount":101},[],{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[],{"intervention":5371,"totalTrials":424,"cells":5372},"Autologous Anti-H3.3K27M TCR-expressing T-cells",{"EARLY_PHASE1":5373,"PHASE1":5375,"PHASE2":5384,"PHASE3":5386,"PHASE4":5388,"NA":5390},{"trials":5374,"activeCount":101},[],{"trials":5376,"activeCount":424,"soonestReadout":196},[5377],{"nctId":5378,"briefTitle":5379,"status":152,"phases":5380,"primaryCompletion":196,"completion":196,"start":5381,"enrollment":2818,"conditions":5382,"interventions":5383},"NCT05478837","Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma",[90],"2023-07-20",[4543],[2382,5244,5371],{"trials":5385,"activeCount":101},[],{"trials":5387,"activeCount":101},[],{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[],{"intervention":3776,"totalTrials":424,"cells":5393},{"EARLY_PHASE1":5394,"PHASE1":5396,"PHASE2":5402,"PHASE3":5404,"PHASE4":5406,"NA":5408},{"trials":5395,"activeCount":101},[],{"trials":5397,"activeCount":424,"soonestReadout":343},[5398],{"nctId":3758,"briefTitle":3759,"status":152,"phases":5399,"primaryCompletion":343,"completion":3761,"start":3762,"enrollment":3763,"conditions":5400,"interventions":5401},[90],[3765,3766,3767,3768,3769,3770,3771,3772,3773,3774],[3776,3751],{"trials":5403,"activeCount":101},[],{"trials":5405,"activeCount":101},[],{"trials":5407,"activeCount":101},[],{"trials":5409,"activeCount":101},[],{"intervention":5411,"totalTrials":424,"cells":5412},"(S)-Nicotine",{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5429,"PHASE3":5431,"PHASE4":5433,"NA":5435},{"trials":5414,"activeCount":101},[],{"trials":5416,"activeCount":424,"soonestReadout":694},[5417],{"nctId":5418,"briefTitle":5419,"status":285,"phases":5420,"primaryCompletion":694,"completion":694,"start":5421,"enrollment":5422,"conditions":5423,"interventions":5426},"NCT05962229","Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine",[90],"2024-12-06",18,[5424,5425],"Nicotine Dependence","Nicotine Vaping",[5411,5427,5428],"(R)- nicotine","Racemic nicotine",{"trials":5430,"activeCount":101},[],{"trials":5432,"activeCount":101},[],{"trials":5434,"activeCount":101},[],{"trials":5436,"activeCount":101},[],{"intervention":5427,"totalTrials":424,"cells":5438},{"EARLY_PHASE1":5439,"PHASE1":5441,"PHASE2":5447,"PHASE3":5449,"PHASE4":5451,"NA":5453},{"trials":5440,"activeCount":101},[],{"trials":5442,"activeCount":424,"soonestReadout":694},[5443],{"nctId":5418,"briefTitle":5419,"status":285,"phases":5444,"primaryCompletion":694,"completion":694,"start":5421,"enrollment":5422,"conditions":5445,"interventions":5446},[90],[5424,5425],[5411,5427,5428],{"trials":5448,"activeCount":101},[],{"trials":5450,"activeCount":101},[],{"trials":5452,"activeCount":101},[],{"trials":5454,"activeCount":101},[],{"intervention":5428,"totalTrials":424,"cells":5456},{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5465,"PHASE3":5467,"PHASE4":5469,"NA":5471},{"trials":5458,"activeCount":101},[],{"trials":5460,"activeCount":424,"soonestReadout":694},[5461],{"nctId":5418,"briefTitle":5419,"status":285,"phases":5462,"primaryCompletion":694,"completion":694,"start":5421,"enrollment":5422,"conditions":5463,"interventions":5464},[90],[5424,5425],[5411,5427,5428],{"trials":5466,"activeCount":101},[],{"trials":5468,"activeCount":101},[],{"trials":5470,"activeCount":101},[],{"trials":5472,"activeCount":101},[],{"intervention":5474,"totalTrials":424,"cells":5475},"Bicalutamide 50 mg",{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5477,"activeCount":101},[],{"trials":5479,"activeCount":424,"soonestReadout":4315},[5480],{"nctId":5481,"briefTitle":5482,"status":285,"phases":5483,"primaryCompletion":4315,"completion":4315,"start":5484,"enrollment":434,"conditions":5485,"interventions":5487},"NCT05979389","Bicalutamide Therapy in Young Women With NAFLD and PCOS",[90],"2024-02-14",[5486,3723],"NAFLD",[5474],{"trials":5489,"activeCount":101},[],{"trials":5491,"activeCount":101},[],{"trials":5493,"activeCount":101},[],{"trials":5495,"activeCount":101},[],{"intervention":63,"totalTrials":424,"cells":5497},{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5509,"PHASE3":5511,"PHASE4":5513,"NA":5515},{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":424,"soonestReadout":62},[5502],{"nctId":60,"briefTitle":61,"status":152,"phases":5503,"primaryCompletion":62,"completion":5094,"start":5504,"enrollment":1060,"conditions":5505,"interventions":5506},[90],"2022-05-26",[30],[63,5507,5508],"Psilocybin","Sublingual Psilocin",{"trials":5510,"activeCount":101},[],{"trials":5512,"activeCount":101},[],{"trials":5514,"activeCount":101},[],{"trials":5516,"activeCount":101},[],{"intervention":5507,"totalTrials":424,"cells":5518},{"EARLY_PHASE1":5519,"PHASE1":5521,"PHASE2":5527,"PHASE3":5529,"PHASE4":5531,"NA":5533},{"trials":5520,"activeCount":101},[],{"trials":5522,"activeCount":424,"soonestReadout":62},[5523],{"nctId":60,"briefTitle":61,"status":152,"phases":5524,"primaryCompletion":62,"completion":5094,"start":5504,"enrollment":1060,"conditions":5525,"interventions":5526},[90],[30],[63,5507,5508],{"trials":5528,"activeCount":101},[],{"trials":5530,"activeCount":101},[],{"trials":5532,"activeCount":101},[],{"trials":5534,"activeCount":101},[],{"intervention":5508,"totalTrials":424,"cells":5536},{"EARLY_PHASE1":5537,"PHASE1":5539,"PHASE2":5545,"PHASE3":5547,"PHASE4":5549,"NA":5551},{"trials":5538,"activeCount":101},[],{"trials":5540,"activeCount":424,"soonestReadout":62},[5541],{"nctId":60,"briefTitle":61,"status":152,"phases":5542,"primaryCompletion":62,"completion":5094,"start":5504,"enrollment":1060,"conditions":5543,"interventions":5544},[90],[30],[63,5507,5508],{"trials":5546,"activeCount":101},[],{"trials":5548,"activeCount":101},[],{"trials":5550,"activeCount":101},[],{"trials":5552,"activeCount":101},[],{"intervention":5554,"totalTrials":424,"cells":5555},"Aldurazyme",{"EARLY_PHASE1":5556,"PHASE1":5558,"PHASE2":5575,"PHASE3":5577,"PHASE4":5579,"NA":5581},{"trials":5557,"activeCount":101},[],{"trials":5559,"activeCount":424,"soonestReadout":5564},[5560],{"nctId":5561,"briefTitle":5562,"status":285,"phases":5563,"primaryCompletion":5564,"completion":5565,"start":988,"enrollment":345,"conditions":5566,"interventions":5574},"NCT04532047","PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)",[90],"2031-07-31","2032-07-31",[5567,5568,5075,5076,5569,5570,5571,5572,5573],"MPS I","MPS II","Mps VII","Gaucher Disease, Type 2","Gaucher Disease, Type 3","Pompe Disease Infantile-Onset","Wolman Disease",[5554],{"trials":5576,"activeCount":101},[],{"trials":5578,"activeCount":101},[],{"trials":5580,"activeCount":101},[],{"trials":5582,"activeCount":101},[],{"intervention":5335,"totalTrials":424,"cells":5584},{"EARLY_PHASE1":5585,"PHASE1":5587,"PHASE2":5593,"PHASE3":5595,"PHASE4":5597,"NA":5599},{"trials":5586,"activeCount":101},[],{"trials":5588,"activeCount":424,"soonestReadout":3478},[5589],{"nctId":5324,"briefTitle":5325,"status":285,"phases":5590,"primaryCompletion":3478,"completion":3478,"start":5327,"enrollment":1202,"conditions":5591,"interventions":5592},[90],[5329,5330,5331,5332,5333],[5335,3599],{"trials":5594,"activeCount":101},[],{"trials":5596,"activeCount":101},[],{"trials":5598,"activeCount":101},[],{"trials":5600,"activeCount":101},[],{"intervention":5602,"totalTrials":424,"cells":5603},"Typhoid VI Polysaccharide Vaccine Injectable Solution",{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5618,"PHASE3":5620,"PHASE4":5622,"NA":5624},{"trials":5605,"activeCount":101},[],{"trials":5607,"activeCount":424,"soonestReadout":5612},[5608],{"nctId":5609,"briefTitle":5610,"status":285,"phases":5611,"primaryCompletion":5612,"completion":5612,"start":5613,"enrollment":5614,"conditions":5615,"interventions":5617},"NCT06630884","Inflammatory Challenge and Fear",[90],"2028-11","2025-03-28",288,[5616],"Posttraumatic Stress Disorder (PTSD)",[5602],{"trials":5619,"activeCount":101},[],{"trials":5621,"activeCount":101},[],{"trials":5623,"activeCount":101},[],{"trials":5625,"activeCount":101},[],{"intervention":5627,"totalTrials":424,"cells":5628},"Aripiprazole 10 MG",{"EARLY_PHASE1":5629,"PHASE1":5631,"PHASE2":5641,"PHASE3":5643,"PHASE4":5645,"NA":5647},{"trials":5630,"activeCount":101},[],{"trials":5632,"activeCount":424,"soonestReadout":343},[5633],{"nctId":5634,"briefTitle":5635,"status":285,"phases":5636,"primaryCompletion":343,"completion":343,"start":5637,"enrollment":28,"conditions":5638,"interventions":5640},"NCT07215884","Dopamine and Sensorimotor Function in Stuttering",[90],"2025-09-30",[5639],"Stuttering, Adult",[5627],{"trials":5642,"activeCount":101},[],{"trials":5644,"activeCount":101},[],{"trials":5646,"activeCount":101},[],{"trials":5648,"activeCount":101},[],{"intervention":5650,"totalTrials":424,"cells":5651},"[89]Zr-DFO-VRC-HIVMAB060-00-AB",{"EARLY_PHASE1":5652,"PHASE1":5654,"PHASE2":5663,"PHASE3":5665,"PHASE4":5667,"NA":5669},{"trials":5653,"activeCount":101},[],{"trials":5655,"activeCount":424,"soonestReadout":5660},[5656],{"nctId":5657,"briefTitle":5658,"status":285,"phases":5659,"primaryCompletion":5660,"completion":3005,"start":509,"enrollment":751,"conditions":5661,"interventions":5662},"NCT03729752","PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)",[90],"2026-10-31",[1073],[5650],{"trials":5664,"activeCount":101},[],{"trials":5666,"activeCount":101},[],{"trials":5668,"activeCount":101},[],{"trials":5670,"activeCount":101},[],{"intervention":2398,"totalTrials":555,"cells":5672},{"EARLY_PHASE1":5673,"PHASE1":5675,"PHASE2":5685,"PHASE3":5716,"PHASE4":5718,"NA":5720},{"trials":5674,"activeCount":101},[],{"trials":5676,"activeCount":424,"soonestReadout":196},[5677,5681],{"nctId":5378,"briefTitle":5379,"status":152,"phases":5678,"primaryCompletion":196,"completion":196,"start":5381,"enrollment":2818,"conditions":5679,"interventions":5680},[90],[4543],[2382,5244,5371],{"nctId":4272,"briefTitle":4273,"status":132,"phases":5682,"primaryCompletion":4275,"completion":4275,"start":2723,"enrollment":675,"conditions":5683,"interventions":5684},[90],[4277],[815,2398,4279],{"trials":5686,"activeCount":101},[5687,5696,5708,5712],{"nctId":5688,"briefTitle":5689,"status":132,"phases":5690,"completion":3860,"start":5691,"conditions":5692,"interventions":5694},"NCT00028964","Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer",[90,91],"2001-02",[24,5693],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[2398,5695],"doxorubicin hydrochloride",{"nctId":5697,"briefTitle":5698,"status":132,"phases":5699,"primaryCompletion":5700,"completion":5700,"start":5701,"enrollment":22,"conditions":5702,"interventions":5706},"NCT01554371","Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies",[90,91],"2019-12-31","2012-03-27",[5703,5704,5705],"Malignant Solid Tumour","Breast Cancer Nos Metastatic Recurrent","Neuropathy",[5707,2382],"Eribulin",{"nctId":2368,"briefTitle":2369,"status":120,"phases":5709,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":5710,"interventions":5711},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"nctId":2390,"briefTitle":2391,"status":120,"phases":5713,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":34,"conditions":5714,"interventions":5715},[90,91],[24],[2398,686,2399],{"trials":5717,"activeCount":101},[],{"trials":5719,"activeCount":101},[],{"trials":5721,"activeCount":101},[5722,5740],{"nctId":5723,"briefTitle":5724,"status":132,"phases":5725,"primaryCompletion":3829,"completion":5726,"start":5727,"enrollment":2495,"conditions":5728,"interventions":5735},"NCT00755313","Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer",[],"2014-06-06","2007-05",[24,5729,5730,5731,5732,5733,5734],"Chemotherapeutic Agent Toxicity","Cognitive\u002FFunctional Effects","Fatigue","Long-term Effects Secondary to Cancer Therapy in Adults","Neurotoxicity","Psychosocial Effects of Cancer and Its Treatment",[5736,5737,5738,2398,5739,5695],"trastuzumab","aromatase inhibition therapy","carboplatin","docetaxel",{"nctId":2460,"briefTitle":2461,"status":2462,"phases":5741,"start":2464,"enrollment":675,"conditions":5742,"interventions":5743},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":5244,"totalTrials":480,"cells":5745},{"EARLY_PHASE1":5746,"PHASE1":5748,"PHASE2":5754,"PHASE3":5760,"PHASE4":5762,"NA":5764},{"trials":5747,"activeCount":101},[],{"trials":5749,"activeCount":424,"soonestReadout":196},[5750],{"nctId":5378,"briefTitle":5379,"status":152,"phases":5751,"primaryCompletion":196,"completion":196,"start":5381,"enrollment":2818,"conditions":5752,"interventions":5753},[90],[4543],[2382,5244,5371],{"trials":5755,"activeCount":101},[5756],{"nctId":5230,"briefTitle":5231,"status":120,"phases":5757,"primaryCompletion":5233,"completion":5233,"start":5234,"enrollment":1027,"conditions":5758,"interventions":5759},[91],[5236,5237,5238,5239,5240,5241],[5243,4824,5244,5245],{"trials":5761,"activeCount":101},[],{"trials":5763,"activeCount":101},[],{"trials":5765,"activeCount":101},[5766,5781],{"nctId":5767,"briefTitle":5768,"status":132,"phases":5769,"primaryCompletion":5770,"completion":5770,"start":5771,"enrollment":5772,"conditions":5773,"interventions":5780},"NCT01316549","Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation",[],"2016-04-30","2011-01-01",67,[5774,5775,5776,5777,5778,5257,5779,4083],"Hematologic Malignancies","Nonmalignant Diseases","Immunodeficiencies","Hemoglobinopathies","Genetic Inborn Errors of Metabolism","Thalassemia",[5244],{"nctId":5782,"briefTitle":5783,"status":132,"phases":5784,"primaryCompletion":5785,"completion":5785,"start":5786,"enrollment":751,"conditions":5787,"interventions":5789},"NCT03609814","Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)",[],"2020-06-30","2016-01-26",[5774,5775,5776,5777,5778,5788,5779,4083],"Fanconi's Anemia",[5245,5244],{"intervention":53,"totalTrials":424,"cells":5791},{"EARLY_PHASE1":5792,"PHASE1":5799,"PHASE2":5801,"PHASE3":5803,"PHASE4":5805,"NA":5807},{"trials":5793,"activeCount":424,"soonestReadout":52},[5794],{"nctId":50,"briefTitle":51,"status":285,"phases":5795,"primaryCompletion":52,"completion":2793,"start":5796,"enrollment":345,"conditions":5797,"interventions":5798},[89],"2018-04-01",[1073],[53],{"trials":5800,"activeCount":101},[],{"trials":5802,"activeCount":101},[],{"trials":5804,"activeCount":101},[],{"trials":5806,"activeCount":101},[],{"trials":5808,"activeCount":101},[],{"intervention":5810,"totalTrials":424,"cells":5811},"Doxycycline Pill",{"EARLY_PHASE1":5812,"PHASE1":5824,"PHASE2":5826,"PHASE3":5828,"PHASE4":5830,"NA":5832},{"trials":5813,"activeCount":424,"soonestReadout":5818},[5814],{"nctId":5815,"briefTitle":5816,"status":285,"phases":5817,"primaryCompletion":5818,"completion":5819,"start":5820,"enrollment":3553,"conditions":5821,"interventions":5823},"NCT06414408","Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP",[89],"2026-09-01","2028-09-01","2024-10-18",[5822],"Sexually Transmitted Diseases, Bacterial",[5810],{"trials":5825,"activeCount":101},[],{"trials":5827,"activeCount":101},[],{"trials":5829,"activeCount":101},[],{"trials":5831,"activeCount":101},[],{"trials":5833,"activeCount":101},[],{"intervention":5835,"totalTrials":424,"cells":5836},"Visbiome",{"EARLY_PHASE1":5837,"PHASE1":5848,"PHASE2":5850,"PHASE3":5852,"PHASE4":5854,"NA":5856},{"trials":5838,"activeCount":424,"soonestReadout":5843},[5839],{"nctId":5840,"briefTitle":5841,"status":285,"phases":5842,"primaryCompletion":5843,"completion":693,"start":5844,"enrollment":5845,"conditions":5846,"interventions":5847},"NCT06898788","Probiotic Administration for Adolescent Depression",[89],"2026-08","2025-05-15",77,[27],[5835],{"trials":5849,"activeCount":101},[],{"trials":5851,"activeCount":101},[],{"trials":5853,"activeCount":101},[],{"trials":5855,"activeCount":101},[],{"trials":5857,"activeCount":101},[],{"intervention":5859,"totalTrials":424,"cells":5860},"RNA and DNA Sequencing",{"EARLY_PHASE1":5861,"PHASE1":5863,"PHASE2":5865,"PHASE3":5867,"PHASE4":5869,"NA":5871},{"trials":5862,"activeCount":101},[],{"trials":5864,"activeCount":101},[],{"trials":5866,"activeCount":101},[],{"trials":5868,"activeCount":101},[],{"trials":5870,"activeCount":101},[],{"trials":5872,"activeCount":424,"soonestReadout":5877},[5873],{"nctId":5874,"briefTitle":5875,"status":285,"phases":5876,"primaryCompletion":5877,"completion":4004,"start":5878,"enrollment":5879,"conditions":5880,"interventions":5889},"NCT06809868","Role of Transposable Elements in Septic Immune Aging",[],"2028-02-14","2025-02-14",116,[5881,5882,5883,5884,5885,5886,5887,5888],"Sepsis","Sepsis and Septic Shock","Sepsis With Multiple Organ Dysfunction (MOD)","Sepsis With Acute Organ Dysfunction","Sepsis, Severe","Sepsis at Intensive Care Unit","Sepsis, Severe Sepsis and Septic Shock","Sepsis, Septic Shock",[5859],{"intervention":5891,"totalTrials":424,"cells":5892},"Galcanezumab",{"EARLY_PHASE1":5893,"PHASE1":5895,"PHASE2":5897,"PHASE3":5899,"PHASE4":5901,"NA":5903},{"trials":5894,"activeCount":101},[],{"trials":5896,"activeCount":101},[],{"trials":5898,"activeCount":101},[],{"trials":5900,"activeCount":101},[],{"trials":5902,"activeCount":101},[],{"trials":5904,"activeCount":424,"soonestReadout":1801},[5905],{"nctId":5906,"briefTitle":5907,"status":285,"phases":5908,"primaryCompletion":1801,"completion":1801,"start":5909,"enrollment":751,"conditions":5910,"interventions":5912},"NCT06085144","Emgality for Migraine in Breastmilk",[],"2024-02-26",[5911],"Migraine",[5891],{"intervention":5914,"totalTrials":424,"cells":5915},"Clinic-Administered LAI-ART",{"EARLY_PHASE1":5916,"PHASE1":5918,"PHASE2":5920,"PHASE3":5922,"PHASE4":5924,"NA":5926},{"trials":5917,"activeCount":101},[],{"trials":5919,"activeCount":101},[],{"trials":5921,"activeCount":101},[],{"trials":5923,"activeCount":101},[],{"trials":5925,"activeCount":101},[],{"trials":5927,"activeCount":424,"soonestReadout":740},[5928],{"nctId":5929,"briefTitle":5930,"status":691,"phases":5931,"primaryCompletion":740,"completion":5932,"start":5933,"enrollment":5934,"conditions":5935,"interventions":5936},"NCT06488846","Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home",[],"2027-09-29","2026-02-16",1000,[18],[5914,5937],"Oral ART",{"intervention":5937,"totalTrials":424,"cells":5939},{"EARLY_PHASE1":5940,"PHASE1":5942,"PHASE2":5944,"PHASE3":5946,"PHASE4":5948,"NA":5950},{"trials":5941,"activeCount":101},[],{"trials":5943,"activeCount":101},[],{"trials":5945,"activeCount":101},[],{"trials":5947,"activeCount":101},[],{"trials":5949,"activeCount":101},[],{"trials":5951,"activeCount":424,"soonestReadout":740},[5952],{"nctId":5929,"briefTitle":5930,"status":691,"phases":5953,"primaryCompletion":740,"completion":5932,"start":5933,"enrollment":5934,"conditions":5954,"interventions":5955},[],[18],[5914,5937],{"intervention":5957,"totalTrials":424,"cells":5958},"Non-Investigational Antibody-Drug Conjugates",{"EARLY_PHASE1":5959,"PHASE1":5961,"PHASE2":5963,"PHASE3":5965,"PHASE4":5967,"NA":5969},{"trials":5960,"activeCount":101},[],{"trials":5962,"activeCount":101},[],{"trials":5964,"activeCount":101},[],{"trials":5966,"activeCount":101},[],{"trials":5968,"activeCount":101},[],{"trials":5970,"activeCount":424,"soonestReadout":5975},[5971],{"nctId":5972,"briefTitle":5973,"status":285,"phases":5974,"primaryCompletion":5975,"completion":5975,"start":5976,"enrollment":1220,"conditions":5977,"interventions":5983},"NCT06774027","Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer",[],"2030-12-31","2025-10-08",[5978,5979,2884,5980,5981,5982],"HER2-negative Breast Cancer","HER2 Negative Breast Carcinoma","HR+ HER2 Breast Cancer","Metastatic Triple Negative Breast Cancers","Metastatic Triple-Negative Breast Carcinoma",[5957],{"intervention":5985,"totalTrials":424,"cells":5986},"Fluorodeoxyglucose F18",{"EARLY_PHASE1":5987,"PHASE1":5989,"PHASE2":5991,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5988,"activeCount":101},[],{"trials":5990,"activeCount":101},[],{"trials":5992,"activeCount":101},[],{"trials":5994,"activeCount":101},[],{"trials":5996,"activeCount":101},[],{"trials":5998,"activeCount":424,"soonestReadout":6003},[5999],{"nctId":6000,"briefTitle":6001,"status":285,"phases":6002,"primaryCompletion":6003,"completion":6004,"start":1705,"enrollment":751,"conditions":6005,"interventions":6006},"NCT06630845","Comparison of Whole Body DWI to FDG PET",[94],"2027-10-31","2029-10-31",[3862],[5985],{"intervention":6008,"totalTrials":424,"cells":6009},"Deuterated Glucose",{"EARLY_PHASE1":6010,"PHASE1":6012,"PHASE2":6014,"PHASE3":6016,"PHASE4":6018,"NA":6020},{"trials":6011,"activeCount":101},[],{"trials":6013,"activeCount":101},[],{"trials":6015,"activeCount":101},[],{"trials":6017,"activeCount":101},[],{"trials":6019,"activeCount":101},[],{"trials":6021,"activeCount":424,"soonestReadout":4604},[6022],{"nctId":6023,"briefTitle":6024,"status":152,"phases":6025,"primaryCompletion":4604,"completion":4604,"start":6026,"enrollment":2335,"conditions":6027,"interventions":6029},"NCT06594315","Assessing Brain Metabolism Using MRS With Deuterated Glucose",[],"2022-07-20",[6028],"Glioma",[6008],{"intervention":6031,"totalTrials":2818,"cells":6032},"Oxytocin",{"EARLY_PHASE1":6033,"PHASE1":6093,"PHASE2":6139,"PHASE3":6141,"PHASE4":6143,"NA":6153},{"trials":6034,"activeCount":101},[6035,6047,6055,6065,6076,6085],{"nctId":6036,"briefTitle":6037,"status":132,"phases":6038,"primaryCompletion":6039,"completion":6039,"start":3829,"enrollment":6040,"conditions":6041,"interventions":6045},"NCT02566356","Adult Study Oxytocin - fMRI",[89],"2017-09",59,[6042,6031,6043,6044],"Schizophrenia","Social Cognition","Functional Magnetic Resonance Imaging (fMRI)",[6031,6046],"Saline Nasal Spray",{"nctId":6048,"briefTitle":6049,"status":132,"phases":6050,"primaryCompletion":6051,"completion":6051,"start":6052,"enrollment":3797,"conditions":6053,"interventions":6054},"NCT02577575","Adult Oxytocin Study",[89],"2015-11","2010-08",[6042,6031,6043],[6031,6046],{"nctId":6056,"briefTitle":6057,"status":132,"phases":6058,"primaryCompletion":6059,"completion":6059,"start":806,"enrollment":6060,"conditions":6061,"interventions":6064},"NCT02469259","The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD",[89],"2018-02-28",88,[6062,6063],"Stress Disorders, Post-Traumatic","Alcoholism",[6031],{"nctId":6066,"briefTitle":6067,"status":132,"phases":6068,"primaryCompletion":6069,"completion":6069,"start":1913,"enrollment":6070,"conditions":6071,"interventions":6075},"NCT01728909","Methadone Oxytocin Option",[89],"2014-10",64,[6072,6073,6074],"Substance Abuse","Opioid Dependence","Methadone Treatment",[6031,6046],{"nctId":6077,"briefTitle":6078,"status":132,"phases":6079,"primaryCompletion":6080,"completion":6080,"start":2407,"enrollment":6081,"conditions":6082,"interventions":6084},"NCT02567032","Adult Study Oxytocin - Behavioral",[89],"2019-08",324,[6042,6031,6043,6083],"Psychotic Disorders",[6031,6046],{"nctId":6086,"briefTitle":6087,"status":132,"phases":6088,"primaryCompletion":6089,"completion":6089,"start":2436,"enrollment":28,"conditions":6090,"interventions":6092},"NCT02568709","Oxytocin MEG Study",[89],"2016-12",[6042,6031,6091,6043],"Magnetoencephalography (MEG)",[6031,6046],{"trials":6094,"activeCount":101},[6095,6105,6113,6121,6128],{"nctId":6096,"briefTitle":6097,"status":132,"phases":6098,"primaryCompletion":6099,"completion":6099,"start":6100,"enrollment":6101,"conditions":6102,"interventions":6104},"NCT02302209","Dyad Oxytocin Study (DOS)",[90],"2017-10","2011-04",104,[6042,6103],"Autism Spectrum Disorder",[6031],{"nctId":6106,"briefTitle":6107,"status":111,"phases":6108,"primaryCompletion":6109,"completion":6109,"start":2418,"enrollment":101,"conditions":6110,"interventions":6112},"NCT01912378","Triadic Interactions of Families With Autism and Oxytocin",[90],"2015-05",[6111],"Autism Disorder",[6031],{"nctId":6114,"briefTitle":6115,"status":132,"phases":6116,"primaryCompletion":205,"completion":205,"start":6117,"enrollment":751,"conditions":6118,"interventions":6120},"NCT02028533","Cocaine Opioid Oxytocin Option - Limited",[90],"2014-07",[1569,6119],"Cocaine Use Disorder",[6031],{"nctId":6122,"briefTitle":6123,"status":132,"phases":6124,"primaryCompletion":1245,"completion":1245,"start":226,"enrollment":3553,"conditions":6125,"interventions":6127},"NCT02881177","Oxytocin HIV Meth Study",[90],[6126],"Amphetamine Use Disorders",[6031],{"nctId":6129,"briefTitle":6130,"status":132,"phases":6131,"primaryCompletion":6132,"completion":6133,"start":6134,"enrollment":6135,"conditions":6136,"interventions":6138},"NCT02302430","Intranasal Oxytocin and Enhancement of Team Cohesion",[90],"2018-05","2019-05-31","2015-10",486,[6137],"Unit Cohesion",[6031],{"trials":6140,"activeCount":101},[],{"trials":6142,"activeCount":101},[],{"trials":6144,"activeCount":101},[6145],{"nctId":6146,"briefTitle":6147,"status":132,"phases":6148,"primaryCompletion":6149,"completion":165,"start":3818,"enrollment":34,"conditions":6150,"interventions":6152},"NCT01829516","Intranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers",[93],"2014-05",[6151],"AOD Use, Abuse, and Dependence",[6031],{"trials":6154,"activeCount":101},[],{"intervention":815,"totalTrials":2818,"cells":6156},{"EARLY_PHASE1":6157,"PHASE1":6159,"PHASE2":6175,"PHASE3":6223,"PHASE4":6237,"NA":6243},{"trials":6158,"activeCount":101},[],{"trials":6160,"activeCount":101},[6161,6165],{"nctId":4272,"briefTitle":4273,"status":132,"phases":6162,"primaryCompletion":4275,"completion":4275,"start":2723,"enrollment":675,"conditions":6163,"interventions":6164},[90],[4277],[815,2398,4279],{"nctId":6166,"briefTitle":6167,"status":132,"phases":6168,"primaryCompletion":6169,"completion":6170,"start":6171,"enrollment":526,"conditions":6172,"interventions":6174},"NCT02314377","Bevacizumab Therapy for Brain Arteriovenous Malformation",[90],"2018-12-01","2019-12-01","2016-06",[6173],"Brain Arteriovenous Malformation",[476],{"trials":6176,"activeCount":101},[6177,6181,6185,6194,6204,6208,6216],{"nctId":3458,"briefTitle":3459,"status":132,"phases":6178,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":22,"conditions":6179,"interventions":6180},[91],[3464,3465,3466,3467,3468,3469,3470,3471],[476,3473,2896],{"nctId":3815,"briefTitle":3816,"status":132,"phases":6182,"primaryCompletion":3818,"completion":3818,"start":3819,"enrollment":1872,"conditions":6183,"interventions":6184},[91],[3765,3821],[476,3823,3751],{"nctId":6186,"briefTitle":6187,"status":120,"phases":6188,"primaryCompletion":3830,"completion":3830,"start":6189,"enrollment":1060,"conditions":6190,"interventions":6192},"NCT00410774","Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery",[90,91],"2006-07",[6191],"Pancreatic Cancer",[815,6193],"gemcitabine hydrochloride",{"nctId":6195,"briefTitle":6196,"status":132,"phases":6197,"primaryCompletion":6198,"completion":2636,"start":6199,"enrollment":6200,"conditions":6201,"interventions":6202},"NCT00126633","Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer",[91],"2006-09","2004-04",53,[6191],[815,6203,6193],"cisplatin",{"nctId":2768,"briefTitle":2769,"status":132,"phases":6205,"primaryCompletion":2771,"completion":2772,"start":2773,"enrollment":2774,"conditions":6206,"interventions":6207},[91],[24],[815,2777],{"nctId":6209,"briefTitle":6210,"status":132,"phases":6211,"primaryCompletion":2546,"completion":1201,"start":6212,"enrollment":31,"conditions":6213,"interventions":6214},"NCT00365144","Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine",[91],"2006-02",[6191],[815,6215],"erlotinib hydrochloride",{"nctId":6217,"briefTitle":6218,"status":120,"phases":6219,"primaryCompletion":713,"completion":6220,"start":2435,"enrollment":424,"conditions":6221,"interventions":6222},"NCT00293332","Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery",[91],"2007-04",[811],[815,5738,5739],{"trials":6224,"activeCount":101},[6225,6229],{"nctId":802,"briefTitle":803,"status":120,"phases":6226,"primaryCompletion":805,"completion":806,"start":807,"enrollment":31,"conditions":6227,"interventions":6228},[91,92],[809,810,811,812,813],[815,768,816,817],{"nctId":6230,"briefTitle":6231,"status":111,"phases":6232,"primaryCompletion":364,"completion":6233,"start":1070,"enrollment":101,"conditions":6234,"interventions":6236},"NCT02229175","Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema",[91,92],"2027-01-01",[6235],"Diabetic Macular Edema",[815],{"trials":6238,"activeCount":101},[6239],{"nctId":469,"briefTitle":470,"status":111,"phases":6240,"primaryCompletion":472,"completion":472,"start":472,"enrollment":101,"conditions":6241,"interventions":6242},[93],[474],[370,476,406],{"trials":6244,"activeCount":101},[],{"intervention":3876,"totalTrials":407,"cells":6246},{"EARLY_PHASE1":6247,"PHASE1":6249,"PHASE2":6255,"PHASE3":6272,"PHASE4":6274,"NA":6295},{"trials":6248,"activeCount":101},[],{"trials":6250,"activeCount":101},[6251],{"nctId":4130,"briefTitle":4131,"status":4132,"phases":6252,"primaryCompletion":4134,"completion":4134,"start":4135,"enrollment":434,"conditions":6253,"interventions":6254},[90],[4137,4138,3808],[3876,4123],{"trials":6256,"activeCount":101},[6257,6268],{"nctId":6258,"briefTitle":6259,"status":132,"phases":6260,"primaryCompletion":6261,"completion":213,"start":6262,"enrollment":6263,"conditions":6264,"interventions":6267},"NCT01734512","PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children",[91],"2020-01-31","2012-12-13",65,[6265,6266],"Pediatric Recurrent Progressive Low-grade Gliomas","Pediatric Progressive Low-grade Gliomas",[3876],{"nctId":3866,"briefTitle":3867,"status":120,"phases":6269,"primaryCompletion":3869,"completion":3869,"start":3870,"enrollment":3567,"conditions":6270,"interventions":6271},[91],[3768,3872,3873,3874],[3876,3751],{"trials":6273,"activeCount":101},[],{"trials":6275,"activeCount":101},[6276,6285],{"nctId":6277,"briefTitle":6278,"status":132,"phases":6279,"primaryCompletion":6280,"completion":6051,"start":3829,"enrollment":28,"conditions":6281,"interventions":6283},"NCT01624948","Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients",[93],"2015-02",[6282],"BK Virus Infection",[3876,6284],"Mycophenolic acid dose reduction",{"nctId":6286,"briefTitle":6287,"status":132,"phases":6288,"primaryCompletion":6289,"completion":6289,"start":6290,"enrollment":345,"conditions":6291,"interventions":6293},"NCT02429869","Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant",[93],"2018-01-31","2016-02-24",[15,949,6292],"Liver Transplant",[6294],"everolimus",{"trials":6296,"activeCount":101},[],{"intervention":6298,"totalTrials":407,"cells":6299},"Bupivacaine",{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6304,"PHASE3":6306,"PHASE4":6320,"NA":6361},{"trials":6301,"activeCount":101},[],{"trials":6303,"activeCount":101},[],{"trials":6305,"activeCount":101},[],{"trials":6307,"activeCount":101},[6308],{"nctId":6309,"briefTitle":6310,"status":132,"phases":6311,"primaryCompletion":6312,"completion":6312,"start":6313,"enrollment":6314,"conditions":6315,"interventions":6318},"NCT03508830","Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial",[92],"2021-01-30","2018-12-30",91,[6316,3101,6317],"Thoracic Diseases","Opioid Use",[6319,6298],"Liposomal bupivacaine",{"trials":6321,"activeCount":101},[6322,6334,6344,6352],{"nctId":6323,"briefTitle":6324,"status":132,"phases":6325,"primaryCompletion":6326,"completion":6326,"start":6327,"enrollment":6328,"conditions":6329,"interventions":6332},"NCT03196505","The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery",[93],"2019-07-31","2017-12-04",231,[6330,6331],"Bariatric Surgery Candidate","Pain, Postoperative",[6333,6298],"Exparel 266 MG Per 20 ML",{"nctId":6335,"briefTitle":6336,"status":132,"phases":6337,"primaryCompletion":6338,"completion":6338,"start":6339,"enrollment":345,"conditions":6340,"interventions":6341},"NCT03666663","Sphenopalatine Ganglion Blocks RCT",[93],"2021-07-08","2019-02-01",[5911],[6342,6298,6343],"Lidocaine","Ropivacaine",{"nctId":6345,"briefTitle":6346,"status":132,"phases":6347,"primaryCompletion":6348,"completion":6348,"start":6349,"enrollment":3797,"conditions":6350,"interventions":6351},"NCT03307174","Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.",[93],"2019-02-28","2016-04-14",[2994],[6298,1570],{"nctId":6353,"briefTitle":6354,"status":120,"phases":6355,"primaryCompletion":6356,"completion":6356,"start":6357,"enrollment":25,"conditions":6358,"interventions":6359},"NCT03174782","Peripheral Nerve Blocks for Major Lower Extremity Amputations",[93],"2021-04-27","2018-01-01",[3101],[6298,6360],"Saline Solution",{"trials":6362,"activeCount":101},[],{"intervention":6364,"totalTrials":324,"cells":6365},"Bupropion",{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6372,"PHASE4":6384,"NA":6410},{"trials":6367,"activeCount":101},[],{"trials":6369,"activeCount":101},[],{"trials":6371,"activeCount":101},[],{"trials":6373,"activeCount":101},[6374],{"nctId":6375,"briefTitle":6376,"status":132,"phases":6377,"primaryCompletion":2723,"completion":6378,"start":3714,"enrollment":6379,"conditions":6380,"interventions":6382},"NCT00261170","Bupropion for Hospital-Based Smoking Cessation",[92],"2007-02",85,[6381],"Smoking",[6383],"bupropion",{"trials":6385,"activeCount":101},[6386,6397],{"nctId":6387,"briefTitle":6388,"status":132,"phases":6389,"primaryCompletion":6390,"completion":6390,"start":6391,"enrollment":6392,"conditions":6393,"interventions":6394},"NCT05351606","Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya",[93],"2025-01-07","2023-05-16",580,[2661,2660],[6364,6395,6396],"Nicotine patch","Nicotine lozenge",{"nctId":6398,"briefTitle":6399,"status":132,"phases":6400,"primaryCompletion":6401,"completion":6401,"start":6402,"enrollment":6403,"conditions":6404,"interventions":6409},"NCT03950427","PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness",[93],"2025-07-30","2019-07-08",131,[6405,6406,6407,6408],"Smoking Cessation","Smoking, Tobacco","Mental Illness","Tobacco Use Disorder",[6364],{"trials":6411,"activeCount":101},[],{"intervention":926,"totalTrials":324,"cells":6413},{"EARLY_PHASE1":6414,"PHASE1":6416,"PHASE2":6418,"PHASE3":6420,"PHASE4":6426,"NA":6449},{"trials":6415,"activeCount":101},[],{"trials":6417,"activeCount":101},[],{"trials":6419,"activeCount":101},[],{"trials":6421,"activeCount":101},[6422],{"nctId":918,"briefTitle":919,"status":132,"phases":6423,"primaryCompletion":921,"completion":921,"start":236,"enrollment":922,"conditions":6424,"interventions":6425},[92],[322,18],[925,926,907],{"trials":6427,"activeCount":101},[6428,6437],{"nctId":6429,"briefTitle":6430,"status":132,"phases":6431,"primaryCompletion":6432,"completion":6432,"start":2416,"enrollment":6433,"conditions":6434,"interventions":6436},"NCT03453840","Extended Duration Artemether-lumefantrine Treatment for Malaria in Children",[93],"2021-08-31",305,[6435],"Uncomplicated Plasmodium Falciparum Malaria",[926],{"nctId":6438,"briefTitle":6439,"status":132,"phases":6440,"primaryCompletion":6441,"completion":6442,"start":6443,"enrollment":6444,"conditions":6445,"interventions":6447},"NCT03783299","Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic",[93],"2018-11-30","2018-12-31","2017-11-28",39968,[6446],"Plasmodium Falciparum Malaria",[926,6448],"Primaquine Phosphate",{"trials":6450,"activeCount":101},[],{"intervention":6452,"totalTrials":324,"cells":6453},"Dexamethasone",{"EARLY_PHASE1":6454,"PHASE1":6456,"PHASE2":6458,"PHASE3":6483,"PHASE4":6485,"NA":6499},{"trials":6455,"activeCount":101},[],{"trials":6457,"activeCount":101},[],{"trials":6459,"activeCount":101},[6460,6472],{"nctId":6461,"briefTitle":6462,"status":120,"phases":6463,"primaryCompletion":6464,"completion":6464,"start":6465,"enrollment":407,"conditions":6466,"interventions":6469},"NCT04407442","Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab",[91],"2023-04-30","2020-11-30",[6467,6468],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[6470,6471,6452],"Azacitidine","Daratumumab",{"nctId":6473,"briefTitle":6474,"status":132,"phases":6475,"primaryCompletion":6476,"completion":6477,"start":6478,"enrollment":34,"conditions":6479,"interventions":6480},"NCT01036594","Ketoconazole and Dexamethasone in Prostate Cancer",[91],"2012-12-11","2014-10-09","2009-12-11",[21],[6481,6482,6452],"Ketoconazole","Hydrocortisone",{"trials":6484,"activeCount":101},[],{"trials":6486,"activeCount":101},[6487],{"nctId":6488,"briefTitle":6489,"status":132,"phases":6490,"primaryCompletion":6491,"completion":6492,"start":6493,"enrollment":3650,"conditions":6494,"interventions":6498},"NCT02807779","Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging",[93],"2020-10-31","2022-10-31","2016-02-10",[6495,6496,6497],"Peripheral Artery Disease","Vascular Disease","Critical Limb Ischemia",[6452],{"trials":6500,"activeCount":101},[],{"intervention":1570,"totalTrials":526,"cells":6502},{"EARLY_PHASE1":6503,"PHASE1":6505,"PHASE2":6507,"PHASE3":6509,"PHASE4":6511,"NA":6526},{"trials":6504,"activeCount":101},[],{"trials":6506,"activeCount":101},[],{"trials":6508,"activeCount":101},[],{"trials":6510,"activeCount":101},[],{"trials":6512,"activeCount":101},[6513,6522],{"nctId":6514,"briefTitle":6515,"status":132,"phases":6516,"primaryCompletion":236,"completion":236,"start":6517,"enrollment":1730,"conditions":6518,"interventions":6520},"NCT01258296","Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction",[93],"2003-02",[6519],"Postoperative Pain After Breast Reconstruction With Abdominal Flap",[1570,6521],"Inactive patch",{"nctId":6345,"briefTitle":6346,"status":132,"phases":6523,"primaryCompletion":6348,"completion":6348,"start":6349,"enrollment":3797,"conditions":6524,"interventions":6525},[93],[2994],[6298,1570],{"trials":6527,"activeCount":101},[],{"intervention":179,"totalTrials":526,"cells":6529},{"EARLY_PHASE1":6530,"PHASE1":6532,"PHASE2":6538,"PHASE3":6540,"PHASE4":6542,"NA":6548},{"trials":6531,"activeCount":101},[],{"trials":6533,"activeCount":101},[6534],{"nctId":2987,"briefTitle":2988,"status":120,"phases":6535,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":424,"conditions":6536,"interventions":6537},[90],[2993,2994],[2996,2980,179],{"trials":6539,"activeCount":101},[],{"trials":6541,"activeCount":101},[],{"trials":6543,"activeCount":101},[6544],{"nctId":171,"briefTitle":172,"status":132,"phases":6545,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":6546,"interventions":6547},[93],[168],[68,179],{"trials":6549,"activeCount":101},[],{"intervention":6551,"totalTrials":526,"cells":6552},"Tranexamic Acid",{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6559,"PHASE4":6561,"NA":6581},{"trials":6554,"activeCount":101},[],{"trials":6556,"activeCount":101},[],{"trials":6558,"activeCount":101},[],{"trials":6560,"activeCount":101},[],{"trials":6562,"activeCount":101},[6563,6574],{"nctId":6564,"briefTitle":6565,"status":132,"phases":6566,"primaryCompletion":1245,"completion":6567,"start":6568,"enrollment":1071,"conditions":6569,"interventions":6573},"NCT02806024","Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study",[93],"2018-08","2016-11",[6570,6571,6572,6551],"Placenta Accreta","Postpartum Hemorrhage","Cesarean Section",[6551],{"nctId":6575,"briefTitle":6576,"status":120,"phases":6577,"primaryCompletion":1181,"completion":1181,"start":6578,"enrollment":1246,"conditions":6579,"interventions":6580},"NCT05807074","Impact of Topical Tranexamic Acid in Breast Reconstruction",[93],"2023-04-20",[24],[6551],{"trials":6582,"activeCount":101},[],{"intervention":6584,"totalTrials":526,"cells":6585},"Sulfadoxine-pyrimethamine",{"EARLY_PHASE1":6586,"PHASE1":6588,"PHASE2":6590,"PHASE3":6592,"PHASE4":6598,"NA":6608},{"trials":6587,"activeCount":101},[],{"trials":6589,"activeCount":101},[],{"trials":6591,"activeCount":101},[],{"trials":6593,"activeCount":101},[6594],{"nctId":928,"briefTitle":929,"status":132,"phases":6595,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":6596,"interventions":6597},[92],[322],[936,937,938],{"trials":6599,"activeCount":101},[6600],{"nctId":6601,"briefTitle":6602,"status":111,"phases":6603,"primaryCompletion":673,"completion":673,"start":2407,"enrollment":101,"conditions":6604,"interventions":6607},"NCT01184911","Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda",[93],[6605,6606],"Intermittent Preventive Treatment","Placental Malaria",[6584],{"trials":6609,"activeCount":101},[],{"intervention":6611,"totalTrials":526,"cells":6612},"suvorexant",{"EARLY_PHASE1":6613,"PHASE1":6615,"PHASE2":6617,"PHASE3":6619,"PHASE4":6621,"NA":6642},{"trials":6614,"activeCount":101},[],{"trials":6616,"activeCount":101},[],{"trials":6618,"activeCount":101},[],{"trials":6620,"activeCount":101},[],{"trials":6622,"activeCount":101},[6623,6632],{"nctId":6624,"briefTitle":6625,"status":132,"phases":6626,"primaryCompletion":6627,"completion":6627,"start":6628,"enrollment":324,"conditions":6629,"interventions":6631},"NCT02593682","The Role of Orexin in Human Panic Disorder",[93],"2020-03-13","2016-05",[6630],"Panic Disorder",[6611],{"nctId":6633,"briefTitle":6634,"status":132,"phases":6635,"primaryCompletion":2934,"completion":2934,"start":6636,"enrollment":28,"conditions":6637,"interventions":6639},"NCT04014387","Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)",[93],"2019-06-02",[6638],"Treatment",[6640,6641],"Suvorexant","Zolpidem",{"trials":6643,"activeCount":101},[],{"intervention":6645,"totalTrials":526,"cells":6646},"N-acetylcysteine",{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6661,"PHASE4":6663,"NA":6674},{"trials":6648,"activeCount":101},[],{"trials":6650,"activeCount":101},[],{"trials":6652,"activeCount":101},[6653],{"nctId":6654,"briefTitle":6655,"status":132,"phases":6656,"primaryCompletion":6132,"completion":6132,"start":3743,"enrollment":751,"conditions":6657,"interventions":6660},"NCT02791945","N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI",[91],[6658,6659],"Traumatic Brain Injury (TBI)","Hazardous and Harmful Alcohol Use",[6645],{"trials":6662,"activeCount":101},[],{"trials":6664,"activeCount":101},[6665],{"nctId":6666,"briefTitle":6667,"status":120,"phases":6668,"primaryCompletion":6669,"completion":6670,"start":6671,"enrollment":424,"conditions":6672,"interventions":6673},"NCT03581084","Inpatient Clinical Trial of NAC",[93],"2018-07-13","2018-10-06","2018-07-06",[36],[6645],{"trials":6675,"activeCount":101},[],{"intervention":6677,"totalTrials":526,"cells":6678},"Memantine",{"EARLY_PHASE1":6679,"PHASE1":6681,"PHASE2":6683,"PHASE3":6685,"PHASE4":6687,"NA":6709},{"trials":6680,"activeCount":101},[],{"trials":6682,"activeCount":101},[],{"trials":6684,"activeCount":101},[],{"trials":6686,"activeCount":101},[],{"trials":6688,"activeCount":101},[6689,6699],{"nctId":6690,"briefTitle":6691,"status":132,"phases":6692,"primaryCompletion":6693,"completion":6694,"start":6695,"conditions":6696,"interventions":6698},"NCT00187525","A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration",[93],"2005-10","2006-10","2004-05",[6697],"Frontotemporal Lobar Degeneration",[6677],{"nctId":6700,"briefTitle":6701,"status":132,"phases":6702,"primaryCompletion":1200,"completion":1200,"start":3830,"enrollment":2495,"conditions":6703,"interventions":6707},"NCT00545974","Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",[93],[6704,6705,6706],"Frontal Lobe Dementia","Frontotemporal Lobe Dementia","Semantic Dementia",[6708],"memantine",{"trials":6710,"activeCount":101},[],{"intervention":6342,"totalTrials":526,"cells":6712},{"EARLY_PHASE1":6713,"PHASE1":6715,"PHASE2":6717,"PHASE3":6719,"PHASE4":6721,"NA":6736},{"trials":6714,"activeCount":101},[],{"trials":6716,"activeCount":101},[],{"trials":6718,"activeCount":101},[],{"trials":6720,"activeCount":101},[],{"trials":6722,"activeCount":101},[6723,6732],{"nctId":6724,"briefTitle":6725,"status":132,"phases":6726,"primaryCompletion":6727,"completion":3648,"start":6728,"enrollment":1060,"conditions":6729,"interventions":6730},"NCT01622296","Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients",[93],"2012-07","2012-04",[1410],[6731,6342],"Sodium bicarbonate",{"nctId":6335,"briefTitle":6336,"status":132,"phases":6733,"primaryCompletion":6338,"completion":6338,"start":6339,"enrollment":345,"conditions":6734,"interventions":6735},[93],[5911],[6342,6298,6343],{"trials":6737,"activeCount":101},[],{"intervention":6739,"totalTrials":526,"cells":6740},"Sugar pill",{"EARLY_PHASE1":6741,"PHASE1":6743,"PHASE2":6755,"PHASE3":6757,"PHASE4":6759,"NA":6770},{"trials":6742,"activeCount":101},[],{"trials":6744,"activeCount":101},[6745],{"nctId":6746,"briefTitle":6747,"status":132,"phases":6748,"primaryCompletion":1313,"completion":6749,"start":6750,"enrollment":1060,"conditions":6751,"interventions":6753},"NCT02233582","Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude",[90],"2017-06","2014-09",[6752],"High Altitude",[6754,6739],"Ibuprofen",{"trials":6756,"activeCount":101},[],{"trials":6758,"activeCount":101},[],{"trials":6760,"activeCount":101},[6761],{"nctId":6762,"briefTitle":6763,"status":120,"phases":6764,"primaryCompletion":447,"completion":447,"start":6765,"enrollment":2818,"conditions":6766,"interventions":6768},"NCT00767572","Statins and Endothelial Function in Patients With Coarctation of the Aorta",[93],"2008-08",[6767],"Coarctation of the Aorta",[6769,6739],"atorvastatin",{"trials":6771,"activeCount":101},[],{"intervention":6773,"totalTrials":526,"cells":6774},"Risperidone",{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6779,"PHASE3":6781,"PHASE4":6791,"NA":6803},{"trials":6776,"activeCount":101},[],{"trials":6778,"activeCount":101},[],{"trials":6780,"activeCount":101},[],{"trials":6782,"activeCount":101},[6783],{"nctId":6784,"briefTitle":6785,"status":132,"phases":6786,"primaryCompletion":254,"completion":254,"start":255,"enrollment":6787,"conditions":6788,"interventions":6790},"NCT00584701","Pharmacogenomics in Autism Treatment",[91,92],49,[6789],"Autism",[6773],{"trials":6792,"activeCount":101},[6793],{"nctId":6794,"briefTitle":6795,"status":120,"phases":6796,"primaryCompletion":226,"completion":226,"start":4155,"enrollment":480,"conditions":6797,"interventions":6800},"NCT01913327","Antipsychotic Effects on Brain Function in Schizophrenia",[93],[6042,6798,6799],"Schizoaffective Disorder","Schizophreniform Disorder",[6801,6773,6802],"Aripiprazole","Modafinil",{"trials":6804,"activeCount":101},[],{"intervention":6641,"totalTrials":526,"cells":6806},{"EARLY_PHASE1":6807,"PHASE1":6809,"PHASE2":6823,"PHASE3":6825,"PHASE4":6827,"NA":6833},{"trials":6808,"activeCount":101},[],{"trials":6810,"activeCount":101},[6811],{"nctId":6812,"briefTitle":6813,"status":132,"phases":6814,"primaryCompletion":6815,"completion":6815,"start":274,"enrollment":6816,"conditions":6817,"interventions":6822},"NCT03269760","Multimodal Sleep Pathway for Shoulder Arthroplasty",[90],"2020-02-01",122,[6818,6819,6820,6821],"Sleep Disturbance","Shoulder Arthritis","Arthroplasty Complications","Perioperative\u002FPostoperative Complications",[6641],{"trials":6824,"activeCount":101},[],{"trials":6826,"activeCount":101},[],{"trials":6828,"activeCount":101},[6829],{"nctId":6633,"briefTitle":6634,"status":132,"phases":6830,"primaryCompletion":2934,"completion":2934,"start":6636,"enrollment":28,"conditions":6831,"interventions":6832},[93],[6638],[6640,6641],{"trials":6834,"activeCount":101},[],{"intervention":6284,"totalTrials":424,"cells":6836},{"EARLY_PHASE1":6837,"PHASE1":6839,"PHASE2":6841,"PHASE3":6843,"PHASE4":6845,"NA":6851},{"trials":6838,"activeCount":101},[],{"trials":6840,"activeCount":101},[],{"trials":6842,"activeCount":101},[],{"trials":6844,"activeCount":101},[],{"trials":6846,"activeCount":101},[6847],{"nctId":6277,"briefTitle":6278,"status":132,"phases":6848,"primaryCompletion":6280,"completion":6051,"start":3829,"enrollment":28,"conditions":6849,"interventions":6850},[93],[6282],[3876,6284],{"trials":6852,"activeCount":101},[],{"intervention":6521,"totalTrials":424,"cells":6854},{"EARLY_PHASE1":6855,"PHASE1":6857,"PHASE2":6859,"PHASE3":6861,"PHASE4":6863,"NA":6869},{"trials":6856,"activeCount":101},[],{"trials":6858,"activeCount":101},[],{"trials":6860,"activeCount":101},[],{"trials":6862,"activeCount":101},[],{"trials":6864,"activeCount":101},[6865],{"nctId":6514,"briefTitle":6515,"status":132,"phases":6866,"primaryCompletion":236,"completion":236,"start":6517,"enrollment":1730,"conditions":6867,"interventions":6868},[93],[6519],[1570,6521],{"trials":6870,"activeCount":101},[],{"intervention":6396,"totalTrials":424,"cells":6872},{"EARLY_PHASE1":6873,"PHASE1":6875,"PHASE2":6877,"PHASE3":6879,"PHASE4":6881,"NA":6887},{"trials":6874,"activeCount":101},[],{"trials":6876,"activeCount":101},[],{"trials":6878,"activeCount":101},[],{"trials":6880,"activeCount":101},[],{"trials":6882,"activeCount":101},[6883],{"nctId":6387,"briefTitle":6388,"status":132,"phases":6884,"primaryCompletion":6390,"completion":6390,"start":6391,"enrollment":6392,"conditions":6885,"interventions":6886},[93],[2661,2660],[6364,6395,6396],{"trials":6888,"activeCount":101},[],{"intervention":6890,"totalTrials":424,"cells":6891},"n-acetylcystine",{"EARLY_PHASE1":6892,"PHASE1":6894,"PHASE2":6896,"PHASE3":6898,"PHASE4":6900,"NA":6910},{"trials":6893,"activeCount":101},[],{"trials":6895,"activeCount":101},[],{"trials":6897,"activeCount":101},[],{"trials":6899,"activeCount":101},[],{"trials":6901,"activeCount":101},[6902],{"nctId":6903,"briefTitle":6904,"status":120,"phases":6905,"primaryCompletion":1244,"completion":1244,"start":6906,"enrollment":424,"conditions":6907,"interventions":6908},"NCT02605824","Clinical Trial of NAC in Asthma",[93],"2016-03",[36],[6890,6909],"0.9% saline",{"trials":6911,"activeCount":101},[],{"intervention":6909,"totalTrials":424,"cells":6913},{"EARLY_PHASE1":6914,"PHASE1":6916,"PHASE2":6918,"PHASE3":6920,"PHASE4":6922,"NA":6928},{"trials":6915,"activeCount":101},[],{"trials":6917,"activeCount":101},[],{"trials":6919,"activeCount":101},[],{"trials":6921,"activeCount":101},[],{"trials":6923,"activeCount":101},[6924],{"nctId":6903,"briefTitle":6904,"status":120,"phases":6925,"primaryCompletion":1244,"completion":1244,"start":6906,"enrollment":424,"conditions":6926,"interventions":6927},[93],[36],[6890,6909],{"trials":6929,"activeCount":101},[],{"intervention":6931,"totalTrials":424,"cells":6932},"Peripheral Nerve Block",{"EARLY_PHASE1":6933,"PHASE1":6935,"PHASE2":6937,"PHASE3":6939,"PHASE4":6941,"NA":6951},{"trials":6934,"activeCount":101},[],{"trials":6936,"activeCount":101},[],{"trials":6938,"activeCount":101},[],{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[6943],{"nctId":6944,"briefTitle":6945,"status":132,"phases":6946,"primaryCompletion":226,"completion":6039,"start":6280,"enrollment":2335,"conditions":6947,"interventions":6949},"NCT02623361","A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy",[93],[6948,1410],"Muscle Weakness | Patient",[6931,6950],"Sham Block",{"trials":6952,"activeCount":101},[],{"intervention":6950,"totalTrials":424,"cells":6954},{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6959,"PHASE3":6961,"PHASE4":6963,"NA":6969},{"trials":6956,"activeCount":101},[],{"trials":6958,"activeCount":101},[],{"trials":6960,"activeCount":101},[],{"trials":6962,"activeCount":101},[],{"trials":6964,"activeCount":101},[6965],{"nctId":6944,"briefTitle":6945,"status":132,"phases":6966,"primaryCompletion":226,"completion":6039,"start":6280,"enrollment":2335,"conditions":6967,"interventions":6968},[93],[6948,1410],[6931,6950],{"trials":6970,"activeCount":101},[],{"intervention":6972,"totalTrials":424,"cells":6973},"CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste",{"EARLY_PHASE1":6974,"PHASE1":6976,"PHASE2":6978,"PHASE3":6980,"PHASE4":6982,"NA":6993},{"trials":6975,"activeCount":101},[],{"trials":6977,"activeCount":101},[],{"trials":6979,"activeCount":101},[],{"trials":6981,"activeCount":101},[],{"trials":6983,"activeCount":101},[6984],{"nctId":6985,"briefTitle":6986,"status":132,"phases":6987,"primaryCompletion":1313,"completion":1313,"start":3818,"enrollment":28,"conditions":6988,"interventions":6991},"NCT02424097","MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study",[93],[6989,6990],"Dental White Spots","Dental Caries",[6972,6992],"1,100pm F-toothpaste and 0.5%NaF rinse",{"trials":6994,"activeCount":101},[],{"intervention":6992,"totalTrials":424,"cells":6996},{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7003,"PHASE4":7005,"NA":7011},{"trials":6998,"activeCount":101},[],{"trials":7000,"activeCount":101},[],{"trials":7002,"activeCount":101},[],{"trials":7004,"activeCount":101},[],{"trials":7006,"activeCount":101},[7007],{"nctId":6985,"briefTitle":6986,"status":132,"phases":7008,"primaryCompletion":1313,"completion":1313,"start":3818,"enrollment":28,"conditions":7009,"interventions":7010},[93],[6989,6990],[6972,6992],{"trials":7012,"activeCount":101},[],{"intervention":7014,"totalTrials":424,"cells":7015},"Tamsulosin",{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7020,"PHASE3":7022,"PHASE4":7024,"NA":7036},{"trials":7017,"activeCount":101},[],{"trials":7019,"activeCount":101},[],{"trials":7021,"activeCount":101},[],{"trials":7023,"activeCount":101},[],{"trials":7025,"activeCount":101},[7026],{"nctId":7027,"briefTitle":7028,"status":132,"phases":7029,"primaryCompletion":7030,"completion":7030,"start":7031,"enrollment":37,"conditions":7032,"interventions":7035},"NCT05415748","Deprescribing Tamsulosin in Older Men",[93],"2022-07-22","2021-09-18",[7033,7034],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[7014],{"trials":7037,"activeCount":101},[],{"intervention":7039,"totalTrials":424,"cells":7040},"Lidocaine Digital Nerve Block",{"EARLY_PHASE1":7041,"PHASE1":7043,"PHASE2":7045,"PHASE3":7047,"PHASE4":7049,"NA":7059},{"trials":7042,"activeCount":101},[],{"trials":7044,"activeCount":101},[],{"trials":7046,"activeCount":101},[],{"trials":7048,"activeCount":101},[],{"trials":7050,"activeCount":101},[7051],{"nctId":7052,"briefTitle":7053,"status":132,"phases":7054,"primaryCompletion":921,"start":805,"enrollment":2818,"conditions":7055,"interventions":7057},"NCT01508832","Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers",[93],[7056],"Onset and Duration of a Digital Nerve Block",[7039,7058],"Bupivacaine Digital Block",{"trials":7060,"activeCount":101},[],{"intervention":7058,"totalTrials":424,"cells":7062},{"EARLY_PHASE1":7063,"PHASE1":7065,"PHASE2":7067,"PHASE3":7069,"PHASE4":7071,"NA":7077},{"trials":7064,"activeCount":101},[],{"trials":7066,"activeCount":101},[],{"trials":7068,"activeCount":101},[],{"trials":7070,"activeCount":101},[],{"trials":7072,"activeCount":101},[7073],{"nctId":7052,"briefTitle":7053,"status":132,"phases":7074,"primaryCompletion":921,"start":805,"enrollment":2818,"conditions":7075,"interventions":7076},[93],[7056],[7039,7058],{"trials":7078,"activeCount":101},[],{"intervention":7080,"totalTrials":424,"cells":7081},"Pegylated interferon alfa-2a + Ribavirin",{"EARLY_PHASE1":7082,"PHASE1":7084,"PHASE2":7086,"PHASE3":7088,"PHASE4":7090,"NA":7102},{"trials":7083,"activeCount":101},[],{"trials":7085,"activeCount":101},[],{"trials":7087,"activeCount":101},[],{"trials":7089,"activeCount":101},[],{"trials":7091,"activeCount":101},[7092],{"nctId":7093,"briefTitle":7094,"status":132,"phases":7095,"primaryCompletion":7096,"completion":7097,"start":3713,"enrollment":97,"conditions":7098,"interventions":7101},"NCT00845676","Treatment of Acute Hepatitis C Virus in HIV Co-Infection",[93],"2010-12","2013-12",[7099,7100,18],"Hepatitis C","Human Immunodeficiency Virus",[7080],{"trials":7103,"activeCount":101},[],{"intervention":7105,"totalTrials":424,"cells":7106},"Digoxin",{"EARLY_PHASE1":7107,"PHASE1":7109,"PHASE2":7111,"PHASE3":7113,"PHASE4":7115,"NA":7126},{"trials":7108,"activeCount":101},[],{"trials":7110,"activeCount":101},[],{"trials":7112,"activeCount":101},[],{"trials":7114,"activeCount":101},[],{"trials":7116,"activeCount":101},[7117],{"nctId":7118,"briefTitle":7119,"status":132,"phases":7120,"primaryCompletion":4820,"completion":4820,"start":7121,"enrollment":7122,"conditions":7123,"interventions":7125},"NCT03136068","Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation",[93],"2017-02-23",178,[7124],"Abortion",[7105],{"trials":7127,"activeCount":101},[],{"intervention":7129,"totalTrials":424,"cells":7130},"Lopinavir\u002Fritonavir plus Emtricitabine\u002FTenofovir versus Efavirenz plus Emtricitabine\u002FTenofovir",{"EARLY_PHASE1":7131,"PHASE1":7133,"PHASE2":7135,"PHASE3":7137,"PHASE4":7139,"NA":7148},{"trials":7132,"activeCount":101},[],{"trials":7134,"activeCount":101},[],{"trials":7136,"activeCount":101},[],{"trials":7138,"activeCount":101},[],{"trials":7140,"activeCount":101},[7141],{"nctId":7142,"briefTitle":7143,"status":132,"phases":7144,"primaryCompletion":2436,"completion":6727,"start":6220,"enrollment":7145,"conditions":7146,"interventions":7147},"NCT00444379","Anti-Retrovirals for Kaposi's Sarcoma",[93],224,[4021,18],[7129],{"trials":7149,"activeCount":101},[],{"intervention":7151,"totalTrials":424,"cells":7152},"Difluprednate",{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7174},{"trials":7154,"activeCount":101},[],{"trials":7156,"activeCount":101},[],{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[],{"trials":7162,"activeCount":101},[7163],{"nctId":7164,"briefTitle":7165,"status":120,"phases":7166,"primaryCompletion":7167,"completion":7167,"start":7168,"enrollment":2472,"conditions":7169,"interventions":7171},"NCT01939691","Macular Edema Nepafenac vs. Difluprednate Uveitis Trial",[93],"2020-03-31","2018-09-12",[2409,7170],"Macular Edema",[7151,7172,7173],"Nepafenac","Prednisolone acetate",{"trials":7175,"activeCount":101},[],{"intervention":7172,"totalTrials":424,"cells":7177},{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7182,"PHASE3":7184,"PHASE4":7186,"NA":7192},{"trials":7179,"activeCount":101},[],{"trials":7181,"activeCount":101},[],{"trials":7183,"activeCount":101},[],{"trials":7185,"activeCount":101},[],{"trials":7187,"activeCount":101},[7188],{"nctId":7164,"briefTitle":7165,"status":120,"phases":7189,"primaryCompletion":7167,"completion":7167,"start":7168,"enrollment":2472,"conditions":7190,"interventions":7191},[93],[2409,7170],[7151,7172,7173],{"trials":7193,"activeCount":101},[],{"intervention":7173,"totalTrials":424,"cells":7195},{"EARLY_PHASE1":7196,"PHASE1":7198,"PHASE2":7200,"PHASE3":7202,"PHASE4":7204,"NA":7210},{"trials":7197,"activeCount":101},[],{"trials":7199,"activeCount":101},[],{"trials":7201,"activeCount":101},[],{"trials":7203,"activeCount":101},[],{"trials":7205,"activeCount":101},[7206],{"nctId":7164,"briefTitle":7165,"status":120,"phases":7207,"primaryCompletion":7167,"completion":7167,"start":7168,"enrollment":2472,"conditions":7208,"interventions":7209},[93],[2409,7170],[7151,7172,7173],{"trials":7211,"activeCount":101},[],{"intervention":7213,"totalTrials":424,"cells":7214},"Glucagon",{"EARLY_PHASE1":7215,"PHASE1":7217,"PHASE2":7219,"PHASE3":7221,"PHASE4":7223,"NA":7232},{"trials":7216,"activeCount":101},[],{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[],{"trials":7222,"activeCount":101},[],{"trials":7224,"activeCount":101},[7225],{"nctId":7226,"briefTitle":7227,"status":132,"phases":7228,"primaryCompletion":6132,"completion":6132,"start":931,"enrollment":1220,"conditions":7229,"interventions":7231},"NCT02078726","Glucagon Use in Colonoscopies",[93],[7230],"Colon Cancer",[7213],{"trials":7233,"activeCount":101},[],{"intervention":7235,"totalTrials":424,"cells":7236},"Entecavir with continued standard of care antiretroviral therapy",{"EARLY_PHASE1":7237,"PHASE1":7239,"PHASE2":7241,"PHASE3":7243,"PHASE4":7245,"NA":7256},{"trials":7238,"activeCount":101},[],{"trials":7240,"activeCount":101},[],{"trials":7242,"activeCount":101},[],{"trials":7244,"activeCount":101},[],{"trials":7246,"activeCount":101},[7247],{"nctId":7248,"briefTitle":7249,"status":132,"phases":7250,"primaryCompletion":3649,"completion":7251,"start":3696,"enrollment":345,"conditions":7252,"interventions":7254},"NCT00662545","Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection",[93],"2010-05",[18,7253],"Hepatitis B",[7235,7255],"continued standard of care with tenofovir in addition to emtricitabine or lamivudine",{"trials":7257,"activeCount":101},[],{"intervention":7255,"totalTrials":424,"cells":7259},{"EARLY_PHASE1":7260,"PHASE1":7262,"PHASE2":7264,"PHASE3":7266,"PHASE4":7268,"NA":7274},{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[],{"trials":7265,"activeCount":101},[],{"trials":7267,"activeCount":101},[],{"trials":7269,"activeCount":101},[7270],{"nctId":7248,"briefTitle":7249,"status":132,"phases":7271,"primaryCompletion":3649,"completion":7251,"start":3696,"enrollment":345,"conditions":7272,"interventions":7273},[93],[18,7253],[7235,7255],{"trials":7275,"activeCount":101},[],{"intervention":7277,"totalTrials":424,"cells":7278},"Triamcinolone 0.1%",{"EARLY_PHASE1":7279,"PHASE1":7281,"PHASE2":7283,"PHASE3":7285,"PHASE4":7287,"NA":7297},{"trials":7280,"activeCount":101},[],{"trials":7282,"activeCount":101},[],{"trials":7284,"activeCount":101},[],{"trials":7286,"activeCount":101},[],{"trials":7288,"activeCount":101},[7289],{"nctId":7290,"briefTitle":7291,"status":120,"phases":7292,"primaryCompletion":7293,"completion":7293,"start":205,"enrollment":541,"conditions":7294,"interventions":7296},"NCT02317276","A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal",[93],"2017-04-06",[7295],"Dermatitis, Atopic",[7277],{"trials":7298,"activeCount":101},[],{"intervention":7300,"totalTrials":424,"cells":7301},"200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate",{"EARLY_PHASE1":7302,"PHASE1":7304,"PHASE2":7306,"PHASE3":7308,"PHASE4":7310,"NA":7322},{"trials":7303,"activeCount":101},[],{"trials":7305,"activeCount":101},[],{"trials":7307,"activeCount":101},[],{"trials":7309,"activeCount":101},[],{"trials":7311,"activeCount":101},[7312],{"nctId":7313,"briefTitle":7314,"status":132,"phases":7315,"primaryCompletion":7316,"completion":7316,"start":7317,"enrollment":3553,"conditions":7318,"interventions":7321},"NCT04050371","Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy",[93],"2018-05-23","2017-08-03",[7319,7320],"HIV Prevention","Transgender Health",[7300],{"trials":7323,"activeCount":101},[],{"intervention":7325,"totalTrials":424,"cells":7326},"Nicotine nasal spray",{"EARLY_PHASE1":7327,"PHASE1":7329,"PHASE2":7331,"PHASE3":7333,"PHASE4":7335,"NA":7345},{"trials":7328,"activeCount":101},[],{"trials":7330,"activeCount":101},[],{"trials":7332,"activeCount":101},[],{"trials":7334,"activeCount":101},[],{"trials":7336,"activeCount":101},[7337],{"nctId":7338,"briefTitle":7339,"status":132,"phases":7340,"primaryCompletion":5727,"completion":7341,"start":7342,"enrollment":28,"conditions":7343,"interventions":7344},"NCT00625794","Nicotine Replacement and Counseling In Adolescents",[93],"2007-07","2005-09",[6405],[7325],{"trials":7346,"activeCount":101},[],{"intervention":7348,"totalTrials":424,"cells":7349},"Intravenous moderate sedation versus oral medication",{"EARLY_PHASE1":7350,"PHASE1":7352,"PHASE2":7354,"PHASE3":7356,"PHASE4":7358,"NA":7368},{"trials":7351,"activeCount":101},[],{"trials":7353,"activeCount":101},[],{"trials":7355,"activeCount":101},[],{"trials":7357,"activeCount":101},[],{"trials":7359,"activeCount":101},[7360],{"nctId":7361,"briefTitle":7362,"status":120,"phases":7363,"primaryCompletion":2722,"completion":2722,"start":5727,"enrollment":5422,"conditions":7364,"interventions":7367},"NCT01011634","Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions",[93],[7365,7366],"Undesired Intrauterine Pregnancy","First Trimester Pregnancy",[7348],{"trials":7369,"activeCount":101},[],{"intervention":7371,"totalTrials":424,"cells":7372},"Presumptive treatment with Artemether-lumefantrine",{"EARLY_PHASE1":7373,"PHASE1":7375,"PHASE2":7377,"PHASE3":7379,"PHASE4":7381,"NA":7391},{"trials":7374,"activeCount":101},[],{"trials":7376,"activeCount":101},[],{"trials":7378,"activeCount":101},[],{"trials":7380,"activeCount":101},[],{"trials":7382,"activeCount":101},[7383],{"nctId":7384,"briefTitle":7385,"status":132,"phases":7386,"primaryCompletion":5785,"completion":5785,"start":7387,"enrollment":7388,"conditions":7389,"interventions":7390},"NCT04094727","Malaria High-Risk Populations in Namibia",[93],"2019-10-31",3302,[322],[7371],{"trials":7392,"activeCount":101},[],{"intervention":7394,"totalTrials":424,"cells":7395},"Allopurinol",{"EARLY_PHASE1":7396,"PHASE1":7398,"PHASE2":7400,"PHASE3":7402,"PHASE4":7404,"NA":7415},{"trials":7397,"activeCount":101},[],{"trials":7399,"activeCount":101},[],{"trials":7401,"activeCount":101},[],{"trials":7403,"activeCount":101},[],{"trials":7405,"activeCount":101},[7406],{"nctId":7407,"briefTitle":7408,"status":132,"phases":7409,"primaryCompletion":7410,"completion":7410,"start":6568,"enrollment":3567,"conditions":7411,"interventions":7414},"NCT02956278","The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics",[93],"2018-03",[7412,7413],"Chronic Gout","Hyperuricemia",[7394],{"trials":7416,"activeCount":101},[],{"intervention":7418,"totalTrials":424,"cells":7419},"Topical Antibiotic Product",{"EARLY_PHASE1":7420,"PHASE1":7422,"PHASE2":7424,"PHASE3":7426,"PHASE4":7428,"NA":7449},{"trials":7421,"activeCount":101},[],{"trials":7423,"activeCount":101},[],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[7430],{"nctId":7431,"briefTitle":7432,"status":132,"phases":7433,"primaryCompletion":7434,"completion":7434,"start":7435,"enrollment":7436,"conditions":7437,"interventions":7447},"NCT03199911","Topical Antibiotic Prophylaxis for Eyelids",[93],"2019-11-14","2017-10-02",401,[7438,7439,7440,7441,7442,7443,7444,7445,7446],"Antibiotic Side Effect","Eyelid; Wound","Eyelid Diseases","Surgical Wound Infection","Surgical Wound, Recent","Surgical Incision","Skin Cancer Face","Antibiotic Allergy","Surgical Site Infection",[7418,7448],"Topical Non-Antibiotic Ointment",{"trials":7450,"activeCount":101},[],{"intervention":7448,"totalTrials":424,"cells":7452},{"EARLY_PHASE1":7453,"PHASE1":7455,"PHASE2":7457,"PHASE3":7459,"PHASE4":7461,"NA":7467},{"trials":7454,"activeCount":101},[],{"trials":7456,"activeCount":101},[],{"trials":7458,"activeCount":101},[],{"trials":7460,"activeCount":101},[],{"trials":7462,"activeCount":101},[7463],{"nctId":7431,"briefTitle":7432,"status":132,"phases":7464,"primaryCompletion":7434,"completion":7434,"start":7435,"enrollment":7436,"conditions":7465,"interventions":7466},[93],[7438,7439,7440,7441,7442,7443,7444,7445,7446],[7418,7448],{"trials":7468,"activeCount":101},[],{"intervention":7470,"totalTrials":424,"cells":7471},"Sofosbuvir\u002FVelpatasvir",{"EARLY_PHASE1":7472,"PHASE1":7474,"PHASE2":7476,"PHASE3":7478,"PHASE4":7480,"NA":7493},{"trials":7473,"activeCount":101},[],{"trials":7475,"activeCount":101},[],{"trials":7477,"activeCount":101},[],{"trials":7479,"activeCount":101},[],{"trials":7481,"activeCount":101},[7482],{"nctId":7483,"briefTitle":7484,"status":132,"phases":7485,"primaryCompletion":7486,"completion":7487,"start":7488,"enrollment":6816,"conditions":7489,"interventions":7491},"NCT03619837","Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant",[93],"2019-12-21","2020-08-13","2018-07-15",[7099,7490],"Transplantation Disease Transmission",[7470,7492],"Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir",{"trials":7494,"activeCount":101},[],{"intervention":7492,"totalTrials":424,"cells":7496},{"EARLY_PHASE1":7497,"PHASE1":7499,"PHASE2":7501,"PHASE3":7503,"PHASE4":7505,"NA":7511},{"trials":7498,"activeCount":101},[],{"trials":7500,"activeCount":101},[],{"trials":7502,"activeCount":101},[],{"trials":7504,"activeCount":101},[],{"trials":7506,"activeCount":101},[7507],{"nctId":7483,"briefTitle":7484,"status":132,"phases":7508,"primaryCompletion":7486,"completion":7487,"start":7488,"enrollment":6816,"conditions":7509,"interventions":7510},[93],[7099,7490],[7470,7492],{"trials":7512,"activeCount":101},[],{"intervention":7514,"totalTrials":424,"cells":7515},"Acthar gel",{"EARLY_PHASE1":7516,"PHASE1":7518,"PHASE2":7520,"PHASE3":7522,"PHASE4":7524,"NA":7535},{"trials":7517,"activeCount":101},[],{"trials":7519,"activeCount":101},[],{"trials":7521,"activeCount":101},[],{"trials":7523,"activeCount":101},[],{"trials":7525,"activeCount":101},[7526],{"nctId":7527,"briefTitle":7528,"status":120,"phases":7529,"primaryCompletion":7530,"completion":7530,"start":7531,"enrollment":526,"conditions":7532,"interventions":7534},"NCT02523092","Use of CXCL9 as a Biomarker of Acthar Efficacy",[93],"2025-01-31","2022-11-03",[7533],"Sarcoidosis",[7514],{"trials":7536,"activeCount":101},[],{"intervention":7538,"totalTrials":424,"cells":7539},"Mesalamine",{"EARLY_PHASE1":7540,"PHASE1":7542,"PHASE2":7544,"PHASE3":7546,"PHASE4":7548,"NA":7560},{"trials":7541,"activeCount":101},[],{"trials":7543,"activeCount":101},[],{"trials":7545,"activeCount":101},[],{"trials":7547,"activeCount":101},[],{"trials":7549,"activeCount":101},[7550],{"nctId":7551,"briefTitle":7552,"status":132,"phases":7553,"primaryCompletion":1200,"completion":1200,"start":932,"enrollment":3650,"conditions":7554,"interventions":7559},"NCT01090102","Mesalamine to Reduce T Cell Activation in HIV Infection",[93],[18,7555,7556,7557,7558],"Sexually Transmitted Diseases","Immune System Diseases","Lentivirus Infections","Acquired Immunodeficiency Syndrome",[7538],{"trials":7561,"activeCount":101},[],{"intervention":7563,"totalTrials":424,"cells":7564},"Bravelle",{"EARLY_PHASE1":7565,"PHASE1":7567,"PHASE2":7569,"PHASE3":7571,"PHASE4":7573,"NA":7584},{"trials":7566,"activeCount":101},[],{"trials":7568,"activeCount":101},[],{"trials":7570,"activeCount":101},[],{"trials":7572,"activeCount":101},[],{"trials":7574,"activeCount":101},[7575],{"nctId":7576,"briefTitle":7577,"status":132,"phases":7578,"primaryCompletion":7579,"completion":7579,"start":7580,"enrollment":7581,"conditions":7582,"interventions":7583},"NCT00854373","Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial",[93],"2010-04-20","2007-06-01",232,[2809],[7563],{"trials":7585,"activeCount":101},[],{"intervention":7587,"totalTrials":424,"cells":7588},"Harvoni",{"EARLY_PHASE1":7589,"PHASE1":7591,"PHASE2":7593,"PHASE3":7595,"PHASE4":7597,"NA":7607},{"trials":7590,"activeCount":101},[],{"trials":7592,"activeCount":101},[],{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[],{"trials":7598,"activeCount":101},[7599],{"nctId":7600,"briefTitle":7601,"status":132,"phases":7602,"primaryCompletion":5700,"completion":5700,"start":3743,"enrollment":7603,"conditions":7604,"interventions":7606},"NCT02533934","Sofosbuvir Based DAA Therapy in HIV\u002FHCV Coinfected Pre or Post Liver Transplant",[93],68,[15,7099,7605],"Cirrhosis",[7587],{"trials":7608,"activeCount":101},[],{"intervention":7610,"totalTrials":424,"cells":7611},"Rivastigmine Patch 9.5 cm2",{"EARLY_PHASE1":7612,"PHASE1":7614,"PHASE2":7616,"PHASE3":7618,"PHASE4":7620,"NA":7630},{"trials":7613,"activeCount":101},[],{"trials":7615,"activeCount":101},[],{"trials":7617,"activeCount":101},[],{"trials":7619,"activeCount":101},[],{"trials":7621,"activeCount":101},[7622],{"nctId":7623,"briefTitle":7624,"status":132,"phases":7625,"primaryCompletion":6100,"completion":6100,"start":4041,"enrollment":519,"conditions":7626,"interventions":7629},"NCT00988117","The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and\u002For Thinking Problems",[93],[7627,7628],"Parkinsons Disease With Dementia","Parkinsons Disease With Mild to Moderate Memory and\u002For Thinking Problems",[7610],{"trials":7631,"activeCount":101},[],{"intervention":7633,"totalTrials":424,"cells":7634},"Epclusa",{"EARLY_PHASE1":7635,"PHASE1":7637,"PHASE2":7639,"PHASE3":7641,"PHASE4":7643,"NA":7657},{"trials":7636,"activeCount":101},[],{"trials":7638,"activeCount":101},[],{"trials":7640,"activeCount":101},[],{"trials":7642,"activeCount":101},[],{"trials":7644,"activeCount":101},[7645],{"nctId":7646,"briefTitle":7647,"status":132,"phases":7648,"primaryCompletion":7649,"completion":7650,"start":7651,"enrollment":7652,"conditions":7653,"interventions":7655},"NCT03987503","The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study",[93],"2022-10-30","2022-12-29","2020-07-01",87,[7654],"Hepatitis C, Chronic",[7633,7656],"Standard of care",{"trials":7658,"activeCount":101},[],{"intervention":7656,"totalTrials":424,"cells":7660},{"EARLY_PHASE1":7661,"PHASE1":7663,"PHASE2":7665,"PHASE3":7667,"PHASE4":7669,"NA":7675},{"trials":7662,"activeCount":101},[],{"trials":7664,"activeCount":101},[],{"trials":7666,"activeCount":101},[],{"trials":7668,"activeCount":101},[],{"trials":7670,"activeCount":101},[7671],{"nctId":7646,"briefTitle":7647,"status":132,"phases":7672,"primaryCompletion":7649,"completion":7650,"start":7651,"enrollment":7652,"conditions":7673,"interventions":7674},[93],[7654],[7633,7656],{"trials":7676,"activeCount":101},[],{"intervention":7678,"totalTrials":424,"cells":7679},"Microflare protocol for IVF",{"EARLY_PHASE1":7680,"PHASE1":7682,"PHASE2":7684,"PHASE3":7686,"PHASE4":7688,"NA":7699},{"trials":7681,"activeCount":101},[],{"trials":7683,"activeCount":101},[],{"trials":7685,"activeCount":101},[],{"trials":7687,"activeCount":101},[],{"trials":7689,"activeCount":101},[7690],{"nctId":7691,"briefTitle":7692,"status":120,"phases":7693,"primaryCompletion":236,"completion":714,"start":7694,"enrollment":526,"conditions":7695,"interventions":7696},"NCT00334243","Protocols for Improved in Vitro Fertilization (IVF) Outcomes",[93],"2006-06",[2809],[7678,7697,7698],"Antagonist protocol for IVF","Demi-halt protocol for IVF",{"trials":7700,"activeCount":101},[],{"intervention":7697,"totalTrials":424,"cells":7702},{"EARLY_PHASE1":7703,"PHASE1":7705,"PHASE2":7707,"PHASE3":7709,"PHASE4":7711,"NA":7717},{"trials":7704,"activeCount":101},[],{"trials":7706,"activeCount":101},[],{"trials":7708,"activeCount":101},[],{"trials":7710,"activeCount":101},[],{"trials":7712,"activeCount":101},[7713],{"nctId":7691,"briefTitle":7692,"status":120,"phases":7714,"primaryCompletion":236,"completion":714,"start":7694,"enrollment":526,"conditions":7715,"interventions":7716},[93],[2809],[7678,7697,7698],{"trials":7718,"activeCount":101},[],{"intervention":7698,"totalTrials":424,"cells":7720},{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7727,"PHASE4":7729,"NA":7735},{"trials":7722,"activeCount":101},[],{"trials":7724,"activeCount":101},[],{"trials":7726,"activeCount":101},[],{"trials":7728,"activeCount":101},[],{"trials":7730,"activeCount":101},[7731],{"nctId":7691,"briefTitle":7692,"status":120,"phases":7732,"primaryCompletion":236,"completion":714,"start":7694,"enrollment":526,"conditions":7733,"interventions":7734},[93],[2809],[7678,7697,7698],{"trials":7736,"activeCount":101},[],{"intervention":7738,"totalTrials":424,"cells":7739},"Alprazolam",{"EARLY_PHASE1":7740,"PHASE1":7742,"PHASE2":7744,"PHASE3":7746,"PHASE4":7748,"NA":7764},{"trials":7741,"activeCount":101},[],{"trials":7743,"activeCount":101},[],{"trials":7745,"activeCount":101},[],{"trials":7747,"activeCount":101},[],{"trials":7749,"activeCount":101},[7750],{"nctId":7751,"briefTitle":7752,"status":132,"phases":7753,"primaryCompletion":7754,"completion":7754,"start":7755,"enrollment":1060,"conditions":7756,"interventions":7762},"NCT07154147","Oral vs IV Sedation for Cataract Surgery in Older Adults",[93],"2026-01-19","2025-08-12",[7757,7758,7759,7760,7761],"Cataract Surgery","Sedation","Cognition Function","Perioperative Care","Older Adults",[7738,7763],"Midazolam",{"trials":7765,"activeCount":101},[],{"intervention":7763,"totalTrials":424,"cells":7767},{"EARLY_PHASE1":7768,"PHASE1":7770,"PHASE2":7772,"PHASE3":7774,"PHASE4":7776,"NA":7782},{"trials":7769,"activeCount":101},[],{"trials":7771,"activeCount":101},[],{"trials":7773,"activeCount":101},[],{"trials":7775,"activeCount":101},[],{"trials":7777,"activeCount":101},[7778],{"nctId":7751,"briefTitle":7752,"status":132,"phases":7779,"primaryCompletion":7754,"completion":7754,"start":7755,"enrollment":1060,"conditions":7780,"interventions":7781},[93],[7757,7758,7759,7760,7761],[7738,7763],{"trials":7783,"activeCount":101},[],{"intervention":7785,"totalTrials":424,"cells":7786},"0.9% Bacteriostatic Local Anesthetic",{"EARLY_PHASE1":7787,"PHASE1":7789,"PHASE2":7791,"PHASE3":7793,"PHASE4":7795,"NA":7815},{"trials":7788,"activeCount":101},[],{"trials":7790,"activeCount":101},[],{"trials":7792,"activeCount":101},[],{"trials":7794,"activeCount":101},[],{"trials":7796,"activeCount":101},[7797],{"nctId":7798,"briefTitle":7799,"status":132,"phases":7800,"primaryCompletion":7801,"completion":7801,"start":7802,"enrollment":7803,"conditions":7804,"interventions":7813},"NCT05294640","Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures",[93],"2023-02-21","2022-05-17",95,[7805,7806,7807,7808,7809,7810,7811,7812],"Eyelid Tumor","Eyelid Bump","Eyelid Deformity","Eyelid Abscess","Eyelid Boil","Eyelid Papilloma","Anesthesia, Local","Ophthalmology",[7785,7814],"1% Lidocaine with 1:100,000 epinephrine Local Anesthetic",{"trials":7816,"activeCount":101},[],{"intervention":7814,"totalTrials":424,"cells":7818},{"EARLY_PHASE1":7819,"PHASE1":7821,"PHASE2":7823,"PHASE3":7825,"PHASE4":7827,"NA":7833},{"trials":7820,"activeCount":101},[],{"trials":7822,"activeCount":101},[],{"trials":7824,"activeCount":101},[],{"trials":7826,"activeCount":101},[],{"trials":7828,"activeCount":101},[7829],{"nctId":7798,"briefTitle":7799,"status":132,"phases":7830,"primaryCompletion":7801,"completion":7801,"start":7802,"enrollment":7803,"conditions":7831,"interventions":7832},[93],[7805,7806,7807,7808,7809,7810,7811,7812],[7785,7814],{"trials":7834,"activeCount":101},[],{"intervention":7836,"totalTrials":424,"cells":7837},"Lidoderm patch",{"EARLY_PHASE1":7838,"PHASE1":7840,"PHASE2":7842,"PHASE3":7844,"PHASE4":7846,"NA":7856},{"trials":7839,"activeCount":101},[],{"trials":7841,"activeCount":101},[],{"trials":7843,"activeCount":101},[],{"trials":7845,"activeCount":101},[],{"trials":7847,"activeCount":101},[7848],{"nctId":7849,"briefTitle":7850,"status":132,"phases":7851,"primaryCompletion":2545,"completion":2545,"start":2437,"enrollment":97,"conditions":7852,"interventions":7855},"NCT00686127","Symptom Management After Breast Cancer Surgery",[93],[7853,7854],"Neuropathic Pain","Postmastectomy Pain",[7836],{"trials":7857,"activeCount":101},[],{"intervention":7859,"totalTrials":424,"cells":7860},"Azithromycin Oral Product",{"EARLY_PHASE1":7861,"PHASE1":7863,"PHASE2":7865,"PHASE3":7867,"PHASE4":7869,"NA":7881},{"trials":7862,"activeCount":101},[],{"trials":7864,"activeCount":101},[],{"trials":7866,"activeCount":101},[],{"trials":7868,"activeCount":101},[],{"trials":7870,"activeCount":101},[7871],{"nctId":7872,"briefTitle":7873,"status":120,"phases":7874,"primaryCompletion":988,"completion":988,"start":275,"enrollment":526,"conditions":7875,"interventions":7880},"NCT03953118","Azithromycin for Meibomian Gland Disease",[93],[7876,7877,7878,7879],"Dry Eye","Neuropathic Eye Pain","Ocular Microbiome","Depression, Anxiety",[7859],{"trials":7882,"activeCount":101},[],{"intervention":6448,"totalTrials":424,"cells":7884},{"EARLY_PHASE1":7885,"PHASE1":7887,"PHASE2":7889,"PHASE3":7891,"PHASE4":7893,"NA":7899},{"trials":7886,"activeCount":101},[],{"trials":7888,"activeCount":101},[],{"trials":7890,"activeCount":101},[],{"trials":7892,"activeCount":101},[],{"trials":7894,"activeCount":101},[7895],{"nctId":6438,"briefTitle":6439,"status":132,"phases":7896,"primaryCompletion":6441,"completion":6442,"start":6443,"enrollment":6444,"conditions":7897,"interventions":7898},[93],[6446],[926,6448],{"trials":7900,"activeCount":101},[],{"intervention":7902,"totalTrials":424,"cells":7903},"ingenol mebutate gel 0.015%",{"EARLY_PHASE1":7904,"PHASE1":7906,"PHASE2":7908,"PHASE3":7910,"PHASE4":7912,"NA":7923},{"trials":7905,"activeCount":101},[],{"trials":7907,"activeCount":101},[],{"trials":7909,"activeCount":101},[],{"trials":7911,"activeCount":101},[],{"trials":7913,"activeCount":101},[7914],{"nctId":7915,"briefTitle":7916,"status":132,"phases":7917,"primaryCompletion":7918,"completion":7918,"start":7919,"enrollment":1060,"conditions":7920,"interventions":7922},"NCT02866695","Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients",[93],"2018-07-02","2016-10-06",[7921],"Actinic Keratosis",[7902],{"trials":7924,"activeCount":101},[],{"intervention":7926,"totalTrials":424,"cells":7927},"Tildrakizumab Prefilled Syringe",{"EARLY_PHASE1":7928,"PHASE1":7930,"PHASE2":7932,"PHASE3":7934,"PHASE4":7936,"NA":7944},{"trials":7929,"activeCount":101},[],{"trials":7931,"activeCount":101},[],{"trials":7933,"activeCount":101},[],{"trials":7935,"activeCount":101},[],{"trials":7937,"activeCount":101},[7938],{"nctId":7939,"briefTitle":7940,"status":2462,"phases":7941,"primaryCompletion":3073,"completion":3073,"start":461,"enrollment":345,"conditions":7942,"interventions":7943},"NCT05390515","Psoriatic Immune Response to Tildrakizumab",[93],[652],[7926],{"trials":7945,"activeCount":101},[],{"intervention":7947,"totalTrials":424,"cells":7948},"Lisinopril",{"EARLY_PHASE1":7949,"PHASE1":7951,"PHASE2":7953,"PHASE3":7955,"PHASE4":7957,"NA":7965},{"trials":7950,"activeCount":101},[],{"trials":7952,"activeCount":101},[],{"trials":7954,"activeCount":101},[],{"trials":7956,"activeCount":101},[],{"trials":7958,"activeCount":101},[7959],{"nctId":7960,"briefTitle":7961,"status":132,"phases":7962,"primaryCompletion":205,"completion":205,"start":2436,"enrollment":37,"conditions":7963,"interventions":7964},"NCT01535235","ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study",[93],[15],[7947],{"trials":7966,"activeCount":101},[],{"intervention":230,"totalTrials":424,"cells":7968},{"EARLY_PHASE1":7969,"PHASE1":7971,"PHASE2":7973,"PHASE3":7975,"PHASE4":7977,"NA":7983},{"trials":7970,"activeCount":101},[],{"trials":7972,"activeCount":101},[],{"trials":7974,"activeCount":101},[],{"trials":7976,"activeCount":101},[],{"trials":7978,"activeCount":101},[7979],{"nctId":221,"briefTitle":222,"status":111,"phases":7980,"primaryCompletion":224,"completion":225,"start":226,"enrollment":101,"conditions":7981,"interventions":7982},[93],[228],[68,230,231],{"trials":7984,"activeCount":101},[],{"intervention":231,"totalTrials":424,"cells":7986},{"EARLY_PHASE1":7987,"PHASE1":7989,"PHASE2":7991,"PHASE3":7993,"PHASE4":7995,"NA":8001},{"trials":7988,"activeCount":101},[],{"trials":7990,"activeCount":101},[],{"trials":7992,"activeCount":101},[],{"trials":7994,"activeCount":101},[],{"trials":7996,"activeCount":101},[7997],{"nctId":221,"briefTitle":222,"status":111,"phases":7998,"primaryCompletion":224,"completion":225,"start":226,"enrollment":101,"conditions":7999,"interventions":8000},[93],[228],[68,230,231],{"trials":8002,"activeCount":101},[],{"intervention":8004,"totalTrials":424,"cells":8005},"Misoprostol",{"EARLY_PHASE1":8006,"PHASE1":8008,"PHASE2":8010,"PHASE3":8012,"PHASE4":8014,"NA":8025},{"trials":8007,"activeCount":101},[],{"trials":8009,"activeCount":101},[],{"trials":8011,"activeCount":101},[],{"trials":8013,"activeCount":101},[],{"trials":8015,"activeCount":101},[8016],{"nctId":8017,"briefTitle":8018,"status":120,"phases":8019,"primaryCompletion":3073,"completion":3073,"start":8020,"enrollment":498,"conditions":8021,"interventions":8024},"NCT04940013","Missed Period Pill Study",[93],"2021-10-25",[8022,8023],"Menstrual Regulation","Menstrual Irregularity",[8004],{"trials":8026,"activeCount":101},[],{"intervention":8028,"totalTrials":424,"cells":8029},"Euflexxa",{"EARLY_PHASE1":8030,"PHASE1":8032,"PHASE2":8034,"PHASE3":8036,"PHASE4":8038,"NA":8047},{"trials":8031,"activeCount":101},[],{"trials":8033,"activeCount":101},[],{"trials":8035,"activeCount":101},[],{"trials":8037,"activeCount":101},[],{"trials":8039,"activeCount":101},[8040],{"nctId":8041,"briefTitle":8042,"status":132,"phases":8043,"primaryCompletion":6568,"completion":226,"start":2418,"enrollment":2818,"conditions":8044,"interventions":8046},"NCT01895959","To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection",[93],[8045],"Knee Osteoarthritis",[8028],{"trials":8048,"activeCount":101},[],{"intervention":8050,"totalTrials":424,"cells":8051},"Thoracic epidural",{"EARLY_PHASE1":8052,"PHASE1":8054,"PHASE2":8056,"PHASE3":8058,"PHASE4":8060,"NA":8071},{"trials":8053,"activeCount":101},[],{"trials":8055,"activeCount":101},[],{"trials":8057,"activeCount":101},[],{"trials":8059,"activeCount":101},[],{"trials":8061,"activeCount":101},[8062],{"nctId":8063,"briefTitle":8064,"status":132,"phases":8065,"primaryCompletion":8066,"completion":204,"start":6628,"enrollment":1060,"conditions":8067,"interventions":8070},"NCT02721017","Cryoanalgesia vs. Epidural in the Nuss Procedure",[93],"2018-08-28",[8068,8069],"Pectus Excavatum","Funnel Chest",[8050],{"trials":8072,"activeCount":101},[],{"intervention":1251,"totalTrials":424,"cells":8074},{"EARLY_PHASE1":8075,"PHASE1":8077,"PHASE2":8079,"PHASE3":8081,"PHASE4":8083,"NA":8089},{"trials":8076,"activeCount":101},[],{"trials":8078,"activeCount":101},[],{"trials":8080,"activeCount":101},[],{"trials":8082,"activeCount":101},[],{"trials":8084,"activeCount":101},[8085],{"nctId":1241,"briefTitle":1242,"status":132,"phases":8086,"primaryCompletion":1244,"completion":1245,"start":806,"enrollment":1246,"conditions":8087,"interventions":8088},[93],[1248,1249],[1228,1251],{"trials":8090,"activeCount":101},[],{"intervention":8092,"totalTrials":424,"cells":8093},"Vivitrol",{"EARLY_PHASE1":8094,"PHASE1":8096,"PHASE2":8098,"PHASE3":8100,"PHASE4":8102,"NA":8115},{"trials":8095,"activeCount":101},[],{"trials":8097,"activeCount":101},[],{"trials":8099,"activeCount":101},[],{"trials":8101,"activeCount":101},[],{"trials":8103,"activeCount":101},[8104],{"nctId":8105,"briefTitle":8106,"status":120,"phases":8107,"primaryCompletion":308,"completion":308,"start":8108,"enrollment":8109,"conditions":8110,"interventions":8114},"NCT04094584","Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder",[93],"2020-08-14",179,[8111,8112,8113],"Alcohol Use Disorder","Substance Use","Alcohol Abuse or Dependence",[8092],{"trials":8116,"activeCount":101},[],{"intervention":8118,"totalTrials":424,"cells":8119},"Optimal treatment",{"EARLY_PHASE1":8120,"PHASE1":8122,"PHASE2":8124,"PHASE3":8126,"PHASE4":8128,"NA":8138},{"trials":8121,"activeCount":101},[],{"trials":8123,"activeCount":101},[],{"trials":8125,"activeCount":101},[],{"trials":8127,"activeCount":101},[],{"trials":8129,"activeCount":101},[8130],{"nctId":8131,"briefTitle":8132,"status":132,"phases":8133,"completion":713,"start":2435,"enrollment":8134,"conditions":8135,"interventions":8137},"NCT00328640","Quality Improvement in Stroke Prevention (QUISP)",[93],1500,[8136],"Ischemic Stroke",[8118],{"trials":8139,"activeCount":101},[],{"intervention":8141,"totalTrials":424,"cells":8142},"sildenafil",{"EARLY_PHASE1":8143,"PHASE1":8145,"PHASE2":8147,"PHASE3":8149,"PHASE4":8151,"NA":8162},{"trials":8144,"activeCount":101},[],{"trials":8146,"activeCount":101},[],{"trials":8148,"activeCount":101},[],{"trials":8150,"activeCount":101},[],{"trials":8152,"activeCount":101},[8153],{"nctId":8154,"briefTitle":8155,"status":120,"phases":8156,"primaryCompletion":3648,"completion":3625,"start":6212,"enrollment":2472,"conditions":8157,"interventions":8161},"NCT00133679","Chronic Sildenafil for Severe Diaphragmatic Hernia",[93],[8158,8159,8160],"Hernia, Diaphragmatic","Hypertension, Pulmonary","Hypoplasia, Pulmonary",[8141],{"trials":8163,"activeCount":101},[],{"intervention":8165,"totalTrials":424,"cells":8166},"Mifeprex®",{"EARLY_PHASE1":8167,"PHASE1":8169,"PHASE2":8171,"PHASE3":8173,"PHASE4":8175,"NA":8188},{"trials":8168,"activeCount":101},[],{"trials":8170,"activeCount":101},[],{"trials":8172,"activeCount":101},[],{"trials":8174,"activeCount":101},[],{"trials":8176,"activeCount":101},[8177],{"nctId":8178,"briefTitle":8179,"status":111,"phases":8180,"primaryCompletion":8181,"completion":8181,"start":8182,"enrollment":101,"conditions":8183,"interventions":8185},"NCT03829696","Advance Provision of Medication Abortion",[93],"2021-01","2020-01",[8184],"Early Abortion",[8165,8186,8187],"Misoprostol 800 mcg","ella®",{"trials":8189,"activeCount":101},[],{"intervention":8186,"totalTrials":424,"cells":8191},{"EARLY_PHASE1":8192,"PHASE1":8194,"PHASE2":8196,"PHASE3":8198,"PHASE4":8200,"NA":8206},{"trials":8193,"activeCount":101},[],{"trials":8195,"activeCount":101},[],{"trials":8197,"activeCount":101},[],{"trials":8199,"activeCount":101},[],{"trials":8201,"activeCount":101},[8202],{"nctId":8178,"briefTitle":8179,"status":111,"phases":8203,"primaryCompletion":8181,"completion":8181,"start":8182,"enrollment":101,"conditions":8204,"interventions":8205},[93],[8184],[8165,8186,8187],{"trials":8207,"activeCount":101},[],{"intervention":8187,"totalTrials":424,"cells":8209},{"EARLY_PHASE1":8210,"PHASE1":8212,"PHASE2":8214,"PHASE3":8216,"PHASE4":8218,"NA":8224},{"trials":8211,"activeCount":101},[],{"trials":8213,"activeCount":101},[],{"trials":8215,"activeCount":101},[],{"trials":8217,"activeCount":101},[],{"trials":8219,"activeCount":101},[8220],{"nctId":8178,"briefTitle":8179,"status":111,"phases":8221,"primaryCompletion":8181,"completion":8181,"start":8182,"enrollment":101,"conditions":8222,"interventions":8223},[93],[8184],[8165,8186,8187],{"trials":8225,"activeCount":101},[],{"intervention":8227,"totalTrials":424,"cells":8228},"alendronate sodium",{"EARLY_PHASE1":8229,"PHASE1":8231,"PHASE2":8233,"PHASE3":8235,"PHASE4":8237,"NA":8247},{"trials":8230,"activeCount":101},[],{"trials":8232,"activeCount":101},[],{"trials":8234,"activeCount":101},[],{"trials":8236,"activeCount":101},[],{"trials":8238,"activeCount":101},[8239],{"nctId":8240,"briefTitle":8241,"status":132,"phases":8242,"primaryCompletion":2583,"completion":448,"start":6212,"enrollment":6200,"conditions":8243,"interventions":8246},"NCT00504166","Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women",[93],[8244,8245],"Osteopenia","Osteoporosis",[8227],{"trials":8248,"activeCount":101},[],{"intervention":6731,"totalTrials":424,"cells":8250},{"EARLY_PHASE1":8251,"PHASE1":8253,"PHASE2":8255,"PHASE3":8257,"PHASE4":8259,"NA":8265},{"trials":8252,"activeCount":101},[],{"trials":8254,"activeCount":101},[],{"trials":8256,"activeCount":101},[],{"trials":8258,"activeCount":101},[],{"trials":8260,"activeCount":101},[8261],{"nctId":6724,"briefTitle":6725,"status":132,"phases":8262,"primaryCompletion":6727,"completion":3648,"start":6728,"enrollment":1060,"conditions":8263,"interventions":8264},[93],[1410],[6731,6342],{"trials":8266,"activeCount":101},[],{"intervention":8268,"totalTrials":424,"cells":8269},"Clobex Spray",{"EARLY_PHASE1":8270,"PHASE1":8272,"PHASE2":8274,"PHASE3":8276,"PHASE4":8278,"NA":8288},{"trials":8271,"activeCount":101},[],{"trials":8273,"activeCount":101},[],{"trials":8275,"activeCount":101},[],{"trials":8277,"activeCount":101},[],{"trials":8279,"activeCount":101},[8280],{"nctId":8281,"briefTitle":8282,"status":132,"phases":8283,"primaryCompletion":205,"completion":205,"start":932,"enrollment":751,"conditions":8284,"interventions":8286},"NCT01012713","Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis",[93],[8285],"Chronic Stable Plaque Psoriasis",[8268,8287],"Vectical Ointment",{"trials":8289,"activeCount":101},[],{"intervention":8287,"totalTrials":424,"cells":8291},{"EARLY_PHASE1":8292,"PHASE1":8294,"PHASE2":8296,"PHASE3":8298,"PHASE4":8300,"NA":8306},{"trials":8293,"activeCount":101},[],{"trials":8295,"activeCount":101},[],{"trials":8297,"activeCount":101},[],{"trials":8299,"activeCount":101},[],{"trials":8301,"activeCount":101},[8302],{"nctId":8281,"briefTitle":8282,"status":132,"phases":8303,"primaryCompletion":205,"completion":205,"start":932,"enrollment":751,"conditions":8304,"interventions":8305},[93],[8285],[8268,8287],{"trials":8307,"activeCount":101},[],{"intervention":8309,"totalTrials":424,"cells":8310},"Sevoflurane",{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8315,"PHASE3":8317,"PHASE4":8319,"NA":8335},{"trials":8312,"activeCount":101},[],{"trials":8314,"activeCount":101},[],{"trials":8316,"activeCount":101},[],{"trials":8318,"activeCount":101},[],{"trials":8320,"activeCount":101},[8321],{"nctId":8322,"briefTitle":8323,"status":132,"phases":8324,"primaryCompletion":8325,"completion":2418,"start":6052,"enrollment":1097,"conditions":8326,"interventions":8330},"NCT01199237","Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block",[93],"2012-08",[8327,8328,8329],"Airway Reflexes, Protective","Recovery After Neuromuscular Block","Anesthetic Recovery",[8309,8331,8332,8333,8334],"Desflurane","Rocuronium","Neostigmine","Glycopyrrolate",{"trials":8336,"activeCount":101},[],{"intervention":8331,"totalTrials":424,"cells":8338},{"EARLY_PHASE1":8339,"PHASE1":8341,"PHASE2":8343,"PHASE3":8345,"PHASE4":8347,"NA":8353},{"trials":8340,"activeCount":101},[],{"trials":8342,"activeCount":101},[],{"trials":8344,"activeCount":101},[],{"trials":8346,"activeCount":101},[],{"trials":8348,"activeCount":101},[8349],{"nctId":8322,"briefTitle":8323,"status":132,"phases":8350,"primaryCompletion":8325,"completion":2418,"start":6052,"enrollment":1097,"conditions":8351,"interventions":8352},[93],[8327,8328,8329],[8309,8331,8332,8333,8334],{"trials":8354,"activeCount":101},[],{"intervention":8332,"totalTrials":424,"cells":8356},{"EARLY_PHASE1":8357,"PHASE1":8359,"PHASE2":8361,"PHASE3":8363,"PHASE4":8365,"NA":8371},{"trials":8358,"activeCount":101},[],{"trials":8360,"activeCount":101},[],{"trials":8362,"activeCount":101},[],{"trials":8364,"activeCount":101},[],{"trials":8366,"activeCount":101},[8367],{"nctId":8322,"briefTitle":8323,"status":132,"phases":8368,"primaryCompletion":8325,"completion":2418,"start":6052,"enrollment":1097,"conditions":8369,"interventions":8370},[93],[8327,8328,8329],[8309,8331,8332,8333,8334],{"trials":8372,"activeCount":101},[],{"intervention":8333,"totalTrials":424,"cells":8374},{"EARLY_PHASE1":8375,"PHASE1":8377,"PHASE2":8379,"PHASE3":8381,"PHASE4":8383,"NA":8389},{"trials":8376,"activeCount":101},[],{"trials":8378,"activeCount":101},[],{"trials":8380,"activeCount":101},[],{"trials":8382,"activeCount":101},[],{"trials":8384,"activeCount":101},[8385],{"nctId":8322,"briefTitle":8323,"status":132,"phases":8386,"primaryCompletion":8325,"completion":2418,"start":6052,"enrollment":1097,"conditions":8387,"interventions":8388},[93],[8327,8328,8329],[8309,8331,8332,8333,8334],{"trials":8390,"activeCount":101},[],{"intervention":8334,"totalTrials":424,"cells":8392},{"EARLY_PHASE1":8393,"PHASE1":8395,"PHASE2":8397,"PHASE3":8399,"PHASE4":8401,"NA":8407},{"trials":8394,"activeCount":101},[],{"trials":8396,"activeCount":101},[],{"trials":8398,"activeCount":101},[],{"trials":8400,"activeCount":101},[],{"trials":8402,"activeCount":101},[8403],{"nctId":8322,"briefTitle":8323,"status":132,"phases":8404,"primaryCompletion":8325,"completion":2418,"start":6052,"enrollment":1097,"conditions":8405,"interventions":8406},[93],[8327,8328,8329],[8309,8331,8332,8333,8334],{"trials":8408,"activeCount":101},[],{"intervention":6333,"totalTrials":424,"cells":8410},{"EARLY_PHASE1":8411,"PHASE1":8413,"PHASE2":8415,"PHASE3":8417,"PHASE4":8419,"NA":8425},{"trials":8412,"activeCount":101},[],{"trials":8414,"activeCount":101},[],{"trials":8416,"activeCount":101},[],{"trials":8418,"activeCount":101},[],{"trials":8420,"activeCount":101},[8421],{"nctId":6323,"briefTitle":6324,"status":132,"phases":8422,"primaryCompletion":6326,"completion":6326,"start":6327,"enrollment":6328,"conditions":8423,"interventions":8424},[93],[6330,6331],[6333,6298],{"trials":8426,"activeCount":101},[],{"intervention":8428,"totalTrials":424,"cells":8429},"preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine",{"EARLY_PHASE1":8430,"PHASE1":8432,"PHASE2":8434,"PHASE3":8436,"PHASE4":8438,"NA":8451},{"trials":8431,"activeCount":101},[],{"trials":8433,"activeCount":101},[],{"trials":8435,"activeCount":101},[],{"trials":8437,"activeCount":101},[],{"trials":8439,"activeCount":101},[8440],{"nctId":8441,"briefTitle":8442,"status":132,"phases":8443,"primaryCompletion":8444,"completion":8444,"start":431,"enrollment":8445,"conditions":8446,"interventions":8449},"NCT05190120","Adductor Canal Block Versus Femoral Block on Pain and Quadriceps Strength",[93],"2022-03-20",132,[8447,8448],"Anterior Cruciate Ligament Tear","Knee Meniscus Tear",[8428,8450],"Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.",{"trials":8452,"activeCount":101},[],{"intervention":8450,"totalTrials":424,"cells":8454},{"EARLY_PHASE1":8455,"PHASE1":8457,"PHASE2":8459,"PHASE3":8461,"PHASE4":8463,"NA":8469},{"trials":8456,"activeCount":101},[],{"trials":8458,"activeCount":101},[],{"trials":8460,"activeCount":101},[],{"trials":8462,"activeCount":101},[],{"trials":8464,"activeCount":101},[8465],{"nctId":8441,"briefTitle":8442,"status":132,"phases":8466,"primaryCompletion":8444,"completion":8444,"start":431,"enrollment":8445,"conditions":8467,"interventions":8468},[93],[8447,8448],[8428,8450],{"trials":8470,"activeCount":101},[],{"intervention":8472,"totalTrials":424,"cells":8473},"Mass treatment with oral azithromycin to an entire community",{"EARLY_PHASE1":8474,"PHASE1":8476,"PHASE2":8478,"PHASE3":8480,"PHASE4":8482,"NA":8492},{"trials":8475,"activeCount":101},[],{"trials":8477,"activeCount":101},[],{"trials":8479,"activeCount":101},[],{"trials":8481,"activeCount":101},[],{"trials":8483,"activeCount":101},[8484],{"nctId":8485,"briefTitle":8486,"status":132,"phases":8487,"primaryCompletion":5219,"completion":6149,"start":7694,"enrollment":8488,"conditions":8489,"interventions":8491},"NCT00322972","Trachoma Amelioration in Northern Amhara (TANA)",[93],33000,[115,8490],"Chlamydia",[8472],{"trials":8493,"activeCount":101},[],{"intervention":8495,"totalTrials":424,"cells":8496},"Doxycycline Hyclate Delayed-Release 200 mg",{"EARLY_PHASE1":8497,"PHASE1":8499,"PHASE2":8501,"PHASE3":8503,"PHASE4":8505,"NA":8518},{"trials":8498,"activeCount":101},[],{"trials":8500,"activeCount":101},[],{"trials":8502,"activeCount":101},[],{"trials":8504,"activeCount":101},[],{"trials":8506,"activeCount":101},[8507],{"nctId":8508,"briefTitle":8509,"status":132,"phases":8510,"primaryCompletion":8511,"completion":8511,"start":8512,"enrollment":8513,"conditions":8514,"interventions":8517},"NCT03980223","Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men",[93],"2023-06-12","2019-11-26",641,[8515,8490,8516],"Gonorrhea","Syphilis",[8495],{"trials":8519,"activeCount":101},[],{"intervention":8521,"totalTrials":424,"cells":8522},"Fesoterodine",{"EARLY_PHASE1":8523,"PHASE1":8525,"PHASE2":8527,"PHASE3":8529,"PHASE4":8531,"NA":8542},{"trials":8524,"activeCount":101},[],{"trials":8526,"activeCount":101},[],{"trials":8528,"activeCount":101},[],{"trials":8530,"activeCount":101},[],{"trials":8532,"activeCount":101},[8533],{"nctId":8534,"briefTitle":8535,"status":132,"phases":8536,"primaryCompletion":7251,"completion":8537,"start":2546,"enrollment":8538,"conditions":8539,"interventions":8541},"NCT00862745","Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)",[93],"2011-05",645,[8540,1262],"Urge Urinary Incontinence",[8521],{"trials":8543,"activeCount":101},[],{"intervention":6769,"totalTrials":424,"cells":8545},{"EARLY_PHASE1":8546,"PHASE1":8548,"PHASE2":8550,"PHASE3":8552,"PHASE4":8554,"NA":8560},{"trials":8547,"activeCount":101},[],{"trials":8549,"activeCount":101},[],{"trials":8551,"activeCount":101},[],{"trials":8553,"activeCount":101},[],{"trials":8555,"activeCount":101},[8556],{"nctId":6762,"briefTitle":6763,"status":120,"phases":8557,"primaryCompletion":447,"completion":447,"start":6765,"enrollment":2818,"conditions":8558,"interventions":8559},[93],[6767],[6769,6739],{"trials":8561,"activeCount":101},[],{"intervention":6343,"totalTrials":424,"cells":8563},{"EARLY_PHASE1":8564,"PHASE1":8566,"PHASE2":8568,"PHASE3":8570,"PHASE4":8572,"NA":8578},{"trials":8565,"activeCount":101},[],{"trials":8567,"activeCount":101},[],{"trials":8569,"activeCount":101},[],{"trials":8571,"activeCount":101},[],{"trials":8573,"activeCount":101},[8574],{"nctId":6335,"briefTitle":6336,"status":132,"phases":8575,"primaryCompletion":6338,"completion":6338,"start":6339,"enrollment":345,"conditions":8576,"interventions":8577},[93],[5911],[6342,6298,6343],{"trials":8579,"activeCount":101},[],{"intervention":6801,"totalTrials":424,"cells":8581},{"EARLY_PHASE1":8582,"PHASE1":8584,"PHASE2":8586,"PHASE3":8588,"PHASE4":8590,"NA":8596},{"trials":8583,"activeCount":101},[],{"trials":8585,"activeCount":101},[],{"trials":8587,"activeCount":101},[],{"trials":8589,"activeCount":101},[],{"trials":8591,"activeCount":101},[8592],{"nctId":6794,"briefTitle":6795,"status":120,"phases":8593,"primaryCompletion":226,"completion":226,"start":4155,"enrollment":480,"conditions":8594,"interventions":8595},[93],[6042,6798,6799],[6801,6773,6802],{"trials":8597,"activeCount":101},[],{"intervention":6802,"totalTrials":424,"cells":8599},{"EARLY_PHASE1":8600,"PHASE1":8602,"PHASE2":8604,"PHASE3":8606,"PHASE4":8608,"NA":8614},{"trials":8601,"activeCount":101},[],{"trials":8603,"activeCount":101},[],{"trials":8605,"activeCount":101},[],{"trials":8607,"activeCount":101},[],{"trials":8609,"activeCount":101},[8610],{"nctId":6794,"briefTitle":6795,"status":120,"phases":8611,"primaryCompletion":226,"completion":226,"start":4155,"enrollment":480,"conditions":8612,"interventions":8613},[93],[6042,6798,6799],[6801,6773,6802],{"trials":8615,"activeCount":101},[],{"intervention":260,"totalTrials":424,"cells":8617},{"EARLY_PHASE1":8618,"PHASE1":8620,"PHASE2":8622,"PHASE3":8624,"PHASE4":8626,"NA":8632},{"trials":8619,"activeCount":101},[],{"trials":8621,"activeCount":101},[],{"trials":8623,"activeCount":101},[],{"trials":8625,"activeCount":101},[],{"trials":8627,"activeCount":101},[8628],{"nctId":251,"briefTitle":252,"status":132,"phases":8629,"primaryCompletion":254,"completion":237,"start":255,"enrollment":256,"conditions":8630,"interventions":8631},[93],[115,258],[260,68],{"trials":8633,"activeCount":101},[],{"intervention":8635,"totalTrials":424,"cells":8636},"NRT",{"EARLY_PHASE1":8637,"PHASE1":8639,"PHASE2":8641,"PHASE3":8643,"PHASE4":8645,"NA":8655},{"trials":8638,"activeCount":101},[],{"trials":8640,"activeCount":101},[],{"trials":8642,"activeCount":101},[],{"trials":8644,"activeCount":101},[],{"trials":8646,"activeCount":101},[8647],{"nctId":8648,"briefTitle":8649,"status":132,"phases":8650,"primaryCompletion":6628,"completion":432,"start":8651,"enrollment":751,"conditions":8652,"interventions":8654},"NCT02482233","The END Perioperative Smoking Pilot Study",[93],"2015-08",[6381,8653,992],"Nicotine Addiction",[8635],{"trials":8656,"activeCount":101},[],{"intervention":8658,"totalTrials":424,"cells":8659},"Sofosbuvir + Simeprevir",{"EARLY_PHASE1":8660,"PHASE1":8662,"PHASE2":8664,"PHASE3":8666,"PHASE4":8668,"NA":8677},{"trials":8661,"activeCount":101},[],{"trials":8663,"activeCount":101},[],{"trials":8665,"activeCount":101},[],{"trials":8667,"activeCount":101},[],{"trials":8669,"activeCount":101},[8670],{"nctId":8671,"briefTitle":8672,"status":111,"phases":8673,"primaryCompletion":2517,"completion":1871,"start":113,"enrollment":101,"conditions":8674,"interventions":8676},"NCT02206932","A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C",[93],[7654,8675],"HIV CDC Category A1",[8658],{"trials":8678,"activeCount":101},[],{"intervention":8680,"totalTrials":424,"cells":8681},"mass treatment with oral azithromycin",{"EARLY_PHASE1":8682,"PHASE1":8684,"PHASE2":8686,"PHASE3":8688,"PHASE4":8690,"NA":8700},{"trials":8683,"activeCount":101},[],{"trials":8685,"activeCount":101},[],{"trials":8687,"activeCount":101},[],{"trials":8689,"activeCount":101},[],{"trials":8691,"activeCount":101},[8692],{"nctId":8693,"briefTitle":8694,"status":132,"phases":8695,"primaryCompletion":540,"completion":6149,"start":8696,"enrollment":8697,"conditions":8698,"interventions":8699},"NCT01202331","Tripartite International Research for the Elimination of Trachoma",[93],"2010-11",29000,[115,8490],[8680],{"trials":8701,"activeCount":101},[],{"intervention":8703,"totalTrials":424,"cells":8704},"Belatacept",{"EARLY_PHASE1":8705,"PHASE1":8707,"PHASE2":8709,"PHASE3":8711,"PHASE4":8713,"NA":8725},{"trials":8706,"activeCount":101},[],{"trials":8708,"activeCount":101},[],{"trials":8710,"activeCount":101},[],{"trials":8712,"activeCount":101},[],{"trials":8714,"activeCount":101},[8715],{"nctId":8716,"briefTitle":8717,"status":111,"phases":8718,"primaryCompletion":8719,"completion":8720,"start":8721,"enrollment":101,"conditions":8722,"interventions":8724},"NCT02939365","Precision Medicine Offers Belatacept Monotherapy",[93],"2020-02","2022-12","2019-02",[8723],"Transplantation",[8703],{"trials":8726,"activeCount":101},[],{"intervention":8728,"totalTrials":424,"cells":8729},"Isoniazid 300 Mg ORAL",{"EARLY_PHASE1":8730,"PHASE1":8732,"PHASE2":8734,"PHASE3":8736,"PHASE4":8738,"NA":8752},{"trials":8731,"activeCount":101},[],{"trials":8733,"activeCount":101},[],{"trials":8735,"activeCount":101},[],{"trials":8737,"activeCount":101},[],{"trials":8739,"activeCount":101},[8740],{"nctId":8741,"briefTitle":8742,"status":132,"phases":8743,"primaryCompletion":8744,"completion":8744,"start":8745,"enrollment":8746,"conditions":8747,"interventions":8750},"NCT03302299","Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)",[93],"2021-04-01","2017-04-07",302,[8748,33,8749],"Tuberculosis","Alcohol Abuse",[8728,8751],"Pyridoxine 25 Mg Oral",{"trials":8753,"activeCount":101},[],{"intervention":8751,"totalTrials":424,"cells":8755},{"EARLY_PHASE1":8756,"PHASE1":8758,"PHASE2":8760,"PHASE3":8762,"PHASE4":8764,"NA":8770},{"trials":8757,"activeCount":101},[],{"trials":8759,"activeCount":101},[],{"trials":8761,"activeCount":101},[],{"trials":8763,"activeCount":101},[],{"trials":8765,"activeCount":101},[8766],{"nctId":8741,"briefTitle":8742,"status":132,"phases":8767,"primaryCompletion":8744,"completion":8744,"start":8745,"enrollment":8746,"conditions":8768,"interventions":8769},[93],[8748,33,8749],[8728,8751],{"trials":8771,"activeCount":101},[],{"intervention":8773,"totalTrials":424,"cells":8774},"Yasmin",{"EARLY_PHASE1":8775,"PHASE1":8777,"PHASE2":8779,"PHASE3":8781,"PHASE4":8783,"NA":8795},{"trials":8776,"activeCount":101},[],{"trials":8778,"activeCount":101},[],{"trials":8780,"activeCount":101},[],{"trials":8782,"activeCount":101},[],{"trials":8784,"activeCount":101},[8785],{"nctId":8786,"briefTitle":8787,"status":132,"phases":8788,"primaryCompletion":8789,"completion":8789,"start":8790,"enrollment":8791,"conditions":8792,"interventions":8794},"NCT03819140","Continuous Versus Cyclical OCP Use in PCOS",[93],"2022-10-16","2019-04-01",51,[8793],"Polycystic Ovary Syndrome",[8773],{"trials":8796,"activeCount":101},[],{"intervention":8798,"totalTrials":424,"cells":8799},"Botulinum toxin A",{"EARLY_PHASE1":8800,"PHASE1":8802,"PHASE2":8804,"PHASE3":8806,"PHASE4":8808,"NA":8817},{"trials":8801,"activeCount":101},[],{"trials":8803,"activeCount":101},[],{"trials":8805,"activeCount":101},[],{"trials":8807,"activeCount":101},[],{"trials":8809,"activeCount":101},[8810],{"nctId":8811,"briefTitle":8812,"status":132,"phases":8813,"primaryCompletion":2407,"completion":4275,"start":3696,"enrollment":345,"conditions":8814,"interventions":8816},"NCT00773253","Botox for Cervical Dystonia Following EMG Mapping",[93],[8815],"Cervical Dystonia",[8798],{"trials":8818,"activeCount":101},[],{"intervention":8820,"totalTrials":424,"cells":8821},"Raltegravir, tenofovir\u002Femtricitabine",{"EARLY_PHASE1":8822,"PHASE1":8824,"PHASE2":8826,"PHASE3":8828,"PHASE4":8830,"NA":8840},{"trials":8823,"activeCount":101},[],{"trials":8825,"activeCount":101},[],{"trials":8827,"activeCount":101},[],{"trials":8829,"activeCount":101},[],{"trials":8831,"activeCount":101},[8832],{"nctId":8833,"briefTitle":8834,"status":132,"phases":8835,"primaryCompletion":8836,"completion":3625,"start":8837,"enrollment":1027,"conditions":8838,"interventions":8839},"NCT01025427","HIV Persistence and Viral Reservoirs",[93],"2012-11","2009-12",[15,18],[8820],{"trials":8841,"activeCount":101},[],{"intervention":8843,"totalTrials":424,"cells":8844},"Escitalopram",{"EARLY_PHASE1":8845,"PHASE1":8847,"PHASE2":8849,"PHASE3":8851,"PHASE4":8853,"NA":8862},{"trials":8846,"activeCount":101},[],{"trials":8848,"activeCount":101},[],{"trials":8850,"activeCount":101},[],{"trials":8852,"activeCount":101},[],{"trials":8854,"activeCount":101},[8855],{"nctId":8856,"briefTitle":8857,"status":132,"phases":8858,"primaryCompletion":8859,"completion":2722,"start":715,"enrollment":751,"conditions":8860,"interventions":8861},"NCT00812994","Neurotrophic Factors and Depression",[93],"2006-12",[27],[8843],{"trials":8863,"activeCount":101},[],{"intervention":8865,"totalTrials":424,"cells":8866},"Furosemide",{"EARLY_PHASE1":8867,"PHASE1":8869,"PHASE2":8871,"PHASE3":8873,"PHASE4":8875,"NA":8887},{"trials":8868,"activeCount":101},[],{"trials":8870,"activeCount":101},[],{"trials":8872,"activeCount":101},[],{"trials":8874,"activeCount":101},[],{"trials":8876,"activeCount":101},[8877],{"nctId":8878,"briefTitle":8879,"status":120,"phases":8880,"primaryCompletion":8881,"completion":8881,"start":8882,"enrollment":424,"conditions":8883,"interventions":8886},"NCT05158153","Outpatient Recovery From Acute Kidney Injury Requiring Dialysis",[93],"2022-04-19","2021-10-18",[8884,8885],"Acute Kidney Injury","Dialysis Hypotension",[8865],{"trials":8888,"activeCount":101},[],{"intervention":8890,"totalTrials":424,"cells":8891},"Ultravate ointment twice daily + LacHydrin lotion twice daily",{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8896,"PHASE3":8898,"PHASE4":8900,"NA":8910},{"trials":8893,"activeCount":101},[],{"trials":8895,"activeCount":101},[],{"trials":8897,"activeCount":101},[],{"trials":8899,"activeCount":101},[],{"trials":8901,"activeCount":101},[8902],{"nctId":8903,"briefTitle":8904,"status":132,"phases":8905,"primaryCompletion":932,"completion":932,"start":2574,"enrollment":28,"conditions":8906,"interventions":8908},"NCT00990561","Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis",[93],[8907],"Stable Plaque Psoriasis",[8890,8909],"Ultravate ointment once daily + LacHydrin lotion twice daily",{"trials":8911,"activeCount":101},[],{"intervention":8909,"totalTrials":424,"cells":8913},{"EARLY_PHASE1":8914,"PHASE1":8916,"PHASE2":8918,"PHASE3":8920,"PHASE4":8922,"NA":8928},{"trials":8915,"activeCount":101},[],{"trials":8917,"activeCount":101},[],{"trials":8919,"activeCount":101},[],{"trials":8921,"activeCount":101},[],{"trials":8923,"activeCount":101},[8924],{"nctId":8903,"briefTitle":8904,"status":132,"phases":8925,"primaryCompletion":932,"completion":932,"start":2574,"enrollment":28,"conditions":8926,"interventions":8927},[93],[8907],[8890,8909],{"trials":8929,"activeCount":101},[],{"intervention":3726,"totalTrials":424,"cells":8931},{"EARLY_PHASE1":8932,"PHASE1":8934,"PHASE2":8936,"PHASE3":8938,"PHASE4":8940,"NA":8946},{"trials":8933,"activeCount":101},[],{"trials":8935,"activeCount":101},[],{"trials":8937,"activeCount":101},[],{"trials":8939,"activeCount":101},[],{"trials":8941,"activeCount":101},[8942],{"nctId":3718,"briefTitle":3719,"status":120,"phases":8943,"primaryCompletion":275,"completion":275,"start":3721,"enrollment":407,"conditions":8944,"interventions":8945},[93],[3723,27,3724,3707],[3607,3726],{"trials":8947,"activeCount":101},[],{"intervention":281,"totalTrials":424,"cells":8949},{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8954,"PHASE3":8956,"PHASE4":8958,"NA":8964},{"trials":8951,"activeCount":101},[],{"trials":8953,"activeCount":101},[],{"trials":8955,"activeCount":101},[],{"trials":8957,"activeCount":101},[],{"trials":8959,"activeCount":101},[8960],{"nctId":271,"briefTitle":272,"status":132,"phases":8961,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":8962,"interventions":8963},[93],[279],[68,128,281],{"trials":8965,"activeCount":101},[],{"intervention":8967,"totalTrials":424,"cells":8968},"ipratropium bromide",{"EARLY_PHASE1":8969,"PHASE1":8971,"PHASE2":8973,"PHASE3":8975,"PHASE4":8977,"NA":8986},{"trials":8970,"activeCount":101},[],{"trials":8972,"activeCount":101},[],{"trials":8974,"activeCount":101},[],{"trials":8976,"activeCount":101},[],{"trials":8978,"activeCount":101},[8979],{"nctId":8980,"briefTitle":8981,"status":132,"phases":8982,"primaryCompletion":205,"completion":205,"start":1200,"enrollment":1060,"conditions":8983,"interventions":8985},"NCT01691079","Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes",[93],[8984],"Bronchospasm, Exercise-Induced",[8967],{"trials":8987,"activeCount":101},[],{"intervention":8989,"totalTrials":424,"cells":8990},"Ropivacaine 0.2% Injectable Solution",{"EARLY_PHASE1":8991,"PHASE1":8993,"PHASE2":8995,"PHASE3":8997,"PHASE4":8999,"NA":9010},{"trials":8992,"activeCount":101},[],{"trials":8994,"activeCount":101},[],{"trials":8996,"activeCount":101},[],{"trials":8998,"activeCount":101},[],{"trials":9000,"activeCount":101},[9001],{"nctId":9002,"briefTitle":9003,"status":132,"phases":9004,"primaryCompletion":9005,"completion":4144,"start":9006,"enrollment":434,"conditions":9007,"interventions":9009},"NCT04474366","The Effect of Pectoral Blocks on Perioperative Pain in Gender Affirmation Top Surgery",[93],"2022-02-28","2020-06-16",[9008,6317,6331],"Gender Dysphoria",[8989],{"trials":9011,"activeCount":101},[],{"intervention":6360,"totalTrials":424,"cells":9013},{"EARLY_PHASE1":9014,"PHASE1":9016,"PHASE2":9018,"PHASE3":9020,"PHASE4":9022,"NA":9028},{"trials":9015,"activeCount":101},[],{"trials":9017,"activeCount":101},[],{"trials":9019,"activeCount":101},[],{"trials":9021,"activeCount":101},[],{"trials":9023,"activeCount":101},[9024],{"nctId":6353,"briefTitle":6354,"status":120,"phases":9025,"primaryCompletion":6356,"completion":6356,"start":6357,"enrollment":25,"conditions":9026,"interventions":9027},[93],[3101],[6298,6360],{"trials":9029,"activeCount":101},[],{"intervention":9031,"totalTrials":424,"cells":9032},"Xolair",{"EARLY_PHASE1":9033,"PHASE1":9035,"PHASE2":9037,"PHASE3":9039,"PHASE4":9041,"NA":9050},{"trials":9034,"activeCount":101},[],{"trials":9036,"activeCount":101},[],{"trials":9038,"activeCount":101},[],{"trials":9040,"activeCount":101},[],{"trials":9042,"activeCount":101},[9043],{"nctId":9044,"briefTitle":9045,"status":111,"phases":9046,"primaryCompletion":3696,"completion":3696,"start":255,"enrollment":101,"conditions":9047,"interventions":9049},"NCT00603785","Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis",[93],[9048],"Chronic Sinusitis",[9031],{"trials":9051,"activeCount":101},[],{"intervention":9053,"totalTrials":424,"cells":9054},"Parafon Forte",{"EARLY_PHASE1":9055,"PHASE1":9057,"PHASE2":9059,"PHASE3":9061,"PHASE4":9063,"NA":9071},{"trials":9056,"activeCount":101},[],{"trials":9058,"activeCount":101},[],{"trials":9060,"activeCount":101},[],{"trials":9062,"activeCount":101},[],{"trials":9064,"activeCount":101},[9065],{"nctId":9066,"briefTitle":9067,"status":132,"phases":9068,"primaryCompletion":4155,"completion":7097,"start":6100,"enrollment":3553,"conditions":9069,"interventions":9070},"NCT01342341","Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake",[93],[8749],[9053],{"trials":9072,"activeCount":101},[],{"intervention":9074,"totalTrials":424,"cells":9075},"Adefovir dipivoxil",{"EARLY_PHASE1":9076,"PHASE1":9078,"PHASE2":9080,"PHASE3":9082,"PHASE4":9084,"NA":9093},{"trials":9077,"activeCount":101},[],{"trials":9079,"activeCount":101},[],{"trials":9081,"activeCount":101},[],{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[9086],{"nctId":9087,"briefTitle":9088,"status":111,"phases":9089,"primaryCompletion":3696,"completion":3696,"start":9090,"enrollment":101,"conditions":9091,"interventions":9092},"NCT00187746","Effect of Age on the Renal Clearance of Adefovir",[93],"2005-08",[3699],[9074],{"trials":9094,"activeCount":101},[],{"intervention":9096,"totalTrials":424,"cells":9097},"Clonidine",{"EARLY_PHASE1":9098,"PHASE1":9100,"PHASE2":9102,"PHASE3":9104,"PHASE4":9106,"NA":9118},{"trials":9099,"activeCount":101},[],{"trials":9101,"activeCount":101},[],{"trials":9103,"activeCount":101},[],{"trials":9105,"activeCount":101},[],{"trials":9107,"activeCount":101},[9108],{"nctId":9109,"briefTitle":9110,"status":111,"phases":9111,"primaryCompletion":9112,"completion":8720,"start":9113,"enrollment":101,"conditions":9114,"interventions":9116},"NCT04186299","The Effect of Buccal Infiltration Administration of Clonidine on the Success Rate of Inferior Alveolar Nerve Block",[93],"2022-08","2021-08",[9115],"Symptomatic Irreversible Pulpitis",[9096,9117],"Articaine Hydrochloride + Epinephrine",{"trials":9119,"activeCount":101},[],{"intervention":9117,"totalTrials":424,"cells":9121},{"EARLY_PHASE1":9122,"PHASE1":9124,"PHASE2":9126,"PHASE3":9128,"PHASE4":9130,"NA":9136},{"trials":9123,"activeCount":101},[],{"trials":9125,"activeCount":101},[],{"trials":9127,"activeCount":101},[],{"trials":9129,"activeCount":101},[],{"trials":9131,"activeCount":101},[9132],{"nctId":9109,"briefTitle":9110,"status":111,"phases":9133,"primaryCompletion":9112,"completion":8720,"start":9113,"enrollment":101,"conditions":9134,"interventions":9135},[93],[9115],[9096,9117],{"trials":9137,"activeCount":101},[],{"intervention":3736,"totalTrials":424,"cells":9139},{"EARLY_PHASE1":9140,"PHASE1":9142,"PHASE2":9144,"PHASE3":9146,"PHASE4":9148,"NA":9154},{"trials":9141,"activeCount":101},[],{"trials":9143,"activeCount":101},[],{"trials":9145,"activeCount":101},[],{"trials":9147,"activeCount":101},[],{"trials":9149,"activeCount":101},[9150],{"nctId":3728,"briefTitle":3729,"status":132,"phases":9151,"primaryCompletion":2856,"completion":2856,"start":3731,"enrollment":792,"conditions":9152,"interventions":9153},[93],[3733,3734],[3736,3607],{"trials":9155,"activeCount":101},[],{"intervention":9157,"totalTrials":424,"cells":9158},"Ketorolac",{"EARLY_PHASE1":9159,"PHASE1":9161,"PHASE2":9163,"PHASE3":9165,"PHASE4":9167,"NA":9179},{"trials":9160,"activeCount":101},[],{"trials":9162,"activeCount":101},[],{"trials":9164,"activeCount":101},[],{"trials":9166,"activeCount":101},[],{"trials":9168,"activeCount":101},[9169],{"nctId":9170,"briefTitle":9171,"status":111,"phases":9172,"primaryCompletion":9173,"completion":9174,"start":9175,"enrollment":101,"conditions":9176,"interventions":9178},"NCT02465138","A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis",[93],"2025-12","2026-07","2023-11",[9177],"Pancreatitis",[9157],{"trials":9180,"activeCount":101},[],{"intervention":9182,"totalTrials":424,"cells":9183},"Taclonex Ointment and Hydrogel Patch",{"EARLY_PHASE1":9184,"PHASE1":9186,"PHASE2":9188,"PHASE3":9190,"PHASE4":9192,"NA":9202},{"trials":9185,"activeCount":101},[],{"trials":9187,"activeCount":101},[],{"trials":9189,"activeCount":101},[],{"trials":9191,"activeCount":101},[],{"trials":9193,"activeCount":101},[9194],{"nctId":9195,"briefTitle":9196,"status":120,"phases":9197,"primaryCompletion":8837,"completion":8837,"start":9198,"enrollment":675,"conditions":9199,"interventions":9200},"NCT00924950","Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis",[93],"2009-06",[356,652],[9182,9201],"Taclonex Ointment",{"trials":9203,"activeCount":101},[],{"intervention":9201,"totalTrials":424,"cells":9205},{"EARLY_PHASE1":9206,"PHASE1":9208,"PHASE2":9210,"PHASE3":9212,"PHASE4":9214,"NA":9220},{"trials":9207,"activeCount":101},[],{"trials":9209,"activeCount":101},[],{"trials":9211,"activeCount":101},[],{"trials":9213,"activeCount":101},[],{"trials":9215,"activeCount":101},[9216],{"nctId":9195,"briefTitle":9196,"status":120,"phases":9217,"primaryCompletion":8837,"completion":8837,"start":9198,"enrollment":675,"conditions":9218,"interventions":9219},[93],[356,652],[9182,9201],{"trials":9221,"activeCount":101},[],{"intervention":9223,"totalTrials":424,"cells":9224},"Methergine",{"EARLY_PHASE1":9225,"PHASE1":9227,"PHASE2":9229,"PHASE3":9231,"PHASE4":9233,"NA":9245},{"trials":9226,"activeCount":101},[],{"trials":9228,"activeCount":101},[],{"trials":9230,"activeCount":101},[],{"trials":9232,"activeCount":101},[],{"trials":9234,"activeCount":101},[9235],{"nctId":9236,"briefTitle":9237,"status":132,"phases":9238,"primaryCompletion":9239,"completion":9239,"start":9240,"enrollment":9241,"conditions":9242,"interventions":9244},"NCT02408965","Uterotonic Prophylaxis Trial",[93],"2017-03","2015-03",284,[9243],"Hemorrhage",[9223],{"trials":9246,"activeCount":101},[],{"intervention":9248,"totalTrials":424,"cells":9249},"Cabotegravir Injectable Suspension",{"EARLY_PHASE1":9250,"PHASE1":9252,"PHASE2":9254,"PHASE3":9256,"PHASE4":9258,"NA":9269},{"trials":9251,"activeCount":101},[],{"trials":9253,"activeCount":101},[],{"trials":9255,"activeCount":101},[],{"trials":9257,"activeCount":101},[],{"trials":9259,"activeCount":101},[9260],{"nctId":9261,"briefTitle":9262,"status":132,"phases":9263,"primaryCompletion":9264,"completion":67,"start":9265,"enrollment":9266,"conditions":9267,"interventions":9268},"NCT05549726","SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension",[93],"2023-12-18","2023-01-02",984,[15],[9248],{"trials":9270,"activeCount":101},[],{"intervention":9272,"totalTrials":424,"cells":9273},"rifampin IV",{"EARLY_PHASE1":9274,"PHASE1":9276,"PHASE2":9278,"PHASE3":9280,"PHASE4":9282,"NA":9295},{"trials":9275,"activeCount":101},[],{"trials":9277,"activeCount":101},[],{"trials":9279,"activeCount":101},[],{"trials":9281,"activeCount":101},[],{"trials":9283,"activeCount":101},[9284],{"nctId":9285,"briefTitle":9286,"status":132,"phases":9287,"primaryCompletion":9288,"completion":9288,"start":9289,"enrollment":345,"conditions":9290,"interventions":9292},"NCT04029584","Drug-Drug Interaction Between Rifampin and Fluvastatin",[93],"2020-04-25","2019-04-25",[9291],"Drug-drug Interaction",[9272,9293,9294],"Rifadin 300Mg","Fluvastatin 20 MG",{"trials":9296,"activeCount":101},[],{"intervention":9293,"totalTrials":424,"cells":9298},{"EARLY_PHASE1":9299,"PHASE1":9301,"PHASE2":9303,"PHASE3":9305,"PHASE4":9307,"NA":9313},{"trials":9300,"activeCount":101},[],{"trials":9302,"activeCount":101},[],{"trials":9304,"activeCount":101},[],{"trials":9306,"activeCount":101},[],{"trials":9308,"activeCount":101},[9309],{"nctId":9285,"briefTitle":9286,"status":132,"phases":9310,"primaryCompletion":9288,"completion":9288,"start":9289,"enrollment":345,"conditions":9311,"interventions":9312},[93],[9291],[9272,9293,9294],{"trials":9314,"activeCount":101},[],{"intervention":9294,"totalTrials":424,"cells":9316},{"EARLY_PHASE1":9317,"PHASE1":9319,"PHASE2":9321,"PHASE3":9323,"PHASE4":9325,"NA":9331},{"trials":9318,"activeCount":101},[],{"trials":9320,"activeCount":101},[],{"trials":9322,"activeCount":101},[],{"trials":9324,"activeCount":101},[],{"trials":9326,"activeCount":101},[9327],{"nctId":9285,"briefTitle":9286,"status":132,"phases":9328,"primaryCompletion":9288,"completion":9288,"start":9289,"enrollment":345,"conditions":9329,"interventions":9330},[93],[9291],[9272,9293,9294],{"trials":9332,"activeCount":101},[],{"intervention":9334,"totalTrials":424,"cells":9335},"Mass treatment with oral azithromycin to an entire village",{"EARLY_PHASE1":9336,"PHASE1":9338,"PHASE2":9340,"PHASE3":9342,"PHASE4":9344,"NA":9355},{"trials":9337,"activeCount":101},[],{"trials":9339,"activeCount":101},[],{"trials":9341,"activeCount":101},[],{"trials":9343,"activeCount":101},[],{"trials":9345,"activeCount":101},[9346],{"nctId":9347,"briefTitle":9348,"status":132,"phases":9349,"primaryCompletion":9350,"completion":9350,"start":9351,"enrollment":9352,"conditions":9353,"interventions":9354},"NCT00221364","Trachoma Elimination Follow-up",[93],"2005-04","2003-03",20000,[115,8490],[9334],{"trials":9356,"activeCount":101},[],{"intervention":9358,"totalTrials":424,"cells":9359},"intravenous nitroglycerin",{"EARLY_PHASE1":9360,"PHASE1":9362,"PHASE2":9364,"PHASE3":9366,"PHASE4":9368,"NA":9378},{"trials":9361,"activeCount":101},[],{"trials":9363,"activeCount":101},[],{"trials":9365,"activeCount":101},[],{"trials":9367,"activeCount":101},[],{"trials":9369,"activeCount":101},[9370],{"nctId":9371,"briefTitle":9372,"status":132,"phases":9373,"primaryCompletion":9374,"completion":9374,"start":6134,"enrollment":5422,"conditions":9375,"interventions":9377},"NCT02265965","Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension",[93],"2018-07-01",[9376],"Prolonged Second Stage of Labor",[9358],{"trials":9379,"activeCount":101},[],{"intervention":9381,"totalTrials":424,"cells":9382},"Venlafaxine 37.5 MG",{"EARLY_PHASE1":9383,"PHASE1":9385,"PHASE2":9387,"PHASE3":9389,"PHASE4":9391,"NA":9403},{"trials":9384,"activeCount":101},[],{"trials":9386,"activeCount":101},[],{"trials":9388,"activeCount":101},[],{"trials":9390,"activeCount":101},[],{"trials":9392,"activeCount":101},[9393],{"nctId":9394,"briefTitle":9395,"status":132,"phases":9396,"primaryCompletion":3518,"completion":3581,"start":9397,"enrollment":1220,"conditions":9398,"interventions":9402},"NCT05023278","The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement",[93],"2021-05-10",[9399,9400,9401,7853],"Acute Pain","Chronic Pain","Knee Pain Chronic",[9381],{"trials":9404,"activeCount":101},[],{"intervention":9406,"totalTrials":424,"cells":9407},"Ganirelix acetate",{"EARLY_PHASE1":9408,"PHASE1":9410,"PHASE2":9412,"PHASE3":9414,"PHASE4":9416,"NA":9426},{"trials":9409,"activeCount":101},[],{"trials":9411,"activeCount":101},[],{"trials":9413,"activeCount":101},[],{"trials":9415,"activeCount":101},[],{"trials":9417,"activeCount":101},[9418],{"nctId":9419,"briefTitle":9420,"status":120,"phases":9421,"primaryCompletion":6117,"completion":6750,"start":1913,"enrollment":751,"conditions":9422,"interventions":9425},"NCT01614067","Delayed Start to Ovarian Stimulation",[93],[9423,2809,9424],"Diminished Ovarian Reserve","In Vitro Fertilization",[9406],{"trials":9427,"activeCount":101},[],{"intervention":9429,"totalTrials":424,"cells":9430},"n-acetylcystine + albuterol",{"EARLY_PHASE1":9431,"PHASE1":9433,"PHASE2":9435,"PHASE3":9437,"PHASE4":9439,"NA":9450},{"trials":9432,"activeCount":101},[],{"trials":9434,"activeCount":101},[],{"trials":9436,"activeCount":101},[],{"trials":9438,"activeCount":101},[],{"trials":9440,"activeCount":101},[9441],{"nctId":9442,"briefTitle":9443,"status":120,"phases":9444,"primaryCompletion":9445,"completion":9445,"start":9446,"enrollment":480,"conditions":9447,"interventions":9448},"NCT03822637","The Effect of NAC on Lung Function and CT Mucus Score",[93],"2025-02-21","2019-02-20",[36],[9429,9449],"0.9% saline + albuterol",{"trials":9451,"activeCount":101},[],{"intervention":9449,"totalTrials":424,"cells":9453},{"EARLY_PHASE1":9454,"PHASE1":9456,"PHASE2":9458,"PHASE3":9460,"PHASE4":9462,"NA":9468},{"trials":9455,"activeCount":101},[],{"trials":9457,"activeCount":101},[],{"trials":9459,"activeCount":101},[],{"trials":9461,"activeCount":101},[],{"trials":9463,"activeCount":101},[9464],{"nctId":9442,"briefTitle":9443,"status":120,"phases":9465,"primaryCompletion":9445,"completion":9445,"start":9446,"enrollment":480,"conditions":9466,"interventions":9467},[93],[36],[9429,9449],{"trials":9469,"activeCount":101},[],{"intervention":9471,"totalTrials":424,"cells":9472},"Fluticasone",{"EARLY_PHASE1":9473,"PHASE1":9475,"PHASE2":9477,"PHASE3":9479,"PHASE4":9481,"NA":9491},{"trials":9474,"activeCount":101},[],{"trials":9476,"activeCount":101},[],{"trials":9478,"activeCount":101},[],{"trials":9480,"activeCount":101},[],{"trials":9482,"activeCount":101},[9483],{"nctId":9484,"briefTitle":9485,"status":132,"phases":9486,"primaryCompletion":9487,"completion":2545,"start":9488,"enrollment":22,"conditions":9489,"interventions":9490},"NCT00606242","Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma",[93],"2002-12","2000-01",[36],[9471],{"trials":9492,"activeCount":101},[],{"intervention":2942,"totalTrials":324,"cells":9494},{"EARLY_PHASE1":9495,"PHASE1":9497,"PHASE2":9499,"PHASE3":9501,"PHASE4":9523,"NA":9525},{"trials":9496,"activeCount":101},[],{"trials":9498,"activeCount":101},[],{"trials":9500,"activeCount":101},[],{"trials":9502,"activeCount":101},[9503,9507,9514],{"nctId":2930,"briefTitle":2931,"status":132,"phases":9504,"primaryCompletion":2933,"completion":2934,"start":2935,"enrollment":2936,"conditions":9505,"interventions":9506},[92],[2938,2939],[2919,2941,2942,2943],{"nctId":9508,"briefTitle":9509,"status":132,"phases":9510,"primaryCompletion":1245,"completion":1245,"start":432,"enrollment":1633,"conditions":9511,"interventions":9512},"NCT02731638","Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers",[92],[3075,2939],[9513,2942],"Intrastromal voriconazole",{"nctId":9515,"briefTitle":9516,"status":132,"phases":9517,"primaryCompletion":6727,"completion":6727,"start":4041,"enrollment":9518,"conditions":9519,"interventions":9521},"NCT00996736","Mycotic Ulcer Treatment Trial I",[92],323,[3075,9520],"Eye Infections, Fungal",[2942,9522],"Voriconazole",{"trials":9524,"activeCount":101},[],{"trials":9526,"activeCount":101},[],{"intervention":440,"totalTrials":324,"cells":9528},{"EARLY_PHASE1":9529,"PHASE1":9531,"PHASE2":9540,"PHASE3":9546,"PHASE4":9556,"NA":9558},{"trials":9530,"activeCount":101},[],{"trials":9532,"activeCount":101},[9533],{"nctId":9534,"briefTitle":9535,"status":132,"phases":9536,"primaryCompletion":673,"completion":8836,"start":4030,"enrollment":1202,"conditions":9537,"interventions":9538},"NCT00719407","Neonatal Erythropoietin in Asphyxiated Term Newborns",[90],[436],[9539],"erythropoietin",{"trials":9541,"activeCount":101},[9542],{"nctId":428,"briefTitle":429,"status":132,"phases":9543,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":9544,"interventions":9545},[90,91],[436,437,438],[440,406],{"trials":9547,"activeCount":101},[9548],{"nctId":9549,"briefTitle":9550,"status":132,"phases":9551,"primaryCompletion":9552,"completion":3660,"start":226,"enrollment":186,"conditions":9553,"interventions":9554},"NCT02811263","High-dose Erythropoietin for Asphyxia and Encephalopathy",[92],"2021-10",[437,438],[9555,440],"Normal saline placebo",{"trials":9557,"activeCount":101},[],{"trials":9559,"activeCount":101},[],{"intervention":797,"totalTrials":324,"cells":9561},{"EARLY_PHASE1":9562,"PHASE1":9564,"PHASE2":9566,"PHASE3":9576,"PHASE4":9582,"NA":9584},{"trials":9563,"activeCount":101},[],{"trials":9565,"activeCount":101},[],{"trials":9567,"activeCount":101},[9568,9572],{"nctId":787,"briefTitle":788,"status":120,"phases":9569,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":9570,"interventions":9571},[91],[794],[796,768,797,798],{"nctId":2368,"briefTitle":2369,"status":120,"phases":9573,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":9574,"interventions":9575},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":9577,"activeCount":101},[9578],{"nctId":802,"briefTitle":803,"status":120,"phases":9579,"primaryCompletion":805,"completion":806,"start":807,"enrollment":31,"conditions":9580,"interventions":9581},[91,92],[809,810,811,812,813],[815,768,816,817],{"trials":9583,"activeCount":101},[],{"trials":9585,"activeCount":101},[],{"intervention":9522,"totalTrials":324,"cells":9587},{"EARLY_PHASE1":9588,"PHASE1":9590,"PHASE2":9592,"PHASE3":9601,"PHASE4":9614,"NA":9616},{"trials":9589,"activeCount":101},[],{"trials":9591,"activeCount":101},[],{"trials":9593,"activeCount":101},[9594],{"nctId":9595,"briefTitle":9596,"status":132,"phases":9597,"primaryCompletion":6765,"completion":6765,"start":714,"enrollment":3797,"conditions":9598,"interventions":9599},"NCT00557362","Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer",[90,91],[2939],[9600,9522],"Natamycin 5%",{"trials":9602,"activeCount":101},[9603,9610],{"nctId":9604,"briefTitle":9605,"status":132,"phases":9606,"primaryCompletion":431,"completion":6906,"start":7251,"enrollment":9607,"conditions":9608,"interventions":9609},"NCT00997035","The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo",[92],240,[3075,9520],[9522],{"nctId":9515,"briefTitle":9516,"status":132,"phases":9611,"primaryCompletion":6727,"completion":6727,"start":4041,"enrollment":9518,"conditions":9612,"interventions":9613},[92],[3075,9520],[2942,9522],{"trials":9615,"activeCount":101},[],{"trials":9617,"activeCount":101},[],{"intervention":2588,"totalTrials":324,"cells":9619},{"EARLY_PHASE1":9620,"PHASE1":9622,"PHASE2":9628,"PHASE3":9637,"PHASE4":9643,"NA":9645},{"trials":9621,"activeCount":101},[],{"trials":9623,"activeCount":101},[9624],{"nctId":2580,"briefTitle":2581,"status":132,"phases":9625,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":407,"conditions":9626,"interventions":9627},[90],[679,717,2359,680],[719,2578,684,2587,685,2588,2362],{"trials":9629,"activeCount":101},[9630],{"nctId":9631,"briefTitle":9632,"status":120,"phases":9633,"primaryCompletion":6198,"completion":6198,"start":3860,"enrollment":2564,"conditions":9634,"interventions":9635},"NCT00293371","Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer",[90,91],[21],[5739,2588,9636],"vatalanib",{"trials":9638,"activeCount":101},[9639],{"nctId":2413,"briefTitle":2414,"status":132,"phases":9640,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":2419,"conditions":9641,"interventions":9642},[92],[2409],[2411,385,2422],{"trials":9644,"activeCount":101},[],{"trials":9646,"activeCount":101},[],{"intervention":9648,"totalTrials":526,"cells":9649},"Clopidogrel",{"EARLY_PHASE1":9650,"PHASE1":9652,"PHASE2":9661,"PHASE3":9663,"PHASE4":9675,"NA":9677},{"trials":9651,"activeCount":101},[],{"trials":9653,"activeCount":101},[9654],{"nctId":9655,"briefTitle":9656,"status":132,"phases":9657,"primaryCompletion":3818,"completion":3818,"start":1146,"enrollment":345,"conditions":9658,"interventions":9659},"NCT01469416","Drug Interaction Study of Clopidogrel and Rosuvastatin",[90],[30],[9660,9648],"Rosuvastatin",{"trials":9662,"activeCount":101},[],{"trials":9664,"activeCount":101},[9665],{"nctId":9666,"briefTitle":9667,"status":120,"phases":9668,"primaryCompletion":9669,"completion":9669,"start":9670,"enrollment":9671,"conditions":9672,"interventions":9674},"NCT00991029","Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial",[92],"2018-04-09","2010-05-28",4881,[9673],"Ischemic Attack, Transient",[9648],{"trials":9676,"activeCount":101},[],{"trials":9678,"activeCount":101},[],{"intervention":2941,"totalTrials":526,"cells":9680},{"EARLY_PHASE1":9681,"PHASE1":9683,"PHASE2":9685,"PHASE3":9687,"PHASE4":9702,"NA":9704},{"trials":9682,"activeCount":101},[],{"trials":9684,"activeCount":101},[],{"trials":9686,"activeCount":101},[],{"trials":9688,"activeCount":101},[9689,9693],{"nctId":2930,"briefTitle":2931,"status":132,"phases":9690,"primaryCompletion":2933,"completion":2934,"start":2935,"enrollment":2936,"conditions":9691,"interventions":9692},[92],[2938,2939],[2919,2941,2942,2943],{"nctId":9694,"briefTitle":9695,"status":132,"phases":9696,"primaryCompletion":9697,"completion":9090,"start":9351,"enrollment":9698,"conditions":9699,"interventions":9700},"NCT00066950","Prevention Management Model for Early Childhood Caries (MAYA Project)",[92],"2005-07",361,[6990],[9701],"Chlorhexidine gluconate",{"trials":9703,"activeCount":101},[],{"trials":9705,"activeCount":101},[],{"intervention":817,"totalTrials":526,"cells":9707},{"EARLY_PHASE1":9708,"PHASE1":9710,"PHASE2":9712,"PHASE3":9718,"PHASE4":9724,"NA":9726},{"trials":9709,"activeCount":101},[],{"trials":9711,"activeCount":101},[],{"trials":9713,"activeCount":101},[9714],{"nctId":787,"briefTitle":788,"status":120,"phases":9715,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":9716,"interventions":9717},[91],[794],[796,768,797,798],{"trials":9719,"activeCount":101},[9720],{"nctId":802,"briefTitle":803,"status":120,"phases":9721,"primaryCompletion":805,"completion":806,"start":807,"enrollment":31,"conditions":9722,"interventions":9723},[91,92],[809,810,811,812,813],[815,768,816,817],{"trials":9725,"activeCount":101},[],{"trials":9727,"activeCount":101},[],{"intervention":9729,"totalTrials":526,"cells":9730},"Rifampin",{"EARLY_PHASE1":9731,"PHASE1":9733,"PHASE2":9747,"PHASE3":9749,"PHASE4":9760,"NA":9762},{"trials":9732,"activeCount":101},[],{"trials":9734,"activeCount":101},[9735],{"nctId":9736,"briefTitle":9737,"status":132,"phases":9738,"primaryCompletion":4155,"completion":4155,"start":3696,"enrollment":9739,"conditions":9740,"interventions":9742},"NCT00877591","Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications",[90],63,[9741,18],"Opioid Dependency",[9743,9744,9729,9745,9746],"Fosamprenavir\u002FRitonavir","Darunavir\u002FRitonavir","Rifabutin","Buprenorphine",{"trials":9748,"activeCount":101},[],{"trials":9750,"activeCount":101},[9751],{"nctId":9752,"briefTitle":9753,"status":132,"phases":9754,"primaryCompletion":2636,"completion":9755,"start":5313,"enrollment":9756,"conditions":9757,"interventions":9758},"NCT00128206","Treatment of Latent TB Infection for Jailed Persons",[92],"2009-09",364,[8748],[9759,9729],"Isoniazid",{"trials":9761,"activeCount":101},[],{"trials":9763,"activeCount":101},[],{"intervention":9765,"totalTrials":526,"cells":9766},"Ga-68 labeled PSMA-11 PET",{"EARLY_PHASE1":9767,"PHASE1":9769,"PHASE2":9771,"PHASE3":9773,"PHASE4":9792,"NA":9794},{"trials":9768,"activeCount":101},[],{"trials":9770,"activeCount":101},[],{"trials":9772,"activeCount":101},[],{"trials":9774,"activeCount":101},[9775,9784],{"nctId":9776,"briefTitle":9777,"status":132,"phases":9778,"primaryCompletion":9779,"completion":9779,"start":9780,"enrollment":9781,"conditions":9782,"interventions":9783},"NCT02918357","Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence",[91,92],"2017-09-21","2016-09-15",385,[21],[9765],{"nctId":9785,"briefTitle":9786,"status":132,"phases":9787,"primaryCompletion":5700,"completion":5700,"start":9788,"enrollment":9789,"conditions":9790,"interventions":9791},"NCT02919111","Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients",[91,92],"2016-09-23",299,[21],[9765],{"trials":9793,"activeCount":101},[],{"trials":9795,"activeCount":101},[],{"intervention":9797,"totalTrials":526,"cells":9798},"Lopinavir\u002FRitonavir",{"EARLY_PHASE1":9799,"PHASE1":9801,"PHASE2":9803,"PHASE3":9805,"PHASE4":9828,"NA":9830},{"trials":9800,"activeCount":101},[],{"trials":9802,"activeCount":101},[],{"trials":9804,"activeCount":101},[],{"trials":9806,"activeCount":101},[9807,9817],{"nctId":9808,"briefTitle":9809,"status":132,"phases":9810,"primaryCompletion":3858,"completion":3858,"start":9755,"enrollment":9811,"conditions":9812,"interventions":9813},"NCT00978068","HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children",[92],176,[322,18],[9797,9814,9815,9816],"Nevirapine","Efavirenz","2 nucleoside reverse transcriptase inhibitor",{"nctId":9818,"briefTitle":9819,"status":132,"phases":9820,"primaryCompletion":3648,"completion":3648,"start":9821,"enrollment":9822,"conditions":9823,"interventions":9824},"NCT00993031","Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women",[92],"2009-12-15",389,[322,18],[9825,9815,9826,9827],"Lopinavir\u002Fritonavir","Zidovudine","Lamivudine",{"trials":9829,"activeCount":101},[],{"trials":9831,"activeCount":101},[],{"intervention":9815,"totalTrials":526,"cells":9833},{"EARLY_PHASE1":9834,"PHASE1":9836,"PHASE2":9838,"PHASE3":9840,"PHASE4":9850,"NA":9852},{"trials":9835,"activeCount":101},[],{"trials":9837,"activeCount":101},[],{"trials":9839,"activeCount":101},[],{"trials":9841,"activeCount":101},[9842,9846],{"nctId":9808,"briefTitle":9809,"status":132,"phases":9843,"primaryCompletion":3858,"completion":3858,"start":9755,"enrollment":9811,"conditions":9844,"interventions":9845},[92],[322,18],[9797,9814,9815,9816],{"nctId":9818,"briefTitle":9819,"status":132,"phases":9847,"primaryCompletion":3648,"completion":3648,"start":9821,"enrollment":9822,"conditions":9848,"interventions":9849},[92],[322,18],[9825,9815,9826,9827],{"trials":9851,"activeCount":101},[],{"trials":9853,"activeCount":101},[],{"intervention":9855,"totalTrials":424,"cells":9856},"Low dose hCG plus FSH co-trigger",{"EARLY_PHASE1":9857,"PHASE1":9859,"PHASE2":9861,"PHASE3":9863,"PHASE4":9874,"NA":9876},{"trials":9858,"activeCount":101},[],{"trials":9860,"activeCount":101},[],{"trials":9862,"activeCount":101},[],{"trials":9864,"activeCount":101},[9865],{"nctId":9866,"briefTitle":9867,"status":132,"phases":9868,"primaryCompletion":9869,"completion":9869,"start":6750,"enrollment":9870,"conditions":9871,"interventions":9872},"NCT02310919","Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles",[92],"2018-06-20",105,[2809],[9855,9873],"Standard dose of hCG",{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":101},[],{"intervention":9873,"totalTrials":424,"cells":9879},{"EARLY_PHASE1":9880,"PHASE1":9882,"PHASE2":9884,"PHASE3":9886,"PHASE4":9892,"NA":9894},{"trials":9881,"activeCount":101},[],{"trials":9883,"activeCount":101},[],{"trials":9885,"activeCount":101},[],{"trials":9887,"activeCount":101},[9888],{"nctId":9866,"briefTitle":9867,"status":132,"phases":9889,"primaryCompletion":9869,"completion":9869,"start":6750,"enrollment":9870,"conditions":9890,"interventions":9891},[92],[2809],[9855,9873],{"trials":9893,"activeCount":101},[],{"trials":9895,"activeCount":101},[],{"intervention":9897,"totalTrials":424,"cells":9898},"hydrochlorothiazide",{"EARLY_PHASE1":9899,"PHASE1":9901,"PHASE2":9903,"PHASE3":9905,"PHASE4":9919,"NA":9921},{"trials":9900,"activeCount":101},[],{"trials":9902,"activeCount":101},[],{"trials":9904,"activeCount":101},[],{"trials":9906,"activeCount":101},[9907],{"nctId":9908,"briefTitle":9909,"status":132,"phases":9910,"primaryCompletion":9911,"start":9912,"enrollment":9913,"conditions":9914,"interventions":9916},"NCT00000525","Diuretics, Hypertension, and Arrhythmias Clinical Trial",[92],"1989-09","1986-07",233,[1222,9915,4720,2672,1223],"Death, Sudden, Cardiac",[9897,9917,9918],"triamterene","chlorthalidone",{"trials":9920,"activeCount":101},[],{"trials":9922,"activeCount":101},[],{"intervention":9917,"totalTrials":424,"cells":9924},{"EARLY_PHASE1":9925,"PHASE1":9927,"PHASE2":9929,"PHASE3":9931,"PHASE4":9937,"NA":9939},{"trials":9926,"activeCount":101},[],{"trials":9928,"activeCount":101},[],{"trials":9930,"activeCount":101},[],{"trials":9932,"activeCount":101},[9933],{"nctId":9908,"briefTitle":9909,"status":132,"phases":9934,"primaryCompletion":9911,"start":9912,"enrollment":9913,"conditions":9935,"interventions":9936},[92],[1222,9915,4720,2672,1223],[9897,9917,9918],{"trials":9938,"activeCount":101},[],{"trials":9940,"activeCount":101},[],{"intervention":9918,"totalTrials":424,"cells":9942},{"EARLY_PHASE1":9943,"PHASE1":9945,"PHASE2":9947,"PHASE3":9949,"PHASE4":9955,"NA":9957},{"trials":9944,"activeCount":101},[],{"trials":9946,"activeCount":101},[],{"trials":9948,"activeCount":101},[],{"trials":9950,"activeCount":101},[9951],{"nctId":9908,"briefTitle":9909,"status":132,"phases":9952,"primaryCompletion":9911,"start":9912,"enrollment":9913,"conditions":9953,"interventions":9954},[92],[1222,9915,4720,2672,1223],[9897,9917,9918],{"trials":9956,"activeCount":101},[],{"trials":9958,"activeCount":101},[],{"intervention":9960,"totalTrials":424,"cells":9961},"Methyl B12",{"EARLY_PHASE1":9962,"PHASE1":9964,"PHASE2":9966,"PHASE3":9968,"PHASE4":9978,"NA":9980},{"trials":9963,"activeCount":101},[],{"trials":9965,"activeCount":101},[],{"trials":9967,"activeCount":101},[],{"trials":9969,"activeCount":101},[9970],{"nctId":9971,"briefTitle":9972,"status":132,"phases":9973,"primaryCompletion":3625,"completion":540,"start":4030,"enrollment":9974,"conditions":9975,"interventions":9977},"NCT01039792","Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism",[91,92],57,[9976],"Autistic Disorder",[9960],{"trials":9979,"activeCount":101},[],{"trials":9981,"activeCount":101},[],{"intervention":9983,"totalTrials":424,"cells":9984},"Bococizumab",{"EARLY_PHASE1":9985,"PHASE1":9987,"PHASE2":9989,"PHASE3":9991,"PHASE4":10001,"NA":10003},{"trials":9986,"activeCount":101},[],{"trials":9988,"activeCount":101},[],{"trials":9990,"activeCount":101},[],{"trials":9992,"activeCount":101},[9993],{"nctId":9994,"briefTitle":9995,"status":120,"phases":9996,"primaryCompletion":9997,"completion":9997,"start":3743,"enrollment":541,"conditions":9998,"interventions":10000},"NCT02524106","Bococizumab HIV Evaluation (B-HIVE) Study",[92],"2017-11",[9999,4033],"Dyslipidemia",[9983],{"trials":10002,"activeCount":101},[],{"trials":10004,"activeCount":101},[],{"intervention":6319,"totalTrials":424,"cells":10006},{"EARLY_PHASE1":10007,"PHASE1":10009,"PHASE2":10011,"PHASE3":10013,"PHASE4":10019,"NA":10021},{"trials":10008,"activeCount":101},[],{"trials":10010,"activeCount":101},[],{"trials":10012,"activeCount":101},[],{"trials":10014,"activeCount":101},[10015],{"nctId":6309,"briefTitle":6310,"status":132,"phases":10016,"primaryCompletion":6312,"completion":6312,"start":6313,"enrollment":6314,"conditions":10017,"interventions":10018},[92],[6316,3101,6317],[6319,6298],{"trials":10020,"activeCount":101},[],{"trials":10022,"activeCount":101},[],{"intervention":10024,"totalTrials":424,"cells":10025},"Remifentanil Hydrochloride",{"EARLY_PHASE1":10026,"PHASE1":10028,"PHASE2":10030,"PHASE3":10032,"PHASE4":10044,"NA":10046},{"trials":10027,"activeCount":101},[],{"trials":10029,"activeCount":101},[],{"trials":10031,"activeCount":101},[],{"trials":10033,"activeCount":101},[10034],{"nctId":10035,"briefTitle":10036,"status":132,"phases":10037,"primaryCompletion":10038,"completion":10038,"start":4196,"enrollment":345,"conditions":10039,"interventions":10043},"NCT05391555","Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age",[91,92],"2023-06-03",[10040,10041,10042],"Opioid Toxicity","Pupillary Miosis","Respiratory Depression",[10024],{"trials":10045,"activeCount":101},[],{"trials":10047,"activeCount":101},[],{"intervention":10049,"totalTrials":424,"cells":10050},"PTH",{"EARLY_PHASE1":10051,"PHASE1":10053,"PHASE2":10055,"PHASE3":10057,"PHASE4":10067,"NA":10069},{"trials":10052,"activeCount":101},[],{"trials":10054,"activeCount":101},[],{"trials":10056,"activeCount":101},[],{"trials":10058,"activeCount":101},[10059],{"nctId":10060,"briefTitle":10061,"status":132,"phases":10062,"primaryCompletion":6100,"completion":6100,"start":10063,"enrollment":22,"conditions":10064,"interventions":10065},"NCT00683163","PTH & Ibandronate Combination Study (PICS)",[91,92],"2008-05",[8245],[10049,10066],"Ibandronate",{"trials":10068,"activeCount":101},[],{"trials":10070,"activeCount":101},[],{"intervention":10066,"totalTrials":424,"cells":10072},{"EARLY_PHASE1":10073,"PHASE1":10075,"PHASE2":10077,"PHASE3":10079,"PHASE4":10085,"NA":10087},{"trials":10074,"activeCount":101},[],{"trials":10076,"activeCount":101},[],{"trials":10078,"activeCount":101},[],{"trials":10080,"activeCount":101},[10081],{"nctId":10060,"briefTitle":10061,"status":132,"phases":10082,"primaryCompletion":6100,"completion":6100,"start":10063,"enrollment":22,"conditions":10083,"interventions":10084},[91,92],[8245],[10049,10066],{"trials":10086,"activeCount":101},[],{"trials":10088,"activeCount":101},[],{"intervention":10090,"totalTrials":424,"cells":10091},"Liquid Vitamin D",{"EARLY_PHASE1":10092,"PHASE1":10094,"PHASE2":10096,"PHASE3":10098,"PHASE4":10106,"NA":10108},{"trials":10093,"activeCount":101},[],{"trials":10095,"activeCount":101},[],{"trials":10097,"activeCount":101},[],{"trials":10099,"activeCount":101},[10100],{"nctId":10101,"briefTitle":10102,"status":132,"phases":10103,"primaryCompletion":2517,"completion":1871,"start":2436,"enrollment":345,"conditions":10104,"interventions":10105},"NCT01535508","Open Label Clinical Trial of Vitamin D in Children With Autism",[91,92],[6789,3724],[10090],{"trials":10107,"activeCount":101},[],{"trials":10109,"activeCount":101},[],{"intervention":10111,"totalTrials":424,"cells":10112},"Morphine plus Ketamine",{"EARLY_PHASE1":10113,"PHASE1":10115,"PHASE2":10117,"PHASE3":10119,"PHASE4":10134,"NA":10136},{"trials":10114,"activeCount":101},[],{"trials":10116,"activeCount":101},[],{"trials":10118,"activeCount":101},[],{"trials":10120,"activeCount":101},[10121],{"nctId":10122,"briefTitle":10123,"status":132,"phases":10124,"primaryCompletion":448,"completion":448,"start":2455,"enrollment":2818,"conditions":10125,"interventions":10132},"NCT00701909","Pain Medicine for Wound Care Procedures",[92],[10126,10127,10128,10129,10130,10131],"Wound Care","Pain Intensity","Hyperalgesia","Nausea","Vomiting","Hallucinations",[10111,10133],"Morphine plus Saline",{"trials":10135,"activeCount":101},[],{"trials":10137,"activeCount":101},[],{"intervention":10133,"totalTrials":424,"cells":10139},{"EARLY_PHASE1":10140,"PHASE1":10142,"PHASE2":10144,"PHASE3":10146,"PHASE4":10152,"NA":10154},{"trials":10141,"activeCount":101},[],{"trials":10143,"activeCount":101},[],{"trials":10145,"activeCount":101},[],{"trials":10147,"activeCount":101},[10148],{"nctId":10122,"briefTitle":10123,"status":132,"phases":10149,"primaryCompletion":448,"completion":448,"start":2455,"enrollment":2818,"conditions":10150,"interventions":10151},[92],[10126,10127,10128,10129,10130,10131],[10111,10133],{"trials":10153,"activeCount":101},[],{"trials":10155,"activeCount":101},[],{"intervention":10157,"totalTrials":424,"cells":10158},"Alirocumab",{"EARLY_PHASE1":10159,"PHASE1":10161,"PHASE2":10163,"PHASE3":10165,"PHASE4":10178,"NA":10180},{"trials":10160,"activeCount":101},[],{"trials":10162,"activeCount":101},[],{"trials":10164,"activeCount":101},[],{"trials":10166,"activeCount":101},[10167],{"nctId":10168,"briefTitle":10169,"status":132,"phases":10170,"primaryCompletion":10171,"completion":10172,"start":10173,"enrollment":10174,"conditions":10175,"interventions":10177},"NCT03207945","Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)",[92],"2025-08-24","2025-09-24","2018-04-30",118,[10176,1222,18],"Dyslipidemias",[10157],{"trials":10179,"activeCount":101},[],{"trials":10181,"activeCount":101},[],{"intervention":9513,"totalTrials":424,"cells":10183},{"EARLY_PHASE1":10184,"PHASE1":10186,"PHASE2":10188,"PHASE3":10190,"PHASE4":10196,"NA":10198},{"trials":10185,"activeCount":101},[],{"trials":10187,"activeCount":101},[],{"trials":10189,"activeCount":101},[],{"trials":10191,"activeCount":101},[10192],{"nctId":9508,"briefTitle":9509,"status":132,"phases":10193,"primaryCompletion":1245,"completion":1245,"start":432,"enrollment":1633,"conditions":10194,"interventions":10195},[92],[3075,2939],[9513,2942],{"trials":10197,"activeCount":101},[],{"trials":10199,"activeCount":101},[],{"intervention":10201,"totalTrials":424,"cells":10202},"methylcobalamin",{"EARLY_PHASE1":10203,"PHASE1":10205,"PHASE2":10207,"PHASE3":10209,"PHASE4":10217,"NA":10219},{"trials":10204,"activeCount":101},[],{"trials":10206,"activeCount":101},[],{"trials":10208,"activeCount":101},[],{"trials":10210,"activeCount":101},[10211],{"nctId":10212,"briefTitle":10213,"status":132,"phases":10214,"primaryCompletion":9198,"completion":237,"start":9697,"enrollment":751,"conditions":10215,"interventions":10216},"NCT00273650","Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism",[91,92],[9976],[10201],{"trials":10218,"activeCount":101},[],{"trials":10220,"activeCount":101},[],{"intervention":10222,"totalTrials":424,"cells":10223},"4.5 mg Naltrexone",{"EARLY_PHASE1":10224,"PHASE1":10226,"PHASE2":10228,"PHASE3":10230,"PHASE4":10239,"NA":10241},{"trials":10225,"activeCount":101},[],{"trials":10227,"activeCount":101},[],{"trials":10229,"activeCount":101},[],{"trials":10231,"activeCount":101},[10232],{"nctId":10233,"briefTitle":10234,"status":132,"phases":10235,"primaryCompletion":714,"completion":714,"start":6378,"enrollment":2335,"conditions":10236,"interventions":10237},"NCT00501696","A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone",[92],[765],[10222,10238],"Naltrexone",{"trials":10240,"activeCount":101},[],{"trials":10242,"activeCount":101},[],{"intervention":10244,"totalTrials":424,"cells":10245},"Valganciclovir Hydrochloride",{"EARLY_PHASE1":10246,"PHASE1":10248,"PHASE2":10250,"PHASE3":10252,"PHASE4":10265,"NA":10267},{"trials":10247,"activeCount":101},[],{"trials":10249,"activeCount":101},[],{"trials":10251,"activeCount":101},[],{"trials":10253,"activeCount":101},[10254],{"nctId":10255,"briefTitle":10256,"status":120,"phases":10257,"primaryCompletion":10258,"completion":10258,"start":10259,"enrollment":8791,"conditions":10260,"interventions":10262},"NCT03586284","Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes",[91,92],"2024-11-13","2020-03-15",[10261],"Cytomegalovirus Anterior Uveitis",[10244,10263,10264],"Ganciclovir Sodium","Topical placebo",{"trials":10266,"activeCount":101},[],{"trials":10268,"activeCount":101},[],{"intervention":10263,"totalTrials":424,"cells":10270},{"EARLY_PHASE1":10271,"PHASE1":10273,"PHASE2":10275,"PHASE3":10277,"PHASE4":10283,"NA":10285},{"trials":10272,"activeCount":101},[],{"trials":10274,"activeCount":101},[],{"trials":10276,"activeCount":101},[],{"trials":10278,"activeCount":101},[10279],{"nctId":10255,"briefTitle":10256,"status":120,"phases":10280,"primaryCompletion":10258,"completion":10258,"start":10259,"enrollment":8791,"conditions":10281,"interventions":10282},[91,92],[10261],[10244,10263,10264],{"trials":10284,"activeCount":101},[],{"trials":10286,"activeCount":101},[],{"intervention":10264,"totalTrials":424,"cells":10288},{"EARLY_PHASE1":10289,"PHASE1":10291,"PHASE2":10293,"PHASE3":10295,"PHASE4":10301,"NA":10303},{"trials":10290,"activeCount":101},[],{"trials":10292,"activeCount":101},[],{"trials":10294,"activeCount":101},[],{"trials":10296,"activeCount":101},[10297],{"nctId":10255,"briefTitle":10256,"status":120,"phases":10298,"primaryCompletion":10258,"completion":10258,"start":10259,"enrollment":8791,"conditions":10299,"interventions":10300},[91,92],[10261],[10244,10263,10264],{"trials":10302,"activeCount":101},[],{"trials":10304,"activeCount":101},[],{"intervention":10306,"totalTrials":424,"cells":10307},"Teriparatide",{"EARLY_PHASE1":10308,"PHASE1":10310,"PHASE2":10312,"PHASE3":10314,"PHASE4":10323,"NA":10325},{"trials":10309,"activeCount":101},[],{"trials":10311,"activeCount":101},[],{"trials":10313,"activeCount":101},[],{"trials":10315,"activeCount":101},[10316],{"nctId":10317,"briefTitle":10318,"status":132,"phases":10319,"primaryCompletion":7342,"completion":7342,"start":10320,"enrollment":434,"conditions":10321,"interventions":10322},"NCT00065637","Once Weekly Parathyroid Hormone for Osteoporosis",[92],"2003-12",[8244,8245],[10306],{"trials":10324,"activeCount":101},[],{"trials":10326,"activeCount":101},[],{"intervention":9814,"totalTrials":424,"cells":10328},{"EARLY_PHASE1":10329,"PHASE1":10331,"PHASE2":10333,"PHASE3":10335,"PHASE4":10341,"NA":10343},{"trials":10330,"activeCount":101},[],{"trials":10332,"activeCount":101},[],{"trials":10334,"activeCount":101},[],{"trials":10336,"activeCount":101},[10337],{"nctId":9808,"briefTitle":9809,"status":132,"phases":10338,"primaryCompletion":3858,"completion":3858,"start":9755,"enrollment":9811,"conditions":10339,"interventions":10340},[92],[322,18],[9797,9814,9815,9816],{"trials":10342,"activeCount":101},[],{"trials":10344,"activeCount":101},[],{"intervention":9816,"totalTrials":424,"cells":10346},{"EARLY_PHASE1":10347,"PHASE1":10349,"PHASE2":10351,"PHASE3":10353,"PHASE4":10359,"NA":10361},{"trials":10348,"activeCount":101},[],{"trials":10350,"activeCount":101},[],{"trials":10352,"activeCount":101},[],{"trials":10354,"activeCount":101},[10355],{"nctId":9808,"briefTitle":9809,"status":132,"phases":10356,"primaryCompletion":3858,"completion":3858,"start":9755,"enrollment":9811,"conditions":10357,"interventions":10358},[92],[322,18],[9797,9814,9815,9816],{"trials":10360,"activeCount":101},[],{"trials":10362,"activeCount":101},[],{"intervention":10364,"totalTrials":424,"cells":10365},"Primaquine double dose over 14 days",{"EARLY_PHASE1":10366,"PHASE1":10368,"PHASE2":10370,"PHASE3":10372,"PHASE4":10386,"NA":10388},{"trials":10367,"activeCount":101},[],{"trials":10369,"activeCount":101},[],{"trials":10371,"activeCount":101},[],{"trials":10373,"activeCount":101},[10374],{"nctId":10375,"briefTitle":10376,"status":111,"phases":10377,"primaryCompletion":10378,"completion":10379,"start":10380,"enrollment":101,"conditions":10381,"interventions":10384},"NCT05232227","Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia",[91,92],"2023-06-05","2023-10-30","2023-01-20",[10382,10383],"Malaria, Vivax","Relapse",[10364,10385],"Primaquine single dose over 14 days",{"trials":10387,"activeCount":101},[],{"trials":10389,"activeCount":101},[],{"intervention":10385,"totalTrials":424,"cells":10391},{"EARLY_PHASE1":10392,"PHASE1":10394,"PHASE2":10396,"PHASE3":10398,"PHASE4":10404,"NA":10406},{"trials":10393,"activeCount":101},[],{"trials":10395,"activeCount":101},[],{"trials":10397,"activeCount":101},[],{"trials":10399,"activeCount":101},[10400],{"nctId":10375,"briefTitle":10376,"status":111,"phases":10401,"primaryCompletion":10378,"completion":10379,"start":10380,"enrollment":101,"conditions":10402,"interventions":10403},[91,92],[10382,10383],[10364,10385],{"trials":10405,"activeCount":101},[],{"trials":10407,"activeCount":101},[],{"intervention":10409,"totalTrials":424,"cells":10410},"Nitroglycerin and lidocaine",{"EARLY_PHASE1":10411,"PHASE1":10413,"PHASE2":10415,"PHASE3":10417,"PHASE4":10429,"NA":10431},{"trials":10412,"activeCount":101},[],{"trials":10414,"activeCount":101},[],{"trials":10416,"activeCount":101},[],{"trials":10418,"activeCount":101},[10419],{"nctId":10420,"briefTitle":10421,"status":132,"phases":10422,"primaryCompletion":10423,"completion":8325,"start":447,"enrollment":10424,"conditions":10425,"interventions":10428},"NCT01155167","Topical Radial Artery Vasodilation",[91,92],"2011-08",86,[10426,10427],"Cardiac Catheterization","Spasm",[10409],{"trials":10430,"activeCount":101},[],{"trials":10432,"activeCount":101},[],{"intervention":10434,"totalTrials":424,"cells":10435},"Nicotine polacrilex, Bupropion",{"EARLY_PHASE1":10436,"PHASE1":10438,"PHASE2":10440,"PHASE3":10442,"PHASE4":10451,"NA":10453},{"trials":10437,"activeCount":101},[],{"trials":10439,"activeCount":101},[],{"trials":10441,"activeCount":101},[],{"trials":10443,"activeCount":101},[10444],{"nctId":10445,"briefTitle":10446,"status":132,"phases":10447,"primaryCompletion":2583,"completion":2583,"start":2670,"enrollment":10448,"conditions":10449,"interventions":10450},"NCT00086385","Maintaining Nonsmoking: Older Smokers - 1",[92],403,[6408],[10434],{"trials":10452,"activeCount":101},[],{"trials":10454,"activeCount":101},[],{"intervention":10456,"totalTrials":424,"cells":10457},"hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents",{"EARLY_PHASE1":10458,"PHASE1":10460,"PHASE2":10462,"PHASE3":10464,"PHASE4":10477,"NA":10479},{"trials":10459,"activeCount":101},[],{"trials":10461,"activeCount":101},[],{"trials":10463,"activeCount":101},[],{"trials":10465,"activeCount":101},[10466],{"nctId":10467,"briefTitle":10468,"status":132,"phases":10469,"primaryCompletion":9198,"completion":9198,"start":10470,"enrollment":10471,"conditions":10472,"interventions":10476},"NCT00324350","Intensive Glycemic Control and Skeletal Health Study",[92],"2003-10",7287,[10473,1222,10474,1223,2674,10475],"Atherosclerosis","Hypercholesterolemia","Coronary Disease",[10456],{"trials":10478,"activeCount":101},[],{"trials":10480,"activeCount":101},[],{"intervention":10482,"totalTrials":424,"cells":10483},"Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily",{"EARLY_PHASE1":10484,"PHASE1":10486,"PHASE2":10488,"PHASE3":10490,"PHASE4":10502,"NA":10504},{"trials":10485,"activeCount":101},[],{"trials":10487,"activeCount":101},[],{"trials":10489,"activeCount":101},[],{"trials":10491,"activeCount":101},[10492],{"nctId":10493,"briefTitle":10494,"status":132,"phases":10495,"completion":10496,"start":10497,"enrollment":10498,"conditions":10499,"interventions":10501},"NCT00319566","Heart and Estrogen-Progestin Replacement Study (HERS)",[92],"2001-07","1992-07",2430,[10500],"Coronary Heart Disease",[10482],{"trials":10503,"activeCount":101},[],{"trials":10505,"activeCount":101},[],{"intervention":10507,"totalTrials":424,"cells":10508},"folinic acid",{"EARLY_PHASE1":10509,"PHASE1":10511,"PHASE2":10513,"PHASE3":10515,"PHASE4":10525,"NA":10527},{"trials":10510,"activeCount":101},[],{"trials":10512,"activeCount":101},[],{"trials":10514,"activeCount":101},[],{"trials":10516,"activeCount":101},[10517],{"nctId":10518,"briefTitle":10519,"status":132,"phases":10520,"primaryCompletion":10521,"completion":10521,"start":10522,"enrollment":5422,"conditions":10523,"interventions":10524},"NCT03771560","Folinic Acid in Autism",[91,92],"2018-06-30","2018-02-15",[6103],[10507],{"trials":10526,"activeCount":101},[],{"trials":10528,"activeCount":101},[],{"intervention":10530,"totalTrials":424,"cells":10531},"Monthly dihydroartemisinin-piperaquine",{"EARLY_PHASE1":10532,"PHASE1":10534,"PHASE2":10536,"PHASE3":10538,"PHASE4":10549,"NA":10551},{"trials":10533,"activeCount":101},[],{"trials":10535,"activeCount":101},[],{"trials":10537,"activeCount":101},[],{"trials":10539,"activeCount":101},[10540],{"nctId":10541,"briefTitle":10542,"status":132,"phases":10543,"primaryCompletion":10544,"completion":10544,"start":10545,"enrollment":5296,"conditions":10546,"interventions":10547},"NCT02282293","Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)",[92],"2016-05-26","2014-12-09",[322,7100],[10530,10548],"Monthly placebo + daily trimethoprim\u002Fsulfamethoxazole",{"trials":10550,"activeCount":101},[],{"trials":10552,"activeCount":101},[],{"intervention":10548,"totalTrials":424,"cells":10554},{"EARLY_PHASE1":10555,"PHASE1":10557,"PHASE2":10559,"PHASE3":10561,"PHASE4":10567,"NA":10569},{"trials":10556,"activeCount":101},[],{"trials":10558,"activeCount":101},[],{"trials":10560,"activeCount":101},[],{"trials":10562,"activeCount":101},[10563],{"nctId":10541,"briefTitle":10542,"status":132,"phases":10564,"primaryCompletion":10544,"completion":10544,"start":10545,"enrollment":5296,"conditions":10565,"interventions":10566},[92],[322,7100],[10530,10548],{"trials":10568,"activeCount":101},[],{"trials":10570,"activeCount":101},[],{"intervention":10572,"totalTrials":424,"cells":10573},"Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy",{"EARLY_PHASE1":10574,"PHASE1":10576,"PHASE2":10578,"PHASE3":10580,"PHASE4":10591,"NA":10593},{"trials":10575,"activeCount":101},[],{"trials":10577,"activeCount":101},[],{"trials":10579,"activeCount":101},[],{"trials":10581,"activeCount":101},[10582],{"nctId":10583,"briefTitle":10584,"status":132,"phases":10585,"primaryCompletion":10586,"completion":10586,"start":432,"enrollment":10587,"conditions":10588,"interventions":10589},"NCT02793622","Prevention of Malaria in HIV-uninfected Pregnant Women and Infants",[92],"2018-12-04",782,[322],[10572,10590],"Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy",{"trials":10592,"activeCount":101},[],{"trials":10594,"activeCount":101},[],{"intervention":10590,"totalTrials":424,"cells":10596},{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10601,"PHASE3":10603,"PHASE4":10609,"NA":10611},{"trials":10598,"activeCount":101},[],{"trials":10600,"activeCount":101},[],{"trials":10602,"activeCount":101},[],{"trials":10604,"activeCount":101},[10605],{"nctId":10583,"briefTitle":10584,"status":132,"phases":10606,"primaryCompletion":10586,"completion":10586,"start":432,"enrollment":10587,"conditions":10607,"interventions":10608},[92],[322],[10572,10590],{"trials":10610,"activeCount":101},[],{"trials":10612,"activeCount":101},[],{"intervention":10614,"totalTrials":424,"cells":10615},"Anti Fungal Drug",{"EARLY_PHASE1":10616,"PHASE1":10618,"PHASE2":10620,"PHASE3":10622,"PHASE4":10636,"NA":10638},{"trials":10617,"activeCount":101},[],{"trials":10619,"activeCount":101},[],{"trials":10621,"activeCount":101},[],{"trials":10623,"activeCount":101},[10624],{"nctId":10625,"briefTitle":10626,"status":132,"phases":10627,"primaryCompletion":10628,"completion":10629,"start":6051,"enrollment":10630,"conditions":10631,"interventions":10635},"NCT02570321","Cross-linking for Corneal Ulcers Treatment Trial",[92],"2018-06-18","2019-03-19",147,[3075,10632,10633,10634],"Infectious Keratitis","Bacterial Ulcer","Fungal Ulcer",[10614],{"trials":10637,"activeCount":101},[],{"trials":10639,"activeCount":101},[],{"intervention":148,"totalTrials":424,"cells":10641},{"EARLY_PHASE1":10642,"PHASE1":10644,"PHASE2":10646,"PHASE3":10648,"PHASE4":10654,"NA":10656},{"trials":10643,"activeCount":101},[],{"trials":10645,"activeCount":101},[],{"trials":10647,"activeCount":101},[],{"trials":10649,"activeCount":101},[10650],{"nctId":141,"briefTitle":142,"status":132,"phases":10651,"primaryCompletion":57,"completion":57,"start":144,"enrollment":145,"conditions":10652,"interventions":10653},[92],[115],[68,148],{"trials":10655,"activeCount":101},[],{"trials":10657,"activeCount":101},[],{"intervention":10659,"totalTrials":424,"cells":10660},"MAP-Target Algorithm",{"EARLY_PHASE1":10661,"PHASE1":10663,"PHASE2":10665,"PHASE3":10667,"PHASE4":10680,"NA":10682},{"trials":10662,"activeCount":101},[],{"trials":10664,"activeCount":101},[],{"trials":10666,"activeCount":101},[],{"trials":10668,"activeCount":101},[10669],{"nctId":10670,"briefTitle":10671,"status":120,"phases":10672,"primaryCompletion":213,"completion":213,"start":10673,"enrollment":2564,"conditions":10674,"interventions":10679},"NCT06000748","NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients",[91,92],"2024-02-01",[8884,7605,10675,10676,10677,10678],"Portal Hypertension","Hepatorenal Syndrome","Acute Tubule Necrosis","Prerenal Failure",[10659],{"trials":10681,"activeCount":101},[],{"trials":10683,"activeCount":101},[],{"intervention":9826,"totalTrials":424,"cells":10685},{"EARLY_PHASE1":10686,"PHASE1":10688,"PHASE2":10690,"PHASE3":10692,"PHASE4":10698,"NA":10700},{"trials":10687,"activeCount":101},[],{"trials":10689,"activeCount":101},[],{"trials":10691,"activeCount":101},[],{"trials":10693,"activeCount":101},[10694],{"nctId":9818,"briefTitle":9819,"status":132,"phases":10695,"primaryCompletion":3648,"completion":3648,"start":9821,"enrollment":9822,"conditions":10696,"interventions":10697},[92],[322,18],[9825,9815,9826,9827],{"trials":10699,"activeCount":101},[],{"trials":10701,"activeCount":101},[],{"intervention":9827,"totalTrials":424,"cells":10703},{"EARLY_PHASE1":10704,"PHASE1":10706,"PHASE2":10708,"PHASE3":10710,"PHASE4":10716,"NA":10718},{"trials":10705,"activeCount":101},[],{"trials":10707,"activeCount":101},[],{"trials":10709,"activeCount":101},[],{"trials":10711,"activeCount":101},[10712],{"nctId":9818,"briefTitle":9819,"status":132,"phases":10713,"primaryCompletion":3648,"completion":3648,"start":9821,"enrollment":9822,"conditions":10714,"interventions":10715},[92],[322,18],[9825,9815,9826,9827],{"trials":10717,"activeCount":101},[],{"trials":10719,"activeCount":101},[],{"intervention":10721,"totalTrials":424,"cells":10722},"inhaled nitric oxide",{"EARLY_PHASE1":10723,"PHASE1":10725,"PHASE2":10727,"PHASE3":10729,"PHASE4":10739,"NA":10741},{"trials":10724,"activeCount":101},[],{"trials":10726,"activeCount":101},[],{"trials":10728,"activeCount":101},[],{"trials":10730,"activeCount":101},[10731],{"nctId":10732,"briefTitle":10733,"status":111,"phases":10734,"primaryCompletion":1244,"completion":1244,"start":2406,"enrollment":101,"conditions":10735,"interventions":10738},"NCT01607983","Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients",[92],[10736,10737],"Congenital Heart Disease","Fontan",[10721],{"trials":10740,"activeCount":101},[],{"trials":10742,"activeCount":101},[],{"intervention":10744,"totalTrials":424,"cells":10745},"Amodiaquine+Artesunate",{"EARLY_PHASE1":10746,"PHASE1":10748,"PHASE2":10750,"PHASE3":10752,"PHASE4":10764,"NA":10766},{"trials":10747,"activeCount":101},[],{"trials":10749,"activeCount":101},[],{"trials":10751,"activeCount":101},[],{"trials":10753,"activeCount":101},[10754],{"nctId":10755,"briefTitle":10756,"status":132,"phases":10757,"primaryCompletion":7694,"completion":10758,"start":5313,"enrollment":10759,"conditions":10760,"interventions":10761},"NCT00123552","Longitudinal Antimalarial Combinations in Uganda",[92],"2008-12",601,[322],[10744,10762,10763],"Amodiaquine+Sulfadoxine\u002FPyrimethamine","Artemether+Lumefantrine",{"trials":10765,"activeCount":101},[],{"trials":10767,"activeCount":101},[],{"intervention":10762,"totalTrials":424,"cells":10769},{"EARLY_PHASE1":10770,"PHASE1":10772,"PHASE2":10774,"PHASE3":10776,"PHASE4":10782,"NA":10784},{"trials":10771,"activeCount":101},[],{"trials":10773,"activeCount":101},[],{"trials":10775,"activeCount":101},[],{"trials":10777,"activeCount":101},[10778],{"nctId":10755,"briefTitle":10756,"status":132,"phases":10779,"primaryCompletion":7694,"completion":10758,"start":5313,"enrollment":10759,"conditions":10780,"interventions":10781},[92],[322],[10744,10762,10763],{"trials":10783,"activeCount":101},[],{"trials":10785,"activeCount":101},[],{"intervention":10763,"totalTrials":424,"cells":10787},{"EARLY_PHASE1":10788,"PHASE1":10790,"PHASE2":10792,"PHASE3":10794,"PHASE4":10800,"NA":10802},{"trials":10789,"activeCount":101},[],{"trials":10791,"activeCount":101},[],{"trials":10793,"activeCount":101},[],{"trials":10795,"activeCount":101},[10796],{"nctId":10755,"briefTitle":10756,"status":132,"phases":10797,"primaryCompletion":7694,"completion":10758,"start":5313,"enrollment":10759,"conditions":10798,"interventions":10799},[92],[322],[10744,10762,10763],{"trials":10801,"activeCount":101},[],{"trials":10803,"activeCount":101},[],{"intervention":9555,"totalTrials":424,"cells":10805},{"EARLY_PHASE1":10806,"PHASE1":10808,"PHASE2":10810,"PHASE3":10812,"PHASE4":10818,"NA":10820},{"trials":10807,"activeCount":101},[],{"trials":10809,"activeCount":101},[],{"trials":10811,"activeCount":101},[],{"trials":10813,"activeCount":101},[10814],{"nctId":9549,"briefTitle":9550,"status":132,"phases":10815,"primaryCompletion":9552,"completion":3660,"start":226,"enrollment":186,"conditions":10816,"interventions":10817},[92],[437,438],[9555,440],{"trials":10819,"activeCount":101},[],{"trials":10821,"activeCount":101},[],{"intervention":10823,"totalTrials":424,"cells":10824},"RACD",{"EARLY_PHASE1":10825,"PHASE1":10827,"PHASE2":10829,"PHASE3":10831,"PHASE4":10842,"NA":10844},{"trials":10826,"activeCount":101},[],{"trials":10828,"activeCount":101},[],{"trials":10830,"activeCount":101},[],{"trials":10832,"activeCount":101},[10833],{"nctId":10834,"briefTitle":10835,"status":132,"phases":10836,"primaryCompletion":1244,"completion":1244,"start":806,"enrollment":10837,"conditions":10838,"interventions":10839},"NCT02610400","Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +\u002F- Reactive Focal Vector Control (RAVC) in Namibia",[92],9845,[322],[10823,10840,10841],"RAVC","rfMDA",{"trials":10843,"activeCount":101},[],{"trials":10845,"activeCount":101},[],{"intervention":10840,"totalTrials":424,"cells":10847},{"EARLY_PHASE1":10848,"PHASE1":10850,"PHASE2":10852,"PHASE3":10854,"PHASE4":10860,"NA":10862},{"trials":10849,"activeCount":101},[],{"trials":10851,"activeCount":101},[],{"trials":10853,"activeCount":101},[],{"trials":10855,"activeCount":101},[10856],{"nctId":10834,"briefTitle":10835,"status":132,"phases":10857,"primaryCompletion":1244,"completion":1244,"start":806,"enrollment":10837,"conditions":10858,"interventions":10859},[92],[322],[10823,10840,10841],{"trials":10861,"activeCount":101},[],{"trials":10863,"activeCount":101},[],{"intervention":10841,"totalTrials":424,"cells":10865},{"EARLY_PHASE1":10866,"PHASE1":10868,"PHASE2":10870,"PHASE3":10872,"PHASE4":10878,"NA":10880},{"trials":10867,"activeCount":101},[],{"trials":10869,"activeCount":101},[],{"trials":10871,"activeCount":101},[],{"trials":10873,"activeCount":101},[10874],{"nctId":10834,"briefTitle":10835,"status":132,"phases":10875,"primaryCompletion":1244,"completion":1244,"start":806,"enrollment":10837,"conditions":10876,"interventions":10877},[92],[322],[10823,10840,10841],{"trials":10879,"activeCount":101},[],{"trials":10881,"activeCount":101},[],{"intervention":9759,"totalTrials":424,"cells":10883},{"EARLY_PHASE1":10884,"PHASE1":10886,"PHASE2":10888,"PHASE3":10890,"PHASE4":10896,"NA":10898},{"trials":10885,"activeCount":101},[],{"trials":10887,"activeCount":101},[],{"trials":10889,"activeCount":101},[],{"trials":10891,"activeCount":101},[10892],{"nctId":9752,"briefTitle":9753,"status":132,"phases":10893,"primaryCompletion":2636,"completion":9755,"start":5313,"enrollment":9756,"conditions":10894,"interventions":10895},[92],[8748],[9759,9729],{"trials":10897,"activeCount":101},[],{"trials":10899,"activeCount":101},[],{"intervention":2760,"totalTrials":2564,"cells":10901},{"EARLY_PHASE1":10902,"PHASE1":10904,"PHASE2":10943,"PHASE3":10958,"PHASE4":10960,"NA":10962},{"trials":10903,"activeCount":101},[],{"trials":10905,"activeCount":101},[10906,10918,10922,10934],{"nctId":10907,"briefTitle":10908,"status":132,"phases":10909,"primaryCompletion":7097,"completion":7097,"start":6212,"enrollment":10910,"conditions":10911,"interventions":10915},"NCT00313599","Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors",[90],28,[3584,2439,24,794,10912,10913,811,10914,21],"Extragonadal Germ Cell Tumor","Gastric Cancer","Ovarian Cancer",[10916,10917],"lapatinib","paclitaxel",{"nctId":2737,"briefTitle":2738,"status":132,"phases":10919,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":10920,"interventions":10921},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"nctId":10923,"briefTitle":10924,"status":132,"phases":10925,"primaryCompletion":921,"completion":540,"start":10926,"enrollment":498,"conditions":10927,"interventions":10931},"NCT01235897","MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies",[90],"2011-03",[10928,10929,10930],"Advanced Solid Tumors","Tumors","Cancer",[10932,2760,10933],"MK-2206","Trastuzumab",{"nctId":10935,"briefTitle":10936,"status":111,"phases":10937,"primaryCompletion":2406,"completion":10938,"start":4030,"enrollment":101,"conditions":10939,"interventions":10940},"NCT01031212","ASA404 in Combination With Carboplatin\u002FPaclitaxel\u002FCetuximab in Treating Patients With Refractory Solid Tumors",[90],"2013-06",[10929],[10941,10942,2764,2760],"ASA404","Cetuximab",{"trials":10944,"activeCount":101},[10945,10954],{"nctId":10946,"briefTitle":10947,"status":132,"phases":10948,"primaryCompletion":10949,"completion":10949,"start":10950,"enrollment":2335,"conditions":10951,"interventions":10952},"NCT00003072","Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer",[91],"1998-10","1997-05",[811,5733,10914],[10953,5738,10917],"amifostine trihydrate",{"nctId":3591,"briefTitle":3592,"status":132,"phases":10955,"primaryCompletion":3594,"completion":3594,"start":3595,"enrollment":31,"conditions":10956,"interventions":10957},[91],[3597],[2896,3599,2760],{"trials":10959,"activeCount":101},[],{"trials":10961,"activeCount":101},[],{"trials":10963,"activeCount":101},[],{"intervention":2578,"totalTrials":480,"cells":10965},{"EARLY_PHASE1":10966,"PHASE1":10968,"PHASE2":10984,"PHASE3":10994,"PHASE4":10996,"NA":10998},{"trials":10967,"activeCount":101},[],{"trials":10969,"activeCount":101},[10970,10976,10980],{"nctId":10971,"briefTitle":10972,"status":132,"phases":10973,"primaryCompletion":4275,"completion":4029,"start":6189,"enrollment":1202,"conditions":10974,"interventions":10975},"NCT00305669","GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer",[90],[21],[2578],{"nctId":2571,"briefTitle":2572,"status":132,"phases":10977,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":792,"conditions":10978,"interventions":10979},[90],[679,717,2359,680],[719,2578,684,685,2470,2362],{"nctId":2580,"briefTitle":2581,"status":132,"phases":10981,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":407,"conditions":10982,"interventions":10983},[90],[679,717,2359,680],[719,2578,684,2587,685,2588,2362],{"trials":10985,"activeCount":101},[10986],{"nctId":10987,"briefTitle":10988,"status":132,"phases":10989,"primaryCompletion":714,"completion":2545,"start":6199,"enrollment":6787,"conditions":10990,"interventions":10991},"NCT00309894","Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy",[91],[21],[2578,10992,10993],"ketoconazole","therapeutic hydrocortisone",{"trials":10995,"activeCount":101},[],{"trials":10997,"activeCount":101},[],{"trials":10999,"activeCount":101},[],{"intervention":2377,"totalTrials":324,"cells":11001},{"EARLY_PHASE1":11002,"PHASE1":11004,"PHASE2":11020,"PHASE3":11026,"PHASE4":11028,"NA":11030},{"trials":11003,"activeCount":101},[],{"trials":11005,"activeCount":101},[11006,11010],{"nctId":2737,"briefTitle":2738,"status":132,"phases":11007,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":11008,"interventions":11009},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"nctId":11011,"briefTitle":11012,"status":132,"phases":11013,"primaryCompletion":7096,"completion":7096,"start":11014,"enrollment":4043,"conditions":11015,"interventions":11017},"NCT00626158","Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers",[90],"2008-02",[6191,11016],"Biliary Cancer",[11018,11019],"gemcitabine","capecitabine",{"trials":11021,"activeCount":101},[11022],{"nctId":2368,"briefTitle":2369,"status":120,"phases":11023,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":11024,"interventions":11025},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":11027,"activeCount":101},[],{"trials":11029,"activeCount":101},[],{"trials":11031,"activeCount":101},[],{"intervention":2897,"totalTrials":324,"cells":11033},{"EARLY_PHASE1":11034,"PHASE1":11036,"PHASE2":11048,"PHASE3":11058,"PHASE4":11060,"NA":11062},{"trials":11035,"activeCount":101},[],{"trials":11037,"activeCount":101},[11038],{"nctId":11039,"briefTitle":11040,"status":132,"phases":11041,"primaryCompletion":11042,"completion":11043,"start":2574,"enrollment":498,"conditions":11044,"interventions":11045},"NCT00788112","Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast",[90],"2011-11-03","2015-08-11",[24],[11046,11047],"vorinostat","protein expression analysis",{"trials":11049,"activeCount":101},[11050,11054],{"nctId":2889,"briefTitle":2890,"status":120,"phases":11051,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":424,"conditions":11052,"interventions":11053},[91],[2746,2754],[2896,2762,2897],{"nctId":2899,"briefTitle":2900,"status":120,"phases":11055,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2904,"conditions":11056,"interventions":11057},[91],[2906],[2762,2897,2896],{"trials":11059,"activeCount":101},[],{"trials":11061,"activeCount":101},[],{"trials":11063,"activeCount":101},[],{"intervention":3864,"totalTrials":324,"cells":11065},{"EARLY_PHASE1":11066,"PHASE1":11068,"PHASE2":11078,"PHASE3":11091,"PHASE4":11093,"NA":11095},{"trials":11067,"activeCount":101},[],{"trials":11069,"activeCount":101},[11070],{"nctId":11071,"briefTitle":11072,"status":120,"phases":11073,"primaryCompletion":3696,"completion":2455,"start":11074,"enrollment":2564,"conditions":11075,"interventions":11076},"NCT00290719","Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery",[90],"2005-11",[794],[6203,11077,3864],"gefitinib",{"trials":11079,"activeCount":101},[11080,11087],{"nctId":11081,"briefTitle":11082,"status":132,"phases":11083,"primaryCompletion":11084,"completion":3858,"start":6695,"enrollment":2472,"conditions":11085,"interventions":11086},"NCT00303992","Trastuzumab and Irinotecan in Treating Patients With HER2\u002FNeu Positive Metastatic Breast Cancer",[91],"2006-11-16",[24],[5736,3864],{"nctId":3855,"briefTitle":3856,"status":132,"phases":11088,"primaryCompletion":3858,"completion":3859,"start":3860,"enrollment":751,"conditions":11089,"interventions":11090},[91],[24,3862],[3864,2445],{"trials":11092,"activeCount":101},[],{"trials":11094,"activeCount":101},[],{"trials":11096,"activeCount":101},[],{"intervention":6203,"totalTrials":324,"cells":11098},{"EARLY_PHASE1":11099,"PHASE1":11101,"PHASE2":11107,"PHASE3":11117,"PHASE4":11119,"NA":11121},{"trials":11100,"activeCount":101},[],{"trials":11102,"activeCount":101},[11103],{"nctId":11071,"briefTitle":11072,"status":120,"phases":11104,"primaryCompletion":3696,"completion":2455,"start":11074,"enrollment":2564,"conditions":11105,"interventions":11106},[90],[794],[6203,11077,3864],{"trials":11108,"activeCount":101},[11109,11113],{"nctId":6195,"briefTitle":6196,"status":132,"phases":11110,"primaryCompletion":6198,"completion":2636,"start":6199,"enrollment":6200,"conditions":11111,"interventions":11112},[91],[6191],[815,6203,6193],{"nctId":3529,"briefTitle":3530,"status":111,"phases":11114,"primaryCompletion":778,"completion":778,"start":3532,"enrollment":101,"conditions":11115,"interventions":11116},[91],[3534,3535,3536,3537,3538,3539,3540,3541,3542,3543],[3545,2896,3546,3547],{"trials":11118,"activeCount":101},[],{"trials":11120,"activeCount":101},[],{"trials":11122,"activeCount":101},[],{"intervention":2386,"totalTrials":324,"cells":11124},{"EARLY_PHASE1":11125,"PHASE1":11127,"PHASE2":11144,"PHASE3":11150,"PHASE4":11152,"NA":11154},{"trials":11126,"activeCount":101},[],{"trials":11128,"activeCount":101},[11129,11140],{"nctId":11130,"briefTitle":11131,"status":120,"phases":11132,"primaryCompletion":11133,"completion":11133,"start":11134,"enrollment":2564,"conditions":11135,"interventions":11138},"NCT02116959","Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma",[90],"2019-05-25","2014-07-23",[11136,11137],"Advanced Intra-Ocular Retinoblastoma","Retinoblastoma",[11139,2764,2386,2383],"Melphalan",{"nctId":2580,"briefTitle":2581,"status":132,"phases":11141,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":407,"conditions":11142,"interventions":11143},[90],[679,717,2359,680],[719,2578,684,2587,685,2588,2362],{"trials":11145,"activeCount":101},[11146],{"nctId":2368,"briefTitle":2369,"status":120,"phases":11147,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":11148,"interventions":11149},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":11151,"activeCount":101},[],{"trials":11153,"activeCount":101},[],{"trials":11155,"activeCount":101},[],{"intervention":6215,"totalTrials":324,"cells":11157},{"EARLY_PHASE1":11158,"PHASE1":11160,"PHASE2":11168,"PHASE3":11182,"PHASE4":11184,"NA":11186},{"trials":11159,"activeCount":101},[],{"trials":11161,"activeCount":101},[11162],{"nctId":11163,"briefTitle":11164,"status":111,"phases":11165,"primaryCompletion":2574,"completion":2574,"start":2546,"enrollment":101,"conditions":11166,"interventions":11167},"NCT00738335","Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases",[90],[811,3862],[6215],{"trials":11169,"activeCount":101},[11170,11178],{"nctId":11171,"briefTitle":11172,"status":111,"phases":11173,"start":674,"enrollment":101,"conditions":11174,"interventions":11176},"NCT00293436","Celecoxib and Erlotinib in Treating Patients With Liver Cancer",[90,91],[11175],"Liver Cancer",[11177,6215],"celecoxib",{"nctId":6209,"briefTitle":6210,"status":132,"phases":11179,"primaryCompletion":2546,"completion":1201,"start":6212,"enrollment":31,"conditions":11180,"interventions":11181},[91],[6191],[815,6215],{"trials":11183,"activeCount":101},[],{"trials":11185,"activeCount":101},[],{"trials":11187,"activeCount":101},[],{"intervention":2399,"totalTrials":526,"cells":11189},{"EARLY_PHASE1":11190,"PHASE1":11192,"PHASE2":11194,"PHASE3":11208,"PHASE4":11210,"NA":11212},{"trials":11191,"activeCount":101},[],{"trials":11193,"activeCount":101},[],{"trials":11195,"activeCount":101},[11196,11204],{"nctId":11197,"briefTitle":11198,"status":120,"phases":11199,"primaryCompletion":11200,"completion":7097,"start":11201,"enrollment":4019,"conditions":11202,"interventions":11203},"NCT00824538","Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow",[91],"2010-11-10","2009-02",[24],[2399],{"nctId":2390,"briefTitle":2391,"status":120,"phases":11205,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":34,"conditions":11206,"interventions":11207},[90,91],[24],[2398,686,2399],{"trials":11209,"activeCount":101},[],{"trials":11211,"activeCount":101},[],{"trials":11213,"activeCount":101},[],{"intervention":2759,"totalTrials":526,"cells":11215},{"EARLY_PHASE1":11216,"PHASE1":11218,"PHASE2":11224,"PHASE3":11230,"PHASE4":11232,"NA":11234},{"trials":11217,"activeCount":101},[],{"trials":11219,"activeCount":101},[11220],{"nctId":2737,"briefTitle":2738,"status":132,"phases":11221,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":11222,"interventions":11223},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"trials":11225,"activeCount":101},[11226],{"nctId":2878,"briefTitle":2879,"status":132,"phases":11227,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":1633,"conditions":11228,"interventions":11229},[91],[2884,2885],[2887,2762,2759],{"trials":11231,"activeCount":101},[],{"trials":11233,"activeCount":101},[],{"trials":11235,"activeCount":101},[],{"intervention":11177,"totalTrials":526,"cells":11237},{"EARLY_PHASE1":11238,"PHASE1":11240,"PHASE2":11242,"PHASE3":11255,"PHASE4":11257,"NA":11259},{"trials":11239,"activeCount":101},[],{"trials":11241,"activeCount":101},[],{"trials":11243,"activeCount":101},[11244,11251],{"nctId":11245,"briefTitle":11246,"status":132,"phases":11247,"completion":7341,"start":5691,"enrollment":1730,"conditions":11248,"interventions":11250},"NCT00023621","Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome",[91],[11249],"Non-melanomatous Skin Cancer",[11177],{"nctId":11171,"briefTitle":11172,"status":111,"phases":11252,"start":674,"enrollment":101,"conditions":11253,"interventions":11254},[90,91],[11175],[11177,6215],{"trials":11256,"activeCount":101},[],{"trials":11258,"activeCount":101},[],{"trials":11260,"activeCount":101},[],{"intervention":5243,"totalTrials":526,"cells":11262},{"EARLY_PHASE1":11263,"PHASE1":11265,"PHASE2":11267,"PHASE3":11277,"PHASE4":11279,"NA":11281},{"trials":11264,"activeCount":101},[],{"trials":11266,"activeCount":101},[],{"trials":11268,"activeCount":101},[11269,11273],{"nctId":5230,"briefTitle":5231,"status":120,"phases":11270,"primaryCompletion":5233,"completion":5233,"start":5234,"enrollment":1027,"conditions":11271,"interventions":11272},[91],[5236,5237,5238,5239,5240,5241],[5243,4824,5244,5245],{"nctId":670,"briefTitle":671,"status":132,"phases":11274,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":11275,"interventions":11276},[91],[677,678,679,680,681],[683,684,661,685,686,687],{"trials":11278,"activeCount":101},[],{"trials":11280,"activeCount":101},[],{"trials":11282,"activeCount":101},[],{"intervention":11284,"totalTrials":526,"cells":11285},"chemotherapy",{"EARLY_PHASE1":11286,"PHASE1":11288,"PHASE2":11290,"PHASE3":11304,"PHASE4":11306,"NA":11308},{"trials":11287,"activeCount":101},[],{"trials":11289,"activeCount":101},[],{"trials":11291,"activeCount":101},[11292,11300],{"nctId":11293,"briefTitle":11294,"status":132,"phases":11295,"primaryCompletion":6220,"start":11296,"enrollment":11297,"conditions":11298,"interventions":11299},"NCT00274755","Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas",[91],"2003-11",250,[2439],[11284],{"nctId":3493,"briefTitle":3494,"status":132,"phases":11301,"primaryCompletion":3496,"completion":3496,"start":3497,"enrollment":695,"conditions":11302,"interventions":11303},[91],[3499,3500],[2896,3502],{"trials":11305,"activeCount":101},[],{"trials":11307,"activeCount":101},[],{"trials":11309,"activeCount":101},[],{"intervention":2488,"totalTrials":526,"cells":11311},{"EARLY_PHASE1":11312,"PHASE1":11314,"PHASE2":11316,"PHASE3":11326,"PHASE4":11328,"NA":11330},{"trials":11313,"activeCount":101},[],{"trials":11315,"activeCount":101},[],{"trials":11317,"activeCount":101},[11318,11322],{"nctId":2481,"briefTitle":2482,"status":132,"phases":11319,"primaryCompletion":226,"completion":226,"start":2484,"enrollment":2335,"conditions":11320,"interventions":11321},[91],[322],[2487,2488,925,2489,2490],{"nctId":2492,"briefTitle":2493,"status":132,"phases":11323,"primaryCompletion":205,"completion":205,"start":433,"enrollment":2495,"conditions":11324,"interventions":11325},[91],[322],[938,2498,2499,2500,2501],{"trials":11327,"activeCount":101},[],{"trials":11329,"activeCount":101},[],{"trials":11331,"activeCount":101},[],{"intervention":11333,"totalTrials":526,"cells":11334},"Dapagliflozin",{"EARLY_PHASE1":11335,"PHASE1":11337,"PHASE2":11339,"PHASE3":11360,"PHASE4":11362,"NA":11364},{"trials":11336,"activeCount":101},[],{"trials":11338,"activeCount":101},[],{"trials":11340,"activeCount":101},[11341,11351],{"nctId":11342,"briefTitle":11343,"status":132,"phases":11344,"primaryCompletion":11345,"completion":11346,"start":11347,"enrollment":345,"conditions":11348,"interventions":11350},"NCT04818034","The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study",[91],"2021-12-13","2022-04-28","2021-08-30",[11349],"Cystinuria",[11333],{"nctId":11352,"briefTitle":11353,"status":111,"phases":11354,"primaryCompletion":11355,"completion":11356,"start":11357,"enrollment":101,"conditions":11358,"interventions":11359},"NCT05058859","Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics",[91],"2024-10-31","2025-11-01","2023-09-01",[11349],[11333],{"trials":11361,"activeCount":101},[],{"trials":11363,"activeCount":101},[],{"trials":11365,"activeCount":101},[],{"intervention":2383,"totalTrials":526,"cells":11367},{"EARLY_PHASE1":11368,"PHASE1":11370,"PHASE2":11376,"PHASE3":11382,"PHASE4":11384,"NA":11386},{"trials":11369,"activeCount":101},[],{"trials":11371,"activeCount":101},[11372],{"nctId":11130,"briefTitle":11131,"status":120,"phases":11373,"primaryCompletion":11133,"completion":11133,"start":11134,"enrollment":2564,"conditions":11374,"interventions":11375},[90],[11136,11137],[11139,2764,2386,2383],{"trials":11377,"activeCount":101},[11378],{"nctId":2368,"briefTitle":2369,"status":120,"phases":11379,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":11380,"interventions":11381},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":11383,"activeCount":101},[],{"trials":11385,"activeCount":101},[],{"trials":11387,"activeCount":101},[],{"intervention":3473,"totalTrials":526,"cells":11389},{"EARLY_PHASE1":11390,"PHASE1":11392,"PHASE2":11398,"PHASE3":11404,"PHASE4":11406,"NA":11408},{"trials":11391,"activeCount":101},[],{"trials":11393,"activeCount":101},[11394],{"nctId":11011,"briefTitle":11012,"status":132,"phases":11395,"primaryCompletion":7096,"completion":7096,"start":11014,"enrollment":4043,"conditions":11396,"interventions":11397},[90],[6191,11016],[11018,11019],{"trials":11399,"activeCount":101},[11400],{"nctId":3458,"briefTitle":3459,"status":132,"phases":11401,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":22,"conditions":11402,"interventions":11403},[91],[3464,3465,3466,3467,3468,3469,3470,3471],[476,3473,2896],{"trials":11405,"activeCount":101},[],{"trials":11407,"activeCount":101},[],{"trials":11409,"activeCount":101},[],{"intervention":4148,"totalTrials":526,"cells":11411},{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11420,"PHASE3":11443,"PHASE4":11445,"NA":11447},{"trials":11413,"activeCount":101},[],{"trials":11415,"activeCount":101},[11416],{"nctId":4141,"briefTitle":4142,"status":120,"phases":11417,"primaryCompletion":4144,"completion":4144,"start":4145,"enrollment":2472,"conditions":11418,"interventions":11419},[90],[3443],[4148,4123],{"trials":11421,"activeCount":101},[11422],{"nctId":11423,"briefTitle":11424,"status":120,"phases":11425,"primaryCompletion":11426,"completion":11426,"start":11427,"enrollment":424,"conditions":11428,"interventions":11439},"NCT02587650","Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF\u002FNRAS Wild-Type Stage III-IV Melanoma",[91],"2018-07-12","2015-03-26",[11429,11430,11431,11432,11433,11434,11435,11436,11437,11438,3569,3570,3571,3572,3573],"ALK Fusion Protein Expression","BRAF wt Allele","Invasive Skin Melanoma","MET Fusion Gene Positive","NRAS wt Allele","NTRK1 Fusion Positive","NTRK2 Fusion Positive","NTRK3 Fusion Positive","RET Fusion Positive","ROS1 Fusion Positive",[11440,4148,11441,11442],"Capmatinib","Entrectinib","Regorafenib",{"trials":11444,"activeCount":101},[],{"trials":11446,"activeCount":101},[],{"trials":11448,"activeCount":101},[],{"intervention":3823,"totalTrials":526,"cells":11450},{"EARLY_PHASE1":11451,"PHASE1":11453,"PHASE2":11455,"PHASE3":11469,"PHASE4":11471,"NA":11473},{"trials":11452,"activeCount":101},[],{"trials":11454,"activeCount":101},[],{"trials":11456,"activeCount":101},[11457,11465],{"nctId":11458,"briefTitle":11459,"status":132,"phases":11460,"primaryCompletion":10926,"completion":10926,"start":2773,"enrollment":1914,"conditions":11461,"interventions":11463},"NCT00187486","Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors",[91],[11462,3821],"Glioblastoma Multiforme",[3823,11464],"Temodar",{"nctId":3815,"briefTitle":3816,"status":132,"phases":11466,"primaryCompletion":3818,"completion":3818,"start":3819,"enrollment":1872,"conditions":11467,"interventions":11468},[91],[3765,3821],[476,3823,3751],{"trials":11470,"activeCount":101},[],{"trials":11472,"activeCount":101},[],{"trials":11474,"activeCount":101},[],{"intervention":6193,"totalTrials":526,"cells":11476},{"EARLY_PHASE1":11477,"PHASE1":11479,"PHASE2":11481,"PHASE3":11491,"PHASE4":11493,"NA":11495},{"trials":11478,"activeCount":101},[],{"trials":11480,"activeCount":101},[],{"trials":11482,"activeCount":101},[11483,11487],{"nctId":6186,"briefTitle":6187,"status":120,"phases":11484,"primaryCompletion":3830,"completion":3830,"start":6189,"enrollment":1060,"conditions":11485,"interventions":11486},[90,91],[6191],[815,6193],{"nctId":6195,"briefTitle":6196,"status":132,"phases":11488,"primaryCompletion":6198,"completion":2636,"start":6199,"enrollment":6200,"conditions":11489,"interventions":11490},[91],[6191],[815,6203,6193],{"trials":11492,"activeCount":101},[],{"trials":11494,"activeCount":101},[],{"trials":11496,"activeCount":101},[],{"intervention":3576,"totalTrials":526,"cells":11498},{"EARLY_PHASE1":11499,"PHASE1":11501,"PHASE2":11503,"PHASE3":11518,"PHASE4":11520,"NA":11522},{"trials":11500,"activeCount":101},[],{"trials":11502,"activeCount":101},[],{"trials":11504,"activeCount":101},[11505,11514],{"nctId":11506,"briefTitle":11507,"status":132,"phases":11508,"primaryCompletion":11509,"completion":4214,"start":11510,"enrollment":434,"conditions":11511,"interventions":11512},"NCT01804465","Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer",[91],"2020-02-27","2014-04-22",[21],[11513,3576],"SipT Treatment",{"nctId":3561,"briefTitle":3562,"status":132,"phases":11515,"primaryCompletion":3564,"completion":3565,"start":3566,"enrollment":3567,"conditions":11516,"interventions":11517},[91],[3569,3570,3571,3572,3573],[3575,3576,2896],{"trials":11519,"activeCount":101},[],{"trials":11521,"activeCount":101},[],{"trials":11523,"activeCount":101},[],{"intervention":11525,"totalTrials":526,"cells":11526},"erlotinib",{"EARLY_PHASE1":11527,"PHASE1":11529,"PHASE2":11531,"PHASE3":11547,"PHASE4":11549,"NA":11551},{"trials":11528,"activeCount":101},[],{"trials":11530,"activeCount":101},[],{"trials":11532,"activeCount":101},[11533,11543],{"nctId":11534,"briefTitle":11535,"status":120,"phases":11536,"primaryCompletion":11537,"completion":11538,"start":11539,"enrollment":498,"conditions":11540,"interventions":11541},"NCT00843531","RAD001 and Erlotinib in Patients With Neuroendocrine Tumors",[91],"2013-07-16","2016-08-20","2009-06-25",[3482],[11542,11525],"RAD001",{"nctId":787,"briefTitle":788,"status":120,"phases":11544,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":11545,"interventions":11546},[91],[794],[796,768,797,798],{"trials":11548,"activeCount":101},[],{"trials":11550,"activeCount":101},[],{"trials":11552,"activeCount":101},[],{"intervention":11554,"totalTrials":526,"cells":11555},"Rifaximin",{"EARLY_PHASE1":11556,"PHASE1":11558,"PHASE2":11560,"PHASE3":11577,"PHASE4":11579,"NA":11581},{"trials":11557,"activeCount":101},[],{"trials":11559,"activeCount":101},[],{"trials":11561,"activeCount":101},[11562,11569],{"nctId":11563,"briefTitle":11564,"status":111,"phases":11565,"primaryCompletion":4029,"completion":205,"start":4155,"enrollment":101,"conditions":11566,"interventions":11568},"NCT01359228","Rifaximin Treatment of Papulopustular Rosacea",[91],[11567],"Rosacea",[11554],{"nctId":11570,"briefTitle":11571,"status":4132,"phases":11572,"primaryCompletion":5843,"completion":5843,"start":11573,"enrollment":10424,"conditions":11574,"interventions":11576},"NCT03575195","Microbiota Intervention to Change the Response of Parkinson's Disease",[90,91],"2019-07-15",[11575],"Parkinson Disease",[11554],{"trials":11578,"activeCount":101},[],{"trials":11580,"activeCount":101},[],{"trials":11582,"activeCount":101},[],{"intervention":6470,"totalTrials":526,"cells":11584},{"EARLY_PHASE1":11585,"PHASE1":11587,"PHASE2":11589,"PHASE3":11609,"PHASE4":11611,"NA":11613},{"trials":11586,"activeCount":101},[],{"trials":11588,"activeCount":101},[],{"trials":11590,"activeCount":101},[11591,11595],{"nctId":6461,"briefTitle":6462,"status":120,"phases":11592,"primaryCompletion":6464,"completion":6464,"start":6465,"enrollment":407,"conditions":11593,"interventions":11594},[91],[6467,6468],[6470,6471,6452],{"nctId":11596,"briefTitle":11597,"status":132,"phases":11598,"primaryCompletion":11599,"completion":11599,"start":11600,"enrollment":498,"conditions":11601,"interventions":11606},"NCT02458235","Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation",[91],"2019-03-15","2015-06-02",[11602,11603,11604,11605],"Acute Myelogenous Leukemia","Acute Lymphoid Leukemia","Juvenile Myelomonocytic Leukemia","Myelodysplastic Syndrome",[11607,11608],"azacitidine","donor lymphocyte",{"trials":11610,"activeCount":101},[],{"trials":11612,"activeCount":101},[],{"trials":11614,"activeCount":101},[],{"intervention":3842,"totalTrials":526,"cells":11616},{"EARLY_PHASE1":11617,"PHASE1":11619,"PHASE2":11621,"PHASE3":11635,"PHASE4":11637,"NA":11639},{"trials":11618,"activeCount":101},[],{"trials":11620,"activeCount":101},[],{"trials":11622,"activeCount":101},[11623,11631],{"nctId":11624,"briefTitle":11625,"status":132,"phases":11626,"primaryCompletion":11627,"completion":11627,"start":11628,"enrollment":4173,"conditions":11629,"interventions":11630},"NCT00293423","GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma",[90,91],"2013-01-12","2005-11-18",[2439],[3842],{"nctId":3835,"briefTitle":3836,"status":132,"phases":11632,"primaryCompletion":3838,"completion":3838,"start":3839,"enrollment":1633,"conditions":11633,"interventions":11634},[91],[2439],[3842,3751],{"trials":11636,"activeCount":101},[],{"trials":11638,"activeCount":101},[],{"trials":11640,"activeCount":101},[],{"intervention":10992,"totalTrials":526,"cells":11642},{"EARLY_PHASE1":11643,"PHASE1":11645,"PHASE2":11647,"PHASE3":11657,"PHASE4":11659,"NA":11661},{"trials":11644,"activeCount":101},[],{"trials":11646,"activeCount":101},[],{"trials":11648,"activeCount":101},[11649,11653],{"nctId":10987,"briefTitle":10988,"status":132,"phases":11650,"primaryCompletion":714,"completion":2545,"start":6199,"enrollment":6787,"conditions":11651,"interventions":11652},[91],[21],[2578,10992,10993],{"nctId":6473,"briefTitle":6474,"status":132,"phases":11654,"primaryCompletion":6476,"completion":6477,"start":6478,"enrollment":34,"conditions":11655,"interventions":11656},[91],[21],[6481,6482,6452],{"trials":11658,"activeCount":101},[],{"trials":11660,"activeCount":101},[],{"trials":11662,"activeCount":101},[],{"intervention":11664,"totalTrials":526,"cells":11665},"Defibrotide",{"EARLY_PHASE1":11666,"PHASE1":11668,"PHASE2":11670,"PHASE3":11689,"PHASE4":11691,"NA":11693},{"trials":11667,"activeCount":101},[],{"trials":11669,"activeCount":101},[],{"trials":11671,"activeCount":101},[11672,11682],{"nctId":11673,"briefTitle":11674,"status":111,"phases":11675,"primaryCompletion":1172,"completion":1172,"start":47,"enrollment":101,"conditions":11676,"interventions":11681},"NCT06182410","Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma",[91],[11677,11678,11679,11680],"Transplant-Associated Thrombotic Microangiopathy","Neuroblastoma","High-risk Neuroblastoma","Thrombotic Microangiopathies",[11664],{"nctId":11683,"briefTitle":11684,"status":132,"phases":11685,"primaryCompletion":245,"completion":245,"start":11686,"enrollment":353,"conditions":11687,"interventions":11688},"NCT03384693","Defibrotide TMA Prophylaxis Pilot Trial",[91],"2018-05-01",[11680],[11664],{"trials":11690,"activeCount":101},[],{"trials":11692,"activeCount":101},[],{"trials":11694,"activeCount":101},[],{"intervention":11696,"totalTrials":424,"cells":11697},"Nexagon",{"EARLY_PHASE1":11698,"PHASE1":11700,"PHASE2":11702,"PHASE3":11714,"PHASE4":11716,"NA":11718},{"trials":11699,"activeCount":101},[],{"trials":11701,"activeCount":101},[],{"trials":11703,"activeCount":101},[11704],{"nctId":11705,"briefTitle":11706,"status":120,"phases":11707,"primaryCompletion":11708,"completion":11708,"start":11709,"enrollment":526,"conditions":11710,"interventions":11712},"NCT01165450","Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects",[91],"2014-02","2011-11",[11711],"Persistent Corneal Epithelial Defects",[11696,11713],"Vehicle only",{"trials":11715,"activeCount":101},[],{"trials":11717,"activeCount":101},[],{"trials":11719,"activeCount":101},[],{"intervention":11713,"totalTrials":424,"cells":11721},{"EARLY_PHASE1":11722,"PHASE1":11724,"PHASE2":11726,"PHASE3":11732,"PHASE4":11734,"NA":11736},{"trials":11723,"activeCount":101},[],{"trials":11725,"activeCount":101},[],{"trials":11727,"activeCount":101},[11728],{"nctId":11705,"briefTitle":11706,"status":120,"phases":11729,"primaryCompletion":11708,"completion":11708,"start":11709,"enrollment":526,"conditions":11730,"interventions":11731},[91],[11711],[11696,11713],{"trials":11733,"activeCount":101},[],{"trials":11735,"activeCount":101},[],{"trials":11737,"activeCount":101},[],{"intervention":11739,"totalTrials":424,"cells":11740},"zafirlukast",{"EARLY_PHASE1":11741,"PHASE1":11743,"PHASE2":11745,"PHASE3":11755,"PHASE4":11757,"NA":11759},{"trials":11742,"activeCount":101},[],{"trials":11744,"activeCount":101},[],{"trials":11746,"activeCount":101},[11747],{"nctId":11748,"briefTitle":11749,"status":120,"phases":11750,"primaryCompletion":11751,"completion":11751,"start":11752,"enrollment":480,"conditions":11753,"interventions":11754},"NCT02950480","Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial",[91],"2018-12-20","2017-03-13",[24],[11739],{"trials":11756,"activeCount":101},[],{"trials":11758,"activeCount":101},[],{"trials":11760,"activeCount":101},[],{"intervention":11762,"totalTrials":424,"cells":11763},"Liposomal Doxorubicin\u002FMelphalan\u002FBortezomib",{"EARLY_PHASE1":11764,"PHASE1":11766,"PHASE2":11768,"PHASE3":11778,"PHASE4":11780,"NA":11782},{"trials":11765,"activeCount":101},[],{"trials":11767,"activeCount":101},[],{"trials":11769,"activeCount":101},[11770],{"nctId":11771,"briefTitle":11772,"status":111,"phases":11773,"primaryCompletion":2407,"completion":7096,"start":11774,"enrollment":101,"conditions":11775,"interventions":11777},"NCT00516191","A Phase I\u002FII Study of Liposomal Doxorubicin (Doxil)\u002FMelphalan\u002FBortezomib (Velcade) in Relapsed\u002FRefractory Multiple Myeloma",[90,91],"2004-10",[11776],"Multiple Myeloma",[11762],{"trials":11779,"activeCount":101},[],{"trials":11781,"activeCount":101},[],{"trials":11783,"activeCount":101},[],{"intervention":11785,"totalTrials":424,"cells":11786},"Intermittent Oral Naltrexone",{"EARLY_PHASE1":11787,"PHASE1":11789,"PHASE2":11791,"PHASE3":11801,"PHASE4":11803,"NA":11805},{"trials":11788,"activeCount":101},[],{"trials":11790,"activeCount":101},[],{"trials":11792,"activeCount":101},[11793],{"nctId":11794,"briefTitle":11795,"status":132,"phases":11796,"primaryCompletion":6069,"completion":165,"start":3818,"enrollment":751,"conditions":11797,"interventions":11800},"NCT01723384","Intermittent Naltrexone Among Polysubstance Users",[91],[11798,11799],"Methamphetamine","Alcohol",[11785],{"trials":11802,"activeCount":101},[],{"trials":11804,"activeCount":101},[],{"trials":11806,"activeCount":101},[],{"intervention":11808,"totalTrials":424,"cells":11809},"Quinacrine",{"EARLY_PHASE1":11810,"PHASE1":11812,"PHASE2":11814,"PHASE3":11824,"PHASE4":11826,"NA":11828},{"trials":11811,"activeCount":101},[],{"trials":11813,"activeCount":101},[],{"trials":11815,"activeCount":101},[11816],{"nctId":11817,"briefTitle":11818,"status":132,"phases":11819,"primaryCompletion":2406,"completion":2406,"start":9350,"enrollment":11820,"conditions":11821,"interventions":11823},"NCT00183092","CJD (Creutzfeldt-Jakob Disease) Quinacrine Study",[91],69,[11822],"Creutzfeldt-Jakob Disease",[11808],{"trials":11825,"activeCount":101},[],{"trials":11827,"activeCount":101},[],{"trials":11829,"activeCount":101},[],{"intervention":11831,"totalTrials":424,"cells":11832},"Docetaxel and GM-CSF",{"EARLY_PHASE1":11833,"PHASE1":11835,"PHASE2":11837,"PHASE3":11848,"PHASE4":11850,"NA":11852},{"trials":11834,"activeCount":101},[],{"trials":11836,"activeCount":101},[],{"trials":11838,"activeCount":101},[11839],{"nctId":11840,"briefTitle":11841,"status":132,"phases":11842,"primaryCompletion":11843,"completion":6149,"start":6220,"enrollment":11844,"conditions":11845,"interventions":11846},"NCT00488982","Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)",[91],"2014-03",125,[21],[11847,11831],"Docetaxel",{"trials":11849,"activeCount":101},[],{"trials":11851,"activeCount":101},[],{"trials":11853,"activeCount":101},[],{"intervention":2887,"totalTrials":424,"cells":11855},{"EARLY_PHASE1":11856,"PHASE1":11858,"PHASE2":11860,"PHASE3":11866,"PHASE4":11868,"NA":11870},{"trials":11857,"activeCount":101},[],{"trials":11859,"activeCount":101},[],{"trials":11861,"activeCount":101},[11862],{"nctId":2878,"briefTitle":2879,"status":132,"phases":11863,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":1633,"conditions":11864,"interventions":11865},[91],[2884,2885],[2887,2762,2759],{"trials":11867,"activeCount":101},[],{"trials":11869,"activeCount":101},[],{"trials":11871,"activeCount":101},[],{"intervention":11873,"totalTrials":424,"cells":11874},"DaxibotulinumtoxinA",{"EARLY_PHASE1":11875,"PHASE1":11877,"PHASE2":11879,"PHASE3":11893,"PHASE4":11895,"NA":11897},{"trials":11876,"activeCount":101},[],{"trials":11878,"activeCount":101},[],{"trials":11880,"activeCount":101},[11881],{"nctId":11882,"briefTitle":11883,"status":132,"phases":11884,"primaryCompletion":11885,"completion":11886,"start":11887,"enrollment":3744,"conditions":11888,"interventions":11892},"NCT05158166","DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia",[90,91],"2025-03-01","2025-03-02","2023-10-13",[11889,11890,11891],"Adductor Spasmodic Dysphonia","Voice Disorders","Spasmodic Dysphonia",[11873],{"trials":11894,"activeCount":101},[],{"trials":11896,"activeCount":101},[],{"trials":11898,"activeCount":101},[],{"intervention":11900,"totalTrials":424,"cells":11901},"Bromocriptine 5 MG",{"EARLY_PHASE1":11902,"PHASE1":11904,"PHASE2":11906,"PHASE3":11920,"PHASE4":11922,"NA":11924},{"trials":11903,"activeCount":101},[],{"trials":11905,"activeCount":101},[],{"trials":11907,"activeCount":101},[11908],{"nctId":11909,"briefTitle":11910,"status":132,"phases":11911,"primaryCompletion":11912,"completion":11912,"start":6441,"enrollment":3582,"conditions":11913,"interventions":11918},"NCT03496545","Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury",[90,91],"2019-11-02",[11914,11915,697,8136,11916,11917],"Subarachnoid Hemorrhage","Subdural Hematoma","Fever","Intracerebral Hemorrhage",[11900,11919],"Acetaminophen 650 MG",{"trials":11921,"activeCount":101},[],{"trials":11923,"activeCount":101},[],{"trials":11925,"activeCount":101},[],{"intervention":11919,"totalTrials":424,"cells":11927},{"EARLY_PHASE1":11928,"PHASE1":11930,"PHASE2":11932,"PHASE3":11938,"PHASE4":11940,"NA":11942},{"trials":11929,"activeCount":101},[],{"trials":11931,"activeCount":101},[],{"trials":11933,"activeCount":101},[11934],{"nctId":11909,"briefTitle":11910,"status":132,"phases":11935,"primaryCompletion":11912,"completion":11912,"start":6441,"enrollment":3582,"conditions":11936,"interventions":11937},[90,91],[11914,11915,697,8136,11916,11917],[11900,11919],{"trials":11939,"activeCount":101},[],{"trials":11941,"activeCount":101},[],{"trials":11943,"activeCount":101},[],{"intervention":11945,"totalTrials":424,"cells":11946},"Enzalutamide",{"EARLY_PHASE1":11947,"PHASE1":11949,"PHASE2":11951,"PHASE3":11963,"PHASE4":11965,"NA":11967},{"trials":11948,"activeCount":101},[],{"trials":11950,"activeCount":101},[],{"trials":11952,"activeCount":101},[11953],{"nctId":11954,"briefTitle":11955,"status":120,"phases":11956,"primaryCompletion":4214,"completion":4214,"start":11957,"enrollment":541,"conditions":11958,"interventions":11961},"NCT02508636","Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer",[91],"2015-12-22",[11959,11960],"Prostatic Neoplasms","Pelvic Nodal",[11945,11962],"Leuprolide",{"trials":11964,"activeCount":101},[],{"trials":11966,"activeCount":101},[],{"trials":11968,"activeCount":101},[],{"intervention":11962,"totalTrials":424,"cells":11970},{"EARLY_PHASE1":11971,"PHASE1":11973,"PHASE2":11975,"PHASE3":11981,"PHASE4":11983,"NA":11985},{"trials":11972,"activeCount":101},[],{"trials":11974,"activeCount":101},[],{"trials":11976,"activeCount":101},[11977],{"nctId":11954,"briefTitle":11955,"status":120,"phases":11978,"primaryCompletion":4214,"completion":4214,"start":11957,"enrollment":541,"conditions":11979,"interventions":11980},[91],[11959,11960],[11945,11962],{"trials":11982,"activeCount":101},[],{"trials":11984,"activeCount":101},[],{"trials":11986,"activeCount":101},[],{"intervention":2487,"totalTrials":424,"cells":11988},{"EARLY_PHASE1":11989,"PHASE1":11991,"PHASE2":11993,"PHASE3":11999,"PHASE4":12001,"NA":12003},{"trials":11990,"activeCount":101},[],{"trials":11992,"activeCount":101},[],{"trials":11994,"activeCount":101},[11995],{"nctId":2481,"briefTitle":2482,"status":132,"phases":11996,"primaryCompletion":226,"completion":226,"start":2484,"enrollment":2335,"conditions":11997,"interventions":11998},[91],[322],[2487,2488,925,2489,2490],{"trials":12000,"activeCount":101},[],{"trials":12002,"activeCount":101},[],{"trials":12004,"activeCount":101},[],{"intervention":2489,"totalTrials":424,"cells":12006},{"EARLY_PHASE1":12007,"PHASE1":12009,"PHASE2":12011,"PHASE3":12017,"PHASE4":12019,"NA":12021},{"trials":12008,"activeCount":101},[],{"trials":12010,"activeCount":101},[],{"trials":12012,"activeCount":101},[12013],{"nctId":2481,"briefTitle":2482,"status":132,"phases":12014,"primaryCompletion":226,"completion":226,"start":2484,"enrollment":2335,"conditions":12015,"interventions":12016},[91],[322],[2487,2488,925,2489,2490],{"trials":12018,"activeCount":101},[],{"trials":12020,"activeCount":101},[],{"trials":12022,"activeCount":101},[],{"intervention":2490,"totalTrials":424,"cells":12024},{"EARLY_PHASE1":12025,"PHASE1":12027,"PHASE2":12029,"PHASE3":12035,"PHASE4":12037,"NA":12039},{"trials":12026,"activeCount":101},[],{"trials":12028,"activeCount":101},[],{"trials":12030,"activeCount":101},[12031],{"nctId":2481,"briefTitle":2482,"status":132,"phases":12032,"primaryCompletion":226,"completion":226,"start":2484,"enrollment":2335,"conditions":12033,"interventions":12034},[91],[322],[2487,2488,925,2489,2490],{"trials":12036,"activeCount":101},[],{"trials":12038,"activeCount":101},[],{"trials":12040,"activeCount":101},[],{"intervention":12042,"totalTrials":424,"cells":12043},"rifabutin plus trimethoprim sulfamethoxazole",{"EARLY_PHASE1":12044,"PHASE1":12046,"PHASE2":12048,"PHASE3":12057,"PHASE4":12059,"NA":12061},{"trials":12045,"activeCount":101},[],{"trials":12047,"activeCount":101},[],{"trials":12049,"activeCount":101},[12050],{"nctId":12051,"briefTitle":12052,"status":120,"phases":12053,"primaryCompletion":7096,"completion":7096,"start":2574,"enrollment":2818,"conditions":12054,"interventions":12056},"NCT00869518","Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults",[91],[12055,18],"Staphylococcus Aureus",[12042],{"trials":12058,"activeCount":101},[],{"trials":12060,"activeCount":101},[],{"trials":12062,"activeCount":101},[],{"intervention":12064,"totalTrials":424,"cells":12065},"Busulfan\u002FFludarabine phosphate\u002FTacrolimus\u002FMethotrexate\u002FG-CSF",{"EARLY_PHASE1":12066,"PHASE1":12068,"PHASE2":12070,"PHASE3":12086,"PHASE4":12088,"NA":12090},{"trials":12067,"activeCount":101},[],{"trials":12069,"activeCount":101},[],{"trials":12071,"activeCount":101},[12072],{"nctId":12073,"briefTitle":12074,"status":132,"phases":12075,"completion":714,"start":12076,"enrollment":31,"conditions":12077,"interventions":12085},"NCT00516152","Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT",[91],"2002-11",[12078,11602,12079,12080,12081,12082,12083,11776,12084],"Chronic Myeloid Leukemia","Myelodysplasia","Acute Lymphocytic Leukemia","Severe Aplastic Anemia","Non-Hodgkin's Lymphoma","Lymphoproliferative Disease","Advanced Myeloproliferative Disease",[12064],{"trials":12087,"activeCount":101},[],{"trials":12089,"activeCount":101},[],{"trials":12091,"activeCount":101},[],{"intervention":12093,"totalTrials":424,"cells":12094},"CEUS",{"EARLY_PHASE1":12095,"PHASE1":12097,"PHASE2":12099,"PHASE3":12111,"PHASE4":12113,"NA":12115},{"trials":12096,"activeCount":101},[],{"trials":12098,"activeCount":101},[],{"trials":12100,"activeCount":101},[12101],{"nctId":12102,"briefTitle":12103,"status":111,"phases":12104,"primaryCompletion":12105,"completion":12105,"start":12106,"enrollment":101,"conditions":12107,"interventions":12110},"NCT03058614","Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient Management",[91],"2022-05-02","2017-06-30",[12108,12109],"Ultrasonography","Nephrolithiasis",[12093],{"trials":12112,"activeCount":101},[],{"trials":12114,"activeCount":101},[],{"trials":12116,"activeCount":101},[],{"intervention":12118,"totalTrials":424,"cells":12119},"Valproic Acid",{"EARLY_PHASE1":12120,"PHASE1":12122,"PHASE2":12124,"PHASE3":12133,"PHASE4":12135,"NA":12137},{"trials":12121,"activeCount":101},[],{"trials":12123,"activeCount":101},[],{"trials":12125,"activeCount":101},[12126],{"nctId":12127,"briefTitle":12128,"status":120,"phases":12129,"primaryCompletion":2583,"completion":2583,"start":236,"enrollment":407,"conditions":12130,"interventions":12132},"NCT00525135","Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer",[91],[12131],"Head and Neck Cancer",[12118],{"trials":12134,"activeCount":101},[],{"trials":12136,"activeCount":101},[],{"trials":12138,"activeCount":101},[],{"intervention":3445,"totalTrials":424,"cells":12140},{"EARLY_PHASE1":12141,"PHASE1":12143,"PHASE2":12145,"PHASE3":12151,"PHASE4":12153,"NA":12155},{"trials":12142,"activeCount":101},[],{"trials":12144,"activeCount":101},[],{"trials":12146,"activeCount":101},[12147],{"nctId":3437,"briefTitle":3438,"status":111,"phases":12148,"primaryCompletion":3440,"completion":3440,"start":3441,"enrollment":101,"conditions":12149,"interventions":12150},[91],[3443],[3445,2896],{"trials":12152,"activeCount":101},[],{"trials":12154,"activeCount":101},[],{"trials":12156,"activeCount":101},[],{"intervention":12158,"totalTrials":424,"cells":12159},"Testosterone Cream",{"EARLY_PHASE1":12160,"PHASE1":12162,"PHASE2":12164,"PHASE3":12176,"PHASE4":12178,"NA":12180},{"trials":12161,"activeCount":101},[],{"trials":12163,"activeCount":101},[],{"trials":12165,"activeCount":101},[12166],{"nctId":12167,"briefTitle":12168,"status":132,"phases":12169,"primaryCompletion":12170,"completion":1200,"start":713,"enrollment":12171,"conditions":12172,"interventions":12174},"NCT00698035","Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients",[91],"2012-10",76,[12173],"Sexual Dysfunction, Physiological",[12158,12175],"Estring",{"trials":12177,"activeCount":101},[],{"trials":12179,"activeCount":101},[],{"trials":12181,"activeCount":101},[],{"intervention":12175,"totalTrials":424,"cells":12183},{"EARLY_PHASE1":12184,"PHASE1":12186,"PHASE2":12188,"PHASE3":12194,"PHASE4":12196,"NA":12198},{"trials":12185,"activeCount":101},[],{"trials":12187,"activeCount":101},[],{"trials":12189,"activeCount":101},[12190],{"nctId":12167,"briefTitle":12168,"status":132,"phases":12191,"primaryCompletion":12170,"completion":1200,"start":713,"enrollment":12171,"conditions":12192,"interventions":12193},[91],[12173],[12158,12175],{"trials":12195,"activeCount":101},[],{"trials":12197,"activeCount":101},[],{"trials":12199,"activeCount":101},[],{"intervention":12201,"totalTrials":424,"cells":12202},"rosiglitazone maleate",{"EARLY_PHASE1":12203,"PHASE1":12205,"PHASE2":12207,"PHASE3":12215,"PHASE4":12217,"NA":12219},{"trials":12204,"activeCount":101},[],{"trials":12206,"activeCount":101},[],{"trials":12208,"activeCount":101},[12209],{"nctId":12210,"briefTitle":12211,"status":2462,"phases":12212,"primaryCompletion":932,"start":11774,"enrollment":353,"conditions":12213,"interventions":12214},"NCT00098852","Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer",[91],[12131],[12201],{"trials":12216,"activeCount":101},[],{"trials":12218,"activeCount":101},[],{"trials":12220,"activeCount":101},[],{"intervention":12222,"totalTrials":424,"cells":12223},"Efalizumab",{"EARLY_PHASE1":12224,"PHASE1":12226,"PHASE2":12228,"PHASE3":12237,"PHASE4":12239,"NA":12241},{"trials":12225,"activeCount":101},[],{"trials":12227,"activeCount":101},[],{"trials":12229,"activeCount":101},[12230],{"nctId":12231,"briefTitle":12232,"status":111,"phases":12233,"primaryCompletion":448,"completion":448,"start":10758,"enrollment":101,"conditions":12234,"interventions":12236},"NCT00777400","Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells",[90,91],[12235],"Autoimmune Diseases",[12222],{"trials":12238,"activeCount":101},[],{"trials":12240,"activeCount":101},[],{"trials":12242,"activeCount":101},[],{"intervention":12244,"totalTrials":424,"cells":12245},"AIJP",{"EARLY_PHASE1":12246,"PHASE1":12248,"PHASE2":12250,"PHASE3":12261,"PHASE4":12263,"NA":12265},{"trials":12247,"activeCount":101},[],{"trials":12249,"activeCount":101},[],{"trials":12251,"activeCount":101},[12252],{"nctId":12253,"briefTitle":12254,"status":132,"phases":12255,"primaryCompletion":12256,"completion":12256,"start":12257,"enrollment":1633,"conditions":12258,"interventions":12260},"NCT00622440","Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream",[91],"2012-12-12","2008-05-14",[12259],"Anus Neoplasms",[12244],{"trials":12262,"activeCount":101},[],{"trials":12264,"activeCount":101},[],{"trials":12266,"activeCount":101},[],{"intervention":12268,"totalTrials":424,"cells":12269},"Doxil, melphalan, bortezomib",{"EARLY_PHASE1":12270,"PHASE1":12272,"PHASE2":12274,"PHASE3":12286,"PHASE4":12288,"NA":12290},{"trials":12271,"activeCount":101},[],{"trials":12273,"activeCount":101},[],{"trials":12275,"activeCount":101},[12276],{"nctId":12277,"briefTitle":12278,"status":120,"phases":12279,"primaryCompletion":12280,"completion":12281,"start":12282,"enrollment":4019,"conditions":12283,"interventions":12285},"NCT00985907","Doxil® + Melphalan + Velcade (DMV) in Relapsed\u002FRefractory Multiple Myeloma",[90,91],"2008-10-07","2010-01-12","2004-10-28",[11776,12284],"Patient Participation",[12268],{"trials":12287,"activeCount":101},[],{"trials":12289,"activeCount":101},[],{"trials":12291,"activeCount":101},[],{"intervention":3456,"totalTrials":424,"cells":12293},{"EARLY_PHASE1":12294,"PHASE1":12296,"PHASE2":12298,"PHASE3":12304,"PHASE4":12306,"NA":12308},{"trials":12295,"activeCount":101},[],{"trials":12297,"activeCount":101},[],{"trials":12299,"activeCount":101},[12300],{"nctId":3447,"briefTitle":3448,"status":132,"phases":12301,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":1202,"conditions":12302,"interventions":12303},[91],[3454],[2896,3456],{"trials":12305,"activeCount":101},[],{"trials":12307,"activeCount":101},[],{"trials":12309,"activeCount":101},[],{"intervention":687,"totalTrials":424,"cells":12311},{"EARLY_PHASE1":12312,"PHASE1":12314,"PHASE2":12316,"PHASE3":12322,"PHASE4":12324,"NA":12326},{"trials":12313,"activeCount":101},[],{"trials":12315,"activeCount":101},[],{"trials":12317,"activeCount":101},[12318],{"nctId":670,"briefTitle":671,"status":132,"phases":12319,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":12320,"interventions":12321},[91],[677,678,679,680,681],[683,684,661,685,686,687],{"trials":12323,"activeCount":101},[],{"trials":12325,"activeCount":101},[],{"trials":12327,"activeCount":101},[],{"intervention":12329,"totalTrials":424,"cells":12330},"PD 0332991",{"EARLY_PHASE1":12331,"PHASE1":12333,"PHASE2":12335,"PHASE3":12345,"PHASE4":12347,"NA":12349},{"trials":12332,"activeCount":101},[],{"trials":12334,"activeCount":101},[],{"trials":12336,"activeCount":101},[12337],{"nctId":12338,"briefTitle":12339,"status":120,"phases":12340,"primaryCompletion":7097,"completion":7097,"start":12341,"enrollment":1246,"conditions":12342,"interventions":12344},"NCT01227434","A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma",[91],"2010-09",[3765,3821,12343],"Anaplastic Astrocytoma",[12329,12329],{"trials":12346,"activeCount":101},[],{"trials":12348,"activeCount":101},[],{"trials":12350,"activeCount":101},[],{"intervention":12352,"totalTrials":424,"cells":12353},"Pregabalin",{"EARLY_PHASE1":12354,"PHASE1":12356,"PHASE2":12358,"PHASE3":12368,"PHASE4":12370,"NA":12372},{"trials":12355,"activeCount":101},[],{"trials":12357,"activeCount":101},[],{"trials":12359,"activeCount":101},[12360],{"nctId":12361,"briefTitle":12362,"status":120,"phases":12363,"primaryCompletion":8859,"completion":8859,"start":7694,"enrollment":510,"conditions":12364,"interventions":12367},"NCT00352651","Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo",[91],[12365,12366],"Herpes Zoster","Postherpetic Neuralgia",[12352],{"trials":12369,"activeCount":101},[],{"trials":12371,"activeCount":101},[],{"trials":12373,"activeCount":101},[],{"intervention":9600,"totalTrials":424,"cells":12375},{"EARLY_PHASE1":12376,"PHASE1":12378,"PHASE2":12380,"PHASE3":12386,"PHASE4":12388,"NA":12390},{"trials":12377,"activeCount":101},[],{"trials":12379,"activeCount":101},[],{"trials":12381,"activeCount":101},[12382],{"nctId":9595,"briefTitle":9596,"status":132,"phases":12383,"primaryCompletion":6765,"completion":6765,"start":714,"enrollment":3797,"conditions":12384,"interventions":12385},[90,91],[2939],[9600,9522],{"trials":12387,"activeCount":101},[],{"trials":12389,"activeCount":101},[],{"trials":12391,"activeCount":101},[],{"intervention":11464,"totalTrials":424,"cells":12393},{"EARLY_PHASE1":12394,"PHASE1":12396,"PHASE2":12398,"PHASE3":12404,"PHASE4":12406,"NA":12408},{"trials":12395,"activeCount":101},[],{"trials":12397,"activeCount":101},[],{"trials":12399,"activeCount":101},[12400],{"nctId":11458,"briefTitle":11459,"status":132,"phases":12401,"primaryCompletion":10926,"completion":10926,"start":2773,"enrollment":1914,"conditions":12402,"interventions":12403},[91],[11462,3821],[3823,11464],{"trials":12405,"activeCount":101},[],{"trials":12407,"activeCount":101},[],{"trials":12409,"activeCount":101},[],{"intervention":12411,"totalTrials":424,"cells":12412},"Gallium Ga 68-Edotreotide",{"EARLY_PHASE1":12413,"PHASE1":12415,"PHASE2":12417,"PHASE3":12429,"PHASE4":12431,"NA":12433},{"trials":12414,"activeCount":101},[],{"trials":12416,"activeCount":101},[],{"trials":12418,"activeCount":101},[12419],{"nctId":12420,"briefTitle":12421,"status":120,"phases":12422,"primaryCompletion":12423,"completion":12423,"start":2371,"enrollment":12424,"conditions":12425,"interventions":12428},"NCT02177773","GA-68 DOTA-TOC of Somatostatin Positive Malignancies",[90,91],"2017-08-07",300,[813,12426,12427,11678],"Paraganglioma","Carcinoid Tumors",[12411],{"trials":12430,"activeCount":101},[],{"trials":12432,"activeCount":101},[],{"trials":12434,"activeCount":101},[],{"intervention":12436,"totalTrials":424,"cells":12437},"Heart failure polypill",{"EARLY_PHASE1":12438,"PHASE1":12440,"PHASE2":12442,"PHASE3":12455,"PHASE4":12457,"NA":12459},{"trials":12439,"activeCount":101},[],{"trials":12441,"activeCount":101},[],{"trials":12443,"activeCount":101},[12444],{"nctId":12445,"briefTitle":12446,"status":132,"phases":12447,"primaryCompletion":12448,"completion":12449,"start":12450,"enrollment":675,"conditions":12451,"interventions":12453},"NCT06029712","Heart Failure Polypill at a Safety Net Hospital",[91],"2024-09-17","2025-01-29","2024-02-27",[12452,18],"Heart Failure With Reduced Ejection Fraction",[12436,12454],"Control Rx",{"trials":12456,"activeCount":101},[],{"trials":12458,"activeCount":101},[],{"trials":12460,"activeCount":101},[],{"intervention":12454,"totalTrials":424,"cells":12462},{"EARLY_PHASE1":12463,"PHASE1":12465,"PHASE2":12467,"PHASE3":12473,"PHASE4":12475,"NA":12477},{"trials":12464,"activeCount":101},[],{"trials":12466,"activeCount":101},[],{"trials":12468,"activeCount":101},[12469],{"nctId":12445,"briefTitle":12446,"status":132,"phases":12470,"primaryCompletion":12448,"completion":12449,"start":12450,"enrollment":675,"conditions":12471,"interventions":12472},[91],[12452,18],[12436,12454],{"trials":12474,"activeCount":101},[],{"trials":12476,"activeCount":101},[],{"trials":12478,"activeCount":101},[],{"intervention":12480,"totalTrials":424,"cells":12481},"dexamethasone 0.5mg\u002F5ml solution",{"EARLY_PHASE1":12482,"PHASE1":12484,"PHASE2":12486,"PHASE3":12501,"PHASE4":12503,"NA":12505},{"trials":12483,"activeCount":101},[],{"trials":12485,"activeCount":101},[],{"trials":12487,"activeCount":101},[12488],{"nctId":12489,"briefTitle":12490,"status":132,"phases":12491,"primaryCompletion":12492,"completion":12492,"start":12493,"enrollment":1183,"conditions":12494,"interventions":12499},"NCT04540133","Dexamethasone Solution and Dexamethasone in Mucolox™",[91],"2023-01-06","2020-12-26",[12495,12496,12497,12498],"Oral Lichen Planus","Mucous Membrane Pemphigoid","Pemphigus Vulgaris","Chronic Graft-versus-host-disease",[12480,12500],"dexamethasone 0.5mg\u002F5ml solution in Mucolox™",{"trials":12502,"activeCount":101},[],{"trials":12504,"activeCount":101},[],{"trials":12506,"activeCount":101},[],{"intervention":12500,"totalTrials":424,"cells":12508},{"EARLY_PHASE1":12509,"PHASE1":12511,"PHASE2":12513,"PHASE3":12519,"PHASE4":12521,"NA":12523},{"trials":12510,"activeCount":101},[],{"trials":12512,"activeCount":101},[],{"trials":12514,"activeCount":101},[12515],{"nctId":12489,"briefTitle":12490,"status":132,"phases":12516,"primaryCompletion":12492,"completion":12492,"start":12493,"enrollment":1183,"conditions":12517,"interventions":12518},[91],[12495,12496,12497,12498],[12480,12500],{"trials":12520,"activeCount":101},[],{"trials":12522,"activeCount":101},[],{"trials":12524,"activeCount":101},[],{"intervention":12526,"totalTrials":424,"cells":12527},"nonavalent human papillomavirus vaccine",{"EARLY_PHASE1":12528,"PHASE1":12530,"PHASE2":12532,"PHASE3":12546,"PHASE4":12548,"NA":12550},{"trials":12529,"activeCount":101},[],{"trials":12531,"activeCount":101},[],{"trials":12533,"activeCount":101},[12534],{"nctId":12535,"briefTitle":12536,"status":132,"phases":12537,"primaryCompletion":2948,"completion":2948,"start":12538,"enrollment":526,"conditions":12539,"interventions":12545},"NCT05087849","Intralesional HPV Vaccine for Condylomata",[90,91],"2022-04-15",[12540,12541,12542,12543,12544],"Human Papilloma Virus","Warts","Warts, Genital","Condyloma","Condylomata Acuminata",[12526],{"trials":12547,"activeCount":101},[],{"trials":12549,"activeCount":101},[],{"trials":12551,"activeCount":101},[],{"intervention":12553,"totalTrials":424,"cells":12554},"Intrauterine infusion of platelet rich plasma",{"EARLY_PHASE1":12555,"PHASE1":12557,"PHASE2":12559,"PHASE3":12568,"PHASE4":12570,"NA":12572},{"trials":12556,"activeCount":101},[],{"trials":12558,"activeCount":101},[],{"trials":12560,"activeCount":101},[12561],{"nctId":12562,"briefTitle":12563,"status":120,"phases":12564,"primaryCompletion":6080,"completion":6080,"start":6568,"enrollment":3567,"conditions":12565,"interventions":12567},"NCT02825849","Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair",[91],[2809,12566],"Asherman's Syndrome",[12553],{"trials":12569,"activeCount":101},[],{"trials":12571,"activeCount":101},[],{"trials":12573,"activeCount":101},[],{"intervention":12575,"totalTrials":424,"cells":12576},"Goserelin Acetate",{"EARLY_PHASE1":12577,"PHASE1":12579,"PHASE2":12581,"PHASE3":12593,"PHASE4":12595,"NA":12597},{"trials":12578,"activeCount":101},[],{"trials":12580,"activeCount":101},[],{"trials":12582,"activeCount":101},[12583],{"nctId":12584,"briefTitle":12585,"status":120,"phases":12586,"primaryCompletion":12587,"completion":12587,"start":12588,"enrollment":9974,"conditions":12589,"interventions":12590},"NCT02168062","Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer",[91],"2018-05-22","2014-06-16",[3424],[12575,12591,12592],"Leuprolide Acetate","Triptorelin Pamoate",{"trials":12594,"activeCount":101},[],{"trials":12596,"activeCount":101},[],{"trials":12598,"activeCount":101},[],{"intervention":12591,"totalTrials":424,"cells":12600},{"EARLY_PHASE1":12601,"PHASE1":12603,"PHASE2":12605,"PHASE3":12611,"PHASE4":12613,"NA":12615},{"trials":12602,"activeCount":101},[],{"trials":12604,"activeCount":101},[],{"trials":12606,"activeCount":101},[12607],{"nctId":12584,"briefTitle":12585,"status":120,"phases":12608,"primaryCompletion":12587,"completion":12587,"start":12588,"enrollment":9974,"conditions":12609,"interventions":12610},[91],[3424],[12575,12591,12592],{"trials":12612,"activeCount":101},[],{"trials":12614,"activeCount":101},[],{"trials":12616,"activeCount":101},[],{"intervention":12592,"totalTrials":424,"cells":12618},{"EARLY_PHASE1":12619,"PHASE1":12621,"PHASE2":12623,"PHASE3":12629,"PHASE4":12631,"NA":12633},{"trials":12620,"activeCount":101},[],{"trials":12622,"activeCount":101},[],{"trials":12624,"activeCount":101},[12625],{"nctId":12584,"briefTitle":12585,"status":120,"phases":12626,"primaryCompletion":12587,"completion":12587,"start":12588,"enrollment":9974,"conditions":12627,"interventions":12628},[91],[3424],[12575,12591,12592],{"trials":12630,"activeCount":101},[],{"trials":12632,"activeCount":101},[],{"trials":12634,"activeCount":101},[],{"intervention":5707,"totalTrials":424,"cells":12636},{"EARLY_PHASE1":12637,"PHASE1":12639,"PHASE2":12641,"PHASE3":12647,"PHASE4":12649,"NA":12651},{"trials":12638,"activeCount":101},[],{"trials":12640,"activeCount":101},[],{"trials":12642,"activeCount":101},[12643],{"nctId":5697,"briefTitle":5698,"status":132,"phases":12644,"primaryCompletion":5700,"completion":5700,"start":5701,"enrollment":22,"conditions":12645,"interventions":12646},[90,91],[5703,5704,5705],[5707,2382],{"trials":12648,"activeCount":101},[],{"trials":12650,"activeCount":101},[],{"trials":12652,"activeCount":101},[],{"intervention":12654,"totalTrials":424,"cells":12655},"Apalutamide",{"EARLY_PHASE1":12656,"PHASE1":12658,"PHASE2":12660,"PHASE3":12672,"PHASE4":12674,"NA":12676},{"trials":12657,"activeCount":101},[],{"trials":12659,"activeCount":101},[],{"trials":12661,"activeCount":101},[12662],{"nctId":12663,"briefTitle":12664,"status":132,"phases":12665,"primaryCompletion":57,"completion":12666,"start":12667,"enrollment":695,"conditions":12668,"interventions":12671},"NCT03503344","Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer",[91],"2025-10-31","2019-12-17",[3421,3422,12669,12670],"PSA Progression","Stage IV Prostate Adenocarcinoma AJCC v7",[12654],{"trials":12673,"activeCount":101},[],{"trials":12675,"activeCount":101},[],{"trials":12677,"activeCount":101},[],{"intervention":12679,"totalTrials":424,"cells":12680},"Abiraterone acetate",{"EARLY_PHASE1":12681,"PHASE1":12683,"PHASE2":12685,"PHASE3":12696,"PHASE4":12698,"NA":12700},{"trials":12682,"activeCount":101},[],{"trials":12684,"activeCount":101},[],{"trials":12686,"activeCount":101},[12687],{"nctId":12688,"briefTitle":12689,"status":132,"phases":12690,"primaryCompletion":12691,"completion":12692,"start":12693,"enrollment":25,"conditions":12694,"interventions":12695},"NCT01199146","Abiraterone Post Ketoconazole for Prostate Cancer",[91],"2013-01-04","2016-03-14","2010-09-10",[21],[12679],{"trials":12697,"activeCount":101},[],{"trials":12699,"activeCount":101},[],{"trials":12701,"activeCount":101},[],{"intervention":12703,"totalTrials":424,"cells":12704},"Oral-B Mouth Sore mouthwash",{"EARLY_PHASE1":12705,"PHASE1":12707,"PHASE2":12709,"PHASE3":12730,"PHASE4":12732,"NA":12734},{"trials":12706,"activeCount":101},[],{"trials":12708,"activeCount":101},[],{"trials":12710,"activeCount":101},[12711],{"nctId":12712,"briefTitle":12713,"status":120,"phases":12714,"primaryCompletion":12715,"completion":12715,"start":12716,"enrollment":12717,"conditions":12718,"interventions":12725},"NCT04409873","Antiseptic Mouthwash \u002F Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)",[91],"2022-09-10","2021-03-31",54,[12719,12720,12721,12722,12723,12724],"COVID-19","SARS-CoV 2","Severe Acute Respiratory Syndrome Coronavirus 2","Virus Disease","Coronavirus Infections","Pharyngeal Diseases",[12703,12726,12727,12728,12729],"Crest Pro-Health Multi-Protection mouthwash","CloSYS Ultra Sensitive Rinse mouthwash","Distilled water","Listerine Zero Mouthwash Product",{"trials":12731,"activeCount":101},[],{"trials":12733,"activeCount":101},[],{"trials":12735,"activeCount":101},[],{"intervention":12726,"totalTrials":424,"cells":12737},{"EARLY_PHASE1":12738,"PHASE1":12740,"PHASE2":12742,"PHASE3":12748,"PHASE4":12750,"NA":12752},{"trials":12739,"activeCount":101},[],{"trials":12741,"activeCount":101},[],{"trials":12743,"activeCount":101},[12744],{"nctId":12712,"briefTitle":12713,"status":120,"phases":12745,"primaryCompletion":12715,"completion":12715,"start":12716,"enrollment":12717,"conditions":12746,"interventions":12747},[91],[12719,12720,12721,12722,12723,12724],[12703,12726,12727,12728,12729],{"trials":12749,"activeCount":101},[],{"trials":12751,"activeCount":101},[],{"trials":12753,"activeCount":101},[],{"intervention":12727,"totalTrials":424,"cells":12755},{"EARLY_PHASE1":12756,"PHASE1":12758,"PHASE2":12760,"PHASE3":12766,"PHASE4":12768,"NA":12770},{"trials":12757,"activeCount":101},[],{"trials":12759,"activeCount":101},[],{"trials":12761,"activeCount":101},[12762],{"nctId":12712,"briefTitle":12713,"status":120,"phases":12763,"primaryCompletion":12715,"completion":12715,"start":12716,"enrollment":12717,"conditions":12764,"interventions":12765},[91],[12719,12720,12721,12722,12723,12724],[12703,12726,12727,12728,12729],{"trials":12767,"activeCount":101},[],{"trials":12769,"activeCount":101},[],{"trials":12771,"activeCount":101},[],{"intervention":12728,"totalTrials":424,"cells":12773},{"EARLY_PHASE1":12774,"PHASE1":12776,"PHASE2":12778,"PHASE3":12784,"PHASE4":12786,"NA":12788},{"trials":12775,"activeCount":101},[],{"trials":12777,"activeCount":101},[],{"trials":12779,"activeCount":101},[12780],{"nctId":12712,"briefTitle":12713,"status":120,"phases":12781,"primaryCompletion":12715,"completion":12715,"start":12716,"enrollment":12717,"conditions":12782,"interventions":12783},[91],[12719,12720,12721,12722,12723,12724],[12703,12726,12727,12728,12729],{"trials":12785,"activeCount":101},[],{"trials":12787,"activeCount":101},[],{"trials":12789,"activeCount":101},[],{"intervention":12729,"totalTrials":424,"cells":12791},{"EARLY_PHASE1":12792,"PHASE1":12794,"PHASE2":12796,"PHASE3":12802,"PHASE4":12804,"NA":12806},{"trials":12793,"activeCount":101},[],{"trials":12795,"activeCount":101},[],{"trials":12797,"activeCount":101},[12798],{"nctId":12712,"briefTitle":12713,"status":120,"phases":12799,"primaryCompletion":12715,"completion":12715,"start":12716,"enrollment":12717,"conditions":12800,"interventions":12801},[91],[12719,12720,12721,12722,12723,12724],[12703,12726,12727,12728,12729],{"trials":12803,"activeCount":101},[],{"trials":12805,"activeCount":101},[],{"trials":12807,"activeCount":101},[],{"intervention":12809,"totalTrials":424,"cells":12810},"Betamethasone",{"EARLY_PHASE1":12811,"PHASE1":12813,"PHASE2":12815,"PHASE3":12824,"PHASE4":12826,"NA":12828},{"trials":12812,"activeCount":101},[],{"trials":12814,"activeCount":101},[],{"trials":12816,"activeCount":101},[12817],{"nctId":12818,"briefTitle":12819,"status":120,"phases":12820,"primaryCompletion":673,"completion":673,"start":3696,"enrollment":424,"conditions":12821,"interventions":12823},"NCT00670956","Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)",[90,91],[12822],"Congenital Cystic Adenomatoid Malformation",[12809],{"trials":12825,"activeCount":101},[],{"trials":12827,"activeCount":101},[],{"trials":12829,"activeCount":101},[],{"intervention":11513,"totalTrials":424,"cells":12831},{"EARLY_PHASE1":12832,"PHASE1":12834,"PHASE2":12836,"PHASE3":12842,"PHASE4":12844,"NA":12846},{"trials":12833,"activeCount":101},[],{"trials":12835,"activeCount":101},[],{"trials":12837,"activeCount":101},[12838],{"nctId":11506,"briefTitle":11507,"status":132,"phases":12839,"primaryCompletion":11509,"completion":4214,"start":11510,"enrollment":434,"conditions":12840,"interventions":12841},[91],[21],[11513,3576],{"trials":12843,"activeCount":101},[],{"trials":12845,"activeCount":101},[],{"trials":12847,"activeCount":101},[],{"intervention":12849,"totalTrials":424,"cells":12850},"Spironolactone 100mg",{"EARLY_PHASE1":12851,"PHASE1":12853,"PHASE2":12855,"PHASE3":12866,"PHASE4":12868,"NA":12870},{"trials":12852,"activeCount":101},[],{"trials":12854,"activeCount":101},[],{"trials":12856,"activeCount":101},[12857],{"nctId":12858,"briefTitle":12859,"status":132,"phases":12860,"primaryCompletion":12861,"completion":12861,"start":12862,"enrollment":1060,"conditions":12863,"interventions":12865},"NCT03576755","Spironolactone Therapy In Young Women With NASH",[90,91],"2023-07-05","2019-01-09",[12864],"NASH - Nonalcoholic Steatohepatitis",[12849],{"trials":12867,"activeCount":101},[],{"trials":12869,"activeCount":101},[],{"trials":12871,"activeCount":101},[],{"intervention":12873,"totalTrials":424,"cells":12874},"LZD",{"EARLY_PHASE1":12875,"PHASE1":12877,"PHASE2":12879,"PHASE3":12892,"PHASE4":12894,"NA":12896},{"trials":12876,"activeCount":101},[],{"trials":12878,"activeCount":101},[],{"trials":12880,"activeCount":101},[12881],{"nctId":12882,"briefTitle":12883,"status":132,"phases":12884,"primaryCompletion":12861,"completion":12885,"start":12886,"enrollment":28,"conditions":12887,"interventions":12889},"NCT04021121","Adjunctive Linezolid for the Treatment of Tuberculous Meningitis",[91],"2023-12-04","2021-05-05",[12888],"Tuberculosis, Meningeal",[12873,12890,12891],"High dose RIF","Standard dose RIF",{"trials":12893,"activeCount":101},[],{"trials":12895,"activeCount":101},[],{"trials":12897,"activeCount":101},[],{"intervention":12890,"totalTrials":424,"cells":12899},{"EARLY_PHASE1":12900,"PHASE1":12902,"PHASE2":12904,"PHASE3":12910,"PHASE4":12912,"NA":12914},{"trials":12901,"activeCount":101},[],{"trials":12903,"activeCount":101},[],{"trials":12905,"activeCount":101},[12906],{"nctId":12882,"briefTitle":12883,"status":132,"phases":12907,"primaryCompletion":12861,"completion":12885,"start":12886,"enrollment":28,"conditions":12908,"interventions":12909},[91],[12888],[12873,12890,12891],{"trials":12911,"activeCount":101},[],{"trials":12913,"activeCount":101},[],{"trials":12915,"activeCount":101},[],{"intervention":12891,"totalTrials":424,"cells":12917},{"EARLY_PHASE1":12918,"PHASE1":12920,"PHASE2":12922,"PHASE3":12928,"PHASE4":12930,"NA":12932},{"trials":12919,"activeCount":101},[],{"trials":12921,"activeCount":101},[],{"trials":12923,"activeCount":101},[12924],{"nctId":12882,"briefTitle":12883,"status":132,"phases":12925,"primaryCompletion":12861,"completion":12885,"start":12886,"enrollment":28,"conditions":12926,"interventions":12927},[91],[12888],[12873,12890,12891],{"trials":12929,"activeCount":101},[],{"trials":12931,"activeCount":101},[],{"trials":12933,"activeCount":101},[],{"intervention":12935,"totalTrials":424,"cells":12936},"NSAID",{"EARLY_PHASE1":12937,"PHASE1":12939,"PHASE2":12941,"PHASE3":12953,"PHASE4":12955,"NA":12957},{"trials":12938,"activeCount":101},[],{"trials":12940,"activeCount":101},[],{"trials":12942,"activeCount":101},[12943],{"nctId":12944,"briefTitle":12945,"status":132,"phases":12946,"primaryCompletion":6749,"completion":6749,"start":7097,"enrollment":12947,"conditions":12948,"interventions":12952},"NCT01958320","Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus",[91],202,[12949,992,12950,12951],"Patent Ductus Arteriosus","Necrotizing Enterocolitis","Intestinal Perforation",[12935],{"trials":12954,"activeCount":101},[],{"trials":12956,"activeCount":101},[],{"trials":12958,"activeCount":101},[],{"intervention":2498,"totalTrials":424,"cells":12960},{"EARLY_PHASE1":12961,"PHASE1":12963,"PHASE2":12965,"PHASE3":12971,"PHASE4":12973,"NA":12975},{"trials":12962,"activeCount":101},[],{"trials":12964,"activeCount":101},[],{"trials":12966,"activeCount":101},[12967],{"nctId":2492,"briefTitle":2493,"status":132,"phases":12968,"primaryCompletion":205,"completion":205,"start":433,"enrollment":2495,"conditions":12969,"interventions":12970},[91],[322],[938,2498,2499,2500,2501],{"trials":12972,"activeCount":101},[],{"trials":12974,"activeCount":101},[],{"trials":12976,"activeCount":101},[],{"intervention":2499,"totalTrials":424,"cells":12978},{"EARLY_PHASE1":12979,"PHASE1":12981,"PHASE2":12983,"PHASE3":12989,"PHASE4":12991,"NA":12993},{"trials":12980,"activeCount":101},[],{"trials":12982,"activeCount":101},[],{"trials":12984,"activeCount":101},[12985],{"nctId":2492,"briefTitle":2493,"status":132,"phases":12986,"primaryCompletion":205,"completion":205,"start":433,"enrollment":2495,"conditions":12987,"interventions":12988},[91],[322],[938,2498,2499,2500,2501],{"trials":12990,"activeCount":101},[],{"trials":12992,"activeCount":101},[],{"trials":12994,"activeCount":101},[],{"intervention":2501,"totalTrials":424,"cells":12996},{"EARLY_PHASE1":12997,"PHASE1":12999,"PHASE2":13001,"PHASE3":13007,"PHASE4":13009,"NA":13011},{"trials":12998,"activeCount":101},[],{"trials":13000,"activeCount":101},[],{"trials":13002,"activeCount":101},[13003],{"nctId":2492,"briefTitle":2493,"status":132,"phases":13004,"primaryCompletion":205,"completion":205,"start":433,"enrollment":2495,"conditions":13005,"interventions":13006},[91],[322],[938,2498,2499,2500,2501],{"trials":13008,"activeCount":101},[],{"trials":13010,"activeCount":101},[],{"trials":13012,"activeCount":101},[],{"intervention":13014,"totalTrials":424,"cells":13015},"5-Aminolevuline Acid",{"EARLY_PHASE1":13016,"PHASE1":13018,"PHASE2":13020,"PHASE3":13030,"PHASE4":13032,"NA":13034},{"trials":13017,"activeCount":101},[],{"trials":13019,"activeCount":101},[],{"trials":13021,"activeCount":101},[13022],{"nctId":13023,"briefTitle":13024,"status":120,"phases":13025,"primaryCompletion":13026,"completion":6348,"start":6052,"enrollment":13027,"conditions":13028,"interventions":13029},"NCT01116661","Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain",[91],"2017-12-28",199,[6028],[13014],{"trials":13031,"activeCount":101},[],{"trials":13033,"activeCount":101},[],{"trials":13035,"activeCount":101},[],{"intervention":13037,"totalTrials":424,"cells":13038},"Sirolimus",{"EARLY_PHASE1":13039,"PHASE1":13041,"PHASE2":13043,"PHASE3":13053,"PHASE4":13055,"NA":13057},{"trials":13040,"activeCount":101},[],{"trials":13042,"activeCount":101},[],{"trials":13044,"activeCount":101},[13045],{"nctId":13046,"briefTitle":13047,"status":111,"phases":13048,"primaryCompletion":6051,"completion":6051,"start":6117,"enrollment":101,"conditions":13049,"interventions":13052},"NCT02177760","Sirolimus Prophylaxis for aGVHD in TME SCID",[91],[4822,13050,13051],"Transplacental Maternal Engraftment","Stem Cell Transplant",[13037],{"trials":13054,"activeCount":101},[],{"trials":13056,"activeCount":101},[],{"trials":13058,"activeCount":101},[],{"intervention":13060,"totalTrials":424,"cells":13061},"Galcanezumab Prefilled Syringe",{"EARLY_PHASE1":13062,"PHASE1":13064,"PHASE2":13066,"PHASE3":13077,"PHASE4":13079,"NA":13081},{"trials":13063,"activeCount":101},[],{"trials":13065,"activeCount":101},[],{"trials":13067,"activeCount":101},[13068],{"nctId":13069,"briefTitle":13070,"status":132,"phases":13071,"primaryCompletion":13072,"completion":13072,"start":13073,"enrollment":28,"conditions":13074,"interventions":13076},"NCT04417361","Galcanezumab for Vestibular Migraine",[91],"2023-09-29","2020-09-18",[13075],"Vestibular Migraine",[13060],{"trials":13078,"activeCount":101},[],{"trials":13080,"activeCount":101},[],{"trials":13082,"activeCount":101},[],{"intervention":10953,"totalTrials":424,"cells":13084},{"EARLY_PHASE1":13085,"PHASE1":13087,"PHASE2":13089,"PHASE3":13095,"PHASE4":13097,"NA":13099},{"trials":13086,"activeCount":101},[],{"trials":13088,"activeCount":101},[],{"trials":13090,"activeCount":101},[13091],{"nctId":10946,"briefTitle":10947,"status":132,"phases":13092,"primaryCompletion":10949,"completion":10949,"start":10950,"enrollment":2335,"conditions":13093,"interventions":13094},[91],[811,5733,10914],[10953,5738,10917],{"trials":13096,"activeCount":101},[],{"trials":13098,"activeCount":101},[],{"trials":13100,"activeCount":101},[],{"intervention":13102,"totalTrials":424,"cells":13103},"VPA FEC100",{"EARLY_PHASE1":13104,"PHASE1":13106,"PHASE2":13108,"PHASE3":13119,"PHASE4":13121,"NA":13123},{"trials":13105,"activeCount":101},[],{"trials":13107,"activeCount":101},[],{"trials":13109,"activeCount":101},[13110],{"nctId":13111,"briefTitle":13112,"status":120,"phases":13113,"primaryCompletion":13114,"completion":13115,"start":13116,"enrollment":2564,"conditions":13117,"interventions":13118},"NCT01010854","Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer",[91],"2010-12-12","2011-07-29","2008-12-10",[24],[13102],{"trials":13120,"activeCount":101},[],{"trials":13122,"activeCount":101},[],{"trials":13124,"activeCount":101},[],{"intervention":11542,"totalTrials":424,"cells":13126},{"EARLY_PHASE1":13127,"PHASE1":13129,"PHASE2":13131,"PHASE3":13137,"PHASE4":13139,"NA":13141},{"trials":13128,"activeCount":101},[],{"trials":13130,"activeCount":101},[],{"trials":13132,"activeCount":101},[13133],{"nctId":11534,"briefTitle":11535,"status":120,"phases":13134,"primaryCompletion":11537,"completion":11538,"start":11539,"enrollment":498,"conditions":13135,"interventions":13136},[91],[3482],[11542,11525],{"trials":13138,"activeCount":101},[],{"trials":13140,"activeCount":101},[],{"trials":13142,"activeCount":101},[],{"intervention":13144,"totalTrials":424,"cells":13145},"Tissue Selective Estrogen Complex",{"EARLY_PHASE1":13146,"PHASE1":13148,"PHASE2":13150,"PHASE3":13160,"PHASE4":13162,"NA":13164},{"trials":13147,"activeCount":101},[],{"trials":13149,"activeCount":101},[],{"trials":13151,"activeCount":101},[13152],{"nctId":13153,"briefTitle":13154,"status":132,"phases":13155,"primaryCompletion":13156,"completion":13156,"start":806,"enrollment":1202,"conditions":13157,"interventions":13159},"NCT02710214","A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis",[91],"2019-04-24",[13158,765],"Menopause",[13144],{"trials":13161,"activeCount":101},[],{"trials":13163,"activeCount":101},[],{"trials":13165,"activeCount":101},[],{"intervention":13167,"totalTrials":424,"cells":13168},"LACTIN-V",{"EARLY_PHASE1":13169,"PHASE1":13171,"PHASE2":13173,"PHASE3":13183,"PHASE4":13185,"NA":13187},{"trials":13170,"activeCount":101},[],{"trials":13172,"activeCount":101},[],{"trials":13174,"activeCount":101},[13175],{"nctId":13176,"briefTitle":13177,"status":132,"phases":13178,"primaryCompletion":13179,"completion":13179,"start":9397,"enrollment":4043,"conditions":13180,"interventions":13182},"NCT05022212","Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition",[91],"2023-03-31",[13181,18],"Bacterial Vaginosis",[13167],{"trials":13184,"activeCount":101},[],{"trials":13186,"activeCount":101},[],{"trials":13188,"activeCount":101},[],{"intervention":13190,"totalTrials":424,"cells":13191},"anakinra",{"EARLY_PHASE1":13192,"PHASE1":13194,"PHASE2":13196,"PHASE3":13205,"PHASE4":13207,"NA":13209},{"trials":13193,"activeCount":101},[],{"trials":13195,"activeCount":101},[],{"trials":13197,"activeCount":101},[13198],{"nctId":13199,"briefTitle":13200,"status":132,"phases":13201,"primaryCompletion":3818,"completion":3648,"start":12170,"enrollment":2564,"conditions":13202,"interventions":13204},"NCT01516749","Anakinra as a Treatment for Hydradenitis Suppurativa",[91],[13203],"Hidradenitis Suppurativa",[13190],{"trials":13206,"activeCount":101},[],{"trials":13208,"activeCount":101},[],{"trials":13210,"activeCount":101},[],{"intervention":13212,"totalTrials":424,"cells":13213},"Chlorhexidine",{"EARLY_PHASE1":13214,"PHASE1":13216,"PHASE2":13218,"PHASE3":13230,"PHASE4":13232,"NA":13234},{"trials":13215,"activeCount":101},[],{"trials":13217,"activeCount":101},[],{"trials":13219,"activeCount":101},[13220],{"nctId":13221,"briefTitle":13222,"status":132,"phases":13223,"primaryCompletion":13224,"completion":13224,"start":6357,"enrollment":6787,"conditions":13225,"interventions":13226},"NCT03484507","Parasitic Ulcer Treatment Trial Pilot",[91],"2022-11-15",[2938],[13212,13227,13228,13229,13228,13229],"Povidone-Iodine","Prednisolone Sodium Phosphate","Hydroxypropyl Methylcellulose",{"trials":13231,"activeCount":101},[],{"trials":13233,"activeCount":101},[],{"trials":13235,"activeCount":101},[],{"intervention":13227,"totalTrials":424,"cells":13237},{"EARLY_PHASE1":13238,"PHASE1":13240,"PHASE2":13242,"PHASE3":13248,"PHASE4":13250,"NA":13252},{"trials":13239,"activeCount":101},[],{"trials":13241,"activeCount":101},[],{"trials":13243,"activeCount":101},[13244],{"nctId":13221,"briefTitle":13222,"status":132,"phases":13245,"primaryCompletion":13224,"completion":13224,"start":6357,"enrollment":6787,"conditions":13246,"interventions":13247},[91],[2938],[13212,13227,13228,13229,13228,13229],{"trials":13249,"activeCount":101},[],{"trials":13251,"activeCount":101},[],{"trials":13253,"activeCount":101},[],{"intervention":13228,"totalTrials":424,"cells":13255},{"EARLY_PHASE1":13256,"PHASE1":13258,"PHASE2":13260,"PHASE3":13266,"PHASE4":13268,"NA":13270},{"trials":13257,"activeCount":101},[],{"trials":13259,"activeCount":101},[],{"trials":13261,"activeCount":101},[13262],{"nctId":13221,"briefTitle":13222,"status":132,"phases":13263,"primaryCompletion":13224,"completion":13224,"start":6357,"enrollment":6787,"conditions":13264,"interventions":13265},[91],[2938],[13212,13227,13228,13229,13228,13229],{"trials":13267,"activeCount":101},[],{"trials":13269,"activeCount":101},[],{"trials":13271,"activeCount":101},[],{"intervention":13229,"totalTrials":424,"cells":13273},{"EARLY_PHASE1":13274,"PHASE1":13276,"PHASE2":13278,"PHASE3":13284,"PHASE4":13286,"NA":13288},{"trials":13275,"activeCount":101},[],{"trials":13277,"activeCount":101},[],{"trials":13279,"activeCount":101},[13280],{"nctId":13221,"briefTitle":13222,"status":132,"phases":13281,"primaryCompletion":13224,"completion":13224,"start":6357,"enrollment":6787,"conditions":13282,"interventions":13283},[91],[2938],[13212,13227,13228,13229,13228,13229],{"trials":13285,"activeCount":101},[],{"trials":13287,"activeCount":101},[],{"trials":13289,"activeCount":101},[],{"intervention":6471,"totalTrials":424,"cells":13291},{"EARLY_PHASE1":13292,"PHASE1":13294,"PHASE2":13296,"PHASE3":13302,"PHASE4":13304,"NA":13306},{"trials":13293,"activeCount":101},[],{"trials":13295,"activeCount":101},[],{"trials":13297,"activeCount":101},[13298],{"nctId":6461,"briefTitle":6462,"status":120,"phases":13299,"primaryCompletion":6464,"completion":6464,"start":6465,"enrollment":407,"conditions":13300,"interventions":13301},[91],[6467,6468],[6470,6471,6452],{"trials":13303,"activeCount":101},[],{"trials":13305,"activeCount":101},[],{"trials":13307,"activeCount":101},[],{"intervention":13309,"totalTrials":424,"cells":13310},"7-hydroxystaurosporine",{"EARLY_PHASE1":13311,"PHASE1":13313,"PHASE2":13315,"PHASE3":13323,"PHASE4":13325,"NA":13327},{"trials":13312,"activeCount":101},[],{"trials":13314,"activeCount":101},[],{"trials":13316,"activeCount":101},[13317],{"nctId":13318,"briefTitle":13319,"status":2462,"phases":13320,"start":9487,"conditions":13321,"interventions":13322},"NCT00030888","UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer",[91],[2466],[13309],{"trials":13324,"activeCount":101},[],{"trials":13326,"activeCount":101},[],{"trials":13328,"activeCount":101},[],{"intervention":13330,"totalTrials":424,"cells":13331},"Carbon C 11 Choline",{"EARLY_PHASE1":13332,"PHASE1":13334,"PHASE2":13336,"PHASE3":13347,"PHASE4":13349,"NA":13351},{"trials":13333,"activeCount":101},[],{"trials":13335,"activeCount":101},[],{"trials":13337,"activeCount":101},[13338],{"nctId":13339,"briefTitle":13340,"status":132,"phases":13341,"primaryCompletion":13342,"completion":13342,"start":13343,"enrollment":5422,"conditions":13344,"interventions":13345},"NCT02397408","11C- and 18F-Choline PET\u002FMR Imaging for Prostate Cancer",[91],"2015-06-30","2015-04-09",[21],[13330,13346],"Fluorine F 18 Choline",{"trials":13348,"activeCount":101},[],{"trials":13350,"activeCount":101},[],{"trials":13352,"activeCount":101},[],{"intervention":13346,"totalTrials":424,"cells":13354},{"EARLY_PHASE1":13355,"PHASE1":13357,"PHASE2":13359,"PHASE3":13365,"PHASE4":13367,"NA":13369},{"trials":13356,"activeCount":101},[],{"trials":13358,"activeCount":101},[],{"trials":13360,"activeCount":101},[13361],{"nctId":13339,"briefTitle":13340,"status":132,"phases":13362,"primaryCompletion":13342,"completion":13342,"start":13343,"enrollment":5422,"conditions":13363,"interventions":13364},[91],[21],[13330,13346],{"trials":13366,"activeCount":101},[],{"trials":13368,"activeCount":101},[],{"trials":13370,"activeCount":101},[],{"intervention":13372,"totalTrials":424,"cells":13373},"Neratinib",{"EARLY_PHASE1":13374,"PHASE1":13376,"PHASE2":13378,"PHASE3":13399,"PHASE4":13401,"NA":13403},{"trials":13375,"activeCount":101},[],{"trials":13377,"activeCount":101},[],{"trials":13379,"activeCount":101},[13380],{"nctId":13381,"briefTitle":13382,"status":132,"phases":13383,"primaryCompletion":6492,"completion":6492,"start":13384,"enrollment":541,"conditions":13385,"interventions":13395},"NCT03094052","Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib",[91],"2018-10-09",[13386,13387,13388,13389,13390,13391,13392,13393,13394],"HER2-positive Breast Cancer","Breast Adenocarcinoma","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage IIIA Breast Cancer AJCC v7","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7",[13372,10933,13396,13397,13398],"Loperamide","Crofelemer","Diphenoxylate\u002FAtropine",{"trials":13400,"activeCount":101},[],{"trials":13402,"activeCount":101},[],{"trials":13404,"activeCount":101},[],{"intervention":13396,"totalTrials":424,"cells":13406},{"EARLY_PHASE1":13407,"PHASE1":13409,"PHASE2":13411,"PHASE3":13417,"PHASE4":13419,"NA":13421},{"trials":13408,"activeCount":101},[],{"trials":13410,"activeCount":101},[],{"trials":13412,"activeCount":101},[13413],{"nctId":13381,"briefTitle":13382,"status":132,"phases":13414,"primaryCompletion":6492,"completion":6492,"start":13384,"enrollment":541,"conditions":13415,"interventions":13416},[91],[13386,13387,13388,13389,13390,13391,13392,13393,13394],[13372,10933,13396,13397,13398],{"trials":13418,"activeCount":101},[],{"trials":13420,"activeCount":101},[],{"trials":13422,"activeCount":101},[],{"intervention":13397,"totalTrials":424,"cells":13424},{"EARLY_PHASE1":13425,"PHASE1":13427,"PHASE2":13429,"PHASE3":13435,"PHASE4":13437,"NA":13439},{"trials":13426,"activeCount":101},[],{"trials":13428,"activeCount":101},[],{"trials":13430,"activeCount":101},[13431],{"nctId":13381,"briefTitle":13382,"status":132,"phases":13432,"primaryCompletion":6492,"completion":6492,"start":13384,"enrollment":541,"conditions":13433,"interventions":13434},[91],[13386,13387,13388,13389,13390,13391,13392,13393,13394],[13372,10933,13396,13397,13398],{"trials":13436,"activeCount":101},[],{"trials":13438,"activeCount":101},[],{"trials":13440,"activeCount":101},[],{"intervention":13398,"totalTrials":424,"cells":13442},{"EARLY_PHASE1":13443,"PHASE1":13445,"PHASE2":13447,"PHASE3":13453,"PHASE4":13455,"NA":13457},{"trials":13444,"activeCount":101},[],{"trials":13446,"activeCount":101},[],{"trials":13448,"activeCount":101},[13449],{"nctId":13381,"briefTitle":13382,"status":132,"phases":13450,"primaryCompletion":6492,"completion":6492,"start":13384,"enrollment":541,"conditions":13451,"interventions":13452},[91],[13386,13387,13388,13389,13390,13391,13392,13393,13394],[13372,10933,13396,13397,13398],{"trials":13454,"activeCount":101},[],{"trials":13456,"activeCount":101},[],{"trials":13458,"activeCount":101},[],{"intervention":13460,"totalTrials":424,"cells":13461},"Avonex",{"EARLY_PHASE1":13462,"PHASE1":13464,"PHASE2":13466,"PHASE3":13475,"PHASE4":13477,"NA":13479},{"trials":13463,"activeCount":101},[],{"trials":13465,"activeCount":101},[],{"trials":13467,"activeCount":101},[13468],{"nctId":13469,"briefTitle":13470,"status":132,"phases":13471,"primaryCompletion":12170,"completion":12170,"start":6189,"enrollment":2774,"conditions":13472,"interventions":13473},"NCT00501943","Neuroprotection With Riluzole Patients With Early Multiple Sclerosis",[91],[765],[13460,13474],"Riluzole",{"trials":13476,"activeCount":101},[],{"trials":13478,"activeCount":101},[],{"trials":13480,"activeCount":101},[],{"intervention":13474,"totalTrials":424,"cells":13482},{"EARLY_PHASE1":13483,"PHASE1":13485,"PHASE2":13487,"PHASE3":13493,"PHASE4":13495,"NA":13497},{"trials":13484,"activeCount":101},[],{"trials":13486,"activeCount":101},[],{"trials":13488,"activeCount":101},[13489],{"nctId":13469,"briefTitle":13470,"status":132,"phases":13490,"primaryCompletion":12170,"completion":12170,"start":6189,"enrollment":2774,"conditions":13491,"interventions":13492},[91],[765],[13460,13474],{"trials":13494,"activeCount":101},[],{"trials":13496,"activeCount":101},[],{"trials":13498,"activeCount":101},[],{"intervention":13500,"totalTrials":424,"cells":13501},"Cord blood stem cells",{"EARLY_PHASE1":13502,"PHASE1":13504,"PHASE2":13506,"PHASE3":13517,"PHASE4":13519,"NA":13521},{"trials":13503,"activeCount":101},[],{"trials":13505,"activeCount":101},[],{"trials":13507,"activeCount":101},[13508],{"nctId":13509,"briefTitle":13510,"status":111,"phases":13511,"primaryCompletion":13512,"completion":13513,"start":275,"enrollment":101,"conditions":13514,"interventions":13516},"NCT04040127","Residual Dental Pulp Tissue and Cord Blood Stem Cells",[91],"2020-01-15","2020-02-28",[13515],"Irreversible Pulpitis",[13500],{"trials":13518,"activeCount":101},[],{"trials":13520,"activeCount":101},[],{"trials":13522,"activeCount":101},[],{"intervention":13524,"totalTrials":424,"cells":13525},"Itraconazole",{"EARLY_PHASE1":13526,"PHASE1":13528,"PHASE2":13530,"PHASE3":13545,"PHASE4":13547,"NA":13549},{"trials":13527,"activeCount":101},[],{"trials":13529,"activeCount":101},[],{"trials":13531,"activeCount":101},[13532],{"nctId":13533,"briefTitle":13534,"status":132,"phases":13535,"primaryCompletion":13536,"completion":13537,"start":13538,"enrollment":97,"conditions":13539,"interventions":13544},"NCT01787331","Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer",[91],"2017-05-30","2018-09-30","2013-10-29",[3424,13540,13541,13542,13543],"Recurrent Prostate Carcinoma","Stage I Prostate Adenocarcinoma AJCC v7","Stage II Prostate Adenocarcinoma AJCC v7","Stage III Prostate Adenocarcinoma AJCC v7",[13524],{"trials":13546,"activeCount":101},[],{"trials":13548,"activeCount":101},[],{"trials":13550,"activeCount":101},[],{"intervention":13552,"totalTrials":424,"cells":13553},"GM-CSF",{"EARLY_PHASE1":13554,"PHASE1":13556,"PHASE2":13558,"PHASE3":13569,"PHASE4":13571,"NA":13573},{"trials":13555,"activeCount":101},[],{"trials":13557,"activeCount":101},[],{"trials":13559,"activeCount":101},[13560],{"nctId":13561,"briefTitle":13562,"status":132,"phases":13563,"primaryCompletion":13564,"completion":13565,"start":13566,"enrollment":751,"conditions":13567,"interventions":13568},"NCT00678054","Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)",[91],"2000-08-11","2015-10-23","1999-04",[21],[13552],{"trials":13570,"activeCount":101},[],{"trials":13572,"activeCount":101},[],{"trials":13574,"activeCount":101},[],{"intervention":3527,"totalTrials":424,"cells":13576},{"EARLY_PHASE1":13577,"PHASE1":13579,"PHASE2":13581,"PHASE3":13587,"PHASE4":13589,"NA":13591},{"trials":13578,"activeCount":101},[],{"trials":13580,"activeCount":101},[],{"trials":13582,"activeCount":101},[13583],{"nctId":3515,"briefTitle":3516,"status":120,"phases":13584,"primaryCompletion":3518,"completion":3518,"start":3519,"enrollment":2564,"conditions":13585,"interventions":13586},[91],[3521,3522,3523,3524,3525],[3527,2896],{"trials":13588,"activeCount":101},[],{"trials":13590,"activeCount":101},[],{"trials":13592,"activeCount":101},[],{"intervention":13594,"totalTrials":424,"cells":13595},"Xigris",{"EARLY_PHASE1":13596,"PHASE1":13598,"PHASE2":13600,"PHASE3":13609,"PHASE4":13611,"NA":13613},{"trials":13597,"activeCount":101},[],{"trials":13599,"activeCount":101},[],{"trials":13601,"activeCount":101},[13602],{"nctId":13603,"briefTitle":13604,"status":120,"phases":13605,"completion":6378,"start":674,"enrollment":4317,"conditions":13606,"interventions":13608},"NCT00112164","Activated Protein C to Treat Acute Lung Injuries",[91],[13607],"Respiratory Distress Syndrome, Adult",[13594],{"trials":13610,"activeCount":101},[],{"trials":13612,"activeCount":101},[],{"trials":13614,"activeCount":101},[],{"intervention":13616,"totalTrials":424,"cells":13617},"Montelukast 10 Mg Oral",{"EARLY_PHASE1":13618,"PHASE1":13620,"PHASE2":13622,"PHASE3":13633,"PHASE4":13635,"NA":13637},{"trials":13619,"activeCount":101},[],{"trials":13621,"activeCount":101},[],{"trials":13623,"activeCount":101},[13624],{"nctId":13625,"briefTitle":13626,"status":132,"phases":13627,"primaryCompletion":213,"completion":213,"start":13628,"enrollment":28,"conditions":13629,"interventions":13632},"NCT04198623","Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions",[91],"2020-03-20",[13630,13631],"Infusion Reaction","Monoclonal Antibody",[13616],{"trials":13634,"activeCount":101},[],{"trials":13636,"activeCount":101},[],{"trials":13638,"activeCount":101},[],{"intervention":3546,"totalTrials":424,"cells":13640},{"EARLY_PHASE1":13641,"PHASE1":13643,"PHASE2":13645,"PHASE3":13651,"PHASE4":13653,"NA":13655},{"trials":13642,"activeCount":101},[],{"trials":13644,"activeCount":101},[],{"trials":13646,"activeCount":101},[13647],{"nctId":3529,"briefTitle":3530,"status":111,"phases":13648,"primaryCompletion":778,"completion":778,"start":3532,"enrollment":101,"conditions":13649,"interventions":13650},[91],[3534,3535,3536,3537,3538,3539,3540,3541,3542,3543],[3545,2896,3546,3547],{"trials":13652,"activeCount":101},[],{"trials":13654,"activeCount":101},[],{"trials":13656,"activeCount":101},[],{"intervention":3547,"totalTrials":424,"cells":13658},{"EARLY_PHASE1":13659,"PHASE1":13661,"PHASE2":13663,"PHASE3":13669,"PHASE4":13671,"NA":13673},{"trials":13660,"activeCount":101},[],{"trials":13662,"activeCount":101},[],{"trials":13664,"activeCount":101},[13665],{"nctId":3529,"briefTitle":3530,"status":111,"phases":13666,"primaryCompletion":778,"completion":778,"start":3532,"enrollment":101,"conditions":13667,"interventions":13668},[91],[3534,3535,3536,3537,3538,3539,3540,3541,3542,3543],[3545,2896,3546,3547],{"trials":13670,"activeCount":101},[],{"trials":13672,"activeCount":101},[],{"trials":13674,"activeCount":101},[],{"intervention":13676,"totalTrials":424,"cells":13677},"Anti-Hypertensive medications",{"EARLY_PHASE1":13678,"PHASE1":13680,"PHASE2":13682,"PHASE3":13696,"PHASE4":13698,"NA":13700},{"trials":13679,"activeCount":101},[],{"trials":13681,"activeCount":101},[],{"trials":13683,"activeCount":101},[13684],{"nctId":13685,"briefTitle":13686,"status":132,"phases":13687,"primaryCompletion":13688,"completion":13688,"start":13689,"enrollment":434,"conditions":13690,"interventions":13695},"NCT03459807","Blood Pressure Lowering in Dialysis (BOLD) Trial",[91],"2018-12-06","2018-03-23",[13691,13692,13693,13694],"Blood Pressure","End Stage Renal Disease on Dialysis (Diagnosis)","Chronic Kidney Diseases","Chronic Kidney Disease Stage 5",[13676],{"trials":13697,"activeCount":101},[],{"trials":13699,"activeCount":101},[],{"trials":13701,"activeCount":101},[],{"intervention":10993,"totalTrials":424,"cells":13703},{"EARLY_PHASE1":13704,"PHASE1":13706,"PHASE2":13708,"PHASE3":13714,"PHASE4":13716,"NA":13718},{"trials":13705,"activeCount":101},[],{"trials":13707,"activeCount":101},[],{"trials":13709,"activeCount":101},[13710],{"nctId":10987,"briefTitle":10988,"status":132,"phases":13711,"primaryCompletion":714,"completion":2545,"start":6199,"enrollment":6787,"conditions":13712,"interventions":13713},[91],[21],[2578,10992,10993],{"trials":13715,"activeCount":101},[],{"trials":13717,"activeCount":101},[],{"trials":13719,"activeCount":101},[],{"intervention":13721,"totalTrials":424,"cells":13722},"Nordihydroguaiaretic Acid",{"EARLY_PHASE1":13723,"PHASE1":13725,"PHASE2":13727,"PHASE3":13737,"PHASE4":13739,"NA":13741},{"trials":13724,"activeCount":101},[],{"trials":13726,"activeCount":101},[],{"trials":13728,"activeCount":101},[13729],{"nctId":13730,"briefTitle":13731,"status":120,"phases":13732,"primaryCompletion":13733,"completion":13734,"start":10063,"enrollment":2818,"conditions":13735,"interventions":13736},"NCT00678015","Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer",[91],"2011-02","2011-06",[21],[13721],{"trials":13738,"activeCount":101},[],{"trials":13740,"activeCount":101},[],{"trials":13742,"activeCount":101},[],{"intervention":13744,"totalTrials":424,"cells":13745},"Sandostatin",{"EARLY_PHASE1":13746,"PHASE1":13748,"PHASE2":13750,"PHASE3":13758,"PHASE4":13760,"NA":13762},{"trials":13747,"activeCount":101},[],{"trials":13749,"activeCount":101},[],{"trials":13751,"activeCount":101},[13752],{"nctId":13753,"briefTitle":13754,"status":120,"phases":13755,"primaryCompletion":237,"completion":237,"start":7341,"enrollment":4019,"conditions":13756,"interventions":13757},"NCT00510224","Sandostatin for Patients With Androgen Independent Prostate Cancer",[91],[21],[13744],{"trials":13759,"activeCount":101},[],{"trials":13761,"activeCount":101},[],{"trials":13763,"activeCount":101},[],{"intervention":13765,"totalTrials":424,"cells":13766},"Group A. \"Muscle relaxant #1\": rocuronium + sugammadex; \"Muscle relaxant #2\": succinylcholine +saline",{"EARLY_PHASE1":13767,"PHASE1":13769,"PHASE2":13771,"PHASE3":13783,"PHASE4":13785,"NA":13787},{"trials":13768,"activeCount":101},[],{"trials":13770,"activeCount":101},[],{"trials":13772,"activeCount":101},[13773],{"nctId":13774,"briefTitle":13775,"status":132,"phases":13776,"primaryCompletion":13777,"completion":987,"start":13778,"enrollment":22,"conditions":13779,"interventions":13781},"NCT03532178","Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)",[91],"2022-03-31","2019-01-01",[13780],"Neuromuscular Blockade",[13765,13782],"Group B. \"Muscle relaxant #2\": succinylcholine +saline; \"Muscle relaxant #1\": rocuronium + sugammadex;",{"trials":13784,"activeCount":101},[],{"trials":13786,"activeCount":101},[],{"trials":13788,"activeCount":101},[],{"intervention":13782,"totalTrials":424,"cells":13790},{"EARLY_PHASE1":13791,"PHASE1":13793,"PHASE2":13795,"PHASE3":13801,"PHASE4":13803,"NA":13805},{"trials":13792,"activeCount":101},[],{"trials":13794,"activeCount":101},[],{"trials":13796,"activeCount":101},[13797],{"nctId":13774,"briefTitle":13775,"status":132,"phases":13798,"primaryCompletion":13777,"completion":987,"start":13778,"enrollment":22,"conditions":13799,"interventions":13800},[91],[13780],[13765,13782],{"trials":13802,"activeCount":101},[],{"trials":13804,"activeCount":101},[],{"trials":13806,"activeCount":101},[],{"intervention":13808,"totalTrials":424,"cells":13809},"Gallium citrate",{"EARLY_PHASE1":13810,"PHASE1":13812,"PHASE2":13814,"PHASE3":13825,"PHASE4":13827,"NA":13829},{"trials":13811,"activeCount":101},[],{"trials":13813,"activeCount":101},[],{"trials":13815,"activeCount":101},[13816],{"nctId":13817,"briefTitle":13818,"status":111,"phases":13819,"primaryCompletion":9669,"completion":9669,"start":13820,"enrollment":101,"conditions":13821,"interventions":13824},"NCT02776891","A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma",[91],"2016-06-13",[13822,13823],"Lymphoma, Large B-Cell, Diffuse","Burkitt Lymphoma",[13808],{"trials":13826,"activeCount":101},[],{"trials":13828,"activeCount":101},[],{"trials":13830,"activeCount":101},[],{"intervention":13832,"totalTrials":424,"cells":13833},"Gly-low",{"EARLY_PHASE1":13834,"PHASE1":13836,"PHASE2":13838,"PHASE3":13849,"PHASE4":13851,"NA":13853},{"trials":13835,"activeCount":101},[],{"trials":13837,"activeCount":101},[],{"trials":13839,"activeCount":101},[13840],{"nctId":13841,"briefTitle":13842,"status":111,"phases":13843,"primaryCompletion":13844,"completion":3005,"start":13845,"enrollment":101,"conditions":13846,"interventions":13848},"NCT05083546","Methylglyoxal (MGO) Lowering Cocktail to Reduce Appetite in Obese Individuals",[90,91],"2025-12-01","2024-12-01",[13847,1709],"Obesity",[13832],{"trials":13850,"activeCount":101},[],{"trials":13852,"activeCount":101},[],{"trials":13854,"activeCount":101},[],{"intervention":13856,"totalTrials":424,"cells":13857},"Zoledronic Acid",{"EARLY_PHASE1":13858,"PHASE1":13860,"PHASE2":13862,"PHASE3":13871,"PHASE4":13873,"NA":13875},{"trials":13859,"activeCount":101},[],{"trials":13861,"activeCount":101},[],{"trials":13863,"activeCount":101},[13864],{"nctId":13865,"briefTitle":13866,"status":132,"phases":13867,"primaryCompletion":13734,"completion":7097,"start":13868,"enrollment":4043,"conditions":13869,"interventions":13870},"NCT00295867","Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer",[91],"2004-11-03",[24],[13856],{"trials":13872,"activeCount":101},[],{"trials":13874,"activeCount":101},[],{"trials":13876,"activeCount":101},[],{"intervention":9636,"totalTrials":424,"cells":13878},{"EARLY_PHASE1":13879,"PHASE1":13881,"PHASE2":13883,"PHASE3":13889,"PHASE4":13891,"NA":13893},{"trials":13880,"activeCount":101},[],{"trials":13882,"activeCount":101},[],{"trials":13884,"activeCount":101},[13885],{"nctId":9631,"briefTitle":9632,"status":120,"phases":13886,"primaryCompletion":6198,"completion":6198,"start":3860,"enrollment":2564,"conditions":13887,"interventions":13888},[90,91],[21],[5739,2588,9636],{"trials":13890,"activeCount":101},[],{"trials":13892,"activeCount":101},[],{"trials":13894,"activeCount":101},[],{"intervention":13896,"totalTrials":424,"cells":13897},"fluvastatin sodium",{"EARLY_PHASE1":13898,"PHASE1":13900,"PHASE2":13902,"PHASE3":13910,"PHASE4":13912,"NA":13914},{"trials":13899,"activeCount":101},[],{"trials":13901,"activeCount":101},[],{"trials":13903,"activeCount":101},[13904],{"nctId":13905,"briefTitle":13906,"status":132,"phases":13907,"primaryCompletion":3819,"completion":13734,"start":6189,"enrollment":675,"conditions":13908,"interventions":13909},"NCT00416403","Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer",[91],[24],[13896],{"trials":13911,"activeCount":101},[],{"trials":13913,"activeCount":101},[],{"trials":13915,"activeCount":101},[],{"intervention":11440,"totalTrials":424,"cells":13917},{"EARLY_PHASE1":13918,"PHASE1":13920,"PHASE2":13922,"PHASE3":13928,"PHASE4":13930,"NA":13932},{"trials":13919,"activeCount":101},[],{"trials":13921,"activeCount":101},[],{"trials":13923,"activeCount":101},[13924],{"nctId":11423,"briefTitle":11424,"status":120,"phases":13925,"primaryCompletion":11426,"completion":11426,"start":11427,"enrollment":424,"conditions":13926,"interventions":13927},[91],[11429,11430,11431,11432,11433,11434,11435,11436,11437,11438,3569,3570,3571,3572,3573],[11440,4148,11441,11442],{"trials":13929,"activeCount":101},[],{"trials":13931,"activeCount":101},[],{"trials":13933,"activeCount":101},[],{"intervention":11441,"totalTrials":424,"cells":13935},{"EARLY_PHASE1":13936,"PHASE1":13938,"PHASE2":13940,"PHASE3":13946,"PHASE4":13948,"NA":13950},{"trials":13937,"activeCount":101},[],{"trials":13939,"activeCount":101},[],{"trials":13941,"activeCount":101},[13942],{"nctId":11423,"briefTitle":11424,"status":120,"phases":13943,"primaryCompletion":11426,"completion":11426,"start":11427,"enrollment":424,"conditions":13944,"interventions":13945},[91],[11429,11430,11431,11432,11433,11434,11435,11436,11437,11438,3569,3570,3571,3572,3573],[11440,4148,11441,11442],{"trials":13947,"activeCount":101},[],{"trials":13949,"activeCount":101},[],{"trials":13951,"activeCount":101},[],{"intervention":11442,"totalTrials":424,"cells":13953},{"EARLY_PHASE1":13954,"PHASE1":13956,"PHASE2":13958,"PHASE3":13964,"PHASE4":13966,"NA":13968},{"trials":13955,"activeCount":101},[],{"trials":13957,"activeCount":101},[],{"trials":13959,"activeCount":101},[13960],{"nctId":11423,"briefTitle":11424,"status":120,"phases":13961,"primaryCompletion":11426,"completion":11426,"start":11427,"enrollment":424,"conditions":13962,"interventions":13963},[91],[11429,11430,11431,11432,11433,11434,11435,11436,11437,11438,3569,3570,3571,3572,3573],[11440,4148,11441,11442],{"trials":13965,"activeCount":101},[],{"trials":13967,"activeCount":101},[],{"trials":13969,"activeCount":101},[],{"intervention":13971,"totalTrials":424,"cells":13972},"indomethacin",{"EARLY_PHASE1":13973,"PHASE1":13975,"PHASE2":13977,"PHASE3":13986,"PHASE4":13988,"NA":13990},{"trials":13974,"activeCount":101},[],{"trials":13976,"activeCount":101},[],{"trials":13978,"activeCount":101},[13979],{"nctId":13980,"briefTitle":13981,"status":132,"phases":13982,"primaryCompletion":6189,"completion":6189,"start":13983,"enrollment":1220,"conditions":13984,"interventions":13985},"NCT00187447","Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at \u003C28 Weeks Gestation With a Persistent Patent Ductus Arteriosus",[91],"2003-08",[12949],[13971],{"trials":13987,"activeCount":101},[],{"trials":13989,"activeCount":101},[],{"trials":13991,"activeCount":101},[],{"intervention":13993,"totalTrials":424,"cells":13994},"Pirfenidone",{"EARLY_PHASE1":13995,"PHASE1":13997,"PHASE2":13999,"PHASE3":14011,"PHASE4":14013,"NA":14015},{"trials":13996,"activeCount":101},[],{"trials":13998,"activeCount":101},[],{"trials":14000,"activeCount":101},[14001],{"nctId":14002,"briefTitle":14003,"status":132,"phases":14004,"primaryCompletion":14005,"completion":14005,"start":14006,"enrollment":345,"conditions":14007,"interventions":14010},"NCT03359863","Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction",[91],"2021-10-28","2018-03-07",[14008,14009],"Restrictive Chronic Lung Allograft Dysfunction","Lung Transplant Rejection",[13993],{"trials":14012,"activeCount":101},[],{"trials":14014,"activeCount":101},[],{"trials":14016,"activeCount":101},[],{"intervention":4367,"totalTrials":424,"cells":14018},{"EARLY_PHASE1":14019,"PHASE1":14021,"PHASE2":14023,"PHASE3":14033,"PHASE4":14035,"NA":14037},{"trials":14020,"activeCount":101},[],{"trials":14022,"activeCount":101},[],{"trials":14024,"activeCount":101},[14025],{"nctId":14026,"briefTitle":14027,"status":132,"phases":14028,"primaryCompletion":14029,"completion":14029,"start":14030,"enrollment":3626,"conditions":14031,"interventions":14032},"NCT02805972","Biology and Experience of Eating in Women With Obesity",[91],"2018-07-25","2017-05-20",[13847],[4367],{"trials":14034,"activeCount":101},[],{"trials":14036,"activeCount":101},[],{"trials":14038,"activeCount":101},[],{"intervention":14040,"totalTrials":424,"cells":14041},"Anti-hypertensive agent: amlodipine",{"EARLY_PHASE1":14042,"PHASE1":14044,"PHASE2":14046,"PHASE3":14056,"PHASE4":14058,"NA":14060},{"trials":14043,"activeCount":101},[],{"trials":14045,"activeCount":101},[],{"trials":14047,"activeCount":101},[14048],{"nctId":14049,"briefTitle":14050,"status":120,"phases":14051,"primaryCompletion":4938,"completion":4938,"start":12538,"enrollment":31,"conditions":14052,"interventions":14053},"NCT05370599","Hypertension in Young Adults Trial",[91],[1223],[14040,14054,14055],"Anti-hypertensive agent: Chlorthalidone","Anti-hypertensive agent: Losartan",{"trials":14057,"activeCount":101},[],{"trials":14059,"activeCount":101},[],{"trials":14061,"activeCount":101},[],{"intervention":14054,"totalTrials":424,"cells":14063},{"EARLY_PHASE1":14064,"PHASE1":14066,"PHASE2":14068,"PHASE3":14074,"PHASE4":14076,"NA":14078},{"trials":14065,"activeCount":101},[],{"trials":14067,"activeCount":101},[],{"trials":14069,"activeCount":101},[14070],{"nctId":14049,"briefTitle":14050,"status":120,"phases":14071,"primaryCompletion":4938,"completion":4938,"start":12538,"enrollment":31,"conditions":14072,"interventions":14073},[91],[1223],[14040,14054,14055],{"trials":14075,"activeCount":101},[],{"trials":14077,"activeCount":101},[],{"trials":14079,"activeCount":101},[],{"intervention":14055,"totalTrials":424,"cells":14081},{"EARLY_PHASE1":14082,"PHASE1":14084,"PHASE2":14086,"PHASE3":14092,"PHASE4":14094,"NA":14096},{"trials":14083,"activeCount":101},[],{"trials":14085,"activeCount":101},[],{"trials":14087,"activeCount":101},[14088],{"nctId":14049,"briefTitle":14050,"status":120,"phases":14089,"primaryCompletion":4938,"completion":4938,"start":12538,"enrollment":31,"conditions":14090,"interventions":14091},[91],[1223],[14040,14054,14055],{"trials":14093,"activeCount":101},[],{"trials":14095,"activeCount":101},[],{"trials":14097,"activeCount":101},[],{"intervention":14099,"totalTrials":424,"cells":14100},"Belatacept and Raptiva",{"EARLY_PHASE1":14101,"PHASE1":14103,"PHASE2":14105,"PHASE3":14114,"PHASE4":14116,"NA":14118},{"trials":14102,"activeCount":101},[],{"trials":14104,"activeCount":101},[],{"trials":14106,"activeCount":101},[14107],{"nctId":14108,"briefTitle":14109,"status":132,"phases":14110,"primaryCompletion":6089,"completion":6089,"start":6378,"enrollment":345,"conditions":14111,"interventions":14113},"NCT00501709","Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus",[90,91],[14112],"Type 1 Diabetes",[14099],{"trials":14115,"activeCount":101},[],{"trials":14117,"activeCount":101},[],{"trials":14119,"activeCount":101},[],{"intervention":14121,"totalTrials":424,"cells":14122},"pegvisomant",{"EARLY_PHASE1":14123,"PHASE1":14125,"PHASE2":14127,"PHASE3":14137,"PHASE4":14139,"NA":14141},{"trials":14124,"activeCount":101},[],{"trials":14126,"activeCount":101},[],{"trials":14128,"activeCount":101},[14129],{"nctId":14130,"briefTitle":14131,"status":132,"phases":14132,"primaryCompletion":8651,"completion":1871,"start":3859,"enrollment":2564,"conditions":14133,"interventions":14136},"NCT02023918","Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes",[91],[14134,14135,3707],"Diabetes","Metabolic Syndrome",[14121],{"trials":14138,"activeCount":101},[],{"trials":14140,"activeCount":101},[],{"trials":14142,"activeCount":101},[],{"intervention":6482,"totalTrials":424,"cells":14144},{"EARLY_PHASE1":14145,"PHASE1":14147,"PHASE2":14149,"PHASE3":14155,"PHASE4":14157,"NA":14159},{"trials":14146,"activeCount":101},[],{"trials":14148,"activeCount":101},[],{"trials":14150,"activeCount":101},[14151],{"nctId":6473,"briefTitle":6474,"status":132,"phases":14152,"primaryCompletion":6476,"completion":6477,"start":6478,"enrollment":34,"conditions":14153,"interventions":14154},[91],[21],[6481,6482,6452],{"trials":14156,"activeCount":101},[],{"trials":14158,"activeCount":101},[],{"trials":14160,"activeCount":101},[],{"intervention":14162,"totalTrials":424,"cells":14163},"N-acetyl cysteine",{"EARLY_PHASE1":14164,"PHASE1":14166,"PHASE2":14168,"PHASE3":14179,"PHASE4":14181,"NA":14183},{"trials":14165,"activeCount":101},[],{"trials":14167,"activeCount":101},[],{"trials":14169,"activeCount":101},[14170],{"nctId":14171,"briefTitle":14172,"status":132,"phases":14173,"primaryCompletion":14174,"completion":14174,"start":14175,"enrollment":519,"conditions":14176,"interventions":14178},"NCT02804594","A Study of Oxidative Pathways in MS Fatigue",[91],"2018-06-01","2016-10-01",[14177,5731],"Progressive Multiple Sclerosis",[14162],{"trials":14180,"activeCount":101},[],{"trials":14182,"activeCount":101},[],{"trials":14184,"activeCount":101},[],{"intervention":14186,"totalTrials":424,"cells":14187},"Imatinib Mesylate",{"EARLY_PHASE1":14188,"PHASE1":14190,"PHASE2":14192,"PHASE3":14206,"PHASE4":14208,"NA":14210},{"trials":14189,"activeCount":101},[],{"trials":14191,"activeCount":101},[],{"trials":14193,"activeCount":101},[14194],{"nctId":14195,"briefTitle":14196,"status":132,"phases":14197,"primaryCompletion":14198,"completion":6132,"start":3859,"enrollment":5772,"conditions":14199,"interventions":14205},"NCT01781975","Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus",[91],"2017-05",[14200,14201,14202,14203,14204],"Diabetes Mellitus, Type I","Diabetes Mellitus, Insulin-Dependent, 1","Type 1 Diabetes Mellitus","Insulin-Dependent Diabetes Mellitus 1","IDDM",[14186],{"trials":14207,"activeCount":101},[],{"trials":14209,"activeCount":101},[],{"trials":14211,"activeCount":101},[],{"intervention":14213,"totalTrials":424,"cells":14214},"Transplant Conditioning with Mobilization Only",{"EARLY_PHASE1":14215,"PHASE1":14217,"PHASE2":14219,"PHASE3":14228,"PHASE4":14230,"NA":14232},{"trials":14216,"activeCount":101},[],{"trials":14218,"activeCount":101},[],{"trials":14220,"activeCount":101},[14221],{"nctId":14222,"briefTitle":14223,"status":120,"phases":14224,"primaryCompletion":433,"completion":433,"start":6052,"enrollment":792,"conditions":14225,"interventions":14226},"NCT01182675","Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim",[91],[4822],[14213,14227],"Transplant Conditioning with Mobilization and Alemtuzumab",{"trials":14229,"activeCount":101},[],{"trials":14231,"activeCount":101},[],{"trials":14233,"activeCount":101},[],{"intervention":14227,"totalTrials":424,"cells":14235},{"EARLY_PHASE1":14236,"PHASE1":14238,"PHASE2":14240,"PHASE3":14246,"PHASE4":14248,"NA":14250},{"trials":14237,"activeCount":101},[],{"trials":14239,"activeCount":101},[],{"trials":14241,"activeCount":101},[14242],{"nctId":14222,"briefTitle":14223,"status":120,"phases":14243,"primaryCompletion":433,"completion":433,"start":6052,"enrollment":792,"conditions":14244,"interventions":14245},[91],[4822],[14213,14227],{"trials":14247,"activeCount":101},[],{"trials":14249,"activeCount":101},[],{"trials":14251,"activeCount":101},[],{"intervention":3575,"totalTrials":424,"cells":14253},{"EARLY_PHASE1":14254,"PHASE1":14256,"PHASE2":14258,"PHASE3":14264,"PHASE4":14266,"NA":14268},{"trials":14255,"activeCount":101},[],{"trials":14257,"activeCount":101},[],{"trials":14259,"activeCount":101},[14260],{"nctId":3561,"briefTitle":3562,"status":132,"phases":14261,"primaryCompletion":3564,"completion":3565,"start":3566,"enrollment":3567,"conditions":14262,"interventions":14263},[91],[3569,3570,3571,3572,3573],[3575,3576,2896],{"trials":14265,"activeCount":101},[],{"trials":14267,"activeCount":101},[],{"trials":14269,"activeCount":101},[],{"intervention":14271,"totalTrials":424,"cells":14272},"Resveratrol",{"EARLY_PHASE1":14273,"PHASE1":14275,"PHASE2":14277,"PHASE3":14285,"PHASE4":14287,"NA":14289},{"trials":14274,"activeCount":101},[],{"trials":14276,"activeCount":101},[],{"trials":14278,"activeCount":101},[14279],{"nctId":14280,"briefTitle":14281,"status":111,"phases":14282,"primaryCompletion":6765,"completion":6765,"start":5727,"enrollment":101,"conditions":14283,"interventions":14284},"NCT00654667","Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome",[91],[3707],[14271],{"trials":14286,"activeCount":101},[],{"trials":14288,"activeCount":101},[],{"trials":14290,"activeCount":101},[],{"intervention":14292,"totalTrials":424,"cells":14293},"Selinexor",{"EARLY_PHASE1":14294,"PHASE1":14296,"PHASE2":14298,"PHASE3":14312,"PHASE4":14314,"NA":14316},{"trials":14295,"activeCount":101},[],{"trials":14297,"activeCount":101},[],{"trials":14299,"activeCount":101},[14300],{"nctId":14301,"briefTitle":14302,"status":120,"phases":14303,"primaryCompletion":14304,"completion":14305,"start":14306,"enrollment":1071,"conditions":14307,"interventions":14311},"NCT02215161","Selinexor in Treating Patients With Abiraterone Acetate and\u002For Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer",[91],"2017-02-15","2018-04-02","2014-09-02",[3421,14308,14309,14310,12669,12670],"Hormone-Resistant Prostate Cancer","Metastatic Prostate Carcinoma in the Soft Tissue","Prostate Carcinoma Metastatic in the Bone",[14292],{"trials":14313,"activeCount":101},[],{"trials":14315,"activeCount":101},[],{"trials":14317,"activeCount":101},[],{"intervention":2788,"totalTrials":424,"cells":14319},{"EARLY_PHASE1":14320,"PHASE1":14322,"PHASE2":14324,"PHASE3":14330,"PHASE4":14332,"NA":14334},{"trials":14321,"activeCount":101},[],{"trials":14323,"activeCount":101},[],{"trials":14325,"activeCount":101},[14326],{"nctId":2779,"briefTitle":2780,"status":132,"phases":14327,"primaryCompletion":2782,"completion":2783,"start":2784,"enrollment":2785,"conditions":14328,"interventions":14329},[90,91],[24],[2777,2788],{"trials":14331,"activeCount":101},[],{"trials":14333,"activeCount":101},[],{"trials":14335,"activeCount":101},[],{"intervention":14337,"totalTrials":424,"cells":14338},"Temsirolimus",{"EARLY_PHASE1":14339,"PHASE1":14341,"PHASE2":14343,"PHASE3":14356,"PHASE4":14358,"NA":14360},{"trials":14340,"activeCount":101},[],{"trials":14342,"activeCount":101},[],{"trials":14344,"activeCount":101},[14345],{"nctId":14346,"briefTitle":14347,"status":132,"phases":14348,"primaryCompletion":14349,"completion":14350,"start":14351,"enrollment":1183,"conditions":14352,"interventions":14354},"NCT01687673","Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma",[91],"2016-04-26","2020-01-09","2012-10-05",[14353],"Hepatocellular Carcinoma",[14337,14355],"Sorafenib:",{"trials":14357,"activeCount":101},[],{"trials":14359,"activeCount":101},[],{"trials":14361,"activeCount":101},[],{"intervention":14355,"totalTrials":424,"cells":14363},{"EARLY_PHASE1":14364,"PHASE1":14366,"PHASE2":14368,"PHASE3":14374,"PHASE4":14376,"NA":14378},{"trials":14365,"activeCount":101},[],{"trials":14367,"activeCount":101},[],{"trials":14369,"activeCount":101},[14370],{"nctId":14346,"briefTitle":14347,"status":132,"phases":14371,"primaryCompletion":14349,"completion":14350,"start":14351,"enrollment":1183,"conditions":14372,"interventions":14373},[91],[14353],[14337,14355],{"trials":14375,"activeCount":101},[],{"trials":14377,"activeCount":101},[],{"trials":14379,"activeCount":101},[],{"intervention":14381,"totalTrials":424,"cells":14382},"Curcuminoids",{"EARLY_PHASE1":14383,"PHASE1":14385,"PHASE2":14387,"PHASE3":14395,"PHASE4":14397,"NA":14399},{"trials":14384,"activeCount":101},[],{"trials":14386,"activeCount":101},[],{"trials":14388,"activeCount":101},[14389],{"nctId":14390,"briefTitle":14391,"status":120,"phases":14392,"completion":2575,"start":6517,"conditions":14393,"interventions":14394},"NCT00226174","A Randomized, Placebo-controlled, Double-blind Clinical Trial of Curcuminoids in Oral Lichen Planus",[91],[12495],[14381],{"trials":14396,"activeCount":101},[],{"trials":14398,"activeCount":101},[],{"trials":14400,"activeCount":101},[],{"intervention":14402,"totalTrials":424,"cells":14403},"Walnuts",{"EARLY_PHASE1":14404,"PHASE1":14406,"PHASE2":14408,"PHASE3":14420,"PHASE4":14422,"NA":14424},{"trials":14405,"activeCount":101},[],{"trials":14407,"activeCount":101},[],{"trials":14409,"activeCount":101},[14410],{"nctId":14411,"briefTitle":14412,"status":132,"phases":14413,"primaryCompletion":14414,"completion":14414,"start":14415,"enrollment":5422,"conditions":14416,"interventions":14419},"NCT03334175","Walnuts to Achieve Lasting NUTrition to Prevent Diabetes",[90,91],"2019-08-05","2018-05-21",[14417,14418],"PreDiabetes","Overweight and Obesity",[14402],{"trials":14421,"activeCount":101},[],{"trials":14423,"activeCount":101},[],{"trials":14425,"activeCount":101},[],{"intervention":2378,"totalTrials":424,"cells":14427},{"EARLY_PHASE1":14428,"PHASE1":14430,"PHASE2":14432,"PHASE3":14438,"PHASE4":14440,"NA":14442},{"trials":14429,"activeCount":101},[],{"trials":14431,"activeCount":101},[],{"trials":14433,"activeCount":101},[14434],{"nctId":2368,"briefTitle":2369,"status":120,"phases":14435,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":14436,"interventions":14437},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":14439,"activeCount":101},[],{"trials":14441,"activeCount":101},[],{"trials":14443,"activeCount":101},[],{"intervention":2379,"totalTrials":424,"cells":14445},{"EARLY_PHASE1":14446,"PHASE1":14448,"PHASE2":14450,"PHASE3":14456,"PHASE4":14458,"NA":14460},{"trials":14447,"activeCount":101},[],{"trials":14449,"activeCount":101},[],{"trials":14451,"activeCount":101},[14452],{"nctId":2368,"briefTitle":2369,"status":120,"phases":14453,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":14454,"interventions":14455},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":14457,"activeCount":101},[],{"trials":14459,"activeCount":101},[],{"trials":14461,"activeCount":101},[],{"intervention":2380,"totalTrials":424,"cells":14463},{"EARLY_PHASE1":14464,"PHASE1":14466,"PHASE2":14468,"PHASE3":14474,"PHASE4":14476,"NA":14478},{"trials":14465,"activeCount":101},[],{"trials":14467,"activeCount":101},[],{"trials":14469,"activeCount":101},[14470],{"nctId":2368,"briefTitle":2369,"status":120,"phases":14471,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":14472,"interventions":14473},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":14475,"activeCount":101},[],{"trials":14477,"activeCount":101},[],{"trials":14479,"activeCount":101},[],{"intervention":2381,"totalTrials":424,"cells":14481},{"EARLY_PHASE1":14482,"PHASE1":14484,"PHASE2":14486,"PHASE3":14492,"PHASE4":14494,"NA":14496},{"trials":14483,"activeCount":101},[],{"trials":14485,"activeCount":101},[],{"trials":14487,"activeCount":101},[14488],{"nctId":2368,"briefTitle":2369,"status":120,"phases":14489,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":14490,"interventions":14491},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":14493,"activeCount":101},[],{"trials":14495,"activeCount":101},[],{"trials":14497,"activeCount":101},[],{"intervention":2387,"totalTrials":424,"cells":14499},{"EARLY_PHASE1":14500,"PHASE1":14502,"PHASE2":14504,"PHASE3":14510,"PHASE4":14512,"NA":14514},{"trials":14501,"activeCount":101},[],{"trials":14503,"activeCount":101},[],{"trials":14505,"activeCount":101},[14506],{"nctId":2368,"briefTitle":2369,"status":120,"phases":14507,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":14508,"interventions":14509},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":14511,"activeCount":101},[],{"trials":14513,"activeCount":101},[],{"trials":14515,"activeCount":101},[],{"intervention":2388,"totalTrials":424,"cells":14517},{"EARLY_PHASE1":14518,"PHASE1":14520,"PHASE2":14522,"PHASE3":14528,"PHASE4":14530,"NA":14532},{"trials":14519,"activeCount":101},[],{"trials":14521,"activeCount":101},[],{"trials":14523,"activeCount":101},[14524],{"nctId":2368,"briefTitle":2369,"status":120,"phases":14525,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":14526,"interventions":14527},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":14529,"activeCount":101},[],{"trials":14531,"activeCount":101},[],{"trials":14533,"activeCount":101},[],{"intervention":14535,"totalTrials":424,"cells":14536},"Lacosamide 100 mg",{"EARLY_PHASE1":14537,"PHASE1":14539,"PHASE2":14541,"PHASE3":14552,"PHASE4":14554,"NA":14556},{"trials":14538,"activeCount":101},[],{"trials":14540,"activeCount":101},[],{"trials":14542,"activeCount":101},[14543],{"nctId":14544,"briefTitle":14545,"status":132,"phases":14546,"primaryCompletion":14547,"completion":14547,"start":14548,"enrollment":480,"conditions":14549,"interventions":14550},"NCT03897348","Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)",[91],"2019-06-12","2018-09-17",[8111],[14535,14551],"Lacosamide 200 mg",{"trials":14553,"activeCount":101},[],{"trials":14555,"activeCount":101},[],{"trials":14557,"activeCount":101},[],{"intervention":14551,"totalTrials":424,"cells":14559},{"EARLY_PHASE1":14560,"PHASE1":14562,"PHASE2":14564,"PHASE3":14570,"PHASE4":14572,"NA":14574},{"trials":14561,"activeCount":101},[],{"trials":14563,"activeCount":101},[],{"trials":14565,"activeCount":101},[14566],{"nctId":14544,"briefTitle":14545,"status":132,"phases":14567,"primaryCompletion":14547,"completion":14547,"start":14548,"enrollment":480,"conditions":14568,"interventions":14569},[91],[8111],[14535,14551],{"trials":14571,"activeCount":101},[],{"trials":14573,"activeCount":101},[],{"trials":14575,"activeCount":101},[],{"intervention":14577,"totalTrials":424,"cells":14578},"Micronutrient",{"EARLY_PHASE1":14579,"PHASE1":14581,"PHASE2":14583,"PHASE3":14594,"PHASE4":14596,"NA":14598},{"trials":14580,"activeCount":101},[],{"trials":14582,"activeCount":101},[],{"trials":14584,"activeCount":101},[14585],{"nctId":14586,"briefTitle":14587,"status":132,"phases":14588,"primaryCompletion":14589,"completion":14590,"start":14591,"enrollment":1027,"conditions":14592,"interventions":14593},"NCT05268744","Micronutrient Supplementation in Children With ASD",[91],"2023-01-14","2023-01-30","2022-11-14",[6103],[14577],{"trials":14595,"activeCount":101},[],{"trials":14597,"activeCount":101},[],{"trials":14599,"activeCount":101},[],{"intervention":11608,"totalTrials":424,"cells":14601},{"EARLY_PHASE1":14602,"PHASE1":14604,"PHASE2":14606,"PHASE3":14612,"PHASE4":14614,"NA":14616},{"trials":14603,"activeCount":101},[],{"trials":14605,"activeCount":101},[],{"trials":14607,"activeCount":101},[14608],{"nctId":11596,"briefTitle":11597,"status":132,"phases":14609,"primaryCompletion":11599,"completion":11599,"start":11600,"enrollment":498,"conditions":14610,"interventions":14611},[91],[11602,11603,11604,11605],[11607,11608],{"trials":14613,"activeCount":101},[],{"trials":14615,"activeCount":101},[],{"trials":14617,"activeCount":101},[],{"intervention":14619,"totalTrials":424,"cells":14620},"Lurbinectedin",{"EARLY_PHASE1":14621,"PHASE1":14623,"PHASE2":14625,"PHASE3":14634,"PHASE4":14636,"NA":14638},{"trials":14622,"activeCount":101},[],{"trials":14624,"activeCount":101},[],{"trials":14626,"activeCount":101},[14627],{"nctId":14628,"briefTitle":14629,"status":111,"phases":14630,"primaryCompletion":4253,"completion":6003,"start":11355,"enrollment":101,"conditions":14631,"interventions":14633},"NCT06217536","Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas",[90,91],[14632],"Locally Advanced Soft Tissue Sarcoma",[14619],{"trials":14635,"activeCount":101},[],{"trials":14637,"activeCount":101},[],{"trials":14639,"activeCount":101},[],{"intervention":14641,"totalTrials":424,"cells":14642},"herba scutellaria barbata",{"EARLY_PHASE1":14643,"PHASE1":14645,"PHASE2":14647,"PHASE3":14657,"PHASE4":14659,"NA":14661},{"trials":14644,"activeCount":101},[],{"trials":14646,"activeCount":101},[],{"trials":14648,"activeCount":101},[14649],{"nctId":14650,"briefTitle":14651,"status":132,"phases":14652,"primaryCompletion":14653,"completion":14653,"start":14654,"enrollment":97,"conditions":14655,"interventions":14656},"NCT00028977","Herbal Therapy in Treating Women With Metastatic Breast Cancer",[90,91],"2006-04","2001-08",[24],[14641],{"trials":14658,"activeCount":101},[],{"trials":14660,"activeCount":101},[],{"trials":14662,"activeCount":101},[],{"intervention":14664,"totalTrials":424,"cells":14665},"BKM120 Combined with Vemurafenib",{"EARLY_PHASE1":14666,"PHASE1":14668,"PHASE2":14670,"PHASE3":14682,"PHASE4":14684,"NA":14686},{"trials":14667,"activeCount":101},[],{"trials":14669,"activeCount":101},[],{"trials":14671,"activeCount":101},[14672],{"nctId":14673,"briefTitle":14674,"status":132,"phases":14675,"primaryCompletion":14676,"completion":14677,"start":14678,"enrollment":555,"conditions":14679,"interventions":14681},"NCT01512251","BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E\u002FK Mutant Advanced Melanoma",[90,91],"2013-12-13","2017-03-21","2012-06-09",[14680],"BRAF Mutant Metastatic Melanoma",[14664],{"trials":14683,"activeCount":101},[],{"trials":14685,"activeCount":101},[],{"trials":14687,"activeCount":101},[],{"intervention":9660,"totalTrials":480,"cells":14689},{"EARLY_PHASE1":14690,"PHASE1":14692,"PHASE2":14722,"PHASE3":14724,"PHASE4":14726,"NA":14728},{"trials":14691,"activeCount":101},[],{"trials":14693,"activeCount":101},[14694,14703,14710,14718],{"nctId":14695,"briefTitle":14696,"status":132,"phases":14697,"primaryCompletion":14698,"completion":14698,"start":14005,"enrollment":541,"conditions":14699,"interventions":14701},"NCT04542382","Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)",[90],"2023-08-11",[14700],"Healthy Volunteers",[9660,9660,14702],"Eltrombopag",{"nctId":14704,"briefTitle":14705,"status":120,"phases":14706,"primaryCompletion":13688,"completion":13688,"start":6280,"enrollment":97,"conditions":14707,"interventions":14709},"NCT02215174","Rosuvastatin Interethnic PK Study",[90],[14708],"Statin Pharmacokinetics Pre and Post Gastric Bypass Surgery",[9660],{"nctId":14711,"briefTitle":14712,"status":132,"phases":14713,"primaryCompletion":14714,"completion":14714,"start":165,"enrollment":1027,"conditions":14715,"interventions":14716},"NCT02106767","The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin",[90],"2016-08-07",[30],[9660,14717],"Rosuvastatin plus rifampin",{"nctId":9655,"briefTitle":9656,"status":132,"phases":14719,"primaryCompletion":3818,"completion":3818,"start":1146,"enrollment":345,"conditions":14720,"interventions":14721},[90],[30],[9660,9648],{"trials":14723,"activeCount":101},[],{"trials":14725,"activeCount":101},[],{"trials":14727,"activeCount":101},[],{"trials":14729,"activeCount":101},[],{"intervention":14731,"totalTrials":526,"cells":14732},"TPI-287 6.3 mg\u002Fm2",{"EARLY_PHASE1":14733,"PHASE1":14735,"PHASE2":14758,"PHASE3":14760,"PHASE4":14762,"NA":14764},{"trials":14734,"activeCount":101},[],{"trials":14736,"activeCount":101},[14737,14747],{"nctId":14738,"briefTitle":14739,"status":132,"phases":14740,"primaryCompletion":14741,"completion":14741,"start":540,"enrollment":1183,"conditions":14742,"interventions":14744},"NCT01966666","A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease",[90],"2019-09",[14743],"Alzheimer's Disease",[14745,14731,14746],"TPI-287 2 mg\u002Fm2","TPI-287 20 mg\u002Fm2",{"nctId":14748,"briefTitle":14749,"status":132,"phases":14750,"primaryCompletion":14741,"completion":14741,"start":6149,"enrollment":22,"conditions":14751,"interventions":14756},"NCT02133846","Safety Study of TPI-287 to Treat CBS and PSP",[90],[14752,14753,14754,14755],"Primary Four Repeat Tauopathies (4RT)","Corticobasal Syndrome (CBS)","Progressive Supranuclear Palsy (PSP)","Corticobasal Degeneration (CBD)",[14757,14746,14731],"TPI 287 2 mg\u002Fm2",{"trials":14759,"activeCount":101},[],{"trials":14761,"activeCount":101},[],{"trials":14763,"activeCount":101},[],{"trials":14765,"activeCount":101},[],{"intervention":14746,"totalTrials":526,"cells":14767},{"EARLY_PHASE1":14768,"PHASE1":14770,"PHASE2":14780,"PHASE3":14782,"PHASE4":14784,"NA":14786},{"trials":14769,"activeCount":101},[],{"trials":14771,"activeCount":101},[14772,14776],{"nctId":14738,"briefTitle":14739,"status":132,"phases":14773,"primaryCompletion":14741,"completion":14741,"start":540,"enrollment":1183,"conditions":14774,"interventions":14775},[90],[14743],[14745,14731,14746],{"nctId":14748,"briefTitle":14749,"status":132,"phases":14777,"primaryCompletion":14741,"completion":14741,"start":6149,"enrollment":22,"conditions":14778,"interventions":14779},[90],[14752,14753,14754,14755],[14757,14746,14731],{"trials":14781,"activeCount":101},[],{"trials":14783,"activeCount":101},[],{"trials":14785,"activeCount":101},[],{"trials":14787,"activeCount":101},[],{"intervention":2761,"totalTrials":526,"cells":14789},{"EARLY_PHASE1":14790,"PHASE1":14792,"PHASE2":14808,"PHASE3":14810,"PHASE4":14812,"NA":14814},{"trials":14791,"activeCount":101},[],{"trials":14793,"activeCount":101},[14794,14798],{"nctId":2737,"briefTitle":2738,"status":132,"phases":14795,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":14796,"interventions":14797},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"nctId":14799,"briefTitle":14800,"status":111,"phases":14801,"primaryCompletion":5700,"completion":3507,"start":14174,"enrollment":101,"conditions":14802,"interventions":14807},"NCT03430687","Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma",[90],[14803,14804,14805,14806],"Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7","Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7","Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7","Stage I Bladder Urothelial Carcinoma AJCC v6 and v7",[2761],{"trials":14809,"activeCount":101},[],{"trials":14811,"activeCount":101},[],{"trials":14813,"activeCount":101},[],{"trials":14815,"activeCount":101},[],{"intervention":14817,"totalTrials":526,"cells":14818},"Towne CMV vaccine",{"EARLY_PHASE1":14819,"PHASE1":14821,"PHASE2":14837,"PHASE3":14839,"PHASE4":14841,"NA":14843},{"trials":14820,"activeCount":101},[],{"trials":14822,"activeCount":101},[14823,14830],{"nctId":14824,"briefTitle":14825,"status":132,"phases":14826,"completion":236,"start":6198,"enrollment":345,"conditions":14827,"interventions":14829},"NCT00370006","Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM",[90],[14828],"Cytomegalovirus Infection",[14817],{"nctId":14831,"briefTitle":14832,"status":132,"phases":14833,"primaryCompletion":11014,"start":6694,"enrollment":1027,"conditions":14834,"interventions":14835},"NCT00373412","Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge",[90],[14828],[14836,14817],"VCL CT02 pDNA vaccine",{"trials":14838,"activeCount":101},[],{"trials":14840,"activeCount":101},[],{"trials":14842,"activeCount":101},[],{"trials":14844,"activeCount":101},[],{"intervention":14846,"totalTrials":526,"cells":14847},"Hyperpolarized Pyruvate",{"EARLY_PHASE1":14848,"PHASE1":14850,"PHASE2":14867,"PHASE3":14869,"PHASE4":14871,"NA":14873},{"trials":14849,"activeCount":101},[],{"trials":14851,"activeCount":101},[14852,14860],{"nctId":14853,"briefTitle":14854,"status":132,"phases":14855,"primaryCompletion":3564,"completion":245,"start":14856,"enrollment":345,"conditions":14857,"interventions":14859},"NCT02947373","Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors",[90],"2017-01-25",[14858],"Pediatric Brain Tumors",[14846],{"nctId":14861,"briefTitle":14862,"status":132,"phases":14863,"primaryCompletion":11709,"completion":2418,"start":2407,"enrollment":37,"conditions":14864,"interventions":14865},"NCT01229618","Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer",[90],[21],[14866],"Hyperpolarized Pyruvate (13C)",{"trials":14868,"activeCount":101},[],{"trials":14870,"activeCount":101},[],{"trials":14872,"activeCount":101},[],{"trials":14874,"activeCount":101},[],{"intervention":14876,"totalTrials":526,"cells":14877},"Doxycycline",{"EARLY_PHASE1":14878,"PHASE1":14880,"PHASE2":14901,"PHASE3":14903,"PHASE4":14905,"NA":14907},{"trials":14879,"activeCount":101},[],{"trials":14881,"activeCount":101},[14882,14891],{"nctId":14883,"briefTitle":14884,"status":132,"phases":14885,"primaryCompletion":1244,"completion":14886,"start":3662,"enrollment":541,"conditions":14887,"interventions":14890},"NCT02753426","A Trial of Doxycycline in Renal Disease",[90],"2018-01",[14888,14889],"Chronic Kidney Disease","Cardiorenal Syndrome",[14876],{"nctId":14892,"briefTitle":14893,"status":132,"phases":14894,"primaryCompletion":2636,"completion":2636,"start":5254,"enrollment":695,"conditions":14895,"interventions":14898},"NCT00243893","Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms",[90],[14896,14897],"Aneurysms","Arteriovenous Malformations",[14899,14900],"minocycline","doxycycline",{"trials":14902,"activeCount":101},[],{"trials":14904,"activeCount":101},[],{"trials":14906,"activeCount":101},[],{"trials":14908,"activeCount":101},[],{"intervention":14910,"totalTrials":526,"cells":14911},"panobinostat",{"EARLY_PHASE1":14912,"PHASE1":14914,"PHASE2":14938,"PHASE3":14940,"PHASE4":14942,"NA":14944},{"trials":14913,"activeCount":101},[],{"trials":14915,"activeCount":101},[14916,14928],{"nctId":14917,"briefTitle":14918,"status":132,"phases":14919,"primaryCompletion":3818,"completion":14920,"start":14921,"enrollment":28,"conditions":14922,"interventions":14924},"NCT00878904","Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors",[90],"2016-10-10","2009-09-13",[14923],"Unspecified Adult Solid Tumor, Protocol Specific",[14925,14910,14926,11047,14927],"epirubicin hydrochloride","gene expression analysis","western blotting",{"nctId":14929,"briefTitle":14930,"status":132,"phases":14931,"primaryCompletion":14932,"completion":1312,"start":805,"enrollment":1183,"conditions":14933,"interventions":14935},"NCT01463046","Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome",[90],"2015-11-14",[5221,14934],"Advanced Myelodysplastic Syndrome",[14936,2385,14937],"Panobinostat","Daunorubicin",{"trials":14939,"activeCount":101},[],{"trials":14941,"activeCount":101},[],{"trials":14943,"activeCount":101},[],{"trials":14945,"activeCount":101},[],{"intervention":11047,"totalTrials":526,"cells":14947},{"EARLY_PHASE1":14948,"PHASE1":14950,"PHASE2":14960,"PHASE3":14962,"PHASE4":14964,"NA":14966},{"trials":14949,"activeCount":101},[],{"trials":14951,"activeCount":101},[14952,14956],{"nctId":14917,"briefTitle":14918,"status":132,"phases":14953,"primaryCompletion":3818,"completion":14920,"start":14921,"enrollment":28,"conditions":14954,"interventions":14955},[90],[14923],[14925,14910,14926,11047,14927],{"nctId":11039,"briefTitle":11040,"status":132,"phases":14957,"primaryCompletion":11042,"completion":11043,"start":2574,"enrollment":498,"conditions":14958,"interventions":14959},[90],[24],[11046,11047],{"trials":14961,"activeCount":101},[],{"trials":14963,"activeCount":101},[],{"trials":14965,"activeCount":101},[],{"trials":14967,"activeCount":101},[],{"intervention":14969,"totalTrials":526,"cells":14970},"Deuterated nicotine and cotinine",{"EARLY_PHASE1":14971,"PHASE1":14973,"PHASE2":14988,"PHASE3":14990,"PHASE4":14992,"NA":14994},{"trials":14972,"activeCount":101},[],{"trials":14974,"activeCount":101},[14975,14982],{"nctId":14976,"briefTitle":14977,"status":132,"phases":14978,"primaryCompletion":3858,"completion":3858,"start":8837,"enrollment":2774,"conditions":14979,"interventions":14981},"NCT01058876","Comparison of Low Yield Cigarettes in African Americans vs. Whites",[90],[14980],"Cigarette Smoking",[14969],{"nctId":14983,"briefTitle":14984,"status":132,"phases":14985,"primaryCompletion":1146,"completion":1146,"start":10758,"enrollment":1633,"conditions":14986,"interventions":14987},"NCT00879918","Pharmacogenetics of Nicotine Metabolism in African-Americans",[90],[14980],[14969],{"trials":14989,"activeCount":101},[],{"trials":14991,"activeCount":101},[],{"trials":14993,"activeCount":101},[],{"trials":14995,"activeCount":101},[],{"intervention":4246,"totalTrials":526,"cells":14997},{"EARLY_PHASE1":14998,"PHASE1":15010,"PHASE2":15016,"PHASE3":15018,"PHASE4":15020,"NA":15022},{"trials":14999,"activeCount":101},[15000],{"nctId":15001,"briefTitle":15002,"status":132,"phases":15003,"primaryCompletion":15004,"completion":15004,"start":15005,"enrollment":2818,"conditions":15006,"interventions":15009},"NCT03316274","Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma",[89],"2021-06-30","2018-05-07",[15007,33,15008],"Kaposi Sarcoma","Immunosuppression",[4246],{"trials":15011,"activeCount":101},[15012],{"nctId":4210,"briefTitle":4211,"status":120,"phases":15013,"primaryCompletion":4213,"completion":4213,"start":4214,"enrollment":526,"conditions":15014,"interventions":15015},[90],[4216,4217,4218,4219,4220,4221,4222,4223,4224,4225,4226,4227,4228,4229,4230,4231,4232,4233,4234,4235,4236,4237,4238,4239,4240,4241,4242,4243],[4186,4245,4246],{"trials":15017,"activeCount":101},[],{"trials":15019,"activeCount":101},[],{"trials":15021,"activeCount":101},[],{"trials":15023,"activeCount":101},[],{"intervention":15025,"totalTrials":424,"cells":15026},"Livionex Dental Gel",{"EARLY_PHASE1":15027,"PHASE1":15029,"PHASE2":15042,"PHASE3":15044,"PHASE4":15046,"NA":15048},{"trials":15028,"activeCount":101},[],{"trials":15030,"activeCount":101},[15031],{"nctId":15032,"briefTitle":15033,"status":132,"phases":15034,"primaryCompletion":319,"completion":319,"start":15035,"enrollment":3763,"conditions":15036,"interventions":15040},"NCT04368533","Livionex on Reducing Plaque Accumulation and Improving Oral Health in Children",[90],"2019-02-08",[15037,15038,15039],"Plaque, Dental","Caries, Dental","Oral Hygiene",[15025,15041],"A standard children's toothpaste containing 1500 ppm fluoride",{"trials":15043,"activeCount":101},[],{"trials":15045,"activeCount":101},[],{"trials":15047,"activeCount":101},[],{"trials":15049,"activeCount":101},[],{"intervention":15041,"totalTrials":424,"cells":15051},{"EARLY_PHASE1":15052,"PHASE1":15054,"PHASE2":15060,"PHASE3":15062,"PHASE4":15064,"NA":15066},{"trials":15053,"activeCount":101},[],{"trials":15055,"activeCount":101},[15056],{"nctId":15032,"briefTitle":15033,"status":132,"phases":15057,"primaryCompletion":319,"completion":319,"start":15035,"enrollment":3763,"conditions":15058,"interventions":15059},[90],[15037,15038,15039],[15025,15041],{"trials":15061,"activeCount":101},[],{"trials":15063,"activeCount":101},[],{"trials":15065,"activeCount":101},[],{"trials":15067,"activeCount":101},[],{"intervention":15069,"totalTrials":424,"cells":15070},"lapatinib ditosylate",{"EARLY_PHASE1":15071,"PHASE1":15073,"PHASE2":15081,"PHASE3":15083,"PHASE4":15085,"NA":15087},{"trials":15072,"activeCount":101},[],{"trials":15074,"activeCount":101},[15075],{"nctId":15076,"briefTitle":15077,"status":132,"phases":15078,"primaryCompletion":10938,"completion":7097,"start":236,"enrollment":3626,"conditions":15079,"interventions":15080},"NCT00544804","Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2",[90],[24,3862],[15069,14926],{"trials":15082,"activeCount":101},[],{"trials":15084,"activeCount":101},[],{"trials":15086,"activeCount":101},[],{"trials":15088,"activeCount":101},[],{"intervention":10916,"totalTrials":424,"cells":15090},{"EARLY_PHASE1":15091,"PHASE1":15093,"PHASE2":15099,"PHASE3":15101,"PHASE4":15103,"NA":15105},{"trials":15092,"activeCount":101},[],{"trials":15094,"activeCount":101},[15095],{"nctId":10907,"briefTitle":10908,"status":132,"phases":15096,"primaryCompletion":7097,"completion":7097,"start":6212,"enrollment":10910,"conditions":15097,"interventions":15098},[90],[3584,2439,24,794,10912,10913,811,10914,21],[10916,10917],{"trials":15100,"activeCount":101},[],{"trials":15102,"activeCount":101},[],{"trials":15104,"activeCount":101},[],{"trials":15106,"activeCount":101},[],{"intervention":15108,"totalTrials":424,"cells":15109},"darTreg",{"EARLY_PHASE1":15110,"PHASE1":15112,"PHASE2":15120,"PHASE3":15122,"PHASE4":15124,"NA":15126},{"trials":15111,"activeCount":101},[],{"trials":15113,"activeCount":101},[15114],{"nctId":15115,"briefTitle":15116,"status":132,"phases":15117,"primaryCompletion":6039,"completion":8066,"start":3705,"enrollment":2564,"conditions":15118,"interventions":15119},"NCT02244801","Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )",[90],[1204],[15108],{"trials":15121,"activeCount":101},[],{"trials":15123,"activeCount":101},[],{"trials":15125,"activeCount":101},[],{"trials":15127,"activeCount":101},[],{"intervention":14745,"totalTrials":424,"cells":15129},{"EARLY_PHASE1":15130,"PHASE1":15132,"PHASE2":15138,"PHASE3":15140,"PHASE4":15142,"NA":15144},{"trials":15131,"activeCount":101},[],{"trials":15133,"activeCount":101},[15134],{"nctId":14738,"briefTitle":14739,"status":132,"phases":15135,"primaryCompletion":14741,"completion":14741,"start":540,"enrollment":1183,"conditions":15136,"interventions":15137},[90],[14743],[14745,14731,14746],{"trials":15139,"activeCount":101},[],{"trials":15141,"activeCount":101},[],{"trials":15143,"activeCount":101},[],{"trials":15145,"activeCount":101},[],{"intervention":15147,"totalTrials":424,"cells":15148},"Pulmicort",{"EARLY_PHASE1":15149,"PHASE1":15151,"PHASE2":15160,"PHASE3":15162,"PHASE4":15164,"NA":15166},{"trials":15150,"activeCount":101},[],{"trials":15152,"activeCount":101},[15153],{"nctId":15154,"briefTitle":15155,"status":132,"phases":15156,"primaryCompletion":13734,"completion":13734,"start":6220,"enrollment":15157,"conditions":15158,"interventions":15159},"NCT00595153","Study of the Mechanisms of Asthma",[90],127,[36],[15147],{"trials":15161,"activeCount":101},[],{"trials":15163,"activeCount":101},[],{"trials":15165,"activeCount":101},[],{"trials":15167,"activeCount":101},[],{"intervention":2757,"totalTrials":424,"cells":15169},{"EARLY_PHASE1":15170,"PHASE1":15172,"PHASE2":15178,"PHASE3":15180,"PHASE4":15182,"NA":15184},{"trials":15171,"activeCount":101},[],{"trials":15173,"activeCount":101},[15174],{"nctId":2737,"briefTitle":2738,"status":132,"phases":15175,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":15176,"interventions":15177},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"trials":15179,"activeCount":101},[],{"trials":15181,"activeCount":101},[],{"trials":15183,"activeCount":101},[],{"trials":15185,"activeCount":101},[],{"intervention":2758,"totalTrials":424,"cells":15187},{"EARLY_PHASE1":15188,"PHASE1":15190,"PHASE2":15196,"PHASE3":15198,"PHASE4":15200,"NA":15202},{"trials":15189,"activeCount":101},[],{"trials":15191,"activeCount":101},[15192],{"nctId":2737,"briefTitle":2738,"status":132,"phases":15193,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":15194,"interventions":15195},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"trials":15197,"activeCount":101},[],{"trials":15199,"activeCount":101},[],{"trials":15201,"activeCount":101},[],{"trials":15203,"activeCount":101},[],{"intervention":2763,"totalTrials":424,"cells":15205},{"EARLY_PHASE1":15206,"PHASE1":15208,"PHASE2":15214,"PHASE3":15216,"PHASE4":15218,"NA":15220},{"trials":15207,"activeCount":101},[],{"trials":15209,"activeCount":101},[15210],{"nctId":2737,"briefTitle":2738,"status":132,"phases":15211,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":15212,"interventions":15213},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"trials":15215,"activeCount":101},[],{"trials":15217,"activeCount":101},[],{"trials":15219,"activeCount":101},[],{"trials":15221,"activeCount":101},[],{"intervention":15223,"totalTrials":424,"cells":15224},"Naloxone Hydrochloride",{"EARLY_PHASE1":15225,"PHASE1":15227,"PHASE2":15237,"PHASE3":15239,"PHASE4":15241,"NA":15243},{"trials":15226,"activeCount":101},[],{"trials":15228,"activeCount":101},[15229],{"nctId":15230,"briefTitle":15231,"status":120,"phases":15232,"primaryCompletion":123,"completion":123,"start":15233,"enrollment":345,"conditions":15234,"interventions":15236},"NCT04473950","The Effect of Chronic Pain on Delay Discounting in Methadone Patients",[90],"2020-01-08",[2993,15235],"Chronic Pain Syndrome",[15223],{"trials":15238,"activeCount":101},[],{"trials":15240,"activeCount":101},[],{"trials":15242,"activeCount":101},[],{"trials":15244,"activeCount":101},[],{"intervention":15246,"totalTrials":424,"cells":15247},"Cefotaxime",{"EARLY_PHASE1":15248,"PHASE1":15250,"PHASE2":15260,"PHASE3":15262,"PHASE4":15264,"NA":15266},{"trials":15249,"activeCount":101},[],{"trials":15251,"activeCount":101},[15252],{"nctId":15253,"briefTitle":15254,"status":132,"phases":15255,"primaryCompletion":3828,"completion":7097,"start":15256,"enrollment":1202,"conditions":15257,"interventions":15259},"NCT00187655","Effect of, OAT3, on the Renal Secretion of Cefotaxime",[90],"2004-01",[15258],"Focus Groups",[15246],{"trials":15261,"activeCount":101},[],{"trials":15263,"activeCount":101},[],{"trials":15265,"activeCount":101},[],{"trials":15267,"activeCount":101},[],{"intervention":15269,"totalTrials":424,"cells":15270},"Livionex® Dental Gel",{"EARLY_PHASE1":15271,"PHASE1":15273,"PHASE2":15285,"PHASE3":15287,"PHASE4":15289,"NA":15291},{"trials":15272,"activeCount":101},[],{"trials":15274,"activeCount":101},[15275],{"nctId":15276,"briefTitle":15277,"status":132,"phases":15278,"primaryCompletion":15279,"completion":15279,"start":15280,"enrollment":22,"conditions":15281,"interventions":15283},"NCT02617407","Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients",[90],"2020-01-27","2016-07-28",[15282],"Dental Plaque",[15269,15284],"PreviDent 5000 plus\u002FTom's of Maine Children's toothpaste",{"trials":15286,"activeCount":101},[],{"trials":15288,"activeCount":101},[],{"trials":15290,"activeCount":101},[],{"trials":15292,"activeCount":101},[],{"intervention":15284,"totalTrials":424,"cells":15294},{"EARLY_PHASE1":15295,"PHASE1":15297,"PHASE2":15303,"PHASE3":15305,"PHASE4":15307,"NA":15309},{"trials":15296,"activeCount":101},[],{"trials":15298,"activeCount":101},[15299],{"nctId":15276,"briefTitle":15277,"status":132,"phases":15300,"primaryCompletion":15279,"completion":15279,"start":15280,"enrollment":22,"conditions":15301,"interventions":15302},[90],[15282],[15269,15284],{"trials":15304,"activeCount":101},[],{"trials":15306,"activeCount":101},[],{"trials":15308,"activeCount":101},[],{"trials":15310,"activeCount":101},[],{"intervention":15312,"totalTrials":424,"cells":15313},"Tumor Necrosis Factor",{"EARLY_PHASE1":15314,"PHASE1":15316,"PHASE2":15325,"PHASE3":15327,"PHASE4":15329,"NA":15331},{"trials":15315,"activeCount":101},[],{"trials":15317,"activeCount":101},[15318],{"nctId":15319,"briefTitle":15320,"status":132,"phases":15321,"conditions":15322,"interventions":15324},"NCT00002262","A Phase I\u002FII Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma",[90],[15323,18],"Sarcoma, Kaposi",[15312],{"trials":15326,"activeCount":101},[],{"trials":15328,"activeCount":101},[],{"trials":15330,"activeCount":101},[],{"trials":15332,"activeCount":101},[],{"intervention":3429,"totalTrials":424,"cells":15334},{"EARLY_PHASE1":15335,"PHASE1":15337,"PHASE2":15343,"PHASE3":15345,"PHASE4":15347,"NA":15349},{"trials":15336,"activeCount":101},[],{"trials":15338,"activeCount":101},[15339],{"nctId":3415,"briefTitle":3416,"status":132,"phases":15340,"primaryCompletion":3418,"completion":3418,"start":3419,"enrollment":2774,"conditions":15341,"interventions":15342},[90],[3421,3422,3423,3424,3425,3426,3427],[3429,2896],{"trials":15344,"activeCount":101},[],{"trials":15346,"activeCount":101},[],{"trials":15348,"activeCount":101},[],{"trials":15350,"activeCount":101},[],{"intervention":15352,"totalTrials":424,"cells":15353},"Fresh Frozen Plasma",{"EARLY_PHASE1":15354,"PHASE1":15356,"PHASE2":15366,"PHASE3":15368,"PHASE4":15370,"NA":15372},{"trials":15355,"activeCount":101},[],{"trials":15357,"activeCount":101},[15358],{"nctId":15359,"briefTitle":15360,"status":132,"phases":15361,"primaryCompletion":1244,"completion":15362,"start":6109,"enrollment":2564,"conditions":15363,"interventions":15365},"NCT02460731","Young Plasma Transfusions for Progressive Supranuclear Palsy",[90],"2019-12",[15364],"Progressive Supranuclear Palsy",[15352],{"trials":15367,"activeCount":101},[],{"trials":15369,"activeCount":101},[],{"trials":15371,"activeCount":101},[],{"trials":15373,"activeCount":101},[],{"intervention":15375,"totalTrials":424,"cells":15376},"davunetide",{"EARLY_PHASE1":15377,"PHASE1":15379,"PHASE2":15391,"PHASE3":15393,"PHASE4":15395,"NA":15397},{"trials":15378,"activeCount":101},[],{"trials":15380,"activeCount":101},[15381],{"nctId":15382,"briefTitle":15383,"status":132,"phases":15384,"primaryCompletion":1200,"completion":1200,"start":4030,"enrollment":2818,"conditions":15385,"interventions":15390},"NCT01056965","Davunetide (AL-108) in Predicted Tauopathies - Pilot Study",[90],[15386,15364,15387,15388,15389],"Predicted Tauopathies, Including","Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17","Corticobasal Degeneration Syndrome","Progressive Nonfluent Aphasia",[15375],{"trials":15392,"activeCount":101},[],{"trials":15394,"activeCount":101},[],{"trials":15396,"activeCount":101},[],{"trials":15398,"activeCount":101},[],{"intervention":15400,"totalTrials":424,"cells":15401},"Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide",{"EARLY_PHASE1":15402,"PHASE1":15404,"PHASE2":15414,"PHASE3":15416,"PHASE4":15418,"NA":15420},{"trials":15403,"activeCount":101},[],{"trials":15405,"activeCount":101},[15406],{"nctId":15407,"briefTitle":15408,"status":120,"phases":15409,"primaryCompletion":15410,"completion":6728,"start":5727,"enrollment":2564,"conditions":15411,"interventions":15413},"NCT01300793","Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide",[90],"2011-07",[12082,15412],"B-cell Lymphoma",[15400],{"trials":15415,"activeCount":101},[],{"trials":15417,"activeCount":101},[],{"trials":15419,"activeCount":101},[],{"trials":15421,"activeCount":101},[],{"intervention":15423,"totalTrials":424,"cells":15424},"Kaletra",{"EARLY_PHASE1":15425,"PHASE1":15427,"PHASE2":15436,"PHASE3":15438,"PHASE4":15440,"NA":15442},{"trials":15426,"activeCount":101},[],{"trials":15428,"activeCount":101},[15429],{"nctId":15430,"briefTitle":15431,"status":132,"phases":15432,"primaryCompletion":13733,"completion":673,"start":3649,"enrollment":5422,"conditions":15433,"interventions":15435},"NCT01227590","Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir\u002FRitonavir)",[90],[15434,7100],"Drug Interactions",[15423],{"trials":15437,"activeCount":101},[],{"trials":15439,"activeCount":101},[],{"trials":15441,"activeCount":101},[],{"trials":15443,"activeCount":101},[],{"intervention":15445,"totalTrials":424,"cells":15446},"Disulfiram + Efavirenz",{"EARLY_PHASE1":15447,"PHASE1":15449,"PHASE2":15461,"PHASE3":15463,"PHASE4":15465,"NA":15467},{"trials":15448,"activeCount":101},[],{"trials":15450,"activeCount":101},[15451],{"nctId":15452,"briefTitle":15453,"status":132,"phases":15454,"primaryCompletion":4155,"completion":4155,"start":2722,"enrollment":28,"conditions":15455,"interventions":15457},"NCT00878306","Disulfiram Interactions With HIV Medications: Clinical Implications",[90],[18,15456],"Drug Abuse",[15458,15445,15459,15460],"Disulfiram","Disulfiram + Atazanavir","Disulfiram + Ritonavir",{"trials":15462,"activeCount":101},[],{"trials":15464,"activeCount":101},[],{"trials":15466,"activeCount":101},[],{"trials":15468,"activeCount":101},[],{"intervention":15459,"totalTrials":424,"cells":15470},{"EARLY_PHASE1":15471,"PHASE1":15473,"PHASE2":15479,"PHASE3":15481,"PHASE4":15483,"NA":15485},{"trials":15472,"activeCount":101},[],{"trials":15474,"activeCount":101},[15475],{"nctId":15452,"briefTitle":15453,"status":132,"phases":15476,"primaryCompletion":4155,"completion":4155,"start":2722,"enrollment":28,"conditions":15477,"interventions":15478},[90],[18,15456],[15458,15445,15459,15460],{"trials":15480,"activeCount":101},[],{"trials":15482,"activeCount":101},[],{"trials":15484,"activeCount":101},[],{"trials":15486,"activeCount":101},[],{"intervention":15460,"totalTrials":424,"cells":15488},{"EARLY_PHASE1":15489,"PHASE1":15491,"PHASE2":15497,"PHASE3":15499,"PHASE4":15501,"NA":15503},{"trials":15490,"activeCount":101},[],{"trials":15492,"activeCount":101},[15493],{"nctId":15452,"briefTitle":15453,"status":132,"phases":15494,"primaryCompletion":4155,"completion":4155,"start":2722,"enrollment":28,"conditions":15495,"interventions":15496},[90],[18,15456],[15458,15445,15459,15460],{"trials":15498,"activeCount":101},[],{"trials":15500,"activeCount":101},[],{"trials":15502,"activeCount":101},[],{"trials":15504,"activeCount":101},[],{"intervention":15506,"totalTrials":424,"cells":15507},"BIIB092",{"EARLY_PHASE1":15508,"PHASE1":15510,"PHASE2":15524,"PHASE3":15526,"PHASE4":15528,"NA":15530},{"trials":15509,"activeCount":101},[],{"trials":15511,"activeCount":101},[15512],{"nctId":15513,"briefTitle":15514,"status":120,"phases":15515,"primaryCompletion":15516,"completion":15516,"start":7168,"enrollment":3744,"conditions":15517,"interventions":15523},"NCT03658135","BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES",[90],"2019-12-13",[15518,15388,15519,15520,15521,15522],"Primary Tauopathies","Frontotemporal Lobar Degeneration With Tau Inclusions","MAPT Mutation Carriers, Symptomatic","Traumatic Encephalopathy Syndrome","Nonfluent Aphasia, Progressive",[15506],{"trials":15525,"activeCount":101},[],{"trials":15527,"activeCount":101},[],{"trials":15529,"activeCount":101},[],{"trials":15531,"activeCount":101},[],{"intervention":11077,"totalTrials":424,"cells":15533},{"EARLY_PHASE1":15534,"PHASE1":15536,"PHASE2":15542,"PHASE3":15544,"PHASE4":15546,"NA":15548},{"trials":15535,"activeCount":101},[],{"trials":15537,"activeCount":101},[15538],{"nctId":11071,"briefTitle":11072,"status":120,"phases":15539,"primaryCompletion":3696,"completion":2455,"start":11074,"enrollment":2564,"conditions":15540,"interventions":15541},[90],[794],[6203,11077,3864],{"trials":15543,"activeCount":101},[],{"trials":15545,"activeCount":101},[],{"trials":15547,"activeCount":101},[],{"trials":15549,"activeCount":101},[],{"intervention":15551,"totalTrials":424,"cells":15552},"Nimodipine",{"EARLY_PHASE1":15553,"PHASE1":15555,"PHASE2":15564,"PHASE3":15566,"PHASE4":15568,"NA":15570},{"trials":15554,"activeCount":101},[],{"trials":15556,"activeCount":101},[15557],{"nctId":15558,"briefTitle":15559,"status":132,"phases":15560,"primaryCompletion":6628,"completion":6628,"start":921,"enrollment":555,"conditions":15561,"interventions":15563},"NCT01835665","Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations",[90],[15562],"Progranulin Mutation Carriers",[15551],{"trials":15565,"activeCount":101},[],{"trials":15567,"activeCount":101},[],{"trials":15569,"activeCount":101},[],{"trials":15571,"activeCount":101},[],{"intervention":15573,"totalTrials":424,"cells":15574},"Nanoliposomal CPT-11",{"EARLY_PHASE1":15575,"PHASE1":15577,"PHASE2":15586,"PHASE3":15588,"PHASE4":15590,"NA":15592},{"trials":15576,"activeCount":101},[],{"trials":15578,"activeCount":101},[15579],{"nctId":15580,"briefTitle":15581,"status":132,"phases":15582,"primaryCompletion":205,"completion":205,"start":6765,"enrollment":510,"conditions":15583,"interventions":15585},"NCT00734682","A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas",[90],[3765,3821,12343,15584],"Anaplastic Oligodendroglioma",[15573],{"trials":15587,"activeCount":101},[],{"trials":15589,"activeCount":101},[],{"trials":15591,"activeCount":101},[],{"trials":15593,"activeCount":101},[],{"intervention":10932,"totalTrials":424,"cells":15595},{"EARLY_PHASE1":15596,"PHASE1":15598,"PHASE2":15604,"PHASE3":15606,"PHASE4":15608,"NA":15610},{"trials":15597,"activeCount":101},[],{"trials":15599,"activeCount":101},[15600],{"nctId":10923,"briefTitle":10924,"status":132,"phases":15601,"primaryCompletion":921,"completion":540,"start":10926,"enrollment":498,"conditions":15602,"interventions":15603},[90],[10928,10929,10930],[10932,2760,10933],{"trials":15605,"activeCount":101},[],{"trials":15607,"activeCount":101},[],{"trials":15609,"activeCount":101},[],{"trials":15611,"activeCount":101},[],{"intervention":14757,"totalTrials":424,"cells":15613},{"EARLY_PHASE1":15614,"PHASE1":15616,"PHASE2":15622,"PHASE3":15624,"PHASE4":15626,"NA":15628},{"trials":15615,"activeCount":101},[],{"trials":15617,"activeCount":101},[15618],{"nctId":14748,"briefTitle":14749,"status":132,"phases":15619,"primaryCompletion":14741,"completion":14741,"start":6149,"enrollment":22,"conditions":15620,"interventions":15621},[90],[14752,14753,14754,14755],[14757,14746,14731],{"trials":15623,"activeCount":101},[],{"trials":15625,"activeCount":101},[],{"trials":15627,"activeCount":101},[],{"trials":15629,"activeCount":101},[],{"intervention":4208,"totalTrials":424,"cells":15631},{"EARLY_PHASE1":15632,"PHASE1":15634,"PHASE2":15640,"PHASE3":15642,"PHASE4":15644,"NA":15646},{"trials":15633,"activeCount":101},[],{"trials":15635,"activeCount":101},[15636],{"nctId":4193,"briefTitle":4194,"status":120,"phases":15637,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":324,"conditions":15638,"interventions":15639},[90],[4199,3534,4200,4201,4202,4203,4204,4205,4206],[4186,4208],{"trials":15641,"activeCount":101},[],{"trials":15643,"activeCount":101},[],{"trials":15645,"activeCount":101},[],{"trials":15647,"activeCount":101},[],{"intervention":15649,"totalTrials":424,"cells":15650},"Sirolimus, Cyclophosphamide, Topotecan",{"EARLY_PHASE1":15651,"PHASE1":15653,"PHASE2":15663,"PHASE3":15665,"PHASE4":15667,"NA":15669},{"trials":15652,"activeCount":101},[],{"trials":15654,"activeCount":101},[15655],{"nctId":15656,"briefTitle":15657,"status":132,"phases":15658,"primaryCompletion":432,"completion":432,"start":8325,"enrollment":97,"conditions":15659,"interventions":15662},"NCT01670175","Sirolimus With Cyclophosphamide and Topotecan for Pediatric\u002FAdolescent Relapsed and Refractory Solid Tumors",[90],[15660,15661],"Malignant Solid Tumor","Childhood Solid Tumor",[15649],{"trials":15664,"activeCount":101},[],{"trials":15666,"activeCount":101},[],{"trials":15668,"activeCount":101},[],{"trials":15670,"activeCount":101},[],{"intervention":15672,"totalTrials":424,"cells":15673},"Aminolevulinic Acid Topical 20% Topical Solution",{"EARLY_PHASE1":15674,"PHASE1":15676,"PHASE2":15687,"PHASE3":15689,"PHASE4":15691,"NA":15693},{"trials":15675,"activeCount":101},[],{"trials":15677,"activeCount":101},[15678],{"nctId":15679,"briefTitle":15680,"status":132,"phases":15681,"primaryCompletion":6169,"completion":15682,"start":15683,"enrollment":1202,"conditions":15684,"interventions":15686},"NCT03322293","Daylight Photodynamic Therapy for Actinic Keratosis",[90],"2019-07-01","2017-12-01",[15685],"Actinic Keratoses",[15672],{"trials":15688,"activeCount":101},[],{"trials":15690,"activeCount":101},[],{"trials":15692,"activeCount":101},[],{"trials":15694,"activeCount":101},[],{"intervention":15696,"totalTrials":424,"cells":15697},"Lopinavir\u002FRitonavir, Efavirenz, Artemether\u002Flumefantrine",{"EARLY_PHASE1":15698,"PHASE1":15700,"PHASE2":15708,"PHASE3":15710,"PHASE4":15712,"NA":15714},{"trials":15699,"activeCount":101},[],{"trials":15701,"activeCount":101},[15702],{"nctId":15703,"briefTitle":15704,"status":132,"phases":15705,"primaryCompletion":8696,"completion":8696,"start":2435,"enrollment":3650,"conditions":15706,"interventions":15707},"NCT00266058","Drug Interaction Study Between Antimalarial and Anti-HIV Medications",[90],[18,322],[15696],{"trials":15709,"activeCount":101},[],{"trials":15711,"activeCount":101},[],{"trials":15713,"activeCount":101},[],{"trials":15715,"activeCount":101},[],{"intervention":14925,"totalTrials":424,"cells":15717},{"EARLY_PHASE1":15718,"PHASE1":15720,"PHASE2":15726,"PHASE3":15728,"PHASE4":15730,"NA":15732},{"trials":15719,"activeCount":101},[],{"trials":15721,"activeCount":101},[15722],{"nctId":14917,"briefTitle":14918,"status":132,"phases":15723,"primaryCompletion":3818,"completion":14920,"start":14921,"enrollment":28,"conditions":15724,"interventions":15725},[90],[14923],[14925,14910,14926,11047,14927],{"trials":15727,"activeCount":101},[],{"trials":15729,"activeCount":101},[],{"trials":15731,"activeCount":101},[],{"trials":15733,"activeCount":101},[],{"intervention":14927,"totalTrials":424,"cells":15735},{"EARLY_PHASE1":15736,"PHASE1":15738,"PHASE2":15744,"PHASE3":15746,"PHASE4":15748,"NA":15750},{"trials":15737,"activeCount":101},[],{"trials":15739,"activeCount":101},[15740],{"nctId":14917,"briefTitle":14918,"status":132,"phases":15741,"primaryCompletion":3818,"completion":14920,"start":14921,"enrollment":28,"conditions":15742,"interventions":15743},[90],[14923],[14925,14910,14926,11047,14927],{"trials":15745,"activeCount":101},[],{"trials":15747,"activeCount":101},[],{"trials":15749,"activeCount":101},[],{"trials":15751,"activeCount":101},[],{"intervention":15753,"totalTrials":424,"cells":15754},"Metaiodobenzylguanidine",{"EARLY_PHASE1":15755,"PHASE1":15757,"PHASE2":15765,"PHASE3":15767,"PHASE4":15769,"NA":15771},{"trials":15756,"activeCount":101},[],{"trials":15758,"activeCount":101},[15759],{"nctId":15760,"briefTitle":15761,"status":132,"phases":15762,"primaryCompletion":6149,"completion":6149,"start":10926,"enrollment":34,"conditions":15763,"interventions":15764},"NCT01313936","High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant\u002FRelapsed Neuroblastoma",[90],[11678],[15753],{"trials":15766,"activeCount":101},[],{"trials":15768,"activeCount":101},[],{"trials":15770,"activeCount":101},[],{"trials":15772,"activeCount":101},[],{"intervention":15774,"totalTrials":424,"cells":15775},"Fecal Microbiota",{"EARLY_PHASE1":15776,"PHASE1":15778,"PHASE2":15786,"PHASE3":15788,"PHASE4":15790,"NA":15792},{"trials":15777,"activeCount":101},[],{"trials":15779,"activeCount":101},[15780],{"nctId":15781,"briefTitle":15782,"status":132,"phases":15783,"primaryCompletion":9239,"completion":9239,"start":6069,"enrollment":5422,"conditions":15784,"interventions":15785},"NCT02256592","Fecal Microbiota Transplantation in HIV",[90],[15],[15774],{"trials":15787,"activeCount":101},[],{"trials":15789,"activeCount":101},[],{"trials":15791,"activeCount":101},[],{"trials":15793,"activeCount":101},[],{"intervention":15795,"totalTrials":424,"cells":15796},"Propofol Anesthesia",{"EARLY_PHASE1":15797,"PHASE1":15799,"PHASE2":15808,"PHASE3":15810,"PHASE4":15812,"NA":15814},{"trials":15798,"activeCount":101},[],{"trials":15800,"activeCount":101},[15801],{"nctId":15802,"briefTitle":15803,"status":132,"phases":15804,"primaryCompletion":2407,"completion":2407,"start":6052,"enrollment":1060,"conditions":15805,"interventions":15807},"NCT01191021","Monitoring Exhaled Propofol to Individualize General Anesthesia",[90],[15806],"General Anesthesia",[15795],{"trials":15809,"activeCount":101},[],{"trials":15811,"activeCount":101},[],{"trials":15813,"activeCount":101},[],{"trials":15815,"activeCount":101},[],{"intervention":15817,"totalTrials":424,"cells":15818},"Euphorbia kansui extract powder prepared as tea",{"EARLY_PHASE1":15819,"PHASE1":15821,"PHASE2":15831,"PHASE3":15833,"PHASE4":15835,"NA":15837},{"trials":15820,"activeCount":101},[],{"trials":15822,"activeCount":101},[15823],{"nctId":15824,"briefTitle":15825,"status":120,"phases":15826,"primaryCompletion":15827,"completion":15827,"start":15828,"enrollment":407,"conditions":15829,"interventions":15830},"NCT02531295","Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study",[90],"2020-03-19","2019-05-15",[15,7100],[15817],{"trials":15832,"activeCount":101},[],{"trials":15834,"activeCount":101},[],{"trials":15836,"activeCount":101},[],{"trials":15838,"activeCount":101},[],{"intervention":15840,"totalTrials":424,"cells":15841},"Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells",{"EARLY_PHASE1":15842,"PHASE1":15844,"PHASE2":15852,"PHASE3":15854,"PHASE4":15856,"NA":15858},{"trials":15843,"activeCount":101},[],{"trials":15845,"activeCount":101},[15846],{"nctId":15847,"briefTitle":15848,"status":132,"phases":15849,"primaryCompletion":6089,"completion":226,"start":8696,"enrollment":1027,"conditions":15850,"interventions":15851},"NCT01210664","T1DM Immunotherapy Using CD4+CD127lo\u002F-CD25+ Polyclonal Tregs",[90],[14202],[15840],{"trials":15853,"activeCount":101},[],{"trials":15855,"activeCount":101},[],{"trials":15857,"activeCount":101},[],{"trials":15859,"activeCount":101},[],{"intervention":15861,"totalTrials":424,"cells":15862},"nab-paclitaxel, gemcitabine, capecitabine",{"EARLY_PHASE1":15863,"PHASE1":15865,"PHASE2":15875,"PHASE3":15877,"PHASE4":15879,"NA":15881},{"trials":15864,"activeCount":101},[],{"trials":15866,"activeCount":101},[15867],{"nctId":15868,"briefTitle":15869,"status":132,"phases":15870,"primaryCompletion":12170,"completion":12170,"start":447,"enrollment":519,"conditions":15871,"interventions":15874},"NCT01161186","Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma",[90],[15872,6191,15873],"Pancreatic Neoplasms","Adenocarcinoma",[15861],{"trials":15876,"activeCount":101},[],{"trials":15878,"activeCount":101},[],{"trials":15880,"activeCount":101},[],{"trials":15882,"activeCount":101},[],{"intervention":3635,"totalTrials":424,"cells":15884},{"EARLY_PHASE1":15885,"PHASE1":15887,"PHASE2":15893,"PHASE3":15895,"PHASE4":15897,"NA":15899},{"trials":15886,"activeCount":101},[],{"trials":15888,"activeCount":101},[15889],{"nctId":3630,"briefTitle":3631,"status":132,"phases":15890,"primaryCompletion":921,"completion":921,"start":673,"enrollment":345,"conditions":15891,"interventions":15892},[90],[30],[3635,3607],{"trials":15894,"activeCount":101},[],{"trials":15896,"activeCount":101},[],{"trials":15898,"activeCount":101},[],{"trials":15900,"activeCount":101},[],{"intervention":14702,"totalTrials":424,"cells":15902},{"EARLY_PHASE1":15903,"PHASE1":15905,"PHASE2":15911,"PHASE3":15913,"PHASE4":15915,"NA":15917},{"trials":15904,"activeCount":101},[],{"trials":15906,"activeCount":101},[15907],{"nctId":14695,"briefTitle":14696,"status":132,"phases":15908,"primaryCompletion":14698,"completion":14698,"start":14005,"enrollment":541,"conditions":15909,"interventions":15910},[90],[14700],[9660,9660,14702],{"trials":15912,"activeCount":101},[],{"trials":15914,"activeCount":101},[],{"trials":15916,"activeCount":101},[],{"trials":15918,"activeCount":101},[],{"intervention":15920,"totalTrials":424,"cells":15921},"Cigarette",{"EARLY_PHASE1":15922,"PHASE1":15924,"PHASE2":15934,"PHASE3":15936,"PHASE4":15938,"NA":15940},{"trials":15923,"activeCount":101},[],{"trials":15925,"activeCount":101},[15926],{"nctId":15927,"briefTitle":15928,"status":132,"phases":15929,"primaryCompletion":7096,"completion":10926,"start":15930,"enrollment":4019,"conditions":15931,"interventions":15932},"NCT00992550","Comparison of Hookah and Cigarette Smoking",[90],"2009-10",[6381],[15920,15933],"Hookah",{"trials":15935,"activeCount":101},[],{"trials":15937,"activeCount":101},[],{"trials":15939,"activeCount":101},[],{"trials":15941,"activeCount":101},[],{"intervention":15933,"totalTrials":424,"cells":15943},{"EARLY_PHASE1":15944,"PHASE1":15946,"PHASE2":15952,"PHASE3":15954,"PHASE4":15956,"NA":15958},{"trials":15945,"activeCount":101},[],{"trials":15947,"activeCount":101},[15948],{"nctId":15927,"briefTitle":15928,"status":132,"phases":15949,"primaryCompletion":7096,"completion":10926,"start":15930,"enrollment":4019,"conditions":15950,"interventions":15951},[90],[6381],[15920,15933],{"trials":15953,"activeCount":101},[],{"trials":15955,"activeCount":101},[],{"trials":15957,"activeCount":101},[],{"trials":15959,"activeCount":101},[],{"intervention":9743,"totalTrials":424,"cells":15961},{"EARLY_PHASE1":15962,"PHASE1":15964,"PHASE2":15970,"PHASE3":15972,"PHASE4":15974,"NA":15976},{"trials":15963,"activeCount":101},[],{"trials":15965,"activeCount":101},[15966],{"nctId":9736,"briefTitle":9737,"status":132,"phases":15967,"primaryCompletion":4155,"completion":4155,"start":3696,"enrollment":9739,"conditions":15968,"interventions":15969},[90],[9741,18],[9743,9744,9729,9745,9746],{"trials":15971,"activeCount":101},[],{"trials":15973,"activeCount":101},[],{"trials":15975,"activeCount":101},[],{"trials":15977,"activeCount":101},[],{"intervention":9744,"totalTrials":424,"cells":15979},{"EARLY_PHASE1":15980,"PHASE1":15982,"PHASE2":15988,"PHASE3":15990,"PHASE4":15992,"NA":15994},{"trials":15981,"activeCount":101},[],{"trials":15983,"activeCount":101},[15984],{"nctId":9736,"briefTitle":9737,"status":132,"phases":15985,"primaryCompletion":4155,"completion":4155,"start":3696,"enrollment":9739,"conditions":15986,"interventions":15987},[90],[9741,18],[9743,9744,9729,9745,9746],{"trials":15989,"activeCount":101},[],{"trials":15991,"activeCount":101},[],{"trials":15993,"activeCount":101},[],{"trials":15995,"activeCount":101},[],{"intervention":9745,"totalTrials":424,"cells":15997},{"EARLY_PHASE1":15998,"PHASE1":16000,"PHASE2":16006,"PHASE3":16008,"PHASE4":16010,"NA":16012},{"trials":15999,"activeCount":101},[],{"trials":16001,"activeCount":101},[16002],{"nctId":9736,"briefTitle":9737,"status":132,"phases":16003,"primaryCompletion":4155,"completion":4155,"start":3696,"enrollment":9739,"conditions":16004,"interventions":16005},[90],[9741,18],[9743,9744,9729,9745,9746],{"trials":16007,"activeCount":101},[],{"trials":16009,"activeCount":101},[],{"trials":16011,"activeCount":101},[],{"trials":16013,"activeCount":101},[],{"intervention":9746,"totalTrials":424,"cells":16015},{"EARLY_PHASE1":16016,"PHASE1":16018,"PHASE2":16024,"PHASE3":16026,"PHASE4":16028,"NA":16030},{"trials":16017,"activeCount":101},[],{"trials":16019,"activeCount":101},[16020],{"nctId":9736,"briefTitle":9737,"status":132,"phases":16021,"primaryCompletion":4155,"completion":4155,"start":3696,"enrollment":9739,"conditions":16022,"interventions":16023},[90],[9741,18],[9743,9744,9729,9745,9746],{"trials":16025,"activeCount":101},[],{"trials":16027,"activeCount":101},[],{"trials":16029,"activeCount":101},[],{"trials":16031,"activeCount":101},[],{"intervention":16033,"totalTrials":424,"cells":16034},"XmAb22841",{"EARLY_PHASE1":16035,"PHASE1":16037,"PHASE2":16049,"PHASE3":16051,"PHASE4":16053,"NA":16055},{"trials":16036,"activeCount":101},[],{"trials":16038,"activeCount":101},[16039],{"nctId":16040,"briefTitle":16041,"status":120,"phases":16042,"primaryCompletion":899,"completion":899,"start":16043,"enrollment":2564,"conditions":16044,"interventions":16047},"NCT05695898","XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy",[90],"2023-02-28",[16045,16046],"Metastatic Melanoma","Advanced Melanoma",[16033,16048],"XmAb23104",{"trials":16050,"activeCount":101},[],{"trials":16052,"activeCount":101},[],{"trials":16054,"activeCount":101},[],{"trials":16056,"activeCount":101},[],{"intervention":16048,"totalTrials":424,"cells":16058},{"EARLY_PHASE1":16059,"PHASE1":16061,"PHASE2":16067,"PHASE3":16069,"PHASE4":16071,"NA":16073},{"trials":16060,"activeCount":101},[],{"trials":16062,"activeCount":101},[16063],{"nctId":16040,"briefTitle":16041,"status":120,"phases":16064,"primaryCompletion":899,"completion":899,"start":16043,"enrollment":2564,"conditions":16065,"interventions":16066},[90],[16045,16046],[16033,16048],{"trials":16068,"activeCount":101},[],{"trials":16070,"activeCount":101},[],{"trials":16072,"activeCount":101},[],{"trials":16074,"activeCount":101},[],{"intervention":16076,"totalTrials":424,"cells":16077},"Gemcitabine, Bosutinib",{"EARLY_PHASE1":16078,"PHASE1":16080,"PHASE2":16088,"PHASE3":16090,"PHASE4":16092,"NA":16094},{"trials":16079,"activeCount":101},[],{"trials":16081,"activeCount":101},[16082],{"nctId":16083,"briefTitle":16084,"status":120,"phases":16085,"primaryCompletion":1913,"completion":10938,"start":7251,"enrollment":324,"conditions":16086,"interventions":16087},"NCT01025570","A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer",[90],[6191],[16076],{"trials":16089,"activeCount":101},[],{"trials":16091,"activeCount":101},[],{"trials":16093,"activeCount":101},[],{"trials":16095,"activeCount":101},[],{"intervention":16097,"totalTrials":424,"cells":16098},"Treg",{"EARLY_PHASE1":16099,"PHASE1":16101,"PHASE2":16111,"PHASE3":16113,"PHASE4":16115,"NA":16117},{"trials":16100,"activeCount":101},[],{"trials":16102,"activeCount":101},[16103],{"nctId":16104,"briefTitle":16105,"status":132,"phases":16106,"primaryCompletion":16107,"completion":16107,"start":11843,"enrollment":324,"conditions":16108,"interventions":16110},"NCT02088931","Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation",[90],"2016-12-31",[16109],"Late Complication From Kidney Transplant",[16097],{"trials":16112,"activeCount":101},[],{"trials":16114,"activeCount":101},[],{"trials":16116,"activeCount":101},[],{"trials":16118,"activeCount":101},[],{"intervention":1206,"totalTrials":424,"cells":16120},{"EARLY_PHASE1":16121,"PHASE1":16123,"PHASE2":16129,"PHASE3":16131,"PHASE4":16133,"NA":16135},{"trials":16122,"activeCount":101},[],{"trials":16124,"activeCount":101},[16125],{"nctId":1197,"briefTitle":1198,"status":132,"phases":16126,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":16127,"interventions":16128},[90],[1204],[1206,1190,1207],{"trials":16130,"activeCount":101},[],{"trials":16132,"activeCount":101},[],{"trials":16134,"activeCount":101},[],{"trials":16136,"activeCount":101},[],{"intervention":1207,"totalTrials":424,"cells":16138},{"EARLY_PHASE1":16139,"PHASE1":16141,"PHASE2":16147,"PHASE3":16149,"PHASE4":16151,"NA":16153},{"trials":16140,"activeCount":101},[],{"trials":16142,"activeCount":101},[16143],{"nctId":1197,"briefTitle":1198,"status":132,"phases":16144,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":16145,"interventions":16146},[90],[1204],[1206,1190,1207],{"trials":16148,"activeCount":101},[],{"trials":16150,"activeCount":101},[],{"trials":16152,"activeCount":101},[],{"trials":16154,"activeCount":101},[],{"intervention":16156,"totalTrials":424,"cells":16157},"RAD001 and Sorafenib",{"EARLY_PHASE1":16158,"PHASE1":16160,"PHASE2":16169,"PHASE3":16171,"PHASE4":16173,"NA":16175},{"trials":16159,"activeCount":101},[],{"trials":16161,"activeCount":101},[16162],{"nctId":16163,"briefTitle":16164,"status":132,"phases":16165,"primaryCompletion":7097,"completion":11843,"start":6694,"enrollment":97,"conditions":16166,"interventions":16168},"NCT00384969","Sorafenib and RAD001 Renal Cell Carcinoma",[90],[16167],"Renal Cell Carcinoma",[16156],{"trials":16170,"activeCount":101},[],{"trials":16172,"activeCount":101},[],{"trials":16174,"activeCount":101},[],{"trials":16176,"activeCount":101},[],{"intervention":16178,"totalTrials":424,"cells":16179},"(-)-Epicatechin",{"EARLY_PHASE1":16180,"PHASE1":16182,"PHASE2":16191,"PHASE3":16193,"PHASE4":16195,"NA":16197},{"trials":16181,"activeCount":101},[],{"trials":16183,"activeCount":101},[16184],{"nctId":16185,"briefTitle":16186,"status":111,"phases":16187,"primaryCompletion":3859,"completion":3859,"start":3648,"enrollment":101,"conditions":16188,"interventions":16190},"NCT01880866","(-)-Epicatechin and Pulmonary Arterial Hypertension",[90],[16189],"Pulmonary Arterial Hypertension",[16178],{"trials":16192,"activeCount":101},[],{"trials":16194,"activeCount":101},[],{"trials":16196,"activeCount":101},[],{"trials":16198,"activeCount":101},[],{"intervention":16200,"totalTrials":424,"cells":16201},"18F-FDG",{"EARLY_PHASE1":16202,"PHASE1":16204,"PHASE2":16221,"PHASE3":16223,"PHASE4":16225,"NA":16227},{"trials":16203,"activeCount":101},[],{"trials":16205,"activeCount":101},[16206],{"nctId":16207,"briefTitle":16208,"status":132,"phases":16209,"primaryCompletion":16210,"completion":16210,"start":16211,"enrollment":2472,"conditions":16212,"interventions":16220},"NCT03590769","Arterial Imaging of Inflammation and Resolution After Endovascular Surgery",[90],"2019-09-03","2017-06-01",[16213,16214,16215,16216,16217,16218,16219],"Peripheral Arterial Disease","Claudication, Intermittent","Claudication","PAD","SFA - Superficial Femoral Artery Stenosis","Iliac Artery Disease","Vascular Calcification",[16200],{"trials":16222,"activeCount":101},[],{"trials":16224,"activeCount":101},[],{"trials":16226,"activeCount":101},[],{"trials":16228,"activeCount":101},[],{"intervention":16230,"totalTrials":424,"cells":16231},"Pravastatin alone",{"EARLY_PHASE1":16232,"PHASE1":16234,"PHASE2":16243,"PHASE3":16245,"PHASE4":16247,"NA":16249},{"trials":16233,"activeCount":101},[],{"trials":16235,"activeCount":101},[16236],{"nctId":16237,"briefTitle":16238,"status":132,"phases":16239,"primaryCompletion":3818,"completion":7097,"start":3828,"enrollment":97,"conditions":16240,"interventions":16241},"NCT01497483","Drug-Drug Interaction Study With Pravastatin and Cyclosporine",[90],[30],[16230,16242],"Pravastatin and Cyclosporine",{"trials":16244,"activeCount":101},[],{"trials":16246,"activeCount":101},[],{"trials":16248,"activeCount":101},[],{"trials":16250,"activeCount":101},[],{"intervention":16242,"totalTrials":424,"cells":16252},{"EARLY_PHASE1":16253,"PHASE1":16255,"PHASE2":16261,"PHASE3":16263,"PHASE4":16265,"NA":16267},{"trials":16254,"activeCount":101},[],{"trials":16256,"activeCount":101},[16257],{"nctId":16237,"briefTitle":16238,"status":132,"phases":16258,"primaryCompletion":3818,"completion":7097,"start":3828,"enrollment":97,"conditions":16259,"interventions":16260},[90],[30],[16230,16242],{"trials":16262,"activeCount":101},[],{"trials":16264,"activeCount":101},[],{"trials":16266,"activeCount":101},[],{"trials":16268,"activeCount":101},[],{"intervention":16270,"totalTrials":424,"cells":16271},"Tas-102",{"EARLY_PHASE1":16272,"PHASE1":16274,"PHASE2":16286,"PHASE3":16288,"PHASE4":16290,"NA":16292},{"trials":16273,"activeCount":101},[],{"trials":16275,"activeCount":101},[16276],{"nctId":16277,"briefTitle":16278,"status":132,"phases":16279,"primaryCompletion":16280,"completion":6432,"start":16281,"enrollment":97,"conditions":16282,"interventions":16285},"NCT02602327","Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases",[90],"2021-05-20","2017-01-09",[7230,16283,16284],"Rectal Cancer","Liver Metastases",[16270],{"trials":16287,"activeCount":101},[],{"trials":16289,"activeCount":101},[],{"trials":16291,"activeCount":101},[],{"trials":16293,"activeCount":101},[],{"intervention":16295,"totalTrials":424,"cells":16296},"sorafenib with temsirolimus",{"EARLY_PHASE1":16297,"PHASE1":16299,"PHASE2":16310,"PHASE3":16312,"PHASE4":16314,"NA":16316},{"trials":16298,"activeCount":101},[],{"trials":16300,"activeCount":101},[16301],{"nctId":16302,"briefTitle":16303,"status":132,"phases":16304,"primaryCompletion":16305,"completion":16306,"start":16307,"enrollment":353,"conditions":16308,"interventions":16309},"NCT01008917","Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma",[90],"2012-09-12","2013-06-27","2009-11-17",[14353],[16295],{"trials":16311,"activeCount":101},[],{"trials":16313,"activeCount":101},[],{"trials":16315,"activeCount":101},[],{"trials":16317,"activeCount":101},[],{"intervention":16319,"totalTrials":424,"cells":16320},"Pharmacokinetic dosing",{"EARLY_PHASE1":16321,"PHASE1":16323,"PHASE2":16333,"PHASE3":16335,"PHASE4":16337,"NA":16339},{"trials":16322,"activeCount":101},[],{"trials":16324,"activeCount":101},[16325],{"nctId":16326,"briefTitle":16327,"status":132,"phases":16328,"primaryCompletion":13734,"completion":13734,"start":16329,"enrollment":19,"conditions":16330,"interventions":16332},"NCT00994591","Cotinine Metabolism in Infants and Children",[90],"2007-01",[16331],"Secondhand Smoke Exposure",[16319],{"trials":16334,"activeCount":101},[],{"trials":16336,"activeCount":101},[],{"trials":16338,"activeCount":101},[],{"trials":16340,"activeCount":101},[],{"intervention":14836,"totalTrials":424,"cells":16342},{"EARLY_PHASE1":16343,"PHASE1":16345,"PHASE2":16351,"PHASE3":16353,"PHASE4":16355,"NA":16357},{"trials":16344,"activeCount":101},[],{"trials":16346,"activeCount":101},[16347],{"nctId":14831,"briefTitle":14832,"status":132,"phases":16348,"primaryCompletion":11014,"start":6694,"enrollment":1027,"conditions":16349,"interventions":16350},[90],[14828],[14836,14817],{"trials":16352,"activeCount":101},[],{"trials":16354,"activeCount":101},[],{"trials":16356,"activeCount":101},[],{"trials":16358,"activeCount":101},[],{"intervention":16360,"totalTrials":424,"cells":16361},"Intraventricular Rituximab Plus MTX",{"EARLY_PHASE1":16362,"PHASE1":16364,"PHASE2":16374,"PHASE3":16376,"PHASE4":16378,"NA":16380},{"trials":16363,"activeCount":101},[],{"trials":16365,"activeCount":101},[16366],{"nctId":16367,"briefTitle":16368,"status":132,"phases":16369,"primaryCompletion":805,"completion":921,"start":6220,"enrollment":1071,"conditions":16370,"interventions":16373},"NCT00221325","A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma",[90],[16371,16372],"Central Nervous System Lymphoma","Intraocular Lymphoma",[16360],{"trials":16375,"activeCount":101},[],{"trials":16377,"activeCount":101},[],{"trials":16379,"activeCount":101},[],{"trials":16381,"activeCount":101},[],{"intervention":4245,"totalTrials":424,"cells":16383},{"EARLY_PHASE1":16384,"PHASE1":16386,"PHASE2":16392,"PHASE3":16394,"PHASE4":16396,"NA":16398},{"trials":16385,"activeCount":101},[],{"trials":16387,"activeCount":101},[16388],{"nctId":4210,"briefTitle":4211,"status":120,"phases":16389,"primaryCompletion":4213,"completion":4213,"start":4214,"enrollment":526,"conditions":16390,"interventions":16391},[90],[4216,4217,4218,4219,4220,4221,4222,4223,4224,4225,4226,4227,4228,4229,4230,4231,4232,4233,4234,4235,4236,4237,4238,4239,4240,4241,4242,4243],[4186,4245,4246],{"trials":16393,"activeCount":101},[],{"trials":16395,"activeCount":101},[],{"trials":16397,"activeCount":101},[],{"trials":16399,"activeCount":101},[],{"intervention":16401,"totalTrials":424,"cells":16402},"Mivacurium",{"EARLY_PHASE1":16403,"PHASE1":16405,"PHASE2":16415,"PHASE3":16417,"PHASE4":16419,"NA":16421},{"trials":16404,"activeCount":101},[],{"trials":16406,"activeCount":101},[16407],{"nctId":16408,"briefTitle":16409,"status":132,"phases":16410,"primaryCompletion":3648,"completion":3648,"start":921,"enrollment":1060,"conditions":16411,"interventions":16414},"NCT01906528","Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium",[90],[16412,16413],"Muscle Relaxation","Sex",[16401],{"trials":16416,"activeCount":101},[],{"trials":16418,"activeCount":101},[],{"trials":16420,"activeCount":101},[],{"trials":16422,"activeCount":101},[],{"intervention":16424,"totalTrials":424,"cells":16425},"Remifentanil",{"EARLY_PHASE1":16426,"PHASE1":16428,"PHASE2":16440,"PHASE3":16442,"PHASE4":16444,"NA":16446},{"trials":16427,"activeCount":101},[],{"trials":16429,"activeCount":101},[16430],{"nctId":16431,"briefTitle":16432,"status":132,"phases":16433,"primaryCompletion":16210,"completion":16210,"start":16434,"enrollment":1060,"conditions":16435,"interventions":16439},"NCT04301895","Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression",[90],"2019-04-30",[16436,9399,16437,10042,16438],"Opioid; Intoxication, Perception Disturbance (Acute)","Overdose of Opiate","Safety Issues",[16424],{"trials":16441,"activeCount":101},[],{"trials":16443,"activeCount":101},[],{"trials":16445,"activeCount":101},[],{"trials":16447,"activeCount":101},[],{"intervention":16449,"totalTrials":424,"cells":16450},"Ritonavir-boosted Atazanavir",{"EARLY_PHASE1":16451,"PHASE1":16453,"PHASE2":16463,"PHASE3":16465,"PHASE4":16467,"NA":16469},{"trials":16452,"activeCount":101},[],{"trials":16454,"activeCount":101},[16455],{"nctId":16456,"briefTitle":16457,"status":132,"phases":16458,"primaryCompletion":3859,"completion":3859,"start":3858,"enrollment":555,"conditions":16459,"interventions":16460},"NCT01759875","Effects of Gastric pH on the Pharmacokinetics of Atazanavir",[90],[30],[16449,16461,16462],"Ritonavir-boosted Atazanavir plus Rabeprazole","Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride",{"trials":16464,"activeCount":101},[],{"trials":16466,"activeCount":101},[],{"trials":16468,"activeCount":101},[],{"trials":16470,"activeCount":101},[],{"intervention":16461,"totalTrials":424,"cells":16472},{"EARLY_PHASE1":16473,"PHASE1":16475,"PHASE2":16481,"PHASE3":16483,"PHASE4":16485,"NA":16487},{"trials":16474,"activeCount":101},[],{"trials":16476,"activeCount":101},[16477],{"nctId":16456,"briefTitle":16457,"status":132,"phases":16478,"primaryCompletion":3859,"completion":3859,"start":3858,"enrollment":555,"conditions":16479,"interventions":16480},[90],[30],[16449,16461,16462],{"trials":16482,"activeCount":101},[],{"trials":16484,"activeCount":101},[],{"trials":16486,"activeCount":101},[],{"trials":16488,"activeCount":101},[],{"intervention":16462,"totalTrials":424,"cells":16490},{"EARLY_PHASE1":16491,"PHASE1":16493,"PHASE2":16499,"PHASE3":16501,"PHASE4":16503,"NA":16505},{"trials":16492,"activeCount":101},[],{"trials":16494,"activeCount":101},[16495],{"nctId":16456,"briefTitle":16457,"status":132,"phases":16496,"primaryCompletion":3859,"completion":3859,"start":3858,"enrollment":555,"conditions":16497,"interventions":16498},[90],[30],[16449,16461,16462],{"trials":16500,"activeCount":101},[],{"trials":16502,"activeCount":101},[],{"trials":16504,"activeCount":101},[],{"trials":16506,"activeCount":101},[],{"intervention":16508,"totalTrials":424,"cells":16509},"Dasatinib",{"EARLY_PHASE1":16510,"PHASE1":16512,"PHASE2":16522,"PHASE3":16524,"PHASE4":16526,"NA":16528},{"trials":16511,"activeCount":101},[],{"trials":16513,"activeCount":101},[16514],{"nctId":16515,"briefTitle":16516,"status":132,"phases":16517,"primaryCompletion":11708,"completion":11708,"start":10423,"enrollment":345,"conditions":16518,"interventions":16519},"NCT01398046","Effects of Gastric pH on the Pharmacokinetics of Dasatinib",[90],[30],[16508,16520,16521],"Dasatinib plus Rabeprazole","Dasatinib plus Rabeprazole AND Betaine Hydrochloride",{"trials":16523,"activeCount":101},[],{"trials":16525,"activeCount":101},[],{"trials":16527,"activeCount":101},[],{"trials":16529,"activeCount":101},[],{"intervention":16520,"totalTrials":424,"cells":16531},{"EARLY_PHASE1":16532,"PHASE1":16534,"PHASE2":16540,"PHASE3":16542,"PHASE4":16544,"NA":16546},{"trials":16533,"activeCount":101},[],{"trials":16535,"activeCount":101},[16536],{"nctId":16515,"briefTitle":16516,"status":132,"phases":16537,"primaryCompletion":11708,"completion":11708,"start":10423,"enrollment":345,"conditions":16538,"interventions":16539},[90],[30],[16508,16520,16521],{"trials":16541,"activeCount":101},[],{"trials":16543,"activeCount":101},[],{"trials":16545,"activeCount":101},[],{"trials":16547,"activeCount":101},[],{"intervention":16521,"totalTrials":424,"cells":16549},{"EARLY_PHASE1":16550,"PHASE1":16552,"PHASE2":16558,"PHASE3":16560,"PHASE4":16562,"NA":16564},{"trials":16551,"activeCount":101},[],{"trials":16553,"activeCount":101},[16554],{"nctId":16515,"briefTitle":16516,"status":132,"phases":16555,"primaryCompletion":11708,"completion":11708,"start":10423,"enrollment":345,"conditions":16556,"interventions":16557},[90],[30],[16508,16520,16521],{"trials":16559,"activeCount":101},[],{"trials":16561,"activeCount":101},[],{"trials":16563,"activeCount":101},[],{"trials":16565,"activeCount":101},[],{"intervention":16567,"totalTrials":424,"cells":16568},"nanoliposomal irinotecan",{"EARLY_PHASE1":16569,"PHASE1":16571,"PHASE2":16581,"PHASE3":16583,"PHASE4":16585,"NA":16587},{"trials":16570,"activeCount":101},[],{"trials":16572,"activeCount":101},[16573],{"nctId":16574,"briefTitle":16575,"status":132,"phases":16576,"primaryCompletion":3507,"completion":16577,"start":16578,"enrollment":5422,"conditions":16579,"interventions":16580},"NCT02022644","Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma",[90],"2023-05-31","2014-10-23",[3808],[16567],{"trials":16582,"activeCount":101},[],{"trials":16584,"activeCount":101},[],{"trials":16586,"activeCount":101},[],{"trials":16588,"activeCount":101},[],{"intervention":16590,"totalTrials":424,"cells":16591},"Crude Coal Tar Only",{"EARLY_PHASE1":16592,"PHASE1":16594,"PHASE2":16604,"PHASE3":16606,"PHASE4":16608,"NA":16610},{"trials":16593,"activeCount":101},[],{"trials":16595,"activeCount":101},[16596],{"nctId":16597,"briefTitle":16598,"status":120,"phases":16599,"primaryCompletion":16600,"completion":16600,"start":16601,"enrollment":480,"conditions":16602,"interventions":16603},"NCT03662685","Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris",[90],"2024-05-31","2018-08-01",[652,366],[16590],{"trials":16605,"activeCount":101},[],{"trials":16607,"activeCount":101},[],{"trials":16609,"activeCount":101},[],{"trials":16611,"activeCount":101},[],{"intervention":16613,"totalTrials":424,"cells":16614},"Nitroglycerin 15mg",{"EARLY_PHASE1":16615,"PHASE1":16617,"PHASE2":16629,"PHASE3":16631,"PHASE4":16633,"NA":16635},{"trials":16616,"activeCount":101},[],{"trials":16618,"activeCount":101},[16619],{"nctId":16620,"briefTitle":16621,"status":132,"phases":16622,"primaryCompletion":10758,"completion":10758,"start":10063,"enrollment":16623,"conditions":16624,"interventions":16625},"NCT00686231","Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter",[90],19,[30],[16613,16626,16627,16628],"Nitroglycerin 30mg","Lidocaine 20mg","Lidocaine 40mg",{"trials":16630,"activeCount":101},[],{"trials":16632,"activeCount":101},[],{"trials":16634,"activeCount":101},[],{"trials":16636,"activeCount":101},[],{"intervention":16626,"totalTrials":424,"cells":16638},{"EARLY_PHASE1":16639,"PHASE1":16641,"PHASE2":16647,"PHASE3":16649,"PHASE4":16651,"NA":16653},{"trials":16640,"activeCount":101},[],{"trials":16642,"activeCount":101},[16643],{"nctId":16620,"briefTitle":16621,"status":132,"phases":16644,"primaryCompletion":10758,"completion":10758,"start":10063,"enrollment":16623,"conditions":16645,"interventions":16646},[90],[30],[16613,16626,16627,16628],{"trials":16648,"activeCount":101},[],{"trials":16650,"activeCount":101},[],{"trials":16652,"activeCount":101},[],{"trials":16654,"activeCount":101},[],{"intervention":16627,"totalTrials":424,"cells":16656},{"EARLY_PHASE1":16657,"PHASE1":16659,"PHASE2":16665,"PHASE3":16667,"PHASE4":16669,"NA":16671},{"trials":16658,"activeCount":101},[],{"trials":16660,"activeCount":101},[16661],{"nctId":16620,"briefTitle":16621,"status":132,"phases":16662,"primaryCompletion":10758,"completion":10758,"start":10063,"enrollment":16623,"conditions":16663,"interventions":16664},[90],[30],[16613,16626,16627,16628],{"trials":16666,"activeCount":101},[],{"trials":16668,"activeCount":101},[],{"trials":16670,"activeCount":101},[],{"trials":16672,"activeCount":101},[],{"intervention":16628,"totalTrials":424,"cells":16674},{"EARLY_PHASE1":16675,"PHASE1":16677,"PHASE2":16683,"PHASE3":16685,"PHASE4":16687,"NA":16689},{"trials":16676,"activeCount":101},[],{"trials":16678,"activeCount":101},[16679],{"nctId":16620,"briefTitle":16621,"status":132,"phases":16680,"primaryCompletion":10758,"completion":10758,"start":10063,"enrollment":16623,"conditions":16681,"interventions":16682},[90],[30],[16613,16626,16627,16628],{"trials":16684,"activeCount":101},[],{"trials":16686,"activeCount":101},[],{"trials":16688,"activeCount":101},[],{"trials":16690,"activeCount":101},[],{"intervention":16692,"totalTrials":424,"cells":16693},"Zoledronate",{"EARLY_PHASE1":16694,"PHASE1":16696,"PHASE2":16707,"PHASE3":16709,"PHASE4":16711,"NA":16713},{"trials":16695,"activeCount":101},[],{"trials":16697,"activeCount":101},[16698],{"nctId":16699,"briefTitle":16700,"status":120,"phases":16701,"primaryCompletion":16702,"completion":16702,"start":9350,"enrollment":2818,"conditions":16703,"interventions":16706},"NCT00278434","Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2\u002F3 or 3",[90],"2008-07",[16704,16705],"Cervical Cancer","Precancerous Condition",[16692],{"trials":16708,"activeCount":101},[],{"trials":16710,"activeCount":101},[],{"trials":16712,"activeCount":101},[],{"trials":16714,"activeCount":101},[],{"intervention":16716,"totalTrials":424,"cells":16717},"in utero hematopoietic stem cell transplantation",{"EARLY_PHASE1":16718,"PHASE1":16720,"PHASE2":16738,"PHASE3":16740,"PHASE4":16742,"NA":16744},{"trials":16719,"activeCount":101},[],{"trials":16721,"activeCount":101},[16722],{"nctId":16723,"briefTitle":16724,"status":120,"phases":16725,"primaryCompletion":16726,"completion":57,"start":16727,"enrollment":2564,"conditions":16728,"interventions":16737},"NCT02986698","In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)",[90],"2024-04-30","2017-10-05",[16729,16730,5777,16731,16732,16733,16734,16735,16736],"Alpha Thalassemia Major","Hemoglobinopathy; With Thalassemia","Fetal Anemia","Fetal Hydrops","Alpha; Thalassemia","Thalassemia Major","Thalassemia Alpha","A-Thalassemia",[16716],{"trials":16739,"activeCount":101},[],{"trials":16741,"activeCount":101},[],{"trials":16743,"activeCount":101},[],{"trials":16745,"activeCount":101},[],{"intervention":11799,"totalTrials":424,"cells":16747},{"EARLY_PHASE1":16748,"PHASE1":16750,"PHASE2":16759,"PHASE3":16761,"PHASE4":16763,"NA":16765},{"trials":16749,"activeCount":101},[],{"trials":16751,"activeCount":101},[16752],{"nctId":16753,"briefTitle":16754,"status":132,"phases":16755,"primaryCompletion":4155,"completion":4155,"start":448,"enrollment":751,"conditions":16756,"interventions":16757},"NCT00879047","Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV\u002FAIDS and HIV\u002FAIDS With Hepatitis C Virus (HCV) Co-Infection",[90],[18,7099],[11799,16758],"Alcohol placebo",{"trials":16760,"activeCount":101},[],{"trials":16762,"activeCount":101},[],{"trials":16764,"activeCount":101},[],{"trials":16766,"activeCount":101},[],{"intervention":16758,"totalTrials":424,"cells":16768},{"EARLY_PHASE1":16769,"PHASE1":16771,"PHASE2":16777,"PHASE3":16779,"PHASE4":16781,"NA":16783},{"trials":16770,"activeCount":101},[],{"trials":16772,"activeCount":101},[16773],{"nctId":16753,"briefTitle":16754,"status":132,"phases":16774,"primaryCompletion":4155,"completion":4155,"start":448,"enrollment":751,"conditions":16775,"interventions":16776},[90],[18,7099],[11799,16758],{"trials":16778,"activeCount":101},[],{"trials":16780,"activeCount":101},[],{"trials":16782,"activeCount":101},[],{"trials":16784,"activeCount":101},[],{"intervention":14937,"totalTrials":424,"cells":16786},{"EARLY_PHASE1":16787,"PHASE1":16789,"PHASE2":16795,"PHASE3":16797,"PHASE4":16799,"NA":16801},{"trials":16788,"activeCount":101},[],{"trials":16790,"activeCount":101},[16791],{"nctId":14929,"briefTitle":14930,"status":132,"phases":16792,"primaryCompletion":14932,"completion":1312,"start":805,"enrollment":1183,"conditions":16793,"interventions":16794},[90],[5221,14934],[14936,2385,14937],{"trials":16796,"activeCount":101},[],{"trials":16798,"activeCount":101},[],{"trials":16800,"activeCount":101},[],{"trials":16802,"activeCount":101},[],{"intervention":14717,"totalTrials":424,"cells":16804},{"EARLY_PHASE1":16805,"PHASE1":16807,"PHASE2":16813,"PHASE3":16815,"PHASE4":16817,"NA":16819},{"trials":16806,"activeCount":101},[],{"trials":16808,"activeCount":101},[16809],{"nctId":14711,"briefTitle":14712,"status":132,"phases":16810,"primaryCompletion":14714,"completion":14714,"start":165,"enrollment":1027,"conditions":16811,"interventions":16812},[90],[30],[9660,14717],{"trials":16814,"activeCount":101},[],{"trials":16816,"activeCount":101},[],{"trials":16818,"activeCount":101},[],{"trials":16820,"activeCount":101},[],{"intervention":3787,"totalTrials":424,"cells":16822},{"EARLY_PHASE1":16823,"PHASE1":16825,"PHASE2":16831,"PHASE3":16833,"PHASE4":16835,"NA":16837},{"trials":16824,"activeCount":101},[],{"trials":16826,"activeCount":101},[16827],{"nctId":3778,"briefTitle":3779,"status":132,"phases":16828,"primaryCompletion":3440,"completion":3781,"start":3782,"enrollment":1027,"conditions":16829,"interventions":16830},[90],[3784,3785],[3787,3599,3751],{"trials":16832,"activeCount":101},[],{"trials":16834,"activeCount":101},[],{"trials":16836,"activeCount":101},[],{"trials":16838,"activeCount":101},[],{"intervention":16840,"totalTrials":424,"cells":16841},"masoprocol",{"EARLY_PHASE1":16842,"PHASE1":16844,"PHASE2":16852,"PHASE3":16854,"PHASE4":16856,"NA":16858},{"trials":16843,"activeCount":101},[],{"trials":16845,"activeCount":101},[16846],{"nctId":16847,"briefTitle":16848,"status":120,"phases":16849,"primaryCompletion":6694,"completion":6694,"start":238,"enrollment":519,"conditions":16850,"interventions":16851},"NCT00313534","Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer",[90],[21],[16840],{"trials":16853,"activeCount":101},[],{"trials":16855,"activeCount":101},[],{"trials":16857,"activeCount":101},[],{"trials":16859,"activeCount":101},[],{"intervention":16861,"totalTrials":424,"cells":16862},"Doxycycline or Placebo",{"EARLY_PHASE1":16863,"PHASE1":16865,"PHASE2":16875,"PHASE3":16877,"PHASE4":16879,"NA":16881},{"trials":16864,"activeCount":101},[],{"trials":16866,"activeCount":101},[16867],{"nctId":16868,"briefTitle":16869,"status":132,"phases":16870,"primaryCompletion":7096,"completion":7096,"start":3713,"enrollment":3650,"conditions":16871,"interventions":16874},"NCT00783523","Influence of MMP on Brain AVM Hemorrhage",[90],[14897,16872,16873],"Cavernous Angiomas","Brain Aneurysms",[16861],{"trials":16876,"activeCount":101},[],{"trials":16878,"activeCount":101},[],{"trials":16880,"activeCount":101},[],{"trials":16882,"activeCount":101},[],{"intervention":16884,"totalTrials":424,"cells":16885},"IV L-carnitine",{"EARLY_PHASE1":16886,"PHASE1":16888,"PHASE2":16899,"PHASE3":16901,"PHASE4":16903,"NA":16905},{"trials":16887,"activeCount":101},[],{"trials":16889,"activeCount":101},[16890],{"nctId":16891,"briefTitle":16892,"status":111,"phases":16893,"primaryCompletion":16894,"completion":16894,"start":205,"enrollment":101,"conditions":16895,"interventions":16898},"NCT01825369","Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow",[90],"2020-07",[16896,16897],"Heart Septal Defects, Ventricular","Atrioventricular Septal Defect",[16884],{"trials":16900,"activeCount":101},[],{"trials":16902,"activeCount":101},[],{"trials":16904,"activeCount":101},[],{"trials":16906,"activeCount":101},[],{"intervention":16908,"totalTrials":424,"cells":16909},"glyburide",{"EARLY_PHASE1":16910,"PHASE1":16912,"PHASE2":16923,"PHASE3":16925,"PHASE4":16927,"NA":16929},{"trials":16911,"activeCount":101},[],{"trials":16913,"activeCount":101},[16914],{"nctId":16915,"briefTitle":16916,"status":111,"phases":16917,"primaryCompletion":1201,"completion":4041,"start":3649,"enrollment":101,"conditions":16918,"interventions":16919},"NCT00935363","Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK)",[90],[30],[16908,16920,16921,16922],"glyburide + fluconazole","glyburide + rifampin","glyburide + fluconazole + rifampin",{"trials":16924,"activeCount":101},[],{"trials":16926,"activeCount":101},[],{"trials":16928,"activeCount":101},[],{"trials":16930,"activeCount":101},[],{"intervention":16920,"totalTrials":424,"cells":16932},{"EARLY_PHASE1":16933,"PHASE1":16935,"PHASE2":16941,"PHASE3":16943,"PHASE4":16945,"NA":16947},{"trials":16934,"activeCount":101},[],{"trials":16936,"activeCount":101},[16937],{"nctId":16915,"briefTitle":16916,"status":111,"phases":16938,"primaryCompletion":1201,"completion":4041,"start":3649,"enrollment":101,"conditions":16939,"interventions":16940},[90],[30],[16908,16920,16921,16922],{"trials":16942,"activeCount":101},[],{"trials":16944,"activeCount":101},[],{"trials":16946,"activeCount":101},[],{"trials":16948,"activeCount":101},[],{"intervention":16921,"totalTrials":424,"cells":16950},{"EARLY_PHASE1":16951,"PHASE1":16953,"PHASE2":16959,"PHASE3":16961,"PHASE4":16963,"NA":16965},{"trials":16952,"activeCount":101},[],{"trials":16954,"activeCount":101},[16955],{"nctId":16915,"briefTitle":16916,"status":111,"phases":16956,"primaryCompletion":1201,"completion":4041,"start":3649,"enrollment":101,"conditions":16957,"interventions":16958},[90],[30],[16908,16920,16921,16922],{"trials":16960,"activeCount":101},[],{"trials":16962,"activeCount":101},[],{"trials":16964,"activeCount":101},[],{"trials":16966,"activeCount":101},[],{"intervention":16922,"totalTrials":424,"cells":16968},{"EARLY_PHASE1":16969,"PHASE1":16971,"PHASE2":16977,"PHASE3":16979,"PHASE4":16981,"NA":16983},{"trials":16970,"activeCount":101},[],{"trials":16972,"activeCount":101},[16973],{"nctId":16915,"briefTitle":16916,"status":111,"phases":16974,"primaryCompletion":1201,"completion":4041,"start":3649,"enrollment":101,"conditions":16975,"interventions":16976},[90],[30],[16908,16920,16921,16922],{"trials":16978,"activeCount":101},[],{"trials":16980,"activeCount":101},[],{"trials":16982,"activeCount":101},[],{"trials":16984,"activeCount":101},[],{"intervention":16986,"totalTrials":424,"cells":16987},"Magrolimab",{"EARLY_PHASE1":16988,"PHASE1":16990,"PHASE2":17005,"PHASE3":17007,"PHASE4":17009,"NA":17011},{"trials":16989,"activeCount":101},[],{"trials":16991,"activeCount":101},[16992],{"nctId":16993,"briefTitle":16994,"status":132,"phases":16995,"primaryCompletion":1607,"completion":1607,"start":16996,"enrollment":4019,"conditions":16997,"interventions":17004},"NCT05169944","Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors",[90],"2022-04-22",[16998,16999,17000,17001,17002,17003],"Brain Cancer","Malignant Brain Tumor","Recurrent Brain Tumor","Progressive Malignant Brain Tumor","Brain Tumor, Pediatric","Brain Tumor Adult",[16986],{"trials":17006,"activeCount":101},[],{"trials":17008,"activeCount":101},[],{"trials":17010,"activeCount":101},[],{"trials":17012,"activeCount":101},[],{"intervention":10941,"totalTrials":424,"cells":17014},{"EARLY_PHASE1":17015,"PHASE1":17017,"PHASE2":17023,"PHASE3":17025,"PHASE4":17027,"NA":17029},{"trials":17016,"activeCount":101},[],{"trials":17018,"activeCount":101},[17019],{"nctId":10935,"briefTitle":10936,"status":111,"phases":17020,"primaryCompletion":2406,"completion":10938,"start":4030,"enrollment":101,"conditions":17021,"interventions":17022},[90],[10929],[10941,10942,2764,2760],{"trials":17024,"activeCount":101},[],{"trials":17026,"activeCount":101},[],{"trials":17028,"activeCount":101},[],{"trials":17030,"activeCount":101},[],{"intervention":10942,"totalTrials":424,"cells":17032},{"EARLY_PHASE1":17033,"PHASE1":17035,"PHASE2":17041,"PHASE3":17043,"PHASE4":17045,"NA":17047},{"trials":17034,"activeCount":101},[],{"trials":17036,"activeCount":101},[17037],{"nctId":10935,"briefTitle":10936,"status":111,"phases":17038,"primaryCompletion":2406,"completion":10938,"start":4030,"enrollment":101,"conditions":17039,"interventions":17040},[90],[10929],[10941,10942,2764,2760],{"trials":17042,"activeCount":101},[],{"trials":17044,"activeCount":101},[],{"trials":17046,"activeCount":101},[],{"trials":17048,"activeCount":101},[],{"intervention":2996,"totalTrials":424,"cells":17050},{"EARLY_PHASE1":17051,"PHASE1":17053,"PHASE2":17059,"PHASE3":17061,"PHASE4":17063,"NA":17065},{"trials":17052,"activeCount":101},[],{"trials":17054,"activeCount":101},[17055],{"nctId":2987,"briefTitle":2988,"status":120,"phases":17056,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":424,"conditions":17057,"interventions":17058},[90],[2993,2994],[2996,2980,179],{"trials":17060,"activeCount":101},[],{"trials":17062,"activeCount":101},[],{"trials":17064,"activeCount":101},[],{"trials":17066,"activeCount":101},[],{"intervention":17068,"totalTrials":424,"cells":17069},"Cromolyn Sodium",{"EARLY_PHASE1":17070,"PHASE1":17072,"PHASE2":17083,"PHASE3":17085,"PHASE4":17087,"NA":17089},{"trials":17071,"activeCount":101},[],{"trials":17073,"activeCount":101},[17074],{"nctId":17075,"briefTitle":17076,"status":120,"phases":17077,"primaryCompletion":9239,"completion":6039,"start":2817,"enrollment":1027,"conditions":17078,"interventions":17082},"NCT01841307","Cromolyn Detection of Silent Aspiration",[90],[17079,17080,17081,4008],"Gastroesophageal Reflux","Respiratory Aspiration","Idiopathic Pulmonary Fibrosis",[17068],{"trials":17084,"activeCount":101},[],{"trials":17086,"activeCount":101},[],{"trials":17088,"activeCount":101},[],{"trials":17090,"activeCount":101},[],{"intervention":17092,"totalTrials":424,"cells":17093},"Carfilzomib",{"EARLY_PHASE1":17094,"PHASE1":17096,"PHASE2":17108,"PHASE3":17110,"PHASE4":17112,"NA":17114},{"trials":17095,"activeCount":101},[],{"trials":17097,"activeCount":101},[17098],{"nctId":17099,"briefTitle":17100,"status":132,"phases":17101,"primaryCompletion":12716,"completion":12716,"start":17102,"enrollment":345,"conditions":17103,"interventions":17105},"NCT02187133","Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",[90],"2015-05-05",[17104,717],"Lymphoma, Non-Hodgkin",[17092,17106,17107],"Bendamustine","Rituximab",{"trials":17109,"activeCount":101},[],{"trials":17111,"activeCount":101},[],{"trials":17113,"activeCount":101},[],{"trials":17115,"activeCount":101},[],{"intervention":17106,"totalTrials":424,"cells":17117},{"EARLY_PHASE1":17118,"PHASE1":17120,"PHASE2":17126,"PHASE3":17128,"PHASE4":17130,"NA":17132},{"trials":17119,"activeCount":101},[],{"trials":17121,"activeCount":101},[17122],{"nctId":17099,"briefTitle":17100,"status":132,"phases":17123,"primaryCompletion":12716,"completion":12716,"start":17102,"enrollment":345,"conditions":17124,"interventions":17125},[90],[17104,717],[17092,17106,17107],{"trials":17127,"activeCount":101},[],{"trials":17129,"activeCount":101},[],{"trials":17131,"activeCount":101},[],{"trials":17133,"activeCount":101},[],{"intervention":6046,"totalTrials":407,"cells":17135},{"EARLY_PHASE1":17136,"PHASE1":17158,"PHASE2":17160,"PHASE3":17162,"PHASE4":17164,"NA":17166},{"trials":17137,"activeCount":101},[17138,17142,17146,17150,17154],{"nctId":6036,"briefTitle":6037,"status":132,"phases":17139,"primaryCompletion":6039,"completion":6039,"start":3829,"enrollment":6040,"conditions":17140,"interventions":17141},[89],[6042,6031,6043,6044],[6031,6046],{"nctId":6048,"briefTitle":6049,"status":132,"phases":17143,"primaryCompletion":6051,"completion":6051,"start":6052,"enrollment":3797,"conditions":17144,"interventions":17145},[89],[6042,6031,6043],[6031,6046],{"nctId":6066,"briefTitle":6067,"status":132,"phases":17147,"primaryCompletion":6069,"completion":6069,"start":1913,"enrollment":6070,"conditions":17148,"interventions":17149},[89],[6072,6073,6074],[6031,6046],{"nctId":6077,"briefTitle":6078,"status":132,"phases":17151,"primaryCompletion":6080,"completion":6080,"start":2407,"enrollment":6081,"conditions":17152,"interventions":17153},[89],[6042,6031,6043,6083],[6031,6046],{"nctId":6086,"briefTitle":6087,"status":132,"phases":17155,"primaryCompletion":6089,"completion":6089,"start":2436,"enrollment":28,"conditions":17156,"interventions":17157},[89],[6042,6031,6091,6043],[6031,6046],{"trials":17159,"activeCount":101},[],{"trials":17161,"activeCount":101},[],{"trials":17163,"activeCount":101},[],{"trials":17165,"activeCount":101},[],{"trials":17167,"activeCount":101},[],{"intervention":17169,"totalTrials":526,"cells":17170},"Typhoid Vi Polysaccharide Vaccine",{"EARLY_PHASE1":17171,"PHASE1":17187,"PHASE2":17189,"PHASE3":17191,"PHASE4":17193,"NA":17195},{"trials":17172,"activeCount":101},[17173,17181],{"nctId":17174,"briefTitle":17175,"status":132,"phases":17176,"primaryCompletion":17177,"completion":12716,"start":8790,"enrollment":751,"conditions":17178,"interventions":17180},"NCT03048929","Inflammation and Threat Sensitivity in PTSD",[89],"2020-03-30",[17179],"Posttraumatic Stress Disorder",[17169],{"nctId":17182,"briefTitle":17183,"status":132,"phases":17184,"primaryCompletion":6313,"completion":6313,"start":6357,"enrollment":1202,"conditions":17185,"interventions":17186},"NCT03294564","Cognitive, Emotional, and Neural Responses to Acute Inflammation",[89],[30],[17169],{"trials":17188,"activeCount":101},[],{"trials":17190,"activeCount":101},[],{"trials":17192,"activeCount":101},[],{"trials":17194,"activeCount":101},[],{"trials":17196,"activeCount":101},[],{"intervention":17198,"totalTrials":424,"cells":17199},"Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib",{"EARLY_PHASE1":17200,"PHASE1":17209,"PHASE2":17211,"PHASE3":17213,"PHASE4":17215,"NA":17217},{"trials":17201,"activeCount":101},[17202],{"nctId":17203,"briefTitle":17204,"status":120,"phases":17205,"primaryCompletion":11709,"completion":11709,"start":5727,"enrollment":792,"conditions":17206,"interventions":17208},"NCT00515138","A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant",[89],[17207],"Lymphoma, B-Cell",[17198],{"trials":17210,"activeCount":101},[],{"trials":17212,"activeCount":101},[],{"trials":17214,"activeCount":101},[],{"trials":17216,"activeCount":101},[],{"trials":17218,"activeCount":101},[],{"intervention":17220,"totalTrials":424,"cells":17221},"Fexofenadine Hydrochloride without sodium lauryl sulfate",{"EARLY_PHASE1":17222,"PHASE1":17234,"PHASE2":17236,"PHASE3":17238,"PHASE4":17240,"NA":17242},{"trials":17223,"activeCount":101},[17224],{"nctId":17225,"briefTitle":17226,"status":132,"phases":17227,"primaryCompletion":17228,"completion":17229,"start":42,"enrollment":2818,"conditions":17230,"interventions":17232},"NCT04534153","Excipient Effect on Drug Absorption in Humans",[89],"2025-06-18","2025-08-18",[17231],"The Impact of Excipients on Drug Absorption",[17220,17233],"Fexofenadine Hydrochloride with sodium lauryl sulfate",{"trials":17235,"activeCount":101},[],{"trials":17237,"activeCount":101},[],{"trials":17239,"activeCount":101},[],{"trials":17241,"activeCount":101},[],{"trials":17243,"activeCount":101},[],{"intervention":17233,"totalTrials":424,"cells":17245},{"EARLY_PHASE1":17246,"PHASE1":17252,"PHASE2":17254,"PHASE3":17256,"PHASE4":17258,"NA":17260},{"trials":17247,"activeCount":101},[17248],{"nctId":17225,"briefTitle":17226,"status":132,"phases":17249,"primaryCompletion":17228,"completion":17229,"start":42,"enrollment":2818,"conditions":17250,"interventions":17251},[89],[17231],[17220,17233],{"trials":17253,"activeCount":101},[],{"trials":17255,"activeCount":101},[],{"trials":17257,"activeCount":101},[],{"trials":17259,"activeCount":101},[],{"trials":17261,"activeCount":101},[],{"intervention":17263,"totalTrials":424,"cells":17264},"Brimonidine Tartrate",{"EARLY_PHASE1":17265,"PHASE1":17277,"PHASE2":17279,"PHASE3":17281,"PHASE4":17283,"NA":17285},{"trials":17266,"activeCount":101},[17267],{"nctId":17268,"briefTitle":17269,"status":132,"phases":17270,"primaryCompletion":17271,"completion":17271,"start":11426,"enrollment":1060,"conditions":17272,"interventions":17276},"NCT03497442","Treatment of Asian Flushing Syndrome With Topical Alpha Agonists",[89],"2019-03-25",[17273,17274,17275],"Flushing","Alcohol-Related Disorders","Aldehyde Dehydrogenase Deficiency",[17263],{"trials":17278,"activeCount":101},[],{"trials":17280,"activeCount":101},[],{"trials":17282,"activeCount":101},[],{"trials":17284,"activeCount":101},[],{"trials":17286,"activeCount":101},[],{"intervention":17288,"totalTrials":424,"cells":17289},"Biologically active human fecal material, OpenBiome",{"EARLY_PHASE1":17290,"PHASE1":17301,"PHASE2":17303,"PHASE3":17305,"PHASE4":17307,"NA":17309},{"trials":17291,"activeCount":101},[17292],{"nctId":17293,"briefTitle":17294,"status":132,"phases":17295,"primaryCompletion":17296,"completion":17297,"start":17298,"enrollment":6040,"conditions":17299,"interventions":17300},"NCT02460705","Fecal Microbiota Transplant for Inflammatory Bowel Disease",[89],"2016-12-20","2017-11-04","2015-06",[544],[17288],{"trials":17302,"activeCount":101},[],{"trials":17304,"activeCount":101},[],{"trials":17306,"activeCount":101},[],{"trials":17308,"activeCount":101},[],{"trials":17310,"activeCount":101},[],{"intervention":17312,"totalTrials":424,"cells":17313},"Pyruvate",{"EARLY_PHASE1":17314,"PHASE1":17324,"PHASE2":17326,"PHASE3":17328,"PHASE4":17330,"NA":17332},{"trials":17315,"activeCount":101},[17316],{"nctId":17317,"briefTitle":17318,"status":120,"phases":17319,"primaryCompletion":17320,"completion":17320,"start":17321,"enrollment":407,"conditions":17322,"interventions":17323},"NCT02450201","MRI With C13 Pilot Study Prostate Cancer",[89],"2017-01-17","2016-10-12",[21],[17312],{"trials":17325,"activeCount":101},[],{"trials":17327,"activeCount":101},[],{"trials":17329,"activeCount":101},[],{"trials":17331,"activeCount":101},[],{"trials":17333,"activeCount":101},[],{"intervention":17335,"totalTrials":424,"cells":17336},"Vemurafenib",{"EARLY_PHASE1":17337,"PHASE1":17349,"PHASE2":17351,"PHASE3":17353,"PHASE4":17355,"NA":17357},{"trials":17338,"activeCount":101},[17339],{"nctId":17340,"briefTitle":17341,"status":132,"phases":17342,"primaryCompletion":17343,"completion":17344,"start":17345,"enrollment":28,"conditions":17346,"interventions":17348},"NCT01748149","Vemurafenib in Children With Recurrent\u002FRefractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas",[89],"2018-12-05","2025-07-31","2014-04-29",[17347],"Pediatric Recurrent\u002FRefractory BRAFV600E-mutant Gliomas",[17335],{"trials":17350,"activeCount":101},[],{"trials":17352,"activeCount":101},[],{"trials":17354,"activeCount":101},[],{"trials":17356,"activeCount":101},[],{"trials":17358,"activeCount":101},[],{"intervention":973,"totalTrials":424,"cells":17360},{"EARLY_PHASE1":17361,"PHASE1":17367,"PHASE2":17369,"PHASE3":17371,"PHASE4":17373,"NA":17375},{"trials":17362,"activeCount":101},[17363],{"nctId":964,"briefTitle":965,"status":132,"phases":17364,"primaryCompletion":967,"completion":967,"start":968,"enrollment":28,"conditions":17365,"interventions":17366},[89],[970],[959,972,973,974],{"trials":17368,"activeCount":101},[],{"trials":17370,"activeCount":101},[],{"trials":17372,"activeCount":101},[],{"trials":17374,"activeCount":101},[],{"trials":17376,"activeCount":101},[],{"intervention":974,"totalTrials":424,"cells":17378},{"EARLY_PHASE1":17379,"PHASE1":17385,"PHASE2":17387,"PHASE3":17389,"PHASE4":17391,"NA":17393},{"trials":17380,"activeCount":101},[17381],{"nctId":964,"briefTitle":965,"status":132,"phases":17382,"primaryCompletion":967,"completion":967,"start":968,"enrollment":28,"conditions":17383,"interventions":17384},[89],[970],[959,972,973,974],{"trials":17386,"activeCount":101},[],{"trials":17388,"activeCount":101},[],{"trials":17390,"activeCount":101},[],{"trials":17392,"activeCount":101},[],{"trials":17394,"activeCount":101},[],{"intervention":17396,"totalTrials":424,"cells":17397},"Valacyclovir group",{"EARLY_PHASE1":17398,"PHASE1":17409,"PHASE2":17411,"PHASE3":17413,"PHASE4":17415,"NA":17417},{"trials":17399,"activeCount":101},[17400],{"nctId":17401,"briefTitle":17402,"status":2462,"phases":17403,"primaryCompletion":17404,"completion":17404,"start":17405,"enrollment":28,"conditions":17406,"interventions":17408},"NCT05712343","The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis",[89],"2024-03-01","2023-05-25",[17407],"Severe Periodontitis",[17396],{"trials":17410,"activeCount":101},[],{"trials":17412,"activeCount":101},[],{"trials":17414,"activeCount":101},[],{"trials":17416,"activeCount":101},[],{"trials":17418,"activeCount":101},[],{"intervention":685,"totalTrials":2472,"cells":17420},{"EARLY_PHASE1":17421,"PHASE1":17423,"PHASE2":17440,"PHASE3":17454,"PHASE4":17456,"NA":17458},{"trials":17422,"activeCount":101},[],{"trials":17424,"activeCount":101},[17425,17429,17436],{"nctId":2571,"briefTitle":2572,"status":132,"phases":17426,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":792,"conditions":17427,"interventions":17428},[90],[679,717,2359,680],[719,2578,684,685,2470,2362],{"nctId":17430,"briefTitle":17431,"status":132,"phases":17432,"primaryCompletion":3828,"completion":3828,"start":9350,"enrollment":97,"conditions":17433,"interventions":17434},"NCT00295971","Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease",[90],[677,679,680,681],[719,721,685,17435],"thiotepa",{"nctId":2580,"briefTitle":2581,"status":132,"phases":17437,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":407,"conditions":17438,"interventions":17439},[90],[679,717,2359,680],[719,2578,684,2587,685,2588,2362],{"trials":17441,"activeCount":101},[17442,17446,17450],{"nctId":2352,"briefTitle":2353,"status":111,"phases":17443,"primaryCompletion":714,"start":2355,"enrollment":101,"conditions":17444,"interventions":17445},[91],[2357,2358,679,717,2359,680,2360],[720,684,685,686,2362],{"nctId":5251,"briefTitle":5252,"status":132,"phases":17447,"primaryCompletion":5254,"completion":5254,"start":5255,"enrollment":28,"conditions":17448,"interventions":17449},[90,91],[677,678,5257,679,681,5258],[719,684,685],{"nctId":670,"briefTitle":671,"status":132,"phases":17451,"primaryCompletion":673,"completion":673,"start":674,"enrollment":675,"conditions":17452,"interventions":17453},[91],[677,678,679,680,681],[683,684,661,685,686,687],{"trials":17455,"activeCount":101},[],{"trials":17457,"activeCount":101},[],{"trials":17459,"activeCount":101},[17460,17464,17468],{"nctId":710,"briefTitle":711,"status":120,"phases":17461,"primaryCompletion":713,"completion":714,"start":715,"enrollment":555,"conditions":17462,"interventions":17463},[94],[679,717],[719,720,721,661,685,722,686],{"nctId":2451,"briefTitle":2452,"status":132,"phases":17465,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":353,"conditions":17466,"interventions":17467},[94],[2358,679,717,2359,680],[719,720,721,684,685,686,2362],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":17469,"start":2464,"enrollment":675,"conditions":17470,"interventions":17471},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":719,"totalTrials":792,"cells":17473},{"EARLY_PHASE1":17474,"PHASE1":17476,"PHASE2":17490,"PHASE3":17496,"PHASE4":17498,"NA":17500},{"trials":17475,"activeCount":101},[],{"trials":17477,"activeCount":101},[17478,17482,17486],{"nctId":2571,"briefTitle":2572,"status":132,"phases":17479,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":792,"conditions":17480,"interventions":17481},[90],[679,717,2359,680],[719,2578,684,685,2470,2362],{"nctId":17430,"briefTitle":17431,"status":132,"phases":17483,"primaryCompletion":3828,"completion":3828,"start":9350,"enrollment":97,"conditions":17484,"interventions":17485},[90],[677,679,680,681],[719,721,685,17435],{"nctId":2580,"briefTitle":2581,"status":132,"phases":17487,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":407,"conditions":17488,"interventions":17489},[90],[679,717,2359,680],[719,2578,684,2587,685,2588,2362],{"trials":17491,"activeCount":101},[17492],{"nctId":5251,"briefTitle":5252,"status":132,"phases":17493,"primaryCompletion":5254,"completion":5254,"start":5255,"enrollment":28,"conditions":17494,"interventions":17495},[90,91],[677,678,5257,679,681,5258],[719,684,685],{"trials":17497,"activeCount":101},[],{"trials":17499,"activeCount":101},[],{"trials":17501,"activeCount":101},[17502,17506,17510],{"nctId":710,"briefTitle":711,"status":120,"phases":17503,"primaryCompletion":713,"completion":714,"start":715,"enrollment":555,"conditions":17504,"interventions":17505},[94],[679,717],[719,720,721,661,685,722,686],{"nctId":2451,"briefTitle":2452,"status":132,"phases":17507,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":353,"conditions":17508,"interventions":17509},[94],[2358,679,717,2359,680],[719,720,721,684,685,686,2362],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":17511,"start":2464,"enrollment":675,"conditions":17512,"interventions":17513},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":720,"totalTrials":2564,"cells":17515},{"EARLY_PHASE1":17516,"PHASE1":17518,"PHASE2":17520,"PHASE3":17534,"PHASE4":17536,"NA":17538},{"trials":17517,"activeCount":101},[],{"trials":17519,"activeCount":101},[],{"trials":17521,"activeCount":101},[17522,17526],{"nctId":2352,"briefTitle":2353,"status":111,"phases":17523,"primaryCompletion":714,"start":2355,"enrollment":101,"conditions":17524,"interventions":17525},[91],[2357,2358,679,717,2359,680,2360],[720,684,685,686,2362],{"nctId":17527,"briefTitle":17528,"status":132,"phases":17529,"primaryCompletion":17530,"completion":17530,"start":9350,"enrollment":17531,"conditions":17532,"interventions":17533},"NCT00293319","131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma",[91],"2006-03",164,[11678],[720],{"trials":17535,"activeCount":101},[],{"trials":17537,"activeCount":101},[],{"trials":17539,"activeCount":101},[17540,17544,17548,17552],{"nctId":2432,"briefTitle":2433,"status":132,"phases":17541,"primaryCompletion":2435,"completion":2436,"start":2437,"enrollment":345,"conditions":17542,"interventions":17543},[94],[2439,717],[720,2441,2442,2443,2444,686,2445],{"nctId":710,"briefTitle":711,"status":120,"phases":17545,"primaryCompletion":713,"completion":714,"start":715,"enrollment":555,"conditions":17546,"interventions":17547},[94],[679,717],[719,720,721,661,685,722,686],{"nctId":2451,"briefTitle":2452,"status":132,"phases":17549,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":353,"conditions":17550,"interventions":17551},[94],[2358,679,717,2359,680],[719,720,721,684,685,686,2362],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":17553,"start":2464,"enrollment":675,"conditions":17554,"interventions":17555},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":2764,"totalTrials":2564,"cells":17557},{"EARLY_PHASE1":17558,"PHASE1":17560,"PHASE2":17574,"PHASE3":17584,"PHASE4":17586,"NA":17588},{"trials":17559,"activeCount":101},[],{"trials":17561,"activeCount":101},[17562,17566,17570],{"nctId":2737,"briefTitle":2738,"status":132,"phases":17563,"primaryCompletion":779,"completion":779,"start":2740,"enrollment":1060,"conditions":17564,"interventions":17565},[90],[2742,2743,2744,2745,2746,2747,2748,2749,2750,2751,2752,2753,2754,2755],[2757,2758,2759,2730,2760,2761,2762,2763,2377,2764],{"nctId":11130,"briefTitle":11131,"status":120,"phases":17567,"primaryCompletion":11133,"completion":11133,"start":11134,"enrollment":2564,"conditions":17568,"interventions":17569},[90],[11136,11137],[11139,2764,2386,2383],{"nctId":10935,"briefTitle":10936,"status":111,"phases":17571,"primaryCompletion":2406,"completion":10938,"start":4030,"enrollment":101,"conditions":17572,"interventions":17573},[90],[10929],[10941,10942,2764,2760],{"trials":17575,"activeCount":101},[17576,17580],{"nctId":10946,"briefTitle":10947,"status":132,"phases":17577,"primaryCompletion":10949,"completion":10949,"start":10950,"enrollment":2335,"conditions":17578,"interventions":17579},[91],[811,5733,10914],[10953,5738,10917],{"nctId":6217,"briefTitle":6218,"status":120,"phases":17581,"primaryCompletion":713,"completion":6220,"start":2435,"enrollment":424,"conditions":17582,"interventions":17583},[91],[811],[815,5738,5739],{"trials":17585,"activeCount":101},[],{"trials":17587,"activeCount":101},[],{"trials":17589,"activeCount":101},[17590],{"nctId":5723,"briefTitle":5724,"status":132,"phases":17591,"primaryCompletion":3829,"completion":5726,"start":5727,"enrollment":2495,"conditions":17592,"interventions":17593},[],[24,5729,5730,5731,5732,5733,5734],[5736,5737,5738,2398,5739,5695],{"intervention":2411,"totalTrials":2564,"cells":17595},{"EARLY_PHASE1":17596,"PHASE1":17598,"PHASE2":17604,"PHASE3":17618,"PHASE4":17628,"NA":17630},{"trials":17597,"activeCount":101},[],{"trials":17599,"activeCount":101},[17600],{"nctId":2571,"briefTitle":2572,"status":132,"phases":17601,"primaryCompletion":2574,"completion":2574,"start":2575,"enrollment":792,"conditions":17602,"interventions":17603},[90],[679,717,2359,680],[719,2578,684,685,2470,2362],{"trials":17605,"activeCount":101},[17606],{"nctId":17607,"briefTitle":17608,"status":111,"phases":17609,"primaryCompletion":17610,"completion":17611,"start":17612,"enrollment":101,"conditions":17613,"interventions":17616},"NCT04473924","Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk",[91],"2023-01","2023-05","2022-07",[17614,17615],"Infection","Transplant;Failure,Kidney",[17617,17617],"Mycophenolate Mofetil",{"trials":17619,"activeCount":101},[17620,17624],{"nctId":2403,"briefTitle":2404,"status":132,"phases":17621,"primaryCompletion":2406,"completion":2406,"start":2407,"enrollment":2335,"conditions":17622,"interventions":17623},[92],[2409],[385,2411],{"nctId":2413,"briefTitle":2414,"status":132,"phases":17625,"primaryCompletion":2416,"completion":2417,"start":2418,"enrollment":2419,"conditions":17626,"interventions":17627},[92],[2409],[2411,385,2422],{"trials":17629,"activeCount":101},[],{"trials":17631,"activeCount":101},[17632,17639],{"nctId":17633,"briefTitle":17634,"status":132,"phases":17635,"primaryCompletion":2546,"completion":2546,"start":4059,"enrollment":792,"conditions":17636,"interventions":17638},"NCT00333437","Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement",[94],[17637],"Scleroderma, Systemic",[2411],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":17640,"start":2464,"enrollment":675,"conditions":17641,"interventions":17642},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":17107,"totalTrials":407,"cells":17644},{"EARLY_PHASE1":17645,"PHASE1":17647,"PHASE2":17667,"PHASE3":17669,"PHASE4":17671,"NA":17673},{"trials":17646,"activeCount":101},[],{"trials":17648,"activeCount":101},[17649,17656,17663],{"nctId":17650,"briefTitle":17651,"status":132,"phases":17652,"primaryCompletion":11074,"completion":6220,"start":17653,"enrollment":345,"conditions":17654,"interventions":17655},"NCT00416923","Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma",[90],"2002-08",[2439,717],[2441],{"nctId":17657,"briefTitle":17658,"status":132,"phases":17659,"primaryCompletion":7096,"completion":7096,"start":15256,"enrollment":1060,"conditions":17660,"interventions":17662},"NCT00501748","Safety and Tolerability of Rituximab in Neuromyelitis Optica",[90],[17661],"Neuromyelitis Optica",[17107],{"nctId":17099,"briefTitle":17100,"status":132,"phases":17664,"primaryCompletion":12716,"completion":12716,"start":17102,"enrollment":345,"conditions":17665,"interventions":17666},[90],[17104,717],[17092,17106,17107],{"trials":17668,"activeCount":101},[],{"trials":17670,"activeCount":101},[],{"trials":17672,"activeCount":101},[],{"trials":17674,"activeCount":101},[17675,17679],{"nctId":2432,"briefTitle":2433,"status":132,"phases":17676,"primaryCompletion":2435,"completion":2436,"start":2437,"enrollment":345,"conditions":17677,"interventions":17678},[94],[2439,717],[720,2441,2442,2443,2444,686,2445],{"nctId":17680,"briefTitle":17681,"status":132,"phases":17682,"primaryCompletion":7096,"completion":7096,"start":2773,"enrollment":5422,"conditions":17683,"interventions":17685},"NCT00695097","The Effect of Rituximab on the Development of Anti-Donor Antibodies",[94],[17684],"Renal Transplant Rejection",[17107,17686],"No Rituximab",{"intervention":15458,"totalTrials":480,"cells":17688},{"EARLY_PHASE1":17689,"PHASE1":17691,"PHASE2":17697,"PHASE3":17713,"PHASE4":17715,"NA":17717},{"trials":17690,"activeCount":101},[],{"trials":17692,"activeCount":101},[17693],{"nctId":15452,"briefTitle":15453,"status":132,"phases":17694,"primaryCompletion":4155,"completion":4155,"start":2722,"enrollment":28,"conditions":17695,"interventions":17696},[90],[18,15456],[15458,15445,15459,15460],{"trials":17698,"activeCount":101},[17699,17705],{"nctId":17700,"briefTitle":17701,"status":132,"phases":17702,"primaryCompletion":6149,"completion":6149,"start":433,"enrollment":751,"conditions":17703,"interventions":17704},"NCT01944371","Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study",[90,91],[15,7100],[15458],{"nctId":17706,"briefTitle":17707,"status":120,"phases":17708,"primaryCompletion":9005,"completion":9005,"start":17709,"enrollment":541,"conditions":17710,"interventions":17712},"NCT04485130","DISulfiram for COvid-19 (DISCO) Trial",[91],"2021-08-18",[17711],"Covid19",[15458],{"trials":17714,"activeCount":101},[],{"trials":17716,"activeCount":101},[],{"trials":17718,"activeCount":101},[17719],{"nctId":17720,"briefTitle":17721,"status":132,"phases":17722,"primaryCompletion":6149,"completion":6149,"start":4275,"enrollment":1027,"conditions":17723,"interventions":17725},"NCT01286259","Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals",[94],[17724],"HIV-1 Infection",[15458],{"intervention":14926,"totalTrials":480,"cells":17727},{"EARLY_PHASE1":17728,"PHASE1":17730,"PHASE2":17740,"PHASE3":17742,"PHASE4":17744,"NA":17746},{"trials":17729,"activeCount":101},[],{"trials":17731,"activeCount":101},[17732,17736],{"nctId":15076,"briefTitle":15077,"status":132,"phases":17733,"primaryCompletion":10938,"completion":7097,"start":236,"enrollment":3626,"conditions":17734,"interventions":17735},[90],[24,3862],[15069,14926],{"nctId":14917,"briefTitle":14918,"status":132,"phases":17737,"primaryCompletion":3818,"completion":14920,"start":14921,"enrollment":28,"conditions":17738,"interventions":17739},[90],[14923],[14925,14910,14926,11047,14927],{"trials":17741,"activeCount":101},[],{"trials":17743,"activeCount":101},[],{"trials":17745,"activeCount":101},[],{"trials":17747,"activeCount":101},[17748,17756],{"nctId":17749,"briefTitle":17750,"status":132,"phases":17751,"primaryCompletion":8837,"start":9697,"enrollment":2840,"conditions":17752,"interventions":17753},"NCT00316823","Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules",[94],[12131],[14926,17754,17755],"polymerase chain reaction","reverse transcriptase-polymerase chain reaction",{"nctId":17757,"briefTitle":17758,"status":132,"phases":17759,"primaryCompletion":238,"completion":238,"start":2437,"enrollment":510,"conditions":17760,"interventions":17761},"NCT00739791","Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer",[94],[21],[14926,17754,17762,17755],"proteomic profiling",{"intervention":6395,"totalTrials":480,"cells":17764},{"EARLY_PHASE1":17765,"PHASE1":17767,"PHASE2":17769,"PHASE3":17781,"PHASE4":17783,"NA":17799},{"trials":17766,"activeCount":101},[],{"trials":17768,"activeCount":101},[],{"trials":17770,"activeCount":101},[17771],{"nctId":17772,"briefTitle":17773,"status":120,"phases":17774,"primaryCompletion":17775,"completion":17776,"start":17777,"enrollment":1202,"conditions":17778,"interventions":17780},"NCT00751101","Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer",[91],"2014-03-24","2018-03-24","2007-08-20",[24,5729,17779],"Palmar-plantar Erythrodysesthesia",[6395],{"trials":17782,"activeCount":101},[],{"trials":17784,"activeCount":101},[17785,17789],{"nctId":6387,"briefTitle":6388,"status":132,"phases":17786,"primaryCompletion":6390,"completion":6390,"start":6391,"enrollment":6392,"conditions":17787,"interventions":17788},[93],[2661,2660],[6364,6395,6396],{"nctId":17790,"briefTitle":17791,"status":132,"phases":17792,"primaryCompletion":17793,"completion":17793,"start":17794,"enrollment":8109,"conditions":17795,"interventions":17797},"NCT03163303","Smoking Tobacco and Drinking Study",[93],"2019-06-30","2017-12-18",[6381,17796],"Heavy Episodic Drinking",[17798],"nicotine patch",{"trials":17800,"activeCount":101},[17801],{"nctId":17802,"briefTitle":17803,"status":132,"phases":17804,"primaryCompletion":2435,"completion":2435,"start":17805,"enrollment":7145,"conditions":17806,"interventions":17807},"NCT01207310","Pager-Assisted Smoking Cessation Treatment",[94],"2003-05",[6405],[6395],{"intervention":10238,"totalTrials":480,"cells":17809},{"EARLY_PHASE1":17810,"PHASE1":17821,"PHASE2":17823,"PHASE3":17832,"PHASE4":17838,"NA":17840},{"trials":17811,"activeCount":101},[17812],{"nctId":17813,"briefTitle":17814,"status":132,"phases":17815,"primaryCompletion":3828,"completion":3828,"start":447,"enrollment":25,"conditions":17816,"interventions":17820},"NCT01175512","Stress, Hormones, and Eating",[89],[17817,17818,17819],"Food Addiction","How Opioid Tone Was Related to Self Reported","Drive to Eat Using a Measure of Food Addiction",[10238],{"trials":17822,"activeCount":101},[],{"trials":17824,"activeCount":101},[17825],{"nctId":17826,"briefTitle":17827,"status":132,"phases":17828,"primaryCompletion":8181,"completion":8181,"start":3705,"enrollment":3797,"conditions":17829,"interventions":17831},"NCT02330419","Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)",[91],[17830,15],"Binge Drinking",[10238],{"trials":17833,"activeCount":101},[17834],{"nctId":10233,"briefTitle":10234,"status":132,"phases":17835,"primaryCompletion":714,"completion":714,"start":6378,"enrollment":2335,"conditions":17836,"interventions":17837},[92],[765],[10222,10238],{"trials":17839,"activeCount":101},[],{"trials":17841,"activeCount":101},[17842],{"nctId":17843,"briefTitle":17844,"status":132,"phases":17845,"primaryCompletion":2435,"completion":8859,"start":3860,"conditions":17846,"interventions":17848},"NCT00254670","Naltrexone Effects on Alcohol Intake",[94],[17847],"Social Drinker",[10238],{"intervention":5739,"totalTrials":480,"cells":17850},{"EARLY_PHASE1":17851,"PHASE1":17853,"PHASE2":17855,"PHASE3":17869,"PHASE4":17871,"NA":17873},{"trials":17852,"activeCount":101},[],{"trials":17854,"activeCount":101},[],{"trials":17856,"activeCount":101},[17857,17861,17865],{"nctId":11840,"briefTitle":11841,"status":132,"phases":17858,"primaryCompletion":11843,"completion":6149,"start":6220,"enrollment":11844,"conditions":17859,"interventions":17860},[91],[21],[11847,11831],{"nctId":9631,"briefTitle":9632,"status":120,"phases":17862,"primaryCompletion":6198,"completion":6198,"start":3860,"enrollment":2564,"conditions":17863,"interventions":17864},[90,91],[21],[5739,2588,9636],{"nctId":6217,"briefTitle":6218,"status":120,"phases":17866,"primaryCompletion":713,"completion":6220,"start":2435,"enrollment":424,"conditions":17867,"interventions":17868},[91],[811],[815,5738,5739],{"trials":17870,"activeCount":101},[],{"trials":17872,"activeCount":101},[],{"trials":17874,"activeCount":101},[17875],{"nctId":5723,"briefTitle":5724,"status":132,"phases":17876,"primaryCompletion":3829,"completion":5726,"start":5727,"enrollment":2495,"conditions":17877,"interventions":17878},[],[24,5729,5730,5731,5732,5733,5734],[5736,5737,5738,2398,5739,5695],{"intervention":5736,"totalTrials":480,"cells":17880},{"EARLY_PHASE1":17881,"PHASE1":17883,"PHASE2":17889,"PHASE3":17899,"PHASE4":17901,"NA":17903},{"trials":17882,"activeCount":101},[],{"trials":17884,"activeCount":101},[17885],{"nctId":10923,"briefTitle":10924,"status":132,"phases":17886,"primaryCompletion":921,"completion":540,"start":10926,"enrollment":498,"conditions":17887,"interventions":17888},[90],[10928,10929,10930],[10932,2760,10933],{"trials":17890,"activeCount":101},[17891,17895],{"nctId":11081,"briefTitle":11082,"status":132,"phases":17892,"primaryCompletion":11084,"completion":3858,"start":6695,"enrollment":2472,"conditions":17893,"interventions":17894},[91],[24],[5736,3864],{"nctId":13381,"briefTitle":13382,"status":132,"phases":17896,"primaryCompletion":6492,"completion":6492,"start":13384,"enrollment":541,"conditions":17897,"interventions":17898},[91],[13386,13387,13388,13389,13390,13391,13392,13393,13394],[13372,10933,13396,13397,13398],{"trials":17900,"activeCount":101},[],{"trials":17902,"activeCount":101},[],{"trials":17904,"activeCount":101},[17905],{"nctId":5723,"briefTitle":5724,"status":132,"phases":17906,"primaryCompletion":3829,"completion":5726,"start":5727,"enrollment":2495,"conditions":17907,"interventions":17908},[],[24,5729,5730,5731,5732,5733,5734],[5736,5737,5738,2398,5739,5695],{"intervention":17910,"totalTrials":480,"cells":17911},"raltegravir",{"EARLY_PHASE1":17912,"PHASE1":17914,"PHASE2":17916,"PHASE3":17918,"PHASE4":17920,"NA":17935},{"trials":17913,"activeCount":101},[],{"trials":17915,"activeCount":101},[],{"trials":17917,"activeCount":101},[],{"trials":17919,"activeCount":101},[],{"trials":17921,"activeCount":101},[17922,17929],{"nctId":17923,"briefTitle":17924,"status":132,"phases":17925,"primaryCompletion":9755,"completion":1201,"start":11014,"enrollment":751,"conditions":17926,"interventions":17927},"NCT00631449","Raltegravir Intensification in HIV-infected Patients",[93],[18],[17928],"Raltegravir",{"nctId":17930,"briefTitle":17931,"status":132,"phases":17932,"primaryCompletion":540,"completion":11708,"start":2546,"enrollment":19,"conditions":17933,"interventions":17934},"NCT00843713","Effect of Raltegravir on Endothelial Function in HIV-Infected Patients",[93],[2539,1707,4033,18],[17910],{"trials":17936,"activeCount":101},[17937,17945],{"nctId":17938,"briefTitle":17939,"status":132,"phases":17940,"primaryCompletion":8837,"completion":7096,"start":4042,"enrollment":555,"conditions":17941,"interventions":17942},"NCT00884793","Pilot Study on the Effect of Adding Raltegravir +\u002F- a Second Drug on HIV Levels in the Gut",[94],[18],[17910,17943,17944],"Study NNRTI","Study PI",{"nctId":17946,"briefTitle":17947,"status":132,"phases":17948,"primaryCompletion":2407,"completion":13733,"start":3696,"enrollment":5422,"conditions":17949,"interventions":17950},"NCT00672932","Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients",[94],[18],[17910],{"intervention":721,"totalTrials":480,"cells":17952},{"EARLY_PHASE1":17953,"PHASE1":17955,"PHASE2":17961,"PHASE3":17963,"PHASE4":17965,"NA":17967},{"trials":17954,"activeCount":101},[],{"trials":17956,"activeCount":101},[17957],{"nctId":17430,"briefTitle":17431,"status":132,"phases":17958,"primaryCompletion":3828,"completion":3828,"start":9350,"enrollment":97,"conditions":17959,"interventions":17960},[90],[677,679,680,681],[719,721,685,17435],{"trials":17962,"activeCount":101},[],{"trials":17964,"activeCount":101},[],{"trials":17966,"activeCount":101},[],{"trials":17968,"activeCount":101},[17969,17973,17977],{"nctId":710,"briefTitle":711,"status":120,"phases":17970,"primaryCompletion":713,"completion":714,"start":715,"enrollment":555,"conditions":17971,"interventions":17972},[94],[679,717],[719,720,721,661,685,722,686],{"nctId":2451,"briefTitle":2452,"status":132,"phases":17974,"primaryCompletion":2454,"completion":2455,"start":2456,"enrollment":353,"conditions":17975,"interventions":17976},[94],[2358,679,717,2359,680],[719,720,721,684,685,686,2362],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":17978,"start":2464,"enrollment":675,"conditions":17979,"interventions":17980},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":972,"totalTrials":480,"cells":17982},{"EARLY_PHASE1":17983,"PHASE1":17989,"PHASE2":17998,"PHASE3":18000,"PHASE4":18002,"NA":18004},{"trials":17984,"activeCount":101},[17985],{"nctId":964,"briefTitle":965,"status":132,"phases":17986,"primaryCompletion":967,"completion":967,"start":968,"enrollment":28,"conditions":17987,"interventions":17988},[89],[970],[959,972,973,974],{"trials":17990,"activeCount":101},[17991],{"nctId":17992,"briefTitle":17993,"status":132,"phases":17994,"primaryCompletion":2436,"completion":2436,"start":7096,"enrollment":1027,"conditions":17995,"interventions":17997},"NCT01116700","Dexmedetomidine in Seizure Patients",[90],[17996],"Seizure Disorders",[972],{"trials":17999,"activeCount":101},[],{"trials":18001,"activeCount":101},[],{"trials":18003,"activeCount":101},[],{"trials":18005,"activeCount":101},[18006,18014],{"nctId":18007,"briefTitle":18008,"status":120,"phases":18009,"primaryCompletion":1913,"completion":1200,"start":714,"enrollment":25,"conditions":18010,"interventions":18013},"NCT00464490","Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts",[94],[18011,18012],"Intubation; Difficult","Respiration Disorders",[972],{"nctId":18015,"briefTitle":18016,"status":132,"phases":18017,"primaryCompletion":18018,"completion":509,"start":1913,"enrollment":324,"conditions":18019,"interventions":18021},"NCT01342328","Providing \"Good Sleep\" for ICU Sedation",[94],"2018-10-01",[18020],"Sleep Disorders",[972,18022],"Propofol",{"intervention":18024,"totalTrials":480,"cells":18025},"Topiramate",{"EARLY_PHASE1":18026,"PHASE1":18028,"PHASE2":18030,"PHASE3":18032,"PHASE4":18034,"NA":18059},{"trials":18027,"activeCount":101},[],{"trials":18029,"activeCount":101},[],{"trials":18031,"activeCount":101},[],{"trials":18033,"activeCount":101},[],{"trials":18035,"activeCount":101},[18036,18042,18052],{"nctId":18037,"briefTitle":18038,"status":132,"phases":18039,"primaryCompletion":6134,"completion":6134,"start":8836,"enrollment":34,"conditions":18040,"interventions":18041},"NCT01750268","Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI",[93],[6658,6659],[18024],{"nctId":18043,"briefTitle":18044,"status":132,"phases":18045,"primaryCompletion":18046,"completion":18046,"start":18047,"enrollment":18048,"conditions":18049,"interventions":18051},"NCT01749215","A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD",[93],"2019-07","2013-02",151,[18050,5616],"Alcohol Dependence",[18024],{"nctId":18053,"briefTitle":18054,"status":132,"phases":18055,"primaryCompletion":3829,"completion":7097,"start":4041,"enrollment":751,"conditions":18056,"interventions":18058},"NCT01087736","Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy",[93],[18057,8749,6063],"PTSD",[18024],{"trials":18060,"activeCount":101},[18061],{"nctId":18062,"briefTitle":18063,"status":111,"phases":18064,"primaryCompletion":10423,"start":2722,"enrollment":101,"conditions":18065,"interventions":18068},"NCT00732108","Is Topiramate Effective in Treating Dizziness in Patient's With Migraine-Associated Dizziness",[94],[5911,18066,18067],"Headache","Dizziness",[18069,18070],"topiramate","lactulose placebo pill",{"intervention":2385,"totalTrials":324,"cells":18072},{"EARLY_PHASE1":18073,"PHASE1":18075,"PHASE2":18081,"PHASE3":18087,"PHASE4":18089,"NA":18091},{"trials":18074,"activeCount":101},[],{"trials":18076,"activeCount":101},[18077],{"nctId":14929,"briefTitle":14930,"status":132,"phases":18078,"primaryCompletion":14932,"completion":1312,"start":805,"enrollment":1183,"conditions":18079,"interventions":18080},[90],[5221,14934],[14936,2385,14937],{"trials":18082,"activeCount":101},[18083],{"nctId":2368,"briefTitle":2369,"status":120,"phases":18084,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":18085,"interventions":18086},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":18088,"activeCount":101},[],{"trials":18090,"activeCount":101},[],{"trials":18092,"activeCount":101},[18093],{"nctId":2432,"briefTitle":2433,"status":132,"phases":18094,"primaryCompletion":2435,"completion":2436,"start":2437,"enrollment":345,"conditions":18095,"interventions":18096},[94],[2439,717],[720,2441,2442,2443,2444,686,2445],{"intervention":5695,"totalTrials":324,"cells":18098},{"EARLY_PHASE1":18099,"PHASE1":18101,"PHASE2":18103,"PHASE3":18113,"PHASE4":18115,"NA":18117},{"trials":18100,"activeCount":101},[],{"trials":18102,"activeCount":101},[],{"trials":18104,"activeCount":101},[18105,18109],{"nctId":5688,"briefTitle":5689,"status":132,"phases":18106,"completion":3860,"start":5691,"conditions":18107,"interventions":18108},[90,91],[24,5693],[2398,5695],{"nctId":2368,"briefTitle":2369,"status":120,"phases":18110,"primaryCompletion":2371,"completion":2372,"start":2373,"enrollment":97,"conditions":18111,"interventions":18112},[91],[2375],[2377,2378,2379,2380,2381,2382,2383,797,385,2384,2385,2386,2387,2388],{"trials":18114,"activeCount":101},[],{"trials":18116,"activeCount":101},[],{"trials":18118,"activeCount":101},[18119],{"nctId":5723,"briefTitle":5724,"status":132,"phases":18120,"primaryCompletion":3829,"completion":5726,"start":5727,"enrollment":2495,"conditions":18121,"interventions":18122},[],[24,5729,5730,5731,5732,5733,5734],[5736,5737,5738,2398,5739,5695],{"intervention":17754,"totalTrials":324,"cells":18124},{"EARLY_PHASE1":18125,"PHASE1":18127,"PHASE2":18129,"PHASE3":18131,"PHASE4":18133,"NA":18135},{"trials":18126,"activeCount":101},[],{"trials":18128,"activeCount":101},[],{"trials":18130,"activeCount":101},[],{"trials":18132,"activeCount":101},[],{"trials":18134,"activeCount":101},[],{"trials":18136,"activeCount":101},[18137,18141,18145],{"nctId":17749,"briefTitle":17750,"status":132,"phases":18138,"primaryCompletion":8837,"start":9697,"enrollment":2840,"conditions":18139,"interventions":18140},[94],[12131],[14926,17754,17755],{"nctId":17757,"briefTitle":17758,"status":132,"phases":18142,"primaryCompletion":238,"completion":238,"start":2437,"enrollment":510,"conditions":18143,"interventions":18144},[94],[21],[14926,17754,17762,17755],{"nctId":18146,"briefTitle":18147,"status":132,"phases":18148,"primaryCompletion":18149,"completion":18149,"start":17653,"enrollment":751,"conditions":18150,"interventions":18151},"NCT00429988","Study of Ductal Lavage in Women at High Risk for Breast Cancer",[],"2004-06",[24],[18152,17754,17762],"fluorescence in situ hybridization",{"intervention":18154,"totalTrials":324,"cells":18155},"Minocycline",{"EARLY_PHASE1":18156,"PHASE1":18158,"PHASE2":18164,"PHASE3":18166,"PHASE4":18168,"NA":18170},{"trials":18157,"activeCount":101},[],{"trials":18159,"activeCount":101},[18160],{"nctId":14892,"briefTitle":14893,"status":132,"phases":18161,"primaryCompletion":2636,"completion":2636,"start":5254,"enrollment":695,"conditions":18162,"interventions":18163},[90],[14896,14897],[14899,14900],{"trials":18165,"activeCount":101},[],{"trials":18167,"activeCount":101},[],{"trials":18169,"activeCount":101},[],{"trials":18171,"activeCount":101},[18172,18178],{"nctId":18173,"briefTitle":18174,"status":132,"phases":18175,"primaryCompletion":15930,"completion":15930,"start":9350,"enrollment":792,"conditions":18176,"interventions":18177},"NCT01064752","A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection",[],[2539],[18154],{"nctId":18179,"briefTitle":18180,"status":132,"phases":18181,"primaryCompletion":6039,"completion":6039,"start":11708,"enrollment":8791,"conditions":18182,"interventions":18184},"NCT01802216","Kidney and Periodontal Disease Study",[94],[14888,18183],"Periodontal Disease",[18154],{"intervention":11139,"totalTrials":324,"cells":18186},{"EARLY_PHASE1":18187,"PHASE1":18189,"PHASE2":18195,"PHASE3":18197,"PHASE4":18199,"NA":18201},{"trials":18188,"activeCount":101},[],{"trials":18190,"activeCount":101},[18191],{"nctId":11130,"briefTitle":11131,"status":120,"phases":18192,"primaryCompletion":11133,"completion":11133,"start":11134,"enrollment":2564,"conditions":18193,"interventions":18194},[90],[11136,11137],[11139,2764,2386,2383],{"trials":18196,"activeCount":101},[],{"trials":18198,"activeCount":101},[],{"trials":18200,"activeCount":101},[],{"trials":18202,"activeCount":101},[18203,18207],{"nctId":710,"briefTitle":711,"status":120,"phases":18204,"primaryCompletion":713,"completion":714,"start":715,"enrollment":555,"conditions":18205,"interventions":18206},[94],[679,717],[719,720,721,661,685,722,686],{"nctId":18208,"briefTitle":18209,"status":132,"phases":18210,"primaryCompletion":18211,"completion":18211,"start":18212,"enrollment":353,"conditions":18213,"interventions":18214},"NCT03609827","Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients",[],"2021-05-31","2015-09-01",[5774,5775,5776,5777,5778,5788,5779,4083],[11139],{"intervention":18216,"totalTrials":324,"cells":18217},"Sertraline",{"EARLY_PHASE1":18218,"PHASE1":18220,"PHASE2":18222,"PHASE3":18232,"PHASE4":18234,"NA":18236},{"trials":18219,"activeCount":101},[],{"trials":18221,"activeCount":101},[],{"trials":18223,"activeCount":101},[18224],{"nctId":18225,"briefTitle":18226,"status":111,"phases":18227,"primaryCompletion":18228,"completion":18228,"start":6568,"enrollment":101,"conditions":18229,"interventions":18231},"NCT02908334","Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis",[91],"2019-01-22",[18230],"Coccidioidomycosis",[18216],{"trials":18233,"activeCount":101},[],{"trials":18235,"activeCount":101},[],{"trials":18237,"activeCount":101},[18238,18246],{"nctId":18239,"briefTitle":18240,"status":132,"phases":18241,"completion":18242,"start":3714,"enrollment":1220,"conditions":18243,"interventions":18245},"NCT00283192","Flushes and Sertraline Trial",[94],"2006-01",[18244],"Menopause-Hot Flashes",[18216],{"nctId":18247,"briefTitle":18248,"status":132,"phases":18249,"primaryCompletion":18250,"completion":18250,"start":10926,"enrollment":16623,"conditions":18251,"interventions":18252},"NCT01305889","The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders",[94],"2018-02-16",[1468],[18216],{"intervention":18254,"totalTrials":526,"cells":18255},"Levetiracetam",{"EARLY_PHASE1":18256,"PHASE1":18258,"PHASE2":18260,"PHASE3":18262,"PHASE4":18264,"NA":18266},{"trials":18257,"activeCount":101},[],{"trials":18259,"activeCount":101},[],{"trials":18261,"activeCount":101},[],{"trials":18263,"activeCount":101},[],{"trials":18265,"activeCount":101},[],{"trials":18267,"activeCount":101},[18268,18276],{"nctId":18269,"briefTitle":18270,"status":132,"phases":18271,"primaryCompletion":5312,"completion":9350,"start":18272,"enrollment":1914,"conditions":18273,"interventions":18275},"NCT00254657","Levetiracetam for Treatment of Pain Associated With Fibromyalgia",[94],"2004-03",[18274],"Fibromyalgia",[18254],{"nctId":18277,"briefTitle":18278,"status":132,"phases":18279,"primaryCompletion":5219,"completion":8696,"start":2722,"enrollment":18280,"conditions":18281,"interventions":18282},"NCT01168687","Effects of Levetiracetam (Keppra) on Alcohol Consumption",[94],46,[8749,15456],[18254],{"intervention":18284,"totalTrials":526,"cells":18285},"Ranibizumab",{"EARLY_PHASE1":18286,"PHASE1":18288,"PHASE2":18290,"PHASE3":18299,"PHASE4":18301,"NA":18303},{"trials":18287,"activeCount":101},[],{"trials":18289,"activeCount":101},[],{"trials":18291,"activeCount":101},[18292],{"nctId":18293,"briefTitle":18294,"status":132,"phases":18295,"primaryCompletion":2546,"completion":8837,"start":7341,"enrollment":792,"conditions":18296,"interventions":18298},"NCT00498355","Lucentis for Inflammatory Macular Edema Trial",[90,91],[2409,18297],"Cytoid Macular Edema",[18284],{"trials":18300,"activeCount":101},[],{"trials":18302,"activeCount":101},[],{"trials":18304,"activeCount":101},[18305],{"nctId":18306,"briefTitle":18307,"status":120,"phases":18308,"primaryCompletion":7096,"completion":4275,"start":3696,"enrollment":541,"conditions":18309,"interventions":18311},"NCT00644280","Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery",[94],[18310],"Glaucoma",[18284],{"intervention":18313,"totalTrials":526,"cells":18314},"Thiotepa",{"EARLY_PHASE1":18315,"PHASE1":18317,"PHASE2":18323,"PHASE3":18325,"PHASE4":18327,"NA":18329},{"trials":18316,"activeCount":101},[],{"trials":18318,"activeCount":101},[18319],{"nctId":17430,"briefTitle":17431,"status":132,"phases":18320,"primaryCompletion":3828,"completion":3828,"start":9350,"enrollment":97,"conditions":18321,"interventions":18322},[90],[677,679,680,681],[719,721,685,17435],{"trials":18324,"activeCount":101},[],{"trials":18326,"activeCount":101},[],{"trials":18328,"activeCount":101},[],{"trials":18330,"activeCount":101},[18331],{"nctId":18332,"briefTitle":18333,"status":132,"phases":18334,"primaryCompletion":18335,"completion":18335,"start":18336,"enrollment":353,"conditions":18337,"interventions":18339},"NCT03609840","Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients",[],"2023-07-31","2017-05-24",[5774,5775,18338,5777,5778,5257,5779,4083],"Immune Deficiency",[18313],{"intervention":5245,"totalTrials":526,"cells":18341},{"EARLY_PHASE1":18342,"PHASE1":18344,"PHASE2":18346,"PHASE3":18352,"PHASE4":18354,"NA":18356},{"trials":18343,"activeCount":101},[],{"trials":18345,"activeCount":101},[],{"trials":18347,"activeCount":101},[18348],{"nctId":5230,"briefTitle":5231,"status":120,"phases":18349,"primaryCompletion":5233,"completion":5233,"start":5234,"enrollment":1027,"conditions":18350,"interventions":18351},[91],[5236,5237,5238,5239,5240,5241],[5243,4824,5244,5245],{"trials":18353,"activeCount":101},[],{"trials":18355,"activeCount":101},[],{"trials":18357,"activeCount":101},[18358],{"nctId":5782,"briefTitle":5783,"status":132,"phases":18359,"primaryCompletion":5785,"completion":5785,"start":5786,"enrollment":751,"conditions":18360,"interventions":18361},[],[5774,5775,5776,5777,5778,5788,5779,4083],[5245,5244],{"intervention":18363,"totalTrials":526,"cells":18364},"Mitomycin-C",{"EARLY_PHASE1":18365,"PHASE1":18367,"PHASE2":18369,"PHASE3":18382,"PHASE4":18384,"NA":18386},{"trials":18366,"activeCount":101},[],{"trials":18368,"activeCount":101},[],{"trials":18370,"activeCount":101},[18371],{"nctId":18372,"briefTitle":18373,"status":132,"phases":18374,"primaryCompletion":18375,"completion":18375,"start":6171,"enrollment":18376,"conditions":18377,"interventions":18381},"NCT02805257","Ahmed Glaucoma Valve Surgery With Mitomycin-C",[91],"2020-03",119,[18310,18378,18379,18380],"Primary Open Angle Glaucoma","Secondary Glaucoma","Neovascular Glaucoma",[18363],{"trials":18383,"activeCount":101},[],{"trials":18385,"activeCount":101},[],{"trials":18387,"activeCount":101},[18388],{"nctId":18389,"briefTitle":18390,"status":111,"phases":18391,"primaryCompletion":18392,"completion":18392,"start":18393,"enrollment":101,"conditions":18394,"interventions":18395},"NCT02744690","Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia",[94],"2019-03-01","2015-03-01",[18310],[18363],{"intervention":18397,"totalTrials":526,"cells":18398},"Gallium Ga 68-labeled PSMA-11",{"EARLY_PHASE1":18399,"PHASE1":18401,"PHASE2":18403,"PHASE3":18413,"PHASE4":18415,"NA":18417},{"trials":18400,"activeCount":101},[],{"trials":18402,"activeCount":101},[],{"trials":18404,"activeCount":101},[18405],{"nctId":18406,"briefTitle":18407,"status":120,"phases":18408,"primaryCompletion":3781,"completion":6491,"start":18409,"enrollment":2818,"conditions":18410,"interventions":18412},"NCT03463889","Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer",[91],"2018-03-19",[18411],"Thyroid Gland Carcinoma",[18397],{"trials":18414,"activeCount":101},[],{"trials":18416,"activeCount":101},[],{"trials":18418,"activeCount":101},[18419],{"nctId":18420,"briefTitle":18421,"status":132,"phases":18422,"primaryCompletion":3565,"completion":3565,"start":14305,"enrollment":792,"conditions":18423,"interventions":18425},"NCT03857087","68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer",[],[18424],"Ovarian Carcinoma",[18397],{"intervention":17755,"totalTrials":526,"cells":18427},{"EARLY_PHASE1":18428,"PHASE1":18430,"PHASE2":18432,"PHASE3":18434,"PHASE4":18436,"NA":18438},{"trials":18429,"activeCount":101},[],{"trials":18431,"activeCount":101},[],{"trials":18433,"activeCount":101},[],{"trials":18435,"activeCount":101},[],{"trials":18437,"activeCount":101},[],{"trials":18439,"activeCount":101},[18440,18444],{"nctId":17749,"briefTitle":17750,"status":132,"phases":18441,"primaryCompletion":8837,"start":9697,"enrollment":2840,"conditions":18442,"interventions":18443},[94],[12131],[14926,17754,17755],{"nctId":17757,"briefTitle":17758,"status":132,"phases":18445,"primaryCompletion":238,"completion":238,"start":2437,"enrollment":510,"conditions":18446,"interventions":18447},[94],[21],[14926,17754,17762,17755],{"intervention":6754,"totalTrials":526,"cells":18449},{"EARLY_PHASE1":18450,"PHASE1":18452,"PHASE2":18458,"PHASE3":18460,"PHASE4":18462,"NA":18464},{"trials":18451,"activeCount":101},[],{"trials":18453,"activeCount":101},[18454],{"nctId":6746,"briefTitle":6747,"status":132,"phases":18455,"primaryCompletion":1313,"completion":6749,"start":6750,"enrollment":1060,"conditions":18456,"interventions":18457},[90],[6752],[6754,6739],{"trials":18459,"activeCount":101},[],{"trials":18461,"activeCount":101},[],{"trials":18463,"activeCount":101},[],{"trials":18465,"activeCount":101},[18466],{"nctId":18467,"briefTitle":18468,"status":132,"phases":18469,"primaryCompletion":18470,"completion":18470,"start":6134,"enrollment":18471,"conditions":18472,"interventions":18474},"NCT02588027","Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes",[94],"2022-09",110,[18473],"Rotator Cuff Tear Arthropathy",[6754],{"intervention":2562,"totalTrials":526,"cells":18476},{"EARLY_PHASE1":18477,"PHASE1":18479,"PHASE2":18481,"PHASE3":18489,"PHASE4":18491,"NA":18493},{"trials":18478,"activeCount":101},[],{"trials":18480,"activeCount":101},[],{"trials":18482,"activeCount":101},[18483],{"nctId":18484,"briefTitle":18485,"status":132,"phases":18486,"primaryCompletion":431,"completion":431,"start":8651,"enrollment":10910,"conditions":18487,"interventions":18488},"NCT02535767","Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali",[90,91],[322],[2562],{"trials":18490,"activeCount":101},[],{"trials":18492,"activeCount":101},[],{"trials":18494,"activeCount":101},[18495],{"nctId":2554,"briefTitle":2555,"status":132,"phases":18496,"primaryCompletion":309,"completion":877,"start":2557,"enrollment":2558,"conditions":18497,"interventions":18498},[94],[2560,322],[925,2562],{"intervention":18500,"totalTrials":526,"cells":18501},"warfarin",{"EARLY_PHASE1":18502,"PHASE1":18504,"PHASE2":18512,"PHASE3":18514,"PHASE4":18516,"NA":18518},{"trials":18503,"activeCount":101},[],{"trials":18505,"activeCount":101},[18506],{"nctId":18507,"briefTitle":18508,"status":132,"phases":18509,"primaryCompletion":8721,"completion":8721,"start":6628,"enrollment":345,"conditions":18510,"interventions":18511},"NCT02574754","Assessment of 2012 Bioequivalence Standards for Warfarin",[90],[30],[18500],{"trials":18513,"activeCount":101},[],{"trials":18515,"activeCount":101},[],{"trials":18517,"activeCount":101},[],{"trials":18519,"activeCount":101},[18520],{"nctId":18521,"briefTitle":18522,"status":132,"phases":18523,"primaryCompletion":2583,"completion":2583,"start":2722,"enrollment":345,"conditions":18524,"interventions":18525},"NCT00777855","Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.",[94],[30],[18526,18500],"warfarin plus rifampin",{"intervention":17762,"totalTrials":526,"cells":18528},{"EARLY_PHASE1":18529,"PHASE1":18531,"PHASE2":18533,"PHASE3":18535,"PHASE4":18537,"NA":18539},{"trials":18530,"activeCount":101},[],{"trials":18532,"activeCount":101},[],{"trials":18534,"activeCount":101},[],{"trials":18536,"activeCount":101},[],{"trials":18538,"activeCount":101},[],{"trials":18540,"activeCount":101},[18541,18545],{"nctId":17757,"briefTitle":17758,"status":132,"phases":18542,"primaryCompletion":238,"completion":238,"start":2437,"enrollment":510,"conditions":18543,"interventions":18544},[94],[21],[14926,17754,17762,17755],{"nctId":18146,"briefTitle":18147,"status":132,"phases":18546,"primaryCompletion":18149,"completion":18149,"start":17653,"enrollment":751,"conditions":18547,"interventions":18548},[],[24],[18152,17754,17762],{"intervention":18550,"totalTrials":526,"cells":18551},"varenicline",{"EARLY_PHASE1":18552,"PHASE1":18554,"PHASE2":18556,"PHASE3":18558,"PHASE4":18567,"NA":18569},{"trials":18553,"activeCount":101},[],{"trials":18555,"activeCount":101},[],{"trials":18557,"activeCount":101},[],{"trials":18559,"activeCount":101},[18560],{"nctId":18561,"briefTitle":18562,"status":132,"phases":18563,"primaryCompletion":6171,"completion":6171,"start":7251,"enrollment":2419,"conditions":18564,"interventions":18565},"NCT01162239","Maintaining Nonsmoking",[92],[5424],[18566],"Varenicline",{"trials":18568,"activeCount":101},[],{"trials":18570,"activeCount":101},[18571],{"nctId":18572,"briefTitle":18573,"status":132,"phases":18574,"primaryCompletion":15410,"completion":2406,"start":4030,"enrollment":18575,"conditions":18576,"interventions":18578},"NCT01011907","A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence",[94],99,[18577],"Substance Dependence",[18550],{"intervention":18580,"totalTrials":526,"cells":18581},"Gabapentin",{"EARLY_PHASE1":18582,"PHASE1":18584,"PHASE2":18586,"PHASE3":18588,"PHASE4":18598,"NA":18600},{"trials":18583,"activeCount":101},[],{"trials":18585,"activeCount":101},[],{"trials":18587,"activeCount":101},[],{"trials":18589,"activeCount":101},[18590],{"nctId":18591,"briefTitle":18592,"status":132,"phases":18593,"primaryCompletion":3859,"completion":6117,"start":18242,"enrollment":18594,"conditions":18595,"interventions":18597},"NCT00221338","Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain",[92],750,[3100,3101,6317,18596],"Hospital Length of Stay",[18580],{"trials":18599,"activeCount":101},[],{"trials":18601,"activeCount":101},[18602],{"nctId":18603,"briefTitle":18604,"status":132,"phases":18605,"primaryCompletion":16329,"completion":6765,"start":7342,"enrollment":751,"conditions":18606,"interventions":18607},"NCT00187707","Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin",[94],[30],[18580],{"intervention":18609,"totalTrials":526,"cells":18610},"Tolcapone",{"EARLY_PHASE1":18611,"PHASE1":18613,"PHASE2":18615,"PHASE3":18617,"PHASE4":18619,"NA":18621},{"trials":18612,"activeCount":101},[],{"trials":18614,"activeCount":101},[],{"trials":18616,"activeCount":101},[],{"trials":18618,"activeCount":101},[],{"trials":18620,"activeCount":101},[],{"trials":18622,"activeCount":101},[18623,18630],{"nctId":18624,"briefTitle":18625,"status":132,"phases":18626,"primaryCompletion":2517,"completion":2517,"start":113,"enrollment":16623,"conditions":18627,"interventions":18629},"NCT02772978","Dopamine Responsivity in Gamblers",[94],[18628],"Pathological Gambling",[18609],{"nctId":18631,"briefTitle":18632,"status":132,"phases":18633,"primaryCompletion":1312,"completion":1312,"start":1201,"enrollment":695,"conditions":18634,"interventions":18636},"NCT01158950","A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors",[94],[18635],"Impulsive Behavior",[18609],{"intervention":18638,"totalTrials":526,"cells":18639},"nalbuphine plus naloxone",{"EARLY_PHASE1":18640,"PHASE1":18642,"PHASE2":18644,"PHASE3":18646,"PHASE4":18648,"NA":18650},{"trials":18641,"activeCount":101},[],{"trials":18643,"activeCount":101},[],{"trials":18645,"activeCount":101},[],{"trials":18647,"activeCount":101},[],{"trials":18649,"activeCount":101},[],{"trials":18651,"activeCount":101},[18652,18660],{"nctId":18653,"briefTitle":18654,"status":120,"phases":18655,"primaryCompletion":2406,"completion":2406,"start":4030,"enrollment":324,"conditions":18656,"interventions":18657},"NCT00947284","Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity",[94],[30],[18638,18658,18659],"nalbuphine plus saline","naloxone plus saline",{"nctId":18661,"briefTitle":18662,"status":120,"phases":18663,"primaryCompletion":932,"completion":932,"start":255,"enrollment":18280,"conditions":18664,"interventions":18667},"NCT00716807","Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain",[94],[18665,18666],"Temporomandibular Joint Dysfunction Syndrome","Burning Mouth Syndrome",[18638,18668,18638,18668],"nalbuphine plus placebo",{"intervention":18670,"totalTrials":526,"cells":18671},"Acetaminophen",{"EARLY_PHASE1":18672,"PHASE1":18674,"PHASE2":18676,"PHASE3":18678,"PHASE4":18680,"NA":18689},{"trials":18673,"activeCount":101},[],{"trials":18675,"activeCount":101},[],{"trials":18677,"activeCount":101},[],{"trials":18679,"activeCount":101},[],{"trials":18681,"activeCount":101},[18682],{"nctId":18683,"briefTitle":18684,"status":132,"phases":18685,"primaryCompletion":8651,"completion":8651,"start":433,"enrollment":3626,"conditions":18686,"interventions":18688},"NCT01869699","Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults",[93],[11916,18687],"Critical Illness",[18670],{"trials":18690,"activeCount":101},[18691],{"nctId":18692,"briefTitle":18693,"status":132,"phases":18694,"primaryCompletion":10063,"completion":10063,"start":18695,"enrollment":18696,"conditions":18697,"interventions":18699},"NCT01321710","Sleep Disruption in New Mothers: An Intervention Trial",[94],"2004-12",152,[3031,18698,6818],"Postpartum Period",[18670],{"intervention":2443,"totalTrials":424,"cells":18701},{"EARLY_PHASE1":18702,"PHASE1":18704,"PHASE2":18706,"PHASE3":18708,"PHASE4":18710,"NA":18712},{"trials":18703,"activeCount":101},[],{"trials":18705,"activeCount":101},[],{"trials":18707,"activeCount":101},[],{"trials":18709,"activeCount":101},[],{"trials":18711,"activeCount":101},[],{"trials":18713,"activeCount":101},[18714],{"nctId":2432,"briefTitle":2433,"status":132,"phases":18715,"primaryCompletion":2435,"completion":2436,"start":2437,"enrollment":345,"conditions":18716,"interventions":18717},[94],[2439,717],[720,2441,2442,2443,2444,686,2445],{"intervention":2444,"totalTrials":424,"cells":18719},{"EARLY_PHASE1":18720,"PHASE1":18722,"PHASE2":18724,"PHASE3":18726,"PHASE4":18728,"NA":18730},{"trials":18721,"activeCount":101},[],{"trials":18723,"activeCount":101},[],{"trials":18725,"activeCount":101},[],{"trials":18727,"activeCount":101},[],{"trials":18729,"activeCount":101},[],{"trials":18731,"activeCount":101},[18732],{"nctId":2432,"briefTitle":2433,"status":132,"phases":18733,"primaryCompletion":2435,"completion":2436,"start":2437,"enrollment":345,"conditions":18734,"interventions":18735},[94],[2439,717],[720,2441,2442,2443,2444,686,2445],{"intervention":18737,"totalTrials":424,"cells":18738},"Fosamax",{"EARLY_PHASE1":18739,"PHASE1":18741,"PHASE2":18743,"PHASE3":18745,"PHASE4":18747,"NA":18749},{"trials":18740,"activeCount":101},[],{"trials":18742,"activeCount":101},[],{"trials":18744,"activeCount":101},[],{"trials":18746,"activeCount":101},[],{"trials":18748,"activeCount":101},[],{"trials":18750,"activeCount":101},[18751],{"nctId":18752,"briefTitle":18753,"status":132,"phases":18754,"completion":7341,"start":3697,"enrollment":3553,"conditions":18755,"interventions":18757},"NCT00221312","Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss",[],[18756],"Perimenopausal Bone Loss",[18737],{"intervention":18759,"totalTrials":424,"cells":18760},"Rituxan",{"EARLY_PHASE1":18761,"PHASE1":18763,"PHASE2":18765,"PHASE3":18767,"PHASE4":18769,"NA":18771},{"trials":18762,"activeCount":101},[],{"trials":18764,"activeCount":101},[],{"trials":18766,"activeCount":101},[],{"trials":18768,"activeCount":101},[],{"trials":18770,"activeCount":101},[],{"trials":18772,"activeCount":101},[18773],{"nctId":18774,"briefTitle":18775,"status":132,"phases":18776,"primaryCompletion":1200,"completion":205,"start":5219,"enrollment":1060,"conditions":18777,"interventions":18780},"NCT00844714","Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy",[94],[18778,18779,1707],"Endothelial Function","Rheumatoid Arthritis",[18759],{"intervention":18782,"totalTrials":424,"cells":18783},"Morphine Sulfate and Promethazine",{"EARLY_PHASE1":18784,"PHASE1":18786,"PHASE2":18788,"PHASE3":18790,"PHASE4":18792,"NA":18794},{"trials":18785,"activeCount":101},[],{"trials":18787,"activeCount":101},[],{"trials":18789,"activeCount":101},[],{"trials":18791,"activeCount":101},[],{"trials":18793,"activeCount":101},[],{"trials":18795,"activeCount":101},[18796],{"nctId":18797,"briefTitle":18798,"status":132,"phases":18799,"primaryCompletion":18800,"completion":18800,"start":18801,"enrollment":18802,"conditions":18803,"interventions":18806},"NCT03539562","Therapeutic Rest to Delay Admission in Early Labor: A Prospective Study on Morphine Sleep",[],"2020-04-01","2017-09-27",82,[18804,18805],"Labor Pain","Early Labor",[18782],{"intervention":18808,"totalTrials":424,"cells":18809},"intramuscular injections of morphine",{"EARLY_PHASE1":18810,"PHASE1":18812,"PHASE2":18814,"PHASE3":18816,"PHASE4":18818,"NA":18820},{"trials":18811,"activeCount":101},[],{"trials":18813,"activeCount":101},[],{"trials":18815,"activeCount":101},[],{"trials":18817,"activeCount":101},[],{"trials":18819,"activeCount":101},[],{"trials":18821,"activeCount":101},[18822],{"nctId":18823,"briefTitle":18824,"status":132,"phases":18825,"primaryCompletion":8859,"completion":8859,"start":5312,"enrollment":751,"conditions":18826,"interventions":18827},"NCT00256347","Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine",[94],[14700],[18808],{"intervention":18829,"totalTrials":424,"cells":18830},"Ondansetron",{"EARLY_PHASE1":18831,"PHASE1":18833,"PHASE2":18835,"PHASE3":18837,"PHASE4":18839,"NA":18841},{"trials":18832,"activeCount":101},[],{"trials":18834,"activeCount":101},[],{"trials":18836,"activeCount":101},[],{"trials":18838,"activeCount":101},[],{"trials":18840,"activeCount":101},[],{"trials":18842,"activeCount":101},[18843],{"nctId":18844,"briefTitle":18845,"status":111,"phases":18846,"primaryCompletion":165,"completion":6051,"start":540,"enrollment":101,"conditions":18847,"interventions":18850},"NCT01393288","Developing Individualized Strategies to Prevent Nausea and Vomiting",[94],[18848,18849],"Postoperative Nausea and Vomiting","Genetic Polymorphisms",[18829,18851,18852],"Lorazepam","Aprepitant",{"intervention":18851,"totalTrials":424,"cells":18854},{"EARLY_PHASE1":18855,"PHASE1":18857,"PHASE2":18859,"PHASE3":18861,"PHASE4":18863,"NA":18865},{"trials":18856,"activeCount":101},[],{"trials":18858,"activeCount":101},[],{"trials":18860,"activeCount":101},[],{"trials":18862,"activeCount":101},[],{"trials":18864,"activeCount":101},[],{"trials":18866,"activeCount":101},[18867],{"nctId":18844,"briefTitle":18845,"status":111,"phases":18868,"primaryCompletion":165,"completion":6051,"start":540,"enrollment":101,"conditions":18869,"interventions":18870},[94],[18848,18849],[18829,18851,18852],{"intervention":18852,"totalTrials":424,"cells":18872},{"EARLY_PHASE1":18873,"PHASE1":18875,"PHASE2":18877,"PHASE3":18879,"PHASE4":18881,"NA":18883},{"trials":18874,"activeCount":101},[],{"trials":18876,"activeCount":101},[],{"trials":18878,"activeCount":101},[],{"trials":18880,"activeCount":101},[],{"trials":18882,"activeCount":101},[],{"trials":18884,"activeCount":101},[18885],{"nctId":18844,"briefTitle":18845,"status":111,"phases":18886,"primaryCompletion":165,"completion":6051,"start":540,"enrollment":101,"conditions":18887,"interventions":18888},[94],[18848,18849],[18829,18851,18852],{"intervention":18890,"totalTrials":424,"cells":18891},"Standard ART",{"EARLY_PHASE1":18892,"PHASE1":18894,"PHASE2":18896,"PHASE3":18898,"PHASE4":18900,"NA":18902},{"trials":18893,"activeCount":101},[],{"trials":18895,"activeCount":101},[],{"trials":18897,"activeCount":101},[],{"trials":18899,"activeCount":101},[],{"trials":18901,"activeCount":101},[],{"trials":18903,"activeCount":101},[18904],{"nctId":18905,"briefTitle":18906,"status":132,"phases":18907,"primaryCompletion":17298,"completion":17298,"start":3640,"enrollment":18908,"conditions":18909,"interventions":18910},"NCT01479634","Early HIV Therapy in Patients With High CD4 Cell Counts",[94],279,[15],[18890,18911],"Study-Provided ART",{"intervention":18911,"totalTrials":424,"cells":18913},{"EARLY_PHASE1":18914,"PHASE1":18916,"PHASE2":18918,"PHASE3":18920,"PHASE4":18922,"NA":18924},{"trials":18915,"activeCount":101},[],{"trials":18917,"activeCount":101},[],{"trials":18919,"activeCount":101},[],{"trials":18921,"activeCount":101},[],{"trials":18923,"activeCount":101},[],{"trials":18925,"activeCount":101},[18926],{"nctId":18905,"briefTitle":18906,"status":132,"phases":18927,"primaryCompletion":17298,"completion":17298,"start":3640,"enrollment":18908,"conditions":18928,"interventions":18929},[94],[15],[18890,18911],{"intervention":18931,"totalTrials":424,"cells":18932},"Barium",{"EARLY_PHASE1":18933,"PHASE1":18935,"PHASE2":18937,"PHASE3":18939,"PHASE4":18941,"NA":18943},{"trials":18934,"activeCount":101},[],{"trials":18936,"activeCount":101},[],{"trials":18938,"activeCount":101},[],{"trials":18940,"activeCount":101},[],{"trials":18942,"activeCount":101},[],{"trials":18944,"activeCount":101},[18945],{"nctId":18946,"briefTitle":18947,"status":132,"phases":18948,"primaryCompletion":226,"completion":14886,"start":2517,"enrollment":18949,"conditions":18950,"interventions":18952},"NCT02542046","Uniformity of Oral Contrast Material in the Bowel",[],900,[18951],"Known or Suspected Abdominal Disease",[18931,18953,18954],"Diatrizoate","Iohexol",{"intervention":18953,"totalTrials":424,"cells":18956},{"EARLY_PHASE1":18957,"PHASE1":18959,"PHASE2":18961,"PHASE3":18963,"PHASE4":18965,"NA":18967},{"trials":18958,"activeCount":101},[],{"trials":18960,"activeCount":101},[],{"trials":18962,"activeCount":101},[],{"trials":18964,"activeCount":101},[],{"trials":18966,"activeCount":101},[],{"trials":18968,"activeCount":101},[18969],{"nctId":18946,"briefTitle":18947,"status":132,"phases":18970,"primaryCompletion":226,"completion":14886,"start":2517,"enrollment":18949,"conditions":18971,"interventions":18972},[],[18951],[18931,18953,18954],{"intervention":18954,"totalTrials":424,"cells":18974},{"EARLY_PHASE1":18975,"PHASE1":18977,"PHASE2":18979,"PHASE3":18981,"PHASE4":18983,"NA":18985},{"trials":18976,"activeCount":101},[],{"trials":18978,"activeCount":101},[],{"trials":18980,"activeCount":101},[],{"trials":18982,"activeCount":101},[],{"trials":18984,"activeCount":101},[],{"trials":18986,"activeCount":101},[18987],{"nctId":18946,"briefTitle":18947,"status":132,"phases":18988,"primaryCompletion":226,"completion":14886,"start":2517,"enrollment":18949,"conditions":18989,"interventions":18990},[],[18951],[18931,18953,18954],{"intervention":18992,"totalTrials":424,"cells":18993},"Cimzia",{"EARLY_PHASE1":18994,"PHASE1":18996,"PHASE2":18998,"PHASE3":19000,"PHASE4":19002,"NA":19004},{"trials":18995,"activeCount":101},[],{"trials":18997,"activeCount":101},[],{"trials":18999,"activeCount":101},[],{"trials":19001,"activeCount":101},[],{"trials":19003,"activeCount":101},[],{"trials":19005,"activeCount":101},[19006],{"nctId":19007,"briefTitle":19008,"status":132,"phases":19009,"primaryCompletion":7410,"completion":7410,"start":3625,"enrollment":751,"conditions":19010,"interventions":19011},"NCT01773681","Novel Imaging Markers for Rheumatoid Arthritis",[],[18779],[18992],{"intervention":19013,"totalTrials":424,"cells":19014},"Intralesional Alefacept",{"EARLY_PHASE1":19015,"PHASE1":19017,"PHASE2":19019,"PHASE3":19021,"PHASE4":19023,"NA":19025},{"trials":19016,"activeCount":101},[],{"trials":19018,"activeCount":101},[],{"trials":19020,"activeCount":101},[],{"trials":19022,"activeCount":101},[],{"trials":19024,"activeCount":101},[],{"trials":19026,"activeCount":101},[19027],{"nctId":19028,"briefTitle":19029,"status":132,"phases":19030,"primaryCompletion":13734,"completion":13734,"start":3819,"enrollment":5422,"conditions":19031,"interventions":19033},"NCT00678470","Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis",[94],[19032],"Moderate to Severe Psoriasis",[19013],{"intervention":19035,"totalTrials":424,"cells":19036},"Rabeprazole",{"EARLY_PHASE1":19037,"PHASE1":19039,"PHASE2":19041,"PHASE3":19043,"PHASE4":19045,"NA":19047},{"trials":19038,"activeCount":101},[],{"trials":19040,"activeCount":101},[],{"trials":19042,"activeCount":101},[],{"trials":19044,"activeCount":101},[],{"trials":19046,"activeCount":101},[],{"trials":19048,"activeCount":101},[19049],{"nctId":19050,"briefTitle":19051,"status":132,"phases":19052,"primaryCompletion":15410,"completion":15410,"start":10926,"enrollment":2564,"conditions":19053,"interventions":19055},"NCT01237353","Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers",[94],[19054],"Pharmacodynamic",[19035],{"intervention":19057,"totalTrials":424,"cells":19058},"PrEP",{"EARLY_PHASE1":19059,"PHASE1":19061,"PHASE2":19063,"PHASE3":19065,"PHASE4":19067,"NA":19069},{"trials":19060,"activeCount":101},[],{"trials":19062,"activeCount":101},[],{"trials":19064,"activeCount":101},[],{"trials":19066,"activeCount":101},[],{"trials":19068,"activeCount":101},[],{"trials":19070,"activeCount":101},[19071],{"nctId":19072,"briefTitle":19073,"status":132,"phases":19074,"primaryCompletion":19075,"completion":6326,"start":11752,"enrollment":18280,"conditions":19076,"interventions":19077},"NCT03049176","The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)",[],"2019-06-03",[18],[19057,19078],"Antiretrovirals",{"intervention":19078,"totalTrials":424,"cells":19080},{"EARLY_PHASE1":19081,"PHASE1":19083,"PHASE2":19085,"PHASE3":19087,"PHASE4":19089,"NA":19091},{"trials":19082,"activeCount":101},[],{"trials":19084,"activeCount":101},[],{"trials":19086,"activeCount":101},[],{"trials":19088,"activeCount":101},[],{"trials":19090,"activeCount":101},[],{"trials":19092,"activeCount":101},[19093],{"nctId":19072,"briefTitle":19073,"status":132,"phases":19094,"primaryCompletion":19075,"completion":6326,"start":11752,"enrollment":18280,"conditions":19095,"interventions":19096},[],[18],[19057,19078],{"intervention":19098,"totalTrials":424,"cells":19099},"OCPs",{"EARLY_PHASE1":19100,"PHASE1":19102,"PHASE2":19104,"PHASE3":19106,"PHASE4":19108,"NA":19110},{"trials":19101,"activeCount":101},[],{"trials":19103,"activeCount":101},[],{"trials":19105,"activeCount":101},[],{"trials":19107,"activeCount":101},[],{"trials":19109,"activeCount":101},[],{"trials":19111,"activeCount":101},[19112],{"nctId":19113,"briefTitle":19114,"status":132,"phases":19115,"completion":2773,"start":19116,"enrollment":19117,"conditions":19118,"interventions":19119},"NCT00357526","Oral Contraceptive Pills Compared to Vaginal Rings",[94],"2003-04",130,[3031],[19098],{"intervention":17943,"totalTrials":424,"cells":19121},{"EARLY_PHASE1":19122,"PHASE1":19124,"PHASE2":19126,"PHASE3":19128,"PHASE4":19130,"NA":19132},{"trials":19123,"activeCount":101},[],{"trials":19125,"activeCount":101},[],{"trials":19127,"activeCount":101},[],{"trials":19129,"activeCount":101},[],{"trials":19131,"activeCount":101},[],{"trials":19133,"activeCount":101},[19134],{"nctId":17938,"briefTitle":17939,"status":132,"phases":19135,"primaryCompletion":8837,"completion":7096,"start":4042,"enrollment":555,"conditions":19136,"interventions":19137},[94],[18],[17910,17943,17944],{"intervention":17944,"totalTrials":424,"cells":19139},{"EARLY_PHASE1":19140,"PHASE1":19142,"PHASE2":19144,"PHASE3":19146,"PHASE4":19148,"NA":19150},{"trials":19141,"activeCount":101},[],{"trials":19143,"activeCount":101},[],{"trials":19145,"activeCount":101},[],{"trials":19147,"activeCount":101},[],{"trials":19149,"activeCount":101},[],{"trials":19151,"activeCount":101},[19152],{"nctId":17938,"briefTitle":17939,"status":132,"phases":19153,"primaryCompletion":8837,"completion":7096,"start":4042,"enrollment":555,"conditions":19154,"interventions":19155},[94],[18],[17910,17943,17944],{"intervention":19157,"totalTrials":424,"cells":19158},"Ethanol",{"EARLY_PHASE1":19159,"PHASE1":19161,"PHASE2":19163,"PHASE3":19165,"PHASE4":19167,"NA":19169},{"trials":19160,"activeCount":101},[],{"trials":19162,"activeCount":101},[],{"trials":19164,"activeCount":101},[],{"trials":19166,"activeCount":101},[],{"trials":19168,"activeCount":101},[],{"trials":19170,"activeCount":101},[19171],{"nctId":19172,"briefTitle":19173,"status":132,"phases":19174,"primaryCompletion":19175,"completion":19176,"start":3829,"enrollment":1220,"conditions":19177,"interventions":19179},"NCT01996943","The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study",[94],"2019-05","2020-05",[19178,11799],"Atrial Fibrillation",[19157],{"intervention":19181,"totalTrials":424,"cells":19182},"L-carnitine",{"EARLY_PHASE1":19183,"PHASE1":19185,"PHASE2":19187,"PHASE3":19189,"PHASE4":19191,"NA":19193},{"trials":19184,"activeCount":101},[],{"trials":19186,"activeCount":101},[],{"trials":19188,"activeCount":101},[],{"trials":19190,"activeCount":101},[],{"trials":19192,"activeCount":101},[],{"trials":19194,"activeCount":101},[19195],{"nctId":19196,"briefTitle":19197,"status":111,"phases":19198,"primaryCompletion":11708,"completion":11708,"start":2418,"enrollment":101,"conditions":19199,"interventions":19201},"NCT01523106","L-carnitine to Treat Fatigue Associated With Crohn's Disease",[94],[19200,5731],"Crohn's Disease",[19181],{"intervention":19203,"totalTrials":424,"cells":19204},"Treatment with a GnRh agonists",{"EARLY_PHASE1":19205,"PHASE1":19207,"PHASE2":19209,"PHASE3":19211,"PHASE4":19213,"NA":19215},{"trials":19206,"activeCount":101},[],{"trials":19208,"activeCount":101},[],{"trials":19210,"activeCount":101},[],{"trials":19212,"activeCount":101},[],{"trials":19214,"activeCount":101},[],{"trials":19216,"activeCount":101},[19217],{"nctId":19218,"briefTitle":19219,"status":120,"phases":19220,"primaryCompletion":19221,"completion":19221,"start":19222,"enrollment":324,"conditions":19223,"interventions":19224},"NCT03078829","The Relation of GnRH Treatment to QTc Interval in Transgender Females",[],"2017-08-21","2017-05-01",[9008],[19203],{"intervention":19226,"totalTrials":424,"cells":19227},"fentanyl citrate",{"EARLY_PHASE1":19228,"PHASE1":19230,"PHASE2":19232,"PHASE3":19234,"PHASE4":19236,"NA":19238},{"trials":19229,"activeCount":101},[],{"trials":19231,"activeCount":101},[],{"trials":19233,"activeCount":101},[],{"trials":19235,"activeCount":101},[],{"trials":19237,"activeCount":101},[],{"trials":19239,"activeCount":101},[19240],{"nctId":19241,"briefTitle":19242,"status":132,"phases":19243,"primaryCompletion":3696,"completion":8837,"start":5312,"enrollment":9607,"conditions":19244,"interventions":19247},"NCT00295945","Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer",[],[16704,19245,19246,10914,1410,6821,3784],"Endometrial Cancer","Fallopian Tube Cancer",[19226,19248,19249],"hydromorphone hydrochloride","ropivacaine hydrochloride",{"intervention":19248,"totalTrials":424,"cells":19251},{"EARLY_PHASE1":19252,"PHASE1":19254,"PHASE2":19256,"PHASE3":19258,"PHASE4":19260,"NA":19262},{"trials":19253,"activeCount":101},[],{"trials":19255,"activeCount":101},[],{"trials":19257,"activeCount":101},[],{"trials":19259,"activeCount":101},[],{"trials":19261,"activeCount":101},[],{"trials":19263,"activeCount":101},[19264],{"nctId":19241,"briefTitle":19242,"status":132,"phases":19265,"primaryCompletion":3696,"completion":8837,"start":5312,"enrollment":9607,"conditions":19266,"interventions":19267},[],[16704,19245,19246,10914,1410,6821,3784],[19226,19248,19249],{"intervention":19249,"totalTrials":424,"cells":19269},{"EARLY_PHASE1":19270,"PHASE1":19272,"PHASE2":19274,"PHASE3":19276,"PHASE4":19278,"NA":19280},{"trials":19271,"activeCount":101},[],{"trials":19273,"activeCount":101},[],{"trials":19275,"activeCount":101},[],{"trials":19277,"activeCount":101},[],{"trials":19279,"activeCount":101},[],{"trials":19281,"activeCount":101},[19282],{"nctId":19241,"briefTitle":19242,"status":132,"phases":19283,"primaryCompletion":3696,"completion":8837,"start":5312,"enrollment":9607,"conditions":19284,"interventions":19285},[],[16704,19245,19246,10914,1410,6821,3784],[19226,19248,19249],{"intervention":18526,"totalTrials":424,"cells":19287},{"EARLY_PHASE1":19288,"PHASE1":19290,"PHASE2":19292,"PHASE3":19294,"PHASE4":19296,"NA":19298},{"trials":19289,"activeCount":101},[],{"trials":19291,"activeCount":101},[],{"trials":19293,"activeCount":101},[],{"trials":19295,"activeCount":101},[],{"trials":19297,"activeCount":101},[],{"trials":19299,"activeCount":101},[19300],{"nctId":18521,"briefTitle":18522,"status":132,"phases":19301,"primaryCompletion":2583,"completion":2583,"start":2722,"enrollment":345,"conditions":19302,"interventions":19303},[94],[30],[18526,18500],{"intervention":19305,"totalTrials":424,"cells":19306},"Lidocaine digital block",{"EARLY_PHASE1":19307,"PHASE1":19309,"PHASE2":19311,"PHASE3":19313,"PHASE4":19315,"NA":19317},{"trials":19308,"activeCount":101},[],{"trials":19310,"activeCount":101},[],{"trials":19312,"activeCount":101},[],{"trials":19314,"activeCount":101},[],{"trials":19316,"activeCount":101},[],{"trials":19318,"activeCount":101},[19319],{"nctId":19320,"briefTitle":19321,"status":132,"phases":19322,"primaryCompletion":3640,"completion":3640,"start":6052,"enrollment":1060,"conditions":19323,"interventions":19325},"NCT01284296","Comparison of Three Methods of Hemoglobin Monitoring",[94],[19324],"Digital Block",[19305],{"intervention":19327,"totalTrials":424,"cells":19328},"Nicotine patches",{"EARLY_PHASE1":19329,"PHASE1":19331,"PHASE2":19333,"PHASE3":19335,"PHASE4":19337,"NA":19339},{"trials":19330,"activeCount":101},[],{"trials":19332,"activeCount":101},[],{"trials":19334,"activeCount":101},[],{"trials":19336,"activeCount":101},[],{"trials":19338,"activeCount":101},[],{"trials":19340,"activeCount":101},[19341],{"nctId":19342,"briefTitle":19343,"status":132,"phases":19344,"primaryCompletion":1913,"completion":1913,"start":9198,"enrollment":19345,"conditions":19346,"interventions":19347},"NCT01040260","Low-Cost Contingency Management for Smoking Cessation",[94],103,[2661],[19327],{"intervention":19349,"totalTrials":424,"cells":19350},"Fluorine F 18-fluoroazomycin Arabinoside",{"EARLY_PHASE1":19351,"PHASE1":19353,"PHASE2":19355,"PHASE3":19357,"PHASE4":19359,"NA":19361},{"trials":19352,"activeCount":101},[],{"trials":19354,"activeCount":101},[],{"trials":19356,"activeCount":101},[],{"trials":19358,"activeCount":101},[],{"trials":19360,"activeCount":101},[],{"trials":19362,"activeCount":101},[19363],{"nctId":19364,"briefTitle":19365,"status":132,"phases":19366,"primaryCompletion":19367,"completion":19367,"start":19368,"enrollment":1246,"conditions":19369,"interventions":19380},"NCT04409314","Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy",[],"2023-08-09","2020-04-16",[19370,19371,19372,19373,6467,19374,19375,19376,19377,19378,6468,19379],"Recurrent Aggressive Non-Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent Malignant Neoplasm","Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Refractory Aggressive Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Malignant Neoplasm","Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",[19349],{"intervention":19382,"totalTrials":424,"cells":19383},"Insulin",{"EARLY_PHASE1":19384,"PHASE1":19386,"PHASE2":19388,"PHASE3":19390,"PHASE4":19392,"NA":19394},{"trials":19385,"activeCount":101},[],{"trials":19387,"activeCount":101},[],{"trials":19389,"activeCount":101},[],{"trials":19391,"activeCount":101},[],{"trials":19393,"activeCount":101},[],{"trials":19395,"activeCount":101},[19396],{"nctId":19397,"briefTitle":19398,"status":132,"phases":19399,"primaryCompletion":113,"completion":113,"start":8325,"enrollment":1730,"conditions":19400,"interventions":19402},"NCT01643382","Hyperglycemia in Renal Transplantation",[94],[14134,19401],"End Stage Renal Disease",[19382,19403],"Insulin, Asp(B28)-",{"intervention":19403,"totalTrials":424,"cells":19405},{"EARLY_PHASE1":19406,"PHASE1":19408,"PHASE2":19410,"PHASE3":19412,"PHASE4":19414,"NA":19416},{"trials":19407,"activeCount":101},[],{"trials":19409,"activeCount":101},[],{"trials":19411,"activeCount":101},[],{"trials":19413,"activeCount":101},[],{"trials":19415,"activeCount":101},[],{"trials":19417,"activeCount":101},[19418],{"nctId":19397,"briefTitle":19398,"status":132,"phases":19419,"primaryCompletion":113,"completion":113,"start":8325,"enrollment":1730,"conditions":19420,"interventions":19421},[94],[14134,19401],[19382,19403],{"intervention":19423,"totalTrials":424,"cells":19424},"Blood-based assay",{"EARLY_PHASE1":19425,"PHASE1":19427,"PHASE2":19429,"PHASE3":19431,"PHASE4":19433,"NA":19435},{"trials":19426,"activeCount":101},[],{"trials":19428,"activeCount":101},[],{"trials":19430,"activeCount":101},[],{"trials":19432,"activeCount":101},[],{"trials":19434,"activeCount":101},[],{"trials":19436,"activeCount":101},[19437],{"nctId":19438,"briefTitle":19439,"status":120,"phases":19440,"primaryCompletion":1406,"completion":1406,"start":19441,"enrollment":34,"conditions":19442,"interventions":19443},"NCT05820932","Predicting Cognitive Decline From Androgen Deprivation Therapy",[],"2023-05-22",[21],[19423],{"intervention":17686,"totalTrials":424,"cells":19445},{"EARLY_PHASE1":19446,"PHASE1":19448,"PHASE2":19450,"PHASE3":19452,"PHASE4":19454,"NA":19456},{"trials":19447,"activeCount":101},[],{"trials":19449,"activeCount":101},[],{"trials":19451,"activeCount":101},[],{"trials":19453,"activeCount":101},[],{"trials":19455,"activeCount":101},[],{"trials":19457,"activeCount":101},[19458],{"nctId":17680,"briefTitle":17681,"status":132,"phases":19459,"primaryCompletion":7096,"completion":7096,"start":2773,"enrollment":5422,"conditions":19460,"interventions":19461},[94],[17684],[17107,17686],{"intervention":19463,"totalTrials":424,"cells":19464},"Latanoprost",{"EARLY_PHASE1":19465,"PHASE1":19467,"PHASE2":19469,"PHASE3":19471,"PHASE4":19473,"NA":19475},{"trials":19466,"activeCount":101},[],{"trials":19468,"activeCount":101},[],{"trials":19470,"activeCount":101},[],{"trials":19472,"activeCount":101},[],{"trials":19474,"activeCount":101},[],{"trials":19476,"activeCount":101},[19477],{"nctId":19478,"briefTitle":19479,"status":132,"phases":19480,"primaryCompletion":6212,"completion":17530,"start":238,"enrollment":1071,"conditions":19481,"interventions":19483},"NCT00187577","Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata",[94],[19482],"Alopecia Areata",[19463,19484,19485],"Bimatoprost","Topical application of latanoprost solution to eyelid",{"intervention":19484,"totalTrials":424,"cells":19487},{"EARLY_PHASE1":19488,"PHASE1":19490,"PHASE2":19492,"PHASE3":19494,"PHASE4":19496,"NA":19498},{"trials":19489,"activeCount":101},[],{"trials":19491,"activeCount":101},[],{"trials":19493,"activeCount":101},[],{"trials":19495,"activeCount":101},[],{"trials":19497,"activeCount":101},[],{"trials":19499,"activeCount":101},[19500],{"nctId":19478,"briefTitle":19479,"status":132,"phases":19501,"primaryCompletion":6212,"completion":17530,"start":238,"enrollment":1071,"conditions":19502,"interventions":19503},[94],[19482],[19463,19484,19485],{"intervention":19485,"totalTrials":424,"cells":19505},{"EARLY_PHASE1":19506,"PHASE1":19508,"PHASE2":19510,"PHASE3":19512,"PHASE4":19514,"NA":19516},{"trials":19507,"activeCount":101},[],{"trials":19509,"activeCount":101},[],{"trials":19511,"activeCount":101},[],{"trials":19513,"activeCount":101},[],{"trials":19515,"activeCount":101},[],{"trials":19517,"activeCount":101},[19518],{"nctId":19478,"briefTitle":19479,"status":132,"phases":19519,"primaryCompletion":6212,"completion":17530,"start":238,"enrollment":1071,"conditions":19520,"interventions":19521},[94],[19482],[19463,19484,19485],{"intervention":19523,"totalTrials":424,"cells":19524},"ivacaftor",{"EARLY_PHASE1":19525,"PHASE1":19527,"PHASE2":19529,"PHASE3":19531,"PHASE4":19533,"NA":19535},{"trials":19526,"activeCount":101},[],{"trials":19528,"activeCount":101},[],{"trials":19530,"activeCount":101},[],{"trials":19532,"activeCount":101},[],{"trials":19534,"activeCount":101},[],{"trials":19536,"activeCount":101},[19537],{"nctId":19538,"briefTitle":19539,"status":132,"phases":19540,"primaryCompletion":1871,"completion":1871,"start":3625,"enrollment":345,"conditions":19541,"interventions":19543},"NCT01784419","Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients",[94],[19542],"Cystic Fibrosis",[19523],{"intervention":19545,"totalTrials":424,"cells":19546},"dutasteride",{"EARLY_PHASE1":19547,"PHASE1":19549,"PHASE2":19551,"PHASE3":19553,"PHASE4":19555,"NA":19557},{"trials":19548,"activeCount":101},[],{"trials":19550,"activeCount":101},[],{"trials":19552,"activeCount":101},[],{"trials":19554,"activeCount":101},[],{"trials":19556,"activeCount":101},[],{"trials":19558,"activeCount":101},[19559],{"nctId":19560,"briefTitle":19561,"status":132,"phases":19562,"primaryCompletion":10758,"completion":10423,"start":238,"enrollment":345,"conditions":19563,"interventions":19565},"NCT00706966","MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer",[94],[19564,21],"Nonmalignant Neoplasm",[19545],{"intervention":19567,"totalTrials":424,"cells":19568},"68Gallium-PSMA-11",{"EARLY_PHASE1":19569,"PHASE1":19571,"PHASE2":19573,"PHASE3":19575,"PHASE4":19577,"NA":19579},{"trials":19570,"activeCount":101},[],{"trials":19572,"activeCount":101},[],{"trials":19574,"activeCount":101},[],{"trials":19576,"activeCount":101},[],{"trials":19578,"activeCount":101},[],{"trials":19580,"activeCount":101},[19581],{"nctId":19582,"briefTitle":19583,"status":19584,"phases":19585,"conditions":19586,"interventions":19588},"NCT04377152","Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer","APPROVED_FOR_MARKETING",[],[21,19587,3424],"Prostate",[19567],{"intervention":19590,"totalTrials":424,"cells":19591},"Inhaled fluticasone 500 ug BID for 8 weeks",{"EARLY_PHASE1":19592,"PHASE1":19594,"PHASE2":19596,"PHASE3":19598,"PHASE4":19600,"NA":19602},{"trials":19593,"activeCount":101},[],{"trials":19595,"activeCount":101},[],{"trials":19597,"activeCount":101},[],{"trials":19599,"activeCount":101},[],{"trials":19601,"activeCount":101},[],{"trials":19603,"activeCount":101},[19604],{"nctId":19605,"briefTitle":19606,"status":132,"phases":19607,"completion":3860,"start":2584,"conditions":19608,"interventions":19609},"NCT00187499","Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma",[94],[36],[19590],{"intervention":19611,"totalTrials":424,"cells":19612},"Clofazimine",{"EARLY_PHASE1":19613,"PHASE1":19615,"PHASE2":19617,"PHASE3":19619,"PHASE4":19621,"NA":19623},{"trials":19614,"activeCount":101},[],{"trials":19616,"activeCount":101},[],{"trials":19618,"activeCount":101},[],{"trials":19620,"activeCount":101},[],{"trials":19622,"activeCount":101},[],{"trials":19624,"activeCount":101},[19625],{"nctId":19626,"briefTitle":19627,"status":132,"phases":19628,"conditions":19629,"interventions":19631},"NCT00002058","A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease",[94],[19630,18],"Mycobacterium Avium-intracellulare Infection",[19611],{"intervention":19633,"totalTrials":424,"cells":19634},"Modafinil-Alcohol Interactions",{"EARLY_PHASE1":19635,"PHASE1":19637,"PHASE2":19639,"PHASE3":19641,"PHASE4":19643,"NA":19645},{"trials":19636,"activeCount":101},[],{"trials":19638,"activeCount":101},[],{"trials":19640,"activeCount":101},[],{"trials":19642,"activeCount":101},[],{"trials":19644,"activeCount":101},[],{"trials":19646,"activeCount":101},[19647],{"nctId":19648,"briefTitle":19649,"status":120,"phases":19650,"completion":2723,"start":17530,"enrollment":34,"conditions":19651,"interventions":19652},"NCT00305292","Modafinil-Alcohol Interactions in Healthy Volunteers",[94],[11799],[19633],{"intervention":19654,"totalTrials":424,"cells":19655},"Hepatitis A & B vaccine",{"EARLY_PHASE1":19656,"PHASE1":19658,"PHASE2":19660,"PHASE3":19662,"PHASE4":19664,"NA":19666},{"trials":19657,"activeCount":101},[],{"trials":19659,"activeCount":101},[],{"trials":19661,"activeCount":101},[],{"trials":19663,"activeCount":101},[],{"trials":19665,"activeCount":101},[],{"trials":19667,"activeCount":101},[19668],{"nctId":19669,"briefTitle":19670,"status":132,"phases":19671,"primaryCompletion":2455,"completion":2455,"start":2773,"enrollment":19672,"conditions":19673,"interventions":19678},"NCT00244374","A Randomized Trial of Vaccine Adherence in Young Injection Drug Users",[94],546,[19674,19675,19676,19677,7253,7099],"Medication Adherence","Substance Abuse, Intravenous","Risk Behavior","Hepatitis A",[19654],{"intervention":19680,"totalTrials":424,"cells":19681},"Triamcinolone (TAC) 0.1% cream",{"EARLY_PHASE1":19682,"PHASE1":19684,"PHASE2":19686,"PHASE3":19688,"PHASE4":19690,"NA":19692},{"trials":19683,"activeCount":101},[],{"trials":19685,"activeCount":101},[],{"trials":19687,"activeCount":101},[],{"trials":19689,"activeCount":101},[],{"trials":19691,"activeCount":101},[],{"trials":19693,"activeCount":101},[19694],{"nctId":19695,"briefTitle":19696,"status":120,"phases":19697,"primaryCompletion":673,"completion":6727,"start":16702,"enrollment":1246,"conditions":19698,"interventions":19699},"NCT00924508","Hydrogel Patch for the Treatment of Eczema",[94],[501],[19680],{"intervention":5737,"totalTrials":424,"cells":19701},{"EARLY_PHASE1":19702,"PHASE1":19704,"PHASE2":19706,"PHASE3":19708,"PHASE4":19710,"NA":19712},{"trials":19703,"activeCount":101},[],{"trials":19705,"activeCount":101},[],{"trials":19707,"activeCount":101},[],{"trials":19709,"activeCount":101},[],{"trials":19711,"activeCount":101},[],{"trials":19713,"activeCount":101},[19714],{"nctId":5723,"briefTitle":5724,"status":132,"phases":19715,"primaryCompletion":3829,"completion":5726,"start":5727,"enrollment":2495,"conditions":19716,"interventions":19717},[],[24,5729,5730,5731,5732,5733,5734],[5736,5737,5738,2398,5739,5695],{"intervention":18070,"totalTrials":424,"cells":19719},{"EARLY_PHASE1":19720,"PHASE1":19722,"PHASE2":19724,"PHASE3":19726,"PHASE4":19728,"NA":19730},{"trials":19721,"activeCount":101},[],{"trials":19723,"activeCount":101},[],{"trials":19725,"activeCount":101},[],{"trials":19727,"activeCount":101},[],{"trials":19729,"activeCount":101},[],{"trials":19731,"activeCount":101},[19732],{"nctId":18062,"briefTitle":18063,"status":111,"phases":19733,"primaryCompletion":10423,"start":2722,"enrollment":101,"conditions":19734,"interventions":19735},[94],[5911,18066,18067],[18069,18070],{"intervention":19737,"totalTrials":424,"cells":19738},"Gadavist",{"EARLY_PHASE1":19739,"PHASE1":19741,"PHASE2":19743,"PHASE3":19745,"PHASE4":19747,"NA":19749},{"trials":19740,"activeCount":101},[],{"trials":19742,"activeCount":101},[],{"trials":19744,"activeCount":101},[],{"trials":19746,"activeCount":101},[],{"trials":19748,"activeCount":101},[],{"trials":19750,"activeCount":101},[19751],{"nctId":19752,"briefTitle":19753,"status":132,"phases":19754,"primaryCompletion":19755,"completion":19755,"start":19756,"enrollment":12171,"conditions":19757,"interventions":19758},"NCT00804128","Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)",[],"2024-01-05","2008-10-01",[24],[19737],{"intervention":19760,"totalTrials":424,"cells":19761},"Mitomycin -C",{"EARLY_PHASE1":19762,"PHASE1":19764,"PHASE2":19766,"PHASE3":19768,"PHASE4":19770,"NA":19772},{"trials":19763,"activeCount":101},[],{"trials":19765,"activeCount":101},[],{"trials":19767,"activeCount":101},[],{"trials":19769,"activeCount":101},[],{"trials":19771,"activeCount":101},[],{"trials":19773,"activeCount":101},[19774],{"nctId":19775,"briefTitle":19776,"status":120,"phases":19777,"primaryCompletion":225,"completion":225,"start":8325,"enrollment":519,"conditions":19778,"interventions":19782},"NCT01523275","Study of Mitomycin-C Application in Laryngotracheal Stenosis",[94],[19779,19780,19781],"Laryngeal Stenosis","Subglottic Stenosis","Tracheal Stenosis",[19760],{"intervention":19784,"totalTrials":424,"cells":19785},"controlled-release oral alpha-lipoic acid",{"EARLY_PHASE1":19786,"PHASE1":19788,"PHASE2":19790,"PHASE3":19792,"PHASE4":19794,"NA":19796},{"trials":19787,"activeCount":101},[],{"trials":19789,"activeCount":101},[],{"trials":19791,"activeCount":101},[],{"trials":19793,"activeCount":101},[],{"trials":19795,"activeCount":101},[],{"trials":19797,"activeCount":101},[19798],{"nctId":19799,"briefTitle":19800,"status":132,"phases":19801,"completion":6693,"start":2773,"enrollment":28,"conditions":19802,"interventions":19804},"NCT00187564","Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus",[94],[19803],"Diabetes Mellitus, Type 1",[19784],{"intervention":19806,"totalTrials":424,"cells":19807},"Propranolol Hydrochloride",{"EARLY_PHASE1":19808,"PHASE1":19810,"PHASE2":19812,"PHASE3":19814,"PHASE4":19816,"NA":19818},{"trials":19809,"activeCount":101},[],{"trials":19811,"activeCount":101},[],{"trials":19813,"activeCount":101},[],{"trials":19815,"activeCount":101},[],{"trials":19817,"activeCount":101},[],{"trials":19819,"activeCount":101},[19820],{"nctId":19821,"briefTitle":19822,"status":120,"phases":19823,"primaryCompletion":19824,"completion":5233,"start":1913,"enrollment":6040,"conditions":19825,"interventions":19827},"NCT01555554","Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)",[94],"2018-06",[19826],"Post-traumatic Stress Disorder",[19806],{"intervention":18152,"totalTrials":424,"cells":19829},{"EARLY_PHASE1":19830,"PHASE1":19832,"PHASE2":19834,"PHASE3":19836,"PHASE4":19838,"NA":19840},{"trials":19831,"activeCount":101},[],{"trials":19833,"activeCount":101},[],{"trials":19835,"activeCount":101},[],{"trials":19837,"activeCount":101},[],{"trials":19839,"activeCount":101},[],{"trials":19841,"activeCount":101},[19842],{"nctId":18146,"briefTitle":18147,"status":132,"phases":19843,"primaryCompletion":18149,"completion":18149,"start":17653,"enrollment":751,"conditions":19844,"interventions":19845},[],[24],[18152,17754,17762],{"intervention":19847,"totalTrials":424,"cells":19848},"Anesthesia Premedication, Induction and Maintenance",{"EARLY_PHASE1":19849,"PHASE1":19851,"PHASE2":19853,"PHASE3":19855,"PHASE4":19857,"NA":19859},{"trials":19850,"activeCount":101},[],{"trials":19852,"activeCount":101},[],{"trials":19854,"activeCount":101},[],{"trials":19856,"activeCount":101},[],{"trials":19858,"activeCount":101},[],{"trials":19860,"activeCount":101},[19861],{"nctId":19862,"briefTitle":19863,"status":120,"phases":19864,"primaryCompletion":6568,"completion":6568,"start":8836,"enrollment":1202,"conditions":19865,"interventions":19867},"NCT02058511","Infrared Pupillometry During General Anesthesia to Predict Pain",[94],[3101,19866],"Objective Assessment of Sedation",[19847],{"intervention":3747,"totalTrials":424,"cells":19869},{"EARLY_PHASE1":19870,"PHASE1":19872,"PHASE2":19874,"PHASE3":19876,"PHASE4":19878,"NA":19880},{"trials":19871,"activeCount":101},[],{"trials":19873,"activeCount":101},[],{"trials":19875,"activeCount":101},[],{"trials":19877,"activeCount":101},[],{"trials":19879,"activeCount":101},[],{"trials":19881,"activeCount":101},[19882],{"nctId":3740,"briefTitle":3741,"status":132,"phases":19883,"primaryCompletion":1312,"completion":1312,"start":3743,"enrollment":3744,"conditions":19884,"interventions":19885},[94],[3652],[3747,3748,3749,3607],{"intervention":3748,"totalTrials":424,"cells":19887},{"EARLY_PHASE1":19888,"PHASE1":19890,"PHASE2":19892,"PHASE3":19894,"PHASE4":19896,"NA":19898},{"trials":19889,"activeCount":101},[],{"trials":19891,"activeCount":101},[],{"trials":19893,"activeCount":101},[],{"trials":19895,"activeCount":101},[],{"trials":19897,"activeCount":101},[],{"trials":19899,"activeCount":101},[19900],{"nctId":3740,"briefTitle":3741,"status":132,"phases":19901,"primaryCompletion":1312,"completion":1312,"start":3743,"enrollment":3744,"conditions":19902,"interventions":19903},[94],[3652],[3747,3748,3749,3607],{"intervention":3749,"totalTrials":424,"cells":19905},{"EARLY_PHASE1":19906,"PHASE1":19908,"PHASE2":19910,"PHASE3":19912,"PHASE4":19914,"NA":19916},{"trials":19907,"activeCount":101},[],{"trials":19909,"activeCount":101},[],{"trials":19911,"activeCount":101},[],{"trials":19913,"activeCount":101},[],{"trials":19915,"activeCount":101},[],{"trials":19917,"activeCount":101},[19918],{"nctId":3740,"briefTitle":3741,"status":132,"phases":19919,"primaryCompletion":1312,"completion":1312,"start":3743,"enrollment":3744,"conditions":19920,"interventions":19921},[94],[3652],[3747,3748,3749,3607],{"intervention":19923,"totalTrials":424,"cells":19924},"Fluoxetine",{"EARLY_PHASE1":19925,"PHASE1":19927,"PHASE2":19929,"PHASE3":19931,"PHASE4":19933,"NA":19935},{"trials":19926,"activeCount":101},[],{"trials":19928,"activeCount":101},[],{"trials":19930,"activeCount":101},[],{"trials":19932,"activeCount":101},[],{"trials":19934,"activeCount":101},[],{"trials":19936,"activeCount":101},[19937],{"nctId":19938,"briefTitle":19939,"status":132,"phases":19940,"primaryCompletion":19941,"completion":19941,"start":4214,"enrollment":19942,"conditions":19943,"interventions":19946},"NCT03466346","SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project",[94],"2024-05-06",2162,[19944,17179,19945],"Depression, Unipolar","Trauma",[19923],{"intervention":18658,"totalTrials":424,"cells":19948},{"EARLY_PHASE1":19949,"PHASE1":19951,"PHASE2":19953,"PHASE3":19955,"PHASE4":19957,"NA":19959},{"trials":19950,"activeCount":101},[],{"trials":19952,"activeCount":101},[],{"trials":19954,"activeCount":101},[],{"trials":19956,"activeCount":101},[],{"trials":19958,"activeCount":101},[],{"trials":19960,"activeCount":101},[19961],{"nctId":18653,"briefTitle":18654,"status":120,"phases":19962,"primaryCompletion":2406,"completion":2406,"start":4030,"enrollment":324,"conditions":19963,"interventions":19964},[94],[30],[18638,18658,18659],{"intervention":18659,"totalTrials":424,"cells":19966},{"EARLY_PHASE1":19967,"PHASE1":19969,"PHASE2":19971,"PHASE3":19973,"PHASE4":19975,"NA":19977},{"trials":19968,"activeCount":101},[],{"trials":19970,"activeCount":101},[],{"trials":19972,"activeCount":101},[],{"trials":19974,"activeCount":101},[],{"trials":19976,"activeCount":101},[],{"trials":19978,"activeCount":101},[19979],{"nctId":18653,"briefTitle":18654,"status":120,"phases":19980,"primaryCompletion":2406,"completion":2406,"start":4030,"enrollment":324,"conditions":19981,"interventions":19982},[94],[30],[18638,18658,18659],{"intervention":19984,"totalTrials":424,"cells":19985},"Stribild PEP Substudy",{"EARLY_PHASE1":19986,"PHASE1":19988,"PHASE2":19990,"PHASE3":19992,"PHASE4":19994,"NA":19996},{"trials":19987,"activeCount":101},[],{"trials":19989,"activeCount":101},[],{"trials":19991,"activeCount":101},[],{"trials":19993,"activeCount":101},[],{"trials":19995,"activeCount":101},[],{"trials":19997,"activeCount":101},[19998],{"nctId":19999,"briefTitle":20000,"status":132,"phases":20001,"primaryCompletion":9239,"completion":20002,"start":3818,"enrollment":20003,"conditions":20004,"interventions":20006},"NCT02183909","Connecting Resources for Urban Sexual Health",[94],"2017-08",378,[15,20005],"Sexually Transmitted Infections",[19984],{"intervention":20008,"totalTrials":424,"cells":20009},"131 I-Metaiodobenzylguanidine",{"EARLY_PHASE1":20010,"PHASE1":20012,"PHASE2":20014,"PHASE3":20016,"PHASE4":20018,"NA":20020},{"trials":20011,"activeCount":101},[],{"trials":20013,"activeCount":101},[],{"trials":20015,"activeCount":101},[],{"trials":20017,"activeCount":101},[],{"trials":20019,"activeCount":101},[],{"trials":20021,"activeCount":101},[20022],{"nctId":20023,"briefTitle":20024,"status":19584,"phases":20025,"conditions":20026,"interventions":20028},"NCT01377532","Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma",[],[20027,12426],"Pheochromocytoma",[20008],{"intervention":20030,"totalTrials":424,"cells":20031},"Influenza vaccine",{"EARLY_PHASE1":20032,"PHASE1":20034,"PHASE2":20036,"PHASE3":20038,"PHASE4":20040,"NA":20042},{"trials":20033,"activeCount":101},[],{"trials":20035,"activeCount":101},[],{"trials":20037,"activeCount":101},[],{"trials":20039,"activeCount":101},[],{"trials":20041,"activeCount":101},[],{"trials":20043,"activeCount":101},[20044],{"nctId":20045,"briefTitle":20046,"status":132,"phases":20047,"primaryCompletion":205,"completion":205,"start":3828,"enrollment":2818,"conditions":20048,"interventions":20050},"NCT01581164","Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation",[],[20049],"Hematopoietic Stem Cell Transplant",[20030,20051],"Varicella vaccine",{"intervention":20051,"totalTrials":424,"cells":20053},{"EARLY_PHASE1":20054,"PHASE1":20056,"PHASE2":20058,"PHASE3":20060,"PHASE4":20062,"NA":20064},{"trials":20055,"activeCount":101},[],{"trials":20057,"activeCount":101},[],{"trials":20059,"activeCount":101},[],{"trials":20061,"activeCount":101},[],{"trials":20063,"activeCount":101},[],{"trials":20065,"activeCount":101},[20066],{"nctId":20045,"briefTitle":20046,"status":132,"phases":20067,"primaryCompletion":205,"completion":205,"start":3828,"enrollment":2818,"conditions":20068,"interventions":20069},[],[20049],[20030,20051],{"intervention":18022,"totalTrials":424,"cells":20071},{"EARLY_PHASE1":20072,"PHASE1":20074,"PHASE2":20076,"PHASE3":20078,"PHASE4":20080,"NA":20082},{"trials":20073,"activeCount":101},[],{"trials":20075,"activeCount":101},[],{"trials":20077,"activeCount":101},[],{"trials":20079,"activeCount":101},[],{"trials":20081,"activeCount":101},[],{"trials":20083,"activeCount":101},[20084],{"nctId":18015,"briefTitle":18016,"status":132,"phases":20085,"primaryCompletion":18018,"completion":509,"start":1913,"enrollment":324,"conditions":20086,"interventions":20087},[94],[18020],[972,18022],{"intervention":18668,"totalTrials":424,"cells":20089},{"EARLY_PHASE1":20090,"PHASE1":20092,"PHASE2":20094,"PHASE3":20096,"PHASE4":20098,"NA":20100},{"trials":20091,"activeCount":101},[],{"trials":20093,"activeCount":101},[],{"trials":20095,"activeCount":101},[],{"trials":20097,"activeCount":101},[],{"trials":20099,"activeCount":101},[],{"trials":20101,"activeCount":101},[20102],{"nctId":18661,"briefTitle":18662,"status":120,"phases":20103,"primaryCompletion":932,"completion":932,"start":255,"enrollment":18280,"conditions":20104,"interventions":20105},[94],[18665,18666],[18638,18668,18638,18668],{"intervention":20107,"totalTrials":424,"cells":20108},"Expanded panel cell free DNA testing",{"EARLY_PHASE1":20109,"PHASE1":20111,"PHASE2":20113,"PHASE3":20115,"PHASE4":20117,"NA":20119},{"trials":20110,"activeCount":101},[],{"trials":20112,"activeCount":101},[],{"trials":20114,"activeCount":101},[],{"trials":20116,"activeCount":101},[],{"trials":20118,"activeCount":101},[],{"trials":20120,"activeCount":101},[20121],{"nctId":20122,"briefTitle":20123,"status":132,"phases":20124,"primaryCompletion":20125,"completion":4940,"start":20126,"enrollment":1633,"conditions":20127,"interventions":20130},"NCT04311749","Expanded NIPT for Pregnancy Complications",[],"2024-06-30","2020-02-12",[20128,20129],"Fetal Growth Restriction","Preeclampsia Severe",[20107,20131,20132],"Placental biopsy","Umbilical cord blood",{"intervention":20131,"totalTrials":424,"cells":20134},{"EARLY_PHASE1":20135,"PHASE1":20137,"PHASE2":20139,"PHASE3":20141,"PHASE4":20143,"NA":20145},{"trials":20136,"activeCount":101},[],{"trials":20138,"activeCount":101},[],{"trials":20140,"activeCount":101},[],{"trials":20142,"activeCount":101},[],{"trials":20144,"activeCount":101},[],{"trials":20146,"activeCount":101},[20147],{"nctId":20122,"briefTitle":20123,"status":132,"phases":20148,"primaryCompletion":20125,"completion":4940,"start":20126,"enrollment":1633,"conditions":20149,"interventions":20150},[],[20128,20129],[20107,20131,20132],{"intervention":20132,"totalTrials":424,"cells":20152},{"EARLY_PHASE1":20153,"PHASE1":20155,"PHASE2":20157,"PHASE3":20159,"PHASE4":20161,"NA":20163},{"trials":20154,"activeCount":101},[],{"trials":20156,"activeCount":101},[],{"trials":20158,"activeCount":101},[],{"trials":20160,"activeCount":101},[],{"trials":20162,"activeCount":101},[],{"trials":20164,"activeCount":101},[20165],{"nctId":20122,"briefTitle":20123,"status":132,"phases":20166,"primaryCompletion":20125,"completion":4940,"start":20126,"enrollment":1633,"conditions":20167,"interventions":20168},[],[20128,20129],[20107,20131,20132],{"intervention":20170,"totalTrials":424,"cells":20171},"ORTHO EVRA, the contraceptive patch",{"EARLY_PHASE1":20172,"PHASE1":20174,"PHASE2":20176,"PHASE3":20178,"PHASE4":20180,"NA":20182},{"trials":20173,"activeCount":101},[],{"trials":20175,"activeCount":101},[],{"trials":20177,"activeCount":101},[],{"trials":20179,"activeCount":101},[],{"trials":20181,"activeCount":101},[],{"trials":20183,"activeCount":101},[20184],{"nctId":20185,"briefTitle":20186,"status":111,"phases":20187,"enrollment":101,"conditions":20188,"interventions":20192},"NCT00357981","Continuous Use of the Contraceptive Patch and the Personal Economic Impact.",[94],[20189,20190,20191],"Dysmenorrhea","Menstruation Disturbances","Menstruation Disorders",[20170],{"intervention":20194,"totalTrials":424,"cells":20195},"Oral Anticoagulant",{"EARLY_PHASE1":20196,"PHASE1":20198,"PHASE2":20200,"PHASE3":20202,"PHASE4":20204,"NA":20206},{"trials":20197,"activeCount":101},[],{"trials":20199,"activeCount":101},[],{"trials":20201,"activeCount":101},[],{"trials":20203,"activeCount":101},[],{"trials":20205,"activeCount":101},[],{"trials":20207,"activeCount":101},[20208],{"nctId":20209,"briefTitle":20210,"status":132,"phases":20211,"primaryCompletion":5700,"completion":20212,"start":20213,"enrollment":20214,"conditions":20215,"interventions":20218},"NCT03292666","Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study",[],"2022-06-21","2010-01-01",39603,[20216,20217],"Venous Thromboembolism","Anticoagulants and Bleeding Disorders",[20194],{"intervention":20220,"totalTrials":424,"cells":20221},"Budesonide",{"EARLY_PHASE1":20222,"PHASE1":20224,"PHASE2":20226,"PHASE3":20228,"PHASE4":20230,"NA":20232},{"trials":20223,"activeCount":101},[],{"trials":20225,"activeCount":101},[],{"trials":20227,"activeCount":101},[],{"trials":20229,"activeCount":101},[],{"trials":20231,"activeCount":101},[],{"trials":20233,"activeCount":101},[20234],{"nctId":20235,"briefTitle":20236,"status":132,"phases":20237,"primaryCompletion":2817,"completion":2817,"start":805,"enrollment":20238,"conditions":20239,"interventions":20240},"NCT01484691","Role of microRNAs in T Cell-Driven Inflammation in Asthma",[94],55,[36],[20220],{"intervention":20242,"totalTrials":424,"cells":20243},"Chlorine dioxide and scraper",{"EARLY_PHASE1":20244,"PHASE1":20246,"PHASE2":20248,"PHASE3":20250,"PHASE4":20252,"NA":20254},{"trials":20245,"activeCount":101},[],{"trials":20247,"activeCount":101},[],{"trials":20249,"activeCount":101},[],{"trials":20251,"activeCount":101},[],{"trials":20253,"activeCount":101},[],{"trials":20255,"activeCount":101},[20256],{"nctId":20257,"briefTitle":20258,"status":132,"phases":20259,"primaryCompletion":2583,"completion":9198,"start":3713,"enrollment":3744,"conditions":20260,"interventions":20262},"NCT00867035","Bad Breath Response to Tongue Scraper and Rinses",[94],[20261],"Halitosis",[20242,20263],"Chlorhexidine gluconate and scraper",{"intervention":20263,"totalTrials":424,"cells":20265},{"EARLY_PHASE1":20266,"PHASE1":20268,"PHASE2":20270,"PHASE3":20272,"PHASE4":20274,"NA":20276},{"trials":20267,"activeCount":101},[],{"trials":20269,"activeCount":101},[],{"trials":20271,"activeCount":101},[],{"trials":20273,"activeCount":101},[],{"trials":20275,"activeCount":101},[],{"trials":20277,"activeCount":101},[20278],{"nctId":20257,"briefTitle":20258,"status":132,"phases":20279,"primaryCompletion":2583,"completion":9198,"start":3713,"enrollment":3744,"conditions":20280,"interventions":20281},[94],[20261],[20242,20263],{"intervention":20283,"totalTrials":424,"cells":20284},"local gentamicin",{"EARLY_PHASE1":20285,"PHASE1":20287,"PHASE2":20289,"PHASE3":20291,"PHASE4":20293,"NA":20295},{"trials":20286,"activeCount":101},[],{"trials":20288,"activeCount":101},[],{"trials":20290,"activeCount":101},[],{"trials":20292,"activeCount":101},[],{"trials":20294,"activeCount":101},[],{"trials":20296,"activeCount":101},[20297],{"nctId":20298,"briefTitle":20299,"status":132,"phases":20300,"primaryCompletion":20301,"completion":20301,"start":20302,"enrollment":1220,"conditions":20303,"interventions":20305},"NCT03559400","Pilot RCT Local Gentamicin for Open Tibial Fractures in Tanzania",[94],"2021-09-15","2019-11-19",[20304],"Open Tibia Fracture",[20283],{"intervention":20307,"totalTrials":424,"cells":20308},"levorphanol",{"EARLY_PHASE1":20309,"PHASE1":20311,"PHASE2":20313,"PHASE3":20315,"PHASE4":20317,"NA":20319},{"trials":20310,"activeCount":101},[],{"trials":20312,"activeCount":101},[],{"trials":20314,"activeCount":101},[],{"trials":20316,"activeCount":101},[],{"trials":20318,"activeCount":101},[],{"trials":20320,"activeCount":101},[20321],{"nctId":20322,"briefTitle":20323,"status":132,"phases":20324,"primaryCompletion":11774,"completion":2435,"start":20325,"enrollment":1730,"conditions":20326,"interventions":20327},"NCT00275249","Evolution of Analgesic Tolerance With Opioids",[94],"2001-03",[9400],[20307],{"intervention":20329,"totalTrials":424,"cells":20330},"metoprolol",{"EARLY_PHASE1":20331,"PHASE1":20333,"PHASE2":20335,"PHASE3":20337,"PHASE4":20339,"NA":20341},{"trials":20332,"activeCount":101},[],{"trials":20334,"activeCount":101},[],{"trials":20336,"activeCount":101},[],{"trials":20338,"activeCount":101},[],{"trials":20340,"activeCount":101},[],{"trials":20342,"activeCount":101},[20343],{"nctId":20344,"briefTitle":20345,"status":111,"phases":20346,"primaryCompletion":1146,"completion":1146,"start":10926,"enrollment":101,"conditions":20347,"interventions":20349},"NCT01330654","Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers",[94],[20348],"Cardiac Event Risk",[20329],{"intervention":20351,"totalTrials":424,"cells":20352},"Glatiramer acetate",{"EARLY_PHASE1":20353,"PHASE1":20355,"PHASE2":20357,"PHASE3":20359,"PHASE4":20361,"NA":20363},{"trials":20354,"activeCount":101},[],{"trials":20356,"activeCount":101},[],{"trials":20358,"activeCount":101},[],{"trials":20360,"activeCount":101},[],{"trials":20362,"activeCount":101},[],{"trials":20364,"activeCount":101},[20365],{"nctId":20366,"briefTitle":20367,"status":132,"phases":20368,"primaryCompletion":3829,"completion":3829,"start":10758,"enrollment":498,"conditions":20369,"interventions":20370},"NCT00819195","Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis",[],[765],[20351],{"intervention":20372,"totalTrials":424,"cells":20373},"sodium stibogluconate",{"EARLY_PHASE1":20374,"PHASE1":20376,"PHASE2":20378,"PHASE3":20380,"PHASE4":20382,"NA":20384},{"trials":20375,"activeCount":101},[],{"trials":20377,"activeCount":101},[],{"trials":20379,"activeCount":101},[],{"trials":20381,"activeCount":101},[],{"trials":20383,"activeCount":101},[],{"trials":20385,"activeCount":101},[20386],{"nctId":20387,"briefTitle":20388,"status":20389,"phases":20390,"conditions":20391,"interventions":20394},"NCT00508963","Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis","NO_LONGER_AVAILABLE",[],[20392,20393],"Leishmaniasis, Cutaneous","Leishmaniasis, Mucocutaneous",[20372],{"intervention":2469,"totalTrials":424,"cells":20396},{"EARLY_PHASE1":20397,"PHASE1":20399,"PHASE2":20401,"PHASE3":20403,"PHASE4":20405,"NA":20407},{"trials":20398,"activeCount":101},[],{"trials":20400,"activeCount":101},[],{"trials":20402,"activeCount":101},[],{"trials":20404,"activeCount":101},[],{"trials":20406,"activeCount":101},[],{"trials":20408,"activeCount":101},[20409],{"nctId":2460,"briefTitle":2461,"status":2462,"phases":20410,"start":2464,"enrollment":675,"conditions":20411,"interventions":20412},[94],[2358,2466,679,717,2359,680,2467],[719,720,2469,721,684,2398,685,686,2470,2362],{"intervention":20414,"totalTrials":424,"cells":20415},"polymorphism analysis",{"EARLY_PHASE1":20416,"PHASE1":20418,"PHASE2":20420,"PHASE3":20422,"PHASE4":20424,"NA":20426},{"trials":20417,"activeCount":101},[],{"trials":20419,"activeCount":101},[],{"trials":20421,"activeCount":101},[],{"trials":20423,"activeCount":101},[],{"trials":20425,"activeCount":101},[],{"trials":20427,"activeCount":101},[20428],{"nctId":20429,"briefTitle":20430,"status":132,"phases":20431,"primaryCompletion":6189,"start":20432,"enrollment":20433,"conditions":20434,"interventions":20435},"NCT01009307","Study of Blood and Cheek Cell Samples From Patients With Glioma",[],"2001-10",1709,[2439],[20414],{"intervention":20437,"totalTrials":424,"cells":20438},"Metformin HCl",{"EARLY_PHASE1":20439,"PHASE1":20441,"PHASE2":20443,"PHASE3":20445,"PHASE4":20447,"NA":20449},{"trials":20440,"activeCount":101},[],{"trials":20442,"activeCount":101},[],{"trials":20444,"activeCount":101},[],{"trials":20446,"activeCount":101},[],{"trials":20448,"activeCount":101},[],{"trials":20450,"activeCount":101},[20451],{"nctId":20452,"briefTitle":20453,"status":132,"phases":20454,"primaryCompletion":7341,"completion":7341,"start":14654,"enrollment":1202,"conditions":20455,"interventions":20456},"NCT00187798","Impact of Genetics on Metformin Pharmacokinetics",[94],[3699],[20437],{"intervention":20458,"totalTrials":424,"cells":20459},"Dinitrochlorobenzene",{"EARLY_PHASE1":20460,"PHASE1":20462,"PHASE2":20464,"PHASE3":20466,"PHASE4":20468,"NA":20470},{"trials":20461,"activeCount":101},[],{"trials":20463,"activeCount":101},[],{"trials":20465,"activeCount":101},[],{"trials":20467,"activeCount":101},[],{"trials":20469,"activeCount":101},[],{"trials":20471,"activeCount":101},[20472],{"nctId":20473,"briefTitle":20474,"status":132,"phases":20475,"conditions":20476,"interventions":20477},"NCT00002031","Evaluation of the Epidermal Langerhans Cell Population in AIDS \u002F ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)",[94],[18],[20458]]